[
  {
    "objectID": "soe_gt.html",
    "href": "soe_gt.html",
    "title": "Strength of Evidence",
    "section": "",
    "text": "Recent updates (last 2024-01-02)\n\n\n\n\n\n\n\n\n\n\n\n\nDate               \nModification\n\n\n\n\n2024-01-02\nUpdated regional versus general for consistent language, removed I 2 (can be found in forest plots), and added prediction intervals where relevant"
  },
  {
    "objectID": "soe_gt.html#expanded-preoperative-evaluation",
    "href": "soe_gt.html#expanded-preoperative-evaluation",
    "title": "Strength of Evidence",
    "section": "Expanded Preoperative Evaluation",
    "text": "Expanded Preoperative Evaluation\n Table 1. Strength of evidence summaries — expanded versus standard preoperative evaluation. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      Studies (Pts)\n      Study Design\n      GRADE1\n      ACCF AHA2\n      Importance3\n      Summary\n      Result Detail\n    \n  \n  \n    Delirium incidence\n\n6 ( 1,365)\n\nRCT\n⨁⨁⨁◯\n\nB-R\n+++\nPooled estimate from 6 RCTs was consistent with a lower risk of postoperative delirium for expanded versus standard preoperative evaluation.  RR 0.77  (95% CI, 0.60-0.99; I 2 = 26%) \nIn hip fracture studies  (n = 4)RR 0.84  (95% CI, 0.71-0.99; I 2 = 7%) \nIn studies of various surgeries (n = 2)RR 0.54  (95% CI, 0.33-0.89; I 2 = 0%)\n\nTable: 10  \nFigure: 1  \n\n    \n6 ( 1,774)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 6 non-randomized studies was consistent with a lower risk of postoperative delirium with expanded versus standard preoperative evaluation.  RR 0.65  (95% CI, 0.49-0.87; I 2 = 33%)\n\nTable: 10  \nFigure: 2  \n\n    Delayed neurocognitive recovery\n\n1 (   180)\n\nBefore-after\n⨁◯◯◯\n\nC-LD\n+++\nA single before-after study did not detect a difference in delayed neurocognitive recovery with expanded versus standard preoperative evaluation, RR 0.71 (95% CI, 0.36-1.39).\n\nTable: 11  \n\n    Postoperative neurocognitive disorder\n\n—\n\nNo studies\n\n\n+++\n\n\n    Physical function\n\n4\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nPooled analysis of 4 RCTs (3 different timepoints) was inconclusive concerning difference in physical status with expanded versus standard preoperative evaluation,  SMD -0.00  (95% CI, -0.17 to 0.16; I 2 = 49%)\n\nTable: 12  \nFigure: 3  \n\n    \n3\n\nBefore-after\n⨁◯◯◯\n\nC-LD\n+++\nPooled analysis of 3 non-randomized studies (3 different timepoints) was inconclusive concerning difference in physical status with expanded versus standard preoperative evaluation,  SMD -0.12  (95% CI, -0.42 to 0.18; I 2 = 71%)\n\nTable: 12  \nFigure: 4  \n\n    Myocardial infarction\n\n1 (   319)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nA single RCT reported 1 myocardial infarction; a difference was not detected with expanded versus standard preoperative evaluation, RD -0.6%  (95% CI, -2.3 to 1.1)\n\nTable: 13  \n\n    \n4 ( 1,206)\n\nBefore-after\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 4 non-randomized studies was inconclusive concerning the risk of myocardial infarction with expanded versus standard preoperative evaluation.  RR 0.60  (95% CI, 0.24-1.47; I 2 = 0%)\n\nTable: 13  \nFigure: 5  \n\n    Stroke\n\n—\n\nNo studies\n\n\n\n\n\n    Renal complications\n\n2 (   589)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 2 randomized studies was inconclusive concerning the risk of renal complications with expanded versus standard preoperative evaluation.  RR 2.83  (95% CI, 0.91-8.80; I 2 = 0%)\n\nTable: 13  \nFigure: 10  \n\n    \n3 (   796)\n\nBefore-after\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 3 non-randomized studies was inconclusive concerning the risk of acute kidney injury with expanded versus standard preoperative evaluation.  RR 0.81  (95% CI, 0.57-1.15; I 2 = 0%)\n\nTable: 13  \nFigure: 11  \n\n    Pulmonary complications\n\n3 (   765)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 3 RCTs was inconclusive concerning the risk of pulmonary complications with expanded versus standard preoperative evaluation.  RR 1.18  (95% CI, 0.84-1.67; I 2 = 31%)\n\nTable: 13  \nFigure: 6  \n\n    Pneumonia\n\n2 (   495)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 2 RCTs was inconclusive concerning the risk of pneumonia with expanded versus standard preoperative evaluation.  RR 0.82  (95% CI, 0.42-1.61; I 2 = 0%)\n\nTable: 13  \nFigure: 7  \n\n    \n6 ( 1,856)\n\nBefore-after\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 6 non-randomized studies was inconclusive concerning the risk of pneumonia with expanded versus standard preoperative evaluation.  RR 0.95  (95% CI, 0.56-1.62; I 2 = 17%)\n\nTable: 13  \nFigure: 8  \n\n    Pulmonary embolism\n\n3 (   714)\n\nBefore-after\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 3 non-randomized studies was inconclusive concerning the risk of pulmonary embolism with expanded versus standard preoperative evaluation.  RR 1.21  (95% CI, 0.32-4.67; I 2 = 0%)\n\nTable: 13  \nFigure: 9  \n\n    Respiratory failure\n\n1 (   326)\n\nBefore-after\n⨁◯◯◯\n\nC-LD\n+++\nA single before-after study did not detect a difference in respiratory failure with expanded versus standard preoperative evaluation, RD -5.9%  (95% CI, -13.0 to 1.2).\n\nTable: 13  \n\n    Patient satisfaction\n\n1 (    62)\n\nBefore-after\n⨁◯◯◯\n\nC-LD\n++\nA single before-after study did not detect a difference in patient satisfaction with expanded versus standard preoperative evaluation, RD 3.3% (95% CI, -5.3, 12.0).\n\nTable: 14 \n\n    Length of stay\n\n7 ( 1,832)\n\nRCT\n⨁◯◯◯\n\nC-LD\n++\nPooled estimate from 7 RCTs was inconclusive with respect to length of stay with expanded versus standard evaluation.  MD 0.1  (95% CI, -1.9 to 2.0; I 2 = 95%)\n\nTable: 15 \nFigure: 12  \n\n    \n5 ( 1,326)\n\nRCT\n⨁◯◯◯\n\nC-LD\n++\nPooled estimate from 5 RCTs was inconclusive with respect to length of stay with expanded versus standard evaluation.  MD 0.0  (95% CI, -2.2 to 2.3; I 2 = 95%)\n\nTable: 15 \nFigure: 12  \n\n    \n2 (   506)\n\nRCT\n⨁◯◯◯\n\nC-LD\n++\nPooled estimate from 2 RCTs was inconclusive with respect to length of stay with expanded versus standard evaluation.  MD 0.5  (95% CI, -5.5 to 6.5; I 2 = 86%)\n\nTable: 15 \nFigure: 12  \n\n    \n12 ( 3,453)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n++\nPooled estimate from 11 non-randomized studies was inconclusive with respect to length of stay with expanded versus standard evaluation,  RR -0.9  (95% CI, -2.0 to 0.2; I 2 = 95%)\n\nTable: 15  \nFigure: 13  \n\n    Discharged to institution\n\n4 (   843)\n\nRCT\n⨁⨁◯◯\n\nB-R\n++\nPooled estimate from 4 RCTs was inconclusive with respect to discharge location with expanded versus standard evaluation.  RR 0.98  (95% CI, 0.76-1.27; I 2 = 80%)\n\nTable: 16  \nFigure: 14  \n\n    \n5 ( 1,295)\n\nNRSI\n⨁⨁◯◯\n\nB-NR\n++\nPooled estimate from 5 non-randomized studies was consistent with lower discharge rates to a care facility with expanded versus standard evaluation.  RR 0.69  (95% CI, 0.49-0.98; I 2 = 89%)\n\nTable: 16  \nFigure: 15  \n\n    Hospital & 30-day mortality\n\n4 ( 1,024)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+\nPooled estimate from 4 RCTs was inconclusive with respect to the risk of 30-day mortality with expanded versus standard evaluation.  RR 1.02  (95% CI, 0.30–3.53; I 2 = 60%)\n\nTable: 17 \nFigure: 16  \n\n    \n13 (12,640)\n\nNRSI\n⨁⨁◯◯\n\nC-LD\n+\nPooled estimate from 13 non-randomized studies was consistent with lower in-hospital and 30-day mortality with expanded versus tandard evaluation.  RR 0.68  (95% CI, 0.50-0.92; I 2 = 5%)\n\nTable: 18  \nFigure: 17  \n\n    1-year mortality\n\n5 (10,129)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+\nPooled estimate from5 non-randomized studies was inconclusive with respect to risk of 1-year mortality with expanded versus standard evaluation.  RR 0.71  (95% CI, 0.30-1.64; I 2 = 92%)\n\nTable: 18  \nFigure: 18  \n\n  \n  \n  \n    \n       Pts: patients; RCT: randomized clinical trial; NRSI: non-randomized studies of interventions (inlcudes non-randomized trials, before-after/time series, and observational); GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; ACCF/AHA: American College of Cardiology Foundation/American Heart Association; RR: risk ratio; OR: odds ratio; MD: mean difference; RD: risk difference; PI: prediction interval.\n    \n    \n      1 Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      2 A: high-quality evidence from more than 1 RCT; B-R: moderate-quality evidence from more than 1 RCT; B-NR: moderate-quality evidence from more than one observational study; C-LD: randomized or non-randomized observational or registry studies with limited data; C-EO: consensus of expert opinion.\n    \n    \n      3 Limited +; Important ++; Critical +++.\n    \n  \n\n\n\n\n\nGRADE Domains\n Table 2. GRADE domains for strength of evidence ratings — expanded versus standard preoperative evaluation. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      Design\n      \n      \n        GRADE Domains\n      \n    \n    \n      Bias\n      Inconsistency\n      Indirectness\n      Imprecision\n      Other\n    \n  \n  \n    Delirium incidence\nRCT\n\nserious1\n\nnot serious\n\nnot serious\n\nnot serious\n\nnot serious\n\n    \nNRSI\n\nserious2\n\nnot serious\n\nnot serious\n\nnot serious\n\nnot serious\n\n    Delayed neurocognitive recovery\nBefore-after\n\nserious3\n\nvery serious4\n\nnot serious\n\nserious\n\nnot serious\n\n    Physical function\nRCT\n\nnot serious5\n\nserious6\n\nnot serious\n\nserious7\n\nserious8\n\n    \nBefore-after\n\nserious9\n\nserious10\n\nnot serious\n\nserious7\n\nserious8\n\n    Myocardial infarction\nRCT\n\nnot serious\n\nvery serious4\n\nnot serious\n\nvery serious11\n\nnot serious\n\n    \nBefore-after\n\nserious12\n\nnot serious\n\nnot serious\n\nvery serious13\n\nnot serious\n\n    Renal complications\nRCT\n\nnot serious\n\nserious14\n\nnot serious\n\nvery serious15\n\nnot serious\n\n    \nBefore-after\n\nserious12\n\nnot serious\n\nnot serious\n\nserious13\n\nnot serious\n\n    Pulmonary complications\nRCT\n\nnot serious16\n\nserious6\n\nnot serious\n\nserious7\n\nserious17\n\n    Pneumonia\nRCT\n\nnot serious\n\nserious14\n\nnot serious\n\nvery serious18\n\nnot serious\n\n    \nBefore-after\n\nserious19\n\nserious20\n\nnot serious\n\nserious7\n\nnot serious\n\n    Pulmonary embolism\nBefore-after\n\nserious12\n\nnot serious\n\nnot serious\n\nvery serious18\n\nnot serious\n\n    Respiratory failure\nBefore-after\n\nserious3\n\nvery serious4\n\nnot serious\n\nserious7\n\nnot serious\n\n    Patient satisfaction\nBefore-after\n\nvery serious21\n\nvery serious4\n\nnot serious\n\nserious22\n\nnot serious\n\n    Length of stay\nRCT\n\nnot serious23\n\nserious24\n\nnot serious\n\nserious25\n\nserious26\n\n    \nRCT\n\nnot serious\n\nserious24\n\nnot serious\n\nserious25\n\nserious26\n\n    \nRCT\n\nnot serious\n\nserious24\n\nnot serious\n\nserious25\n\nserious26\n\n    \nNRSI\n\nserious27\n\nserious28\n\nnot serious\n\nserious25\n\nserious26\n\n    Discharged to institution\nRCT\n\nnot serious29\n\nserious30\n\nnot serious\n\nserious31\n\nnot serious\n\n    \nNRSI\n\nserious32\n\nserious33\n\nnot serious\n\nnot serious\n\nnot serious\n\n    Hospital & 30-day mortality\nRCT\n\nnot serious\n\nvery serious34\n\nnot serious\n\nserious31\n\nnot serious\n\n    \nNRSI\n\nnot serious35\n\nnot serious36\n\nnot serious\n\nnot serious\n\nnot serious\n\n    1-year mortality\nNRSI\n\nserious27\n\nserious37\n\nnot serious\n\nserious31\n\nnot serious\n\n  \n  \n  \n    \n       If not specified in footnotes, all references are to 95% confidence and prediction intervals.\n    \n    \n       RCT: randomized clinical trial; NRSI: non-randomized studies of interventions (inlcudes non-randomized trials, before-after/time series, and observational); RR: risk ratio; OR: odds ratio.\n    \n    \n       1 Concerns about missing data and delirium measurement. One study judge at high risk of bias and three with some concerns.2 Five uncontrolled before-after designs; one study selection bias and pontential confounders selected base on statistical significance.3 Uncontrolled before-after design.4 Single study, cannot assess consistency.5 Two with some concerns: 12% dropout; random number table.6 Estimates vary in direction.7 Confidence interval compatible with benefit or harm.8 Heterogeneity in timing of measurement and scale used among the studies.9 Uncontrolled before-after designs; one moderate risk and one serious risk (convenience sample).10 Prediction interval (-1.12 to 0.88).11 Single event.12 All uncontrolled before-after designs.13 Small number of events; confidence interval for pooled estimate compatible with benefit or harm.14 Two studies, limited ability to  assess consistency.15 Very small number of events; confidence interval compatible with wide range of effects.16 Two studies some concerns, but not with respect to complication outcomes.17 Whether pulmonary complication definitions were similar is unclear.18 Very few events; confidence interval compatible with benefit or harm.19 Uncontrolled before-after design (4 studies); two matched.20 Variable point estimates with overlapping confidence intervals, but wide prediction interval (0.27-3.38).21 Uncontrolled before-after design; no description of how satisfaction was measured.22 Confidence interval compatible with wide range of effects.23 One study had 12% loss to follow-up.24 Wide variability in mean differences around the null reflected in the prediction interval.25 Confidence interval compatible with either comparator having shorter length of stay.26 Variation between countries and procedures.27 All have potential confounding.28 Wide prediction interval (-5.2 to 3.3).29 One study had 12% loss to followup.30 Wide prediction interval (0.34-2.88).31 Confidence interval for pooled estimate compatible with benefit or harm.32 All have potential confounding; 2 performed matching.33 Wide prediction interval (0.19-2.52).34 Wide prediction interval.35 Unclear if selection bias likely impacts results.36 Prediction interval (0.37-1.25).37 Wide prediction interval (0.08-6.07)."
  },
  {
    "objectID": "soe_gt.html#regional-versus-general",
    "href": "soe_gt.html#regional-versus-general",
    "title": "Strength of Evidence",
    "section": "Regional versus General",
    "text": "Regional versus General\n Table 3. Strength of evidence summaries — regional versus general anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      Studies (Pts)\n      Study Design\n      GRADE1\n      ACCF AHA2\n      Importance3\n      Summary\n      Result Detail\n    \n  \n  \n    Delirium incidence\n\n12(3,875)\n\nRCT\n⨁⨁⨁◯\n\nB-R\n+++\nThe pooled effect from 12 RCTs favored neither regional nor general anesthesia with respect to the risk of postoperative delirium. \nRR 0.97  (95% CI, 0.69–1.36; PI, 0.52–1.79)\n\nTable: 9  \nFigures: 1 to 5  \n\n    Delayed neurocognitive recovery\n\n4(1,105)\n\nRCT\n⨁⨁◯◯\n\nC-LD\n+++\nThe pooled effect from 4 RCTs favored neither regional nor general anesthesia with respect to the risk of delayed neurocognitive recovery. \nRR 0.91  (95% CI, 0.56–1.48; PI, 0.16–5.20)\n\nTable: 10  \nFigure: 6  \n\n    Postoperative neurocognitive disorder\n\n1(364)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nA single study did not detect a difference in the incidence of postoperative neurocognitive disorder. \nRR  0.98 (95% CI, 0.58–1.67)\n\nTable: 11  \n\n    Physical function\n\n1(59)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nA single RCT did not detect a difference in physical function after 60 days postop between regional and general anesthesia. \nSMD 0.26 (95% CI, -0.25 to 0.78)\n\nTable: 12  \n\n    Myocardial Infarction\n\n6(6,778)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nThe pooled effects from 6 RCTs were inconclusive with respect to the risk of myocardial infarction for regional compared to general anesthesia. \nRR 1.11  (95% CI, 0.50–2.44; PI 0.36–3.83) \nRD 1.9 per 1000 (95% CI, -0.6 to 4.5; PI, -2.4 to 6.2)\n\nTable: 13  \nFigures: 7, 8  \n\n    Cardiac arrest\n\n2(1,762)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nTwo RCTs (with 0 and 2 events) did not detect differences in cardiac arrest for regional compared to general anesthesia.\nRD 2.3 per 1000 (95% CI, -2.2 to 6.7)\n\nTable: 13  \nFigure: 9  \n\n    Stroke\n\n6(6,504)\n\nRCT\n⨁⨁◯◯\n\nC-LD\n+\nThe pooled effects from 6 RCTs for stroke incidence (133 of 155 events from the GALA carotid endarterectomy trial) were compatible with neither regional or general anesthesia being favored.\nRR 0.93  (95% CI, 0.69–1.28; PI: 0.60–1.44) \nRD -1.7 per 1000 (95% CI, -6.2 to 2.7; PI: -8.0 to 4.6)\n\nTable: 13  \nFigures: 10, 11  \n\n    Renal\n\n4(2,247)\n\nRCT\n⨁⨁◯◯\n\nC-LD\n+++\nThe pooled relative effect from 4 RCTs for renal complications favored regional anesthesia, but was effectively obtained from a single trial.\nRR 0.59  (95% CI, 0.39–0.89; PI: 0.24–1.46) \nRD -11.8 per 1000 (95% CI, -28.5 to 4.9; PI: -71 to 48)\n\nTable: 13 \nFigure: 12, 13 \n\n    Pulmonary\n\n2(236)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nThe pooled effects from 2 RCTs were inconclusive with respect to the risk of pulmonary complications for regional compared to general anesthesia. \nRR 0.79  (95% CI, 0.27–2.27; fixed effects) \nRD -14.7 per 1000 (95% CI, -78 to 48)\n\nTable: 13  \nFigures: 14, 15  \n\n    Pneumonia\n\n8(3,588)\n\nRCT\n⨁⨁◯◯\n\nC-LD\n+++\nThe pooled effects from 8 RCTs suggested a lower relative, but not absolute, risk of pneumonia for regional compared with general anesthesia. Few events were observed. \nRR 0.49 (95% CI, 0.27–0.88; PI 0.22–1.08) \nRD per 1000 -3.8 (95% CI, -10.2 to 2.6; PI: -11.1 to 3.5)\n\nTable: 13  \nFigure: 16, 17  \n\n    Pulmonary edema/congestion\n\n1(1,576)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nA single RCT did not detect a difference in pulmonary congestion for regional compared to general anesthesia. \nRR 1.14 (95% CI, 0.44–2.94; ) \nRD per 1000 1.4 (95% CI, -8.8 to 11.6)\n\nTable: 13    RD per 1000 1 (-9 to 12)\n\n    Pulmonary embolism\n\n6(6,570)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nThe pooled effect from 6 RCTs (2 trials reported no events) was inconclusive with respect to pulmonary embolism for regional compared to general anesthesia. \nRR 0.56 (95% CI,0.27–1.16; PI: 0.16–2.0)\nRD -0.1 per 1000 (95% CI, -1.1 to 0.8; PI: -1.5 to 1.2)\n\nTable: 13  \nFigures: 18, 19  \n\n    Reintubation\n\n1(1,576)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nA single RCT did not detect a difference in post-operative reintubation for regional compared to general anesthesia. \nRR 0.58 (95% CI, 0.17–1.97) \nRD per 1000 -3.7 (95% CI, -11.9 to 4.5)\n\nTable: 13  \n\n    Patient satisfaction\n\n10(2,046)\n\nRCT\n⨁◯◯◯\n\nC-LD\n++\nThe pooled effect on patient satisfaction (comparing higher/highest category or categories compared with lower ones) from 10 RCTs was inconclusive for regional compared to general anesthesia. \nRR 1.02 (95% CI, 0.98–1.05; PI 0.98–1.06)\n\nTable: 14  \nFigure: 20  \n\n    Length of stay\n\n15(4,828)\n\nRCT\n⨁◯◯◯\n\nC-LD\n++\nThe pooled effect on length of stay from 14 RCTs was inconclusive for regional compared to general anesthesia.  RD -0.5 days (95% CI, -2.2 to 0.2; PI: -3.2 to 2.2)\n\nTable: 15  \nFigure: 21  \n\n    Discharge location\n\n1(1,554)\n\nRCT\n⨁◯◯◯\n\nC-LD\n++\nA single RCT did not detect a difference in discharge location between regional and general anesthesia.\n\nTable: 16  \n\n    Hospital & 30-day mortality\n\n8 RR(7,419)  10 RD(7,577)\n\nRCT\n⨁⨁◯◯\n\nC-LD\n+\nThe pooled risk ratio from 8 RCTs was inconclusive for hospital and 30-day mortality with regional compared to general anesthesia.  RR 0.68  (95% CI, 0.45–1.05; PI, 0.41–1.14) \nThe pooled risk difference from 10 RCTs was consistent with lower hospital and 30-day mortality for regional compared with general anesthesia.  RD -5.2 per 1000 (95% CI, -7.6 to -0.7; PI, -10.9 to 0.6)\n\nTable: 17  \nFigures: 22, 23  \n\n    90-day mortality\n\n3(868)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+\nThe pooled effects from 3 RCTs were inconclusive for 90-day mortality with regional compared to general anesthesia.  RR 0.99  (95% CI, 0.5, 1.94; PI: 0.01–78)  RD -4.1 per 1000 (95% CI, -16.4 to 8.2; PI: -84 to 76)\n\nTable: 18  \nFigure: 24, 25  \n\n  \n  \n  \n    \n       Pts: patients; RCT: randomized clinical trial; NRSI: non-randomized studies of interventions (inlcudes non-randomized trials, before-after/time series, and observational); GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; ACCF/AHA: American College of Cardiology Foundation/American Heart Association; RR: risk ratio; OR: odds ratio; MD: mean difference; RD: risk difference; PI: prediction interval.\n    \n    \n      1 Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      2 A: high-quality evidence from more than 1 RCT; B-R: moderate-quality evidence from more than 1 RCT; B-NR: moderate-quality evidence from more than one observational study; C-LD: randomized or non-randomized observational or registry studies with limited data; C-EO: consensus of expert opinion.\n    \n    \n      3 Limited +; Important ++; Critical +++.\n    \n  \n\n\n\n\n\nGRADE Domains\n Table 4. GRADE domains for strength of evidence ratings — regional versus general anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      Design\n      \n      \n        GRADE Domains\n      \n    \n    \n      Bias\n      Inconsistency\n      Indirectness\n      Imprecision\n      Other\n    \n  \n  \n    Delirium incidence\nRCT\n\nnot serious\n\nnot serious1\n\nnot serious\n\nserious2\n\nnot serious\n\n    Delayed neurocognitive recovery\nRCT\n\nserious3\n\nserious4\n\nnot serious\n\nserious5\n\nnot serious\n\n    Postoperative neurocognitive disorder\nRCT\n\nserious6\n\nvery serious7\n\nnot serious\n\nserious5\n\nnot serious\n\n    Physical function\nRCT\n\nserious8\n\nvery serious7\n\nnot serious\n\nvery serious9\n\nnot serious\n\n    Myocardial Infarction\nRCT\n\nnot serious\n\nserious10\n\nnot serious\n\nvery serious11\n\nnot serious\n\n    Cardiac arrest\nRCT\n\nnot serious\n\nserious12\n\nnot serious\n\nvery serious13\n\nnot serious\n\n    Stroke\nRCT\n\nnot serious\n\nserious14\n\nnot serious\n\nserious15\n\nserious16\n\n    Renal\nRCT\n\nnot serious\n\nserious17\n\nnot serious\n\nserious18\n\nserious16\n\n    Pulmonary\nRCT\n\nnot serious\n\nserious19\n\nnot serious\n\nvery serious20\n\nnot serious\n\n    Pneumonia\nRCT\n\nnot serious\n\nnot serious\n\nnot serious\n\nvery serious21\n\nserious\n\n    Pulmonary edema/congestion\nRCT\n\nnot serious\n\nvery serious7\n\nnot serious\n\nvery serious22\n\nnot serious\n\n    Pulmonary embolism\nRCT\n\nnot serious\n\nserious23\n\nnot serious\n\nvery serious22\n\nnot serious\n\n    Reintubation\nRCT\n\nnot serious\n\nvery serious7\n\nnot serious\n\nvery serious22\n\nnot serious\n\n    Patient satisfaction\nRCT\n\nvery serious24\n\nserious4\n\nnot serious\n\nserious25\n\nnot serious\n\n    Length of stay\nRCT\n\nvery serious26\n\nserious27\n\nnot serious\n\nserious25\n\nserious28\n\n    Discharge location\nRCT\n\nnot serious\n\nvery serious7\n\nnot serious\n\nserious\n\nnot serious\n\n    Hospital & 30-day mortality\nRCT\n\nnot serious29\n\nserious30\n\nnot serious\n\nserious31\n\nnot serious\n\n    90-day mortality\nRCT\n\nvery serious32\n\nserious4\n\nnot serious\n\nserious25\n\nnot serious\n\n  \n  \n  \n    \n       If not specified in footnotes, all references are to 95% confidence and prediction intervals.\n    \n    \n       RCT: randomized clinical trial; NRSI: non-randomized studies of interventions (inlcudes non-randomized trials, before-after/time series, and observational); RR: risk ratio; OR: odds ratio.\n    \n    \n       1 Variability across small studies with few events (note cumulative meta-analysis).2 Point estimate consistent with a null average treatment effect; confidence interval compatible with either regional or general anesthesia being favored.3 One study at  serious or risk of bias and one studies with some concerns.4 Wide variability in estimates across studies.5 Point estimate consistent with a null average treatment effect; confidence interval compatible with favoring either regional or general anesthesia.6 Confounding  bias present.7 Single study, cannot assess consistency.8 26% of study participants converted from regional  to general anesthesia.9 Single event.10 Wide prediction intervals for RR (0.36–3.83) and RD per 1000 (-2.4 to 6.2).11 Wide confidence interval for pooled estimates including the null and few events.12 Two studies, consistency difficult to assess.13 Only 2 events.14 Wide prediction intervals for RR (0.60–1.44) and RD‰ (-8.0 to 4.6).15 Confidence interval compatible with favoring either regional or general anesthesia (rated down 1 level in conjunction with consistency).16 Result are effectively obtained from a single study.17 Wide prediction intervals for RR (0.24–1.46) and RD‰ (-71 to 48).18 Confidence interval compatible with favoring either regional or general anesthesia; overall event rate low with respect to the RR (rated down 1 level in conjunction with consistency).19 Two studies, consistency difficult to assess but overlapping confidence intervals.20 Confidence interval compatible with favoring either regional or general anesthesia; events uncommon.21 Very few events.22 Confidence interval for pooled estimate compatible with favoring either regional or general anesthesia; very few events.23 Wide prediction interval (0.16–2.00).24 One study at  serious or risk of bias and six studies with some concerns.25 Confidence interval crossing the null.26 Two studies at  serious or risk of bias and four studies with some concerns.27 Wide prediction interval for MD (-3.2 to 2.2 days).28 Variations seen between countries; length of stay often skewed and pooled result required imputation of standard deviations for some studies.29 Two studies at serious or risk of bias and three studies with some concerns, but only one for missing outcome data.30 Wide prediction intervals for RR and RD.31 Confidence interval for pooled RR crosses the null, but tends to favor regional and the RD favors regional anesthesia. The number of events was substantially lower than to achieve the desireable information size.32 One study at  serious or risk of bias and two studies with some concerns."
  },
  {
    "objectID": "soe_gt.html#tiva-versus-inhaled",
    "href": "soe_gt.html#tiva-versus-inhaled",
    "title": "Strength of Evidence",
    "section": "TIVA versus Inhaled",
    "text": "TIVA versus Inhaled\n Table 5. Strength of evidence summaries — TIVA versus inhaled anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      Studies (Pts)\n      Study Design\n      GRADE1\n      ACCF AHA2\n      Importance3\n      Summary\n      Result Detail\n    \n  \n  \n    Delirium incidence\n\n5(393)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 5 RCTs did not detect a difference in postoperative delirium with TIVA compared with inhalation. RR  1.04 (95% CI, 0.40-2.7; I 2 = 35%)\n\nTable: 10  \nFigure: 1  \n\n    \n3(570,455)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 3 non-randomized studies did not detect a difference in postoperative delirium with TIVA compared with Inhalation. RR 0.61 (95% CI, 0.27-1.36; I 2 = 62%)\n\nTable: 10  \nFigure: 2  \n\n    Delayed neurocognitive recovery\n\n7(1,750)\n\nRCT\nLow\n\nC-LD\n+++\nPooled estimate from 7 RCTs suggested less delayed neurocognitive recovery (3-30 days postop) with TIVA compared with inhalation. RR  0.66 (95% CI, 0.47-0.94; I 2 = 28%)\n\nTables: 11  \nFigure: 3 \n\n    \n1(279)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+++\nA single study did not detect a difference in delayed neurocognitive recovery (3-30 days postop). RR  0.74 (95% CI, 0.44-1.24)\n\nTables: 11  \n\n    Postoperative neurocognitive disorder\n\n2(356)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+++\nTwo non-randomized studies did not detect a difference in neurocoginitve disorders\n\nTables: 12  \n\n    Composite cardiac events\n\n5(757)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 5 RCTs did not detect a difference in cardiac complications with TIVA compared with inhalation. OR 1.28 (95% CI, 0.63-2.58; I 2 = 32%)\n\nTable: 13  \nFigure: 5 \n\n    Myocardial Infarction\n\n5(583,652)\n\nRCT/NRSI\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 2 RCTs and 3 non-randomized studies suggest lower risk of myocardial infarction for TIVA compared with inhalation anesthesia. OR 0.90 (95% CI, 0.87-0.94; I 2 = 32%)\n\nTable: 13  \nFigure: 6 \n\n    Cardiac arrest\n\n1(2,576)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+++\nA single study did not detect a difference in cardiac arrest.\n\nTable: 13  \n\n    Stroke\n\n—\n\nNo studies\n\n\n+++\n\n\n    Pneumonia\n\n3(905)\n\nRCT\n⨁⨁◯◯\n\nC-LD\n+++\nPooled estimate from 3 RCTs did not detect a difference in pneumonia for TIVA compared with inhalation anesthesia. OR 0.72 (95% CI, 0.37-1.40; I 2 = 0%)\n\nTable: 13  \nFigure: 8 \n\n    Pulmonary edema/congestion\n\n2(572,836)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+++\nOne study did not detect a difference and a second reported no events.\n\nTable: 13  \nFigure: 4 \n\n    Pulmonary embolism\n\n3(573,004)\n\nRCT/NRSI\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from one RCT and two non-randomized studies suggest higher pulmonary embolism with TIVA compared with inhalation. OR 1.30 (95% CI, 1.09-1.54; I 2 = 0%)\n\nTable: 13  \nFigure: 4 \n\n    Respiratory failure\n\n2(570,453)\n\nRCT/NRSI\n⨁◯◯◯\n\nC-LD\n+++\nOne RCT and one non-randomized study suggested lower respiratory failure with TIVA compared with inhalation. OR 0.84 (95% CI, 0.76-0.94; I 2 = 0%)\n\nTable: 13  \nFigure: 4 \n\n    Acute kidney injury\n\n3(573,618)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from three non-randomized studies were not consistent with a difference in acute kidney injury with TIVA compared with inhalation anesthesia. OR 0.99 (95% CI, 0.91-1.08; I 2 = 5%)\n\nTable: 13  \nFigure: 7 \n\n    Hospital & 30-day mortality\n\n5(1,131)\n\nRCT\n⨁⨁◯◯\n\nC-LD\n+\nPooled estimate from five RCTs was inconclusive with respect to Hospital or 30-day mortality for TIVA compared with inhalation anesthesia. RR 1.16 (95% CI, 0.46-2.92; I 2 = 0%)\n\nTable: 14  \nFigure: 5 \n\n    \n5(583,973)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+\nPooled estimate from five non-randomized studies did not detect a difference in Hospital or 30-day mortality with TIVA compared with inhalation. RR 0.84 (95% CI, 0.28-2.51; I 2 = 84%).\n\nTable: 15  \nFigure: 6 \n\n    1-year mortality\n\n1(88)\n\nRCT\n\n\n++\n\n\n    Length of stay\n\n4(1,394)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+\nPooled estimate from four RCTs did not detect a difference in length of stay with TIVA compared with inhalation. Mean Difference 0.2 days (95% CI, -1.6-1.9; I 2 = 76%)\n\nTable: 16  \nFigure: 7 \n\n    \n3(580,656)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+\nPooled estimate from three non-randomized studies did not detect a difference in length of stay with TIVA compared with inhalation. Mean Difference -0.2 days (95% CI, -0.20-1.5; I 2 = 90%)\n\nTable: 16  \nFigure: 8 \n\n    Patient Satisfaction\n\n3(250)\n\nRCT\nLow\n\nC-LD\n+\nPooled estimate from three RCTs suggest higher patient satisfaction for TIVA compared with inhalation. RR 1.39 (95% CI, 1.19-1.63; I 2 = 0%)\n\nTable: 14  \nFigure: 5 \n\n  \n  \n  \n    \n       Pts: patients; RCT: randomized clinical trial; NRSI: non-randomized studies of interventions (inlcudes non-randomized trials, before-after/time series, and observational); GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; ACCF/AHA: American College of Cardiology Foundation/American Heart Association; RR: risk ratio; OR: odds ratio; MD: mean difference; RD: risk difference; PI: prediction interval.\n    \n    \n      1 Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      2 A: high-quality evidence from more than 1 RCT; B-R: moderate-quality evidence from more than 1 RCT; B-NR: moderate-quality evidence from more than one observational study; C-LD: randomized or non-randomized observational or registry studies with limited data; C-EO: consensus of expert opinion.\n    \n    \n      3 Limited +; Important ++; Critical +++.\n    \n  \n\n\n\n\n\nGRADE Domains\n Table 6. GRADE domains for strength of evidence ratings — TIVA versus inhaled anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      Design\n      \n      \n        GRADE Domains\n      \n    \n    \n      Bias\n      Inconsistency\n      Indirectness\n      Imprecision\n      Other\n    \n  \n  \n    Delirium incidence\nRCT\n\nvery serious1\n\nserious2\n\nnot serious\n\nserious3\n\nnot serious\n\n    \nNRSI\n\nnot serious\n\nnot serious\n\nnot serious\n\nserious4\n\nnot serious\n\n    Delayed neurocognitive recovery\nRCT\n\nserious5\n\nnot serious6\n\nnot serious\n\nserious3\n\nnot serious\n\n    \nNRSI\n\nserious7\n\nvery serious8\n\nnot serious\n\nserious3\n\nnot serious\n\n    Postoperative neurocognitive disorder\nNRSI\n\nserious9\n\nserious10\n\nnot serious\n\nserious11\n\nnot serious\n\n    Composite cardiac events\nRCT\n\nnot serious\n\nserious12\n\nnot serious\n\nvery serious13\n\nnot serious\n\n    Myocardial Infarction\nRCT/NRSI\n\nserious14\n\nnot serious\n\nnot serious\n\nnot serious\n\nnot serious\n\n    Cardiac arrest\nNRSI\n\nserious15\n\nvery serious8\n\nnot serious\n\nserious3\n\nnot serious\n\n    Pneumonia\nRCT\n\nnot serious\n\nnot serious\n\nnot serious\n\nvery serious13\n\nnot serious\n\n    Pulmonary edema/congestion\nNRSI\n\nserious9\n\nserious10\n\nnot serious\n\nserious16\n\nnot serious\n\n    Pulmonary embolism\nRCT/NRSI\n\nserious17\n\nnot serious\n\nnot serious\n\nnot serious\n\nnot serious\n\n    Respiratory failure\nRCT/NRSI\n\nserious18\n\nserious10\n\nnot serious\n\nnot serious\n\nnot serious\n\n    Acute kidney injury\nNRSI\n\nserious9\n\nnot serious\n\nnot serious\n\nnot serious\n\nnot serious\n\n    Hospital & 30-day mortality\nRCT\n\nnot serious\n\nserious19\n\nnot serious\n\nserious3\n\nnot serious\n\n    \nNRSI\n\nserious9\n\nserious20\n\nnot serious\n\nserious3\n\nnot serious\n\n    1-year mortality\nRCT\n\nserious21\n\nvery serious8\n\nNA\nNA\nNA\n    Length of stay\nRCT\n\nnot serious\n\nserious22\n\nnot serious\n\nserious3\n\nserious23\n\n    \nNRSI\n\nserious24\n\nserious25\n\nnot serious\n\nserious3\n\nserious26\n\n    Patient Satisfaction\nRCT\n\nserious27\n\nnot serious\n\nnot serious\n\nserious28\n\nserious29\n\n  \n  \n  \n    \n       If not specified in footnotes, all references are to 95% confidence and prediction intervals.\n    \n    \n       RCT: randomized clinical trial; NRSI: non-randomized studies of interventions (inlcudes non-randomized trials, before-after/time series, and observational); RR: risk ratio; OR: odds ratio.\n    \n    \n       1 Two studies at high risk of bias; two with some concerns.2 Wide prediction interval (0.06-16.95).3 Confidence interval compatible with wide range of effects.4 Two of the three studies have wide confidence intervals.5 One study at high risk of bias; one study with some concerns.6 Wide prediction interval (0.33-1.32).7 Confounding  bias present in study.8 Single study, cannot assess consistency.9 Confounding bias present in all studies.10 Two studies, cannot assess consistency.11 Confidence interval compatible with strong benefit or harm.12 Wide variability in estimates across studies.13 Wide confidence interval for pooled estimate compatible with benefit or harm.14 Confounding bias present in non-randomized studies.15 Confounding bias present in study.16 Low event rate.17 Confounding bias present in two studies.18 Confounding bias is present in one study.19 Wide prediction interval (0.28-4.85).20 Wide prediction interval (0.05-13.91).21 Counfounding bias present.22 Wide prediction interval (-7.5-7.8).23 Variations seen between Chinese and non-Chinese countries.24 Confounding  bias present in all studies.25 Wide prediction interval (-22.2-21.7).26 Variations seen between countries.27 All studies with some concern.28 Small total sample.29 Variable category comparisons."
  },
  {
    "objectID": "soe_gt.html#delirium-prophylaxis",
    "href": "soe_gt.html#delirium-prophylaxis",
    "title": "Strength of Evidence",
    "section": "Delirium Prophylaxis",
    "text": "Delirium Prophylaxis\n Table 7. GRADE domains for strength of evidence ratings — delirium prophylaxis. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      Studies (Pts)\n      Study Design\n      GRADE1\n      ACCF AHA2\n      Importance3\n      Summary\n      Result Detail\n    \n  \n  \n    \n      Dexmedetomidine vs. Placebo/None\n    \n    Delirium incidence\n\n23 (6243)\n\nRCT\n?\n\n?\n+++\nPooled estimate from 23 RCTs suggested less post-operative delirium with dexmedetomidine compared with placebo or no active comparator, but small study effects and inconsistency were apparent.  RR 0.62  (95% CI, 0.51–0.74; I 2 = 59%)\n\nTables: 8    11  \nFigures: 3 to 9  \n\n    Delayed neurocognitive recovery\n\n8 (960)\n\nRCT\n?\n\n?\n+++\nPooled estimate from 8 RCTs suggests less cognitive dysfunction assessed from postoperative day 3 to 30 with dexmedetomidine.\nRR 0.47 (95% CI, 0.31–0.71; I 2 = 19%)\n\nTable: 15  \nFigures: 18 to 21  \nand\n23  \n\n    Postoperative neurocognitive disorder\n\n2 (362)\n\nRCT\nLow\n\nC-LD\n+++\nTwo RCTs did not detect a difference in cognitive dysfunction &gt;30 days.\n\nTable: 18  \n\n    Cardiac complications\n\n19 (5125)\n\nRCT/NRSI\nLow\n\nC-LD\n+\nPooled estimate from 17 RCTs and 2 NRSI suggests less cardiac events with placebo compared with dexmedetomidine \nRR 1.39 (95% CI, 1.09–1.78; I 2 = 40%)\n\nTable: 19  \nFigure: 26 to 27  \n\n    Myocardial infarction\n\n4 (2320)\n\nRCT\nLow\n\nB-R\n+\nPooled estimate from 4 RCTs (two of which reported no events) did not detect a difference in MI with placebo compared with dexmedetomidine  \nRR 1.25 (95% CI, 0.30–5.21; I 2 = 0%)\n\nTable: 19  \nFigure: 26 to 27  \n\n    Cardiac arrest\n\n1 (299)\n\nRCT\nVery low\n\nC-LD\n+\nOne RCT did not detect a difference in cardiac arrest with placebo compared with dexmedetomidine \nRD 0.6 (95% CI, -1.6–2.9)\n\nTable: 19  \n\n    Stroke\n\n6 (2993)\n\nRCT\nLow\n\nB-R\n+\nPooled estimate from 6 RCTs (two of which reported no events) did not detect a difference in stroke with placebo compared with dexmedetomidine  \nRR 0.84 (95% CI, 0.33–2.15; I 2 = 0%)\n\nTable: 19  \nFigure: 26 to 27  \n\n    Acute kidney injury\n\n3 (1477)\n\nRCT\nLow\n\nC-LD\n+\nPooled estimate from 3 RCTs did not detect a difference in acute kidney injury with placebo compared with dexmedetomidine  \nRR 1.05 (95% CI, 0.69–1.59; I 2 = 20%)\n\nTable: 19  \nFigure: 26 to 27  \n\n    Pulmonary complications\n\n6 (1575)\n\nRCT\nLow\n\nC-LD\n+\nPooled estimate from 3 trials suggests lower risk for dexmedetomidine  compared with placebo. RR 0.54 (95% CI, 0.32–0.92)\n\nTable: 19  \nFigure: 26 to 27  \n\n    Pneumonia\n\n2 (861)\n\nRCT\nVery low\n\nC-LD\n+\nPooled estimate from 2 RCTs did not detect a difference in pneumonia with placebo compared with dexmedetomidine \nRR 0.65 (95% CI, 0.03–13.96; I 2 = 75%)\n\nTable: 19  \nFigure: 26 to 27  \n\n    Pulmonary congestion\n\n1 (304)\n\nRCT\nVery low\n\nC-LD\n+\nOne RCT did not detect a difference in pulmonary congestion with placebo compared with dexmedetomidine\n\nTable: 19  \nFigure: 26 to 27  \n\n    Pulmonary embolism\n\n2 (861)\n\nRCT\nVery low\n\nC-LD\n+\nPooled estimate from 2 RCTs did not detect a difference in pulmonary embolism with placebo compared with dexmedetomidine \nRR 1.65 (95% CI, 0.20–13.33; I 2 = 0%)\n\nTable: 19  \nFigure: 26 to 27  \n\n    Hospital & 30-day mortality\n\n9 (4016)\n\nRCT\n⨁◯◯◯\n\nB-R\n+\nPooled estimate from 9 RCTs did not detect a difference in mortality, in-hospital and 30-day, with placebo compared with dexmedetomidine \nRR 0.66 (95% CI, 0.34–1.29; I 2 = 0%)\n\nTable: 22  \nFigures: 32 and 33  \n\n    Length of stay\n\n14 (5196)\n\nRCT\nVery low\n\nB-R\n+++\nPooled estimate of 14 RCTs did not detect a difference in length of stay with placebo compared with dexmedetomidine \nMD -0.4 (95% CI, -0.9–0.2; I 2 = 96%)\n\nTable: 21  \nFigure: 29  \n\n    \n      Ketamine vs. Placebo\n    \n    Delirium incidence\n\n3 (821)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nMeta-analysis of 3 RCTs consistent with a a wide range of compatible RRs. \nRR 0.57 (95% CI, 0.18–1.82; I 2 = 56%)\n\nTable: 12 \nFigure: 10  \n\n    Delayed neurocognitive recovery\n\n3 (194)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 3 RCTs not consistent with an effect of ketamine.\nRR 0.82 (95% CI, 0.24–2.73; I 2 = 76%)\n\nTable: 16  \nFigures: 22 to 23  \n\n    Postoperative neurocognitive disorder\n\n—\nNo studies\n\n\n+++\n\n\n    Hospital & 30-day mortality\n\n—\nNo studies\n\n\n+\n\n\n    \n      Melatonin or Ramelteon vs. Placebo\n    \n    Delirium incidence\n\n10 (1428)\n\nRCT\n⨁⨁◯◯\n\nC-LD\n+++\nTO BE UPDATED Pooled estimate from  RCTs yielded a range of RRs compatible with no effect. \nRR 0.65 (95% CI, 0.42–1.01; I 2 = 57%)\n\nTables: 10    13  \nFigures: 11 and 12  \n\n    \n2 (388)\n\nBefore-After\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 2 before-after studies of ramelteon RR 0.37 (95% CI, 0.17–0.79).\n\nTables: 10    13  \nFigure: 13  \n\n    Delayed neurocognitive recovery\n\n—\nNo studies\n\n\n+\n\n\n    Postoperative neurocognitive disorder\n\n1 (298)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nA single trial reported a RR 0.85 (95% CI, 0.72–1.01).\n\nTable: 18  \n\n    Cardiac complications\n\n1 (82)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+++\nA single trial reported a RD 8.6 (95% CI, -17.8–0.6).\n\nTable: 20  \n\n    Pulmonary complications\n\n1 (306)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+++\nA single trial reported a RD 1.2 (95% CI, -2.6–5.0).\n\nTable: 20  \n\n    Pneumonia\n\n2 (388)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+++\nTwo NRSI studies did not detect a difference in pneumonia between ramelteon and placebo.\n\nTable: 20  \n\n    Hospital & 30-day mortality\n\n3 (792)\n\nRCT\n⨁⨁◯◯\n\nC-LD\n+\nThe pooled estimates for combined hospital and 30-day mortality is inconclusive.\nRR combined 0.87 (95% CI, 0.52–1.44; I 2 = 0%)\n\nTable: 23  \nFigure: 34  \n\n    Length of stay\n\n5 (1133)\n\nRCT\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate of 5 RCTs did not detect a difference in length of stay with placebo compared with melatonin/ramelteon \nMD 0.4 (95% CI, -0.8–1.6; I 2 = 77%)\n\nTable: 21  \nFigure: 30  \n\n  \n  \n  \n    \n       Pts: patients; RCT: randomized clinical trial; NRSI: non-randomized studies of interventions (inlcudes non-randomized trials, before-after/time series, and observational); GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; ACCF/AHA: American College of Cardiology Foundation/American Heart Association; RR: risk ratio; OR: odds ratio; MD: mean difference; RD: risk difference; PI: prediction interval.\n    \n    \n      1 Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      2 A: high-quality evidence from more than 1 RCT; B-R: moderate-quality evidence from more than 1 RCT; B-NR: moderate-quality evidence from more than one observational study; C-LD: randomized or non-randomized observational or registry studies with limited data; C-EO: consensus of expert opinion.\n    \n    \n      3 Limited +; Important ++; Critical +++.\n    \n  \n\n\n\n\n\nGRADE Domains\n Table 8. GRADE domains for strength of evidence rating for outcomes relevant to delirium prophylaxis. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      Design\n      \n      \n        GRADE Domains\n      \n    \n    \n      Bias\n      Inconsistency\n      Indirectness\n      Imprecision\n      Other\n    \n  \n  \n    \n      Dexmedetomidine vs. Placebo/None\n    \n    Delirium incidence\nRCT\n\nserious1\n\nserious2\n\nnot serious\n\nnot serious3\n\nserious4\n\n    Delayed neurocognitive recovery\nRCT\n\nnot serious\n\nnot serious5\n\nnot serious\n\nnot serious\n\nTBD6\n\n    Postoperative neurocognitive disorder\nRCT\n\nnot serious\n\nserious7\n\nnot serious\n\nserious8\n\nnot serious9\n\n    Cardiac complications\nNRSI\n\nserious10\n\nnot serious\n\nnot serious\n\nnot serious\n\nserious11\n\n    Myocardial infarction\nRCT\n\nnot serious\n\nserious12\n\nnot serious\n\nserious13\n\nnot serious\n\n    Cardiac arrest\nRCT\n\nnot serious\n\nvery serious14\n\nnot serious\n\nserious15\n\nNA\n    Stroke\nRCT\n\nnot serious\n\nserious16\n\nnot serious\n\nserious13\n\nnot serious\n\n    Acute kidney injury\nRCT\n\nnot serious\n\nserious17\n\nnot serious\n\nserious18\n\nnot serious\n\n    Pulmonary complications\nRCT\n\nnot serious\n\nnot serious\n\nnot serious\n\nvery serious19\n\nnot serious\n\n    Pneumonia\nRCT\n\nnot serious\n\nserious12\n\nnot serious\n\nvery serious20\n\nnot serious\n\n    Pulmonary congestion\nRCT\n\nnot serious\n\nvery serious14\n\nnot serious\n\nvery serious21\n\nnot serious\n\n    Pulmonary embolism\nRCT\n\nnot serious\n\nserious12\n\nnot serious\n\nvery serious20\n\nnot serious\n\n    Hospital & 30-day mortality\nRCT\n\nnot serious\n\nserious22\n\nnot serious23\n\nserious24\n\nserious25\n\n    Length of stay\nRCT\n\nnot serious\n\nvery serious26\n\nnot serious\n\nserious24\n\nserious27\n\n    \n      Ketamine vs. Placebo\n    \n    Delirium incidence\nRCT\n\nnot serious\n\nserious28\n\nnot serious\n\nvery serious29\n\nnot serious30\n\n    Delayed neurocognitive recovery\nRCT\n\nnot serious\n\nserious31\n\nnot serious23\n\nvery serious32\n\nnot serious30\n\n    \n      Melatonin or Ramelteon vs. Placebo\n    \n    Delirium incidence\nRCT\n\nnot serious\n\nserious33\n\nnot serious\n\nserious34\n\nserious25\n\n    Delirium incidence\nNRSI\n\nserious35\n\nnot serious\n\nnot serious\n\nserious36\n\nnot serious30\n\n    Postoperative neurocognitive disorder\nRCT\n\nnot serious\n\nvery serious14\n\nnot serious23\n\nserious37\n\nnot serious38\n\n    Cardiac complications\nNRSI\n\nserious39\n\nvery serious14\n\nnot serious\n\nserious29\n\nnot serious\n\n    Pulmonary complications\nNRSI\n\nserious39\n\nvery serious14\n\nnot serious\n\nserious29\n\nnot serious\n\n    Pneumonia\nNRSI\n\nserious40\n\nserious41\n\nnot serious\n\nserious29\n\nnot serious\n\n    Hospital & 30-day mortality\nRCT\n\nnot serious\n\nnot serious\n\nnot serious23\n\nvery serious42\n\nnot applicable30\n\n    Length of stay\nRCT\n\nnot serious\n\nserious43\n\nnot serious\n\nvery serious44\n\nserious27\n\n  \n  \n  \n    \n       If not specified in footnotes, all references are to 95% confidence and prediction intervals.\n    \n    \n       RCT: randomized clinical trial; NRSI: non-randomized studies of interventions (inlcudes non-randomized trials, before-after/time series, and observational); RR: risk ratio; OR: odds ratio.\n    \n    \n       1 Four trials judged high risk of bias and 5 with some concerns.2 Prediction interval for RR of (0.31–1.20); discrepancy between country-specfic results (stronger effects for studies conducted in China).3 In non-China subgroup confidence interval 0.23–2.52.4 Results consistent with the presence of small study effects and potential publication bias (Harbord test P = 0.003; funnel plot asymmetry; limit meta-analysis adusted OR 0.91 [95% CI, 0.61–1.38]).5 Prediction interval for pooled RR (0.24–0.92).6 Too few studies to examine small study effects, but funnel plot suggests potential small study effects. Six studies conducted in China, 1 Iran, and 1 Egypt.7 Two studies, cannot assess consistency.8 Wide confidence interval for pooled estimate compatible with benefit or harm.9 Different instruments used.10 Three studies at high risk of bias, two studies with some concerns.11 Variability in cardiac outcomes reported, mostly bradycardia and arrhythmia.12 Two RCTs with wide variability in ranges of plausible RR.13 Wide confidence interval for pooled estimate compatible with benefit or harm, two studies did not report any events.14 Single study, cannot assess consistency.15 Confidence interval crosses the null.16 All RCTs with wide variability in ranges of plausible RR.17 Variability in plausible RR.18 Wide confidence interval for pooled estimate compatible with benefit or harm,one study reported low number of events.19 Three studies with variable control arm event rates; 2 studies no events.20 Wide confidence interval for pooled estimate compatible with benefit or harm,both studies reported low number of events.21 Wide confidence interval compatible with benefit or harm, one event reported.22 Few events with widely variable effect estimates.23 Causal pathway presumes impact on delirium.24 Wide confidence interval compatible with benefit or harm.25 Results consistent with possible small study effects (potential for publication bias).26 Prediction interval for pooled MD (-2.6–1.8) (I 2 = 96%).27 Heterogeneity in types of procedure and country.28 Three RCTs with wide variability in ranges of plausible RR.29 Sparse data; confidence interval compatible with both strong benefit or harm.30 Insufficient number of studies to examine small study effects (potential for publication bias).31 Few studies with widely variable effect estimates (I 2 = 76%).32 Wide confidence interval for pooled estimate compatible with benefit or harm precludes any conclusions.33 Wide prediction interval  for RR — (0.22–1.94).34 Confidence interval compatible wide range of effects (downgraded 1 level in combination with consistency).35 One study at  serious or risk of bias.36 Wide confidence interval for pooled effect and sparse data.37 Confidence interval compatible includes no effect.38 Single study.39 Confounding bias present.40 Confounding bias present in all studies.41 Two NRSIs with wide variability in ranges of plausible RR.42 Exceedingly wide confidence interval for pooled estimate preclude any conclusions.43 Few studies with widely variable effect estimates (I 2 = 77%).44 Wide prediction interval for pooled estimate compatible with benefit or harm precludes any conclusions."
  },
  {
    "objectID": "soe_gt.html#grade",
    "href": "soe_gt.html#grade",
    "title": "Strength of Evidence",
    "section": "GRADE",
    "text": "GRADE\n   High — We are very confident that the true effect lies close to that of the estimate of the effect.\nModerate — We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.\nLow — Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.\nVery Low — We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.\n\n\nDomains (downgrade)\n\nBias — Systematic error (eg, selection bias, confounding bias, measurement bias).\nInconsistency — Unexplained heterogeneity of results; studies find effect estimates that differ widely.\nImprecision — The range of plausible effects estimated from relevant studies.\nIndirectness — Direct evidence consists of research that directly compares the interventions which we are interested in, delivered to the populations in which we are interested, and measures the outcomes important to patients.\nOther (eg, publication bias) — Selective publication or reporting of results (typically of positive results).\n\n\nDomains (upgrade)\nEffect Size — Large effect size (eg, risk ratio &gt;2 or &lt;0.5).\nDose-response — When relevant exposure categories.\nPlausible Residual Confounding — When unaccounted residual confounding would increase the effect magnitude."
  },
  {
    "objectID": "soe_gt.html#accfaha",
    "href": "soe_gt.html#accfaha",
    "title": "Strength of Evidence",
    "section": "ACCF/AHA",
    "text": "ACCF/AHA\n\nLevel A — High-quality evidence from more than 1 RCTs. Meta-analyses of high-quality RCTs. One or more RCTs corroborated by high-quality registry studies.\nLevel B-R — Moderate-quality evidence from 1 or more randomized controlled trials. Meta-analyses of moderate-quality RCTs.\nLevel B-NR — Moderate-quality evidence from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies. Meta-analyses of such studies.\nLevel C-LD — Randomized or nonrandomized observational or registry studies with limitations of design or execution. Meta-analyses of such studies. Physiological or mechanistic studies in human subjects.\nLevel C-EO — Consensus of expert opinion based on clinical experience when evidence is insufficient, vague, or conflicting.\n\n RCT: randomized controlled trial; NR: nonrandomized; LD: limited data; EO: expert opinion"
  },
  {
    "objectID": "workflow.html",
    "href": "workflow.html",
    "title": "Geriatrics Workflow",
    "section": "",
    "text": "Workflow\n\n\n\n\n\nflowchart LR\nR[Data Import&lt;br/&gt;readfiles] --&gt; study_char[study_char_dat]\nstudy_char --&gt; char_munge[link refs&lt;br/&gt;AuYYYYletter]\nR --&gt; DI[Data import] --&gt; Annot[Annotate data&lt;br&gt;&lt;br&gt;View data dictionary&lt;br&gt;to assist coding]\nR --&gt; Do[Data overview] --&gt; F[Observation filtration&lt;br&gt;Missing data patterns&lt;br&gt;Data about data]\nR --&gt; P[Data processing] --&gt; DP[Recode&lt;br&gt;Transform&lt;br&gt;Reshape&lt;br&gt;Merge&lt;br&gt;Aggregate&lt;br&gt;Manipulate]\nR --&gt; Des[Descriptive statistics&lt;br&gt;Univariate or simple&lt;br&gt;stratification]\nR --&gt; An[Analysis&lt;br&gt;Stay close to data] --&gt; DA[Descriptive&lt;br&gt;&lt;br&gt;Avoid tables by using&lt;br&gt;nonparametric smoothers] & FA[Formal]\nR --&gt; CP[Caching&lt;br&gt;Parallel computing&lt;br&gt;Simulation]\n\n\n\n\n\n\n\n\n\n\nflowchart LR\nR[summaries] --&gt; mn_med[means/medians&lt;br/&gt;table_mn_med&lt;br/&gt;pre_mmse&lt;br/&gt;mmse times&lt;br/&gt;moca]\nR --&gt; age_mn_med[table_age_mn_med]\nR --&gt; surgs[surgery] --&gt; surgs_vars[surgs &lt;br/&gt;surgs_single ]\n\n\n\n\n\n\n\n\n\n\nflowchart LR\nR[dichot_dat] --&gt; dncr_dat[dncr_dat&lt;br&gt;up to 30 days]\ndncr_dat --&gt; neurocog_meta_dat[neurocog_meta_dat&lt;br/&gt;for later pooling]\n\nR[dichot_dat] --&gt; ncd_dat[ncd_dat&lt;br/&gt; &gt; 30 days]"
  },
  {
    "objectID": "kq4.html",
    "href": "kq4.html",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "",
    "text": "Among older patients undergoing surgery with general anesthesia, does the use of intravenous agents for maintenance of anesthesia improve postoperative outcomes compared with inhaled agents?"
  },
  {
    "objectID": "kq4.html#key-question",
    "href": "kq4.html#key-question",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "",
    "text": "Among older patients undergoing surgery with general anesthesia, does the use of intravenous agents for maintenance of anesthesia improve postoperative outcomes compared with inhaled agents?"
  },
  {
    "objectID": "kq4.html#outcome-importance",
    "href": "kq4.html#outcome-importance",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Outcome Importance",
    "text": "Outcome Importance\n Table 1. Rankings of the 5 most important outcomes (11 respondents)."
  },
  {
    "objectID": "kq4.html#outcomes-reported",
    "href": "kq4.html#outcomes-reported",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Outcomes Reported",
    "text": "Outcomes Reported\n Table 2. Dichotomous or count outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 27\n      NR Trial, N = 1\n      Prosp Coh, N = 3\n      Retro Coh, N = 9\n    \n  \n  \n    ADL\n—\n—\n—\n—\n    Complications\n9 (33%)\n1 (100%)\n—\n8 (89%)\n    DNCR/PND\n9 (33%)\n1 (100%)\n2 (67%)\n—\n    Delirium\n6 (22%)\n—\n1 (33%)\n2 (22%)\n    Delirium duration\n—\n—\n—\n—\n    Discharge location\n—\n—\n—\n—\n    Mortality\n5 (19%)\n—\n—\n5 (56%)\n    Opioid use\n1 (3.7%)\n—\n—\n—\n    Pain\n1 (3.7%)\n—\n—\n—\n    QoR\n—\n—\n—\n—\n    Readmission\n1 (3.7%)\n—\n—\n—\n    Satisfaction\n3 (11%)\n—\n—\n—\n  \n  \n  \n    \n       ADL: activities of daily living; NCR: neurocognitive recovery; POCD: postoperative neurocognitive disorder; QoR: quality of recovery; RCT: randomized clinical trial; NR Trial: non-randomized trial; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort.\n    \n  \n\n\n\n\n Table 3. Continuous outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 27\n      NR Trial, N = 1\n      Prosp Coh, N = 3\n      Retro Coh, N = 9\n    \n  \n  \n    Delirium duration\n—\n—\n—\n—\n    Length of stay\n5 (19%)\n—\n—\n3 (33%)\n    Opioid use\n2 (7.4%)\n—\n—\n—\n  \n  \n  \n    \n       RCT: randomized clinical trial; NR Trial: non-randomized trial; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort.\n    \n  \n\n\n\n\n Table 4. Likert or ordinal outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 27\n      NR Trial, N = 1\n      Prosp Coh, N = 3\n      Retro Coh, N = 9\n    \n  \n  \n    ADL\n—\n—\n—\n—\n    DNCR/PNCD\n12 (44%)\n1 (100%)\n—\n—\n    Delirium\n2 (7.4%)\n—\n—\n—\n    Complications\n—\n—\n—\n—\n    Pain\n4 (15%)\n—\n—\n—\n    Quality of life\n—\n—\n—\n—\n    QoR\n—\n—\n—\n—\n    Satisfaction\n—\n—\n—\n—\n  \n  \n  \n    \n       ADL: activities of daily living; NCR: neurocognitive recovery; POCD: postoperative neurocognitive disorder; QoR: quality of recovery; RCT: randomized clinical trial; NR Trial: non-randomized trial; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort."
  },
  {
    "objectID": "kq4.html#included-studies",
    "href": "kq4.html#included-studies",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Included Studies",
    "text": "Included Studies\n Table 5. Number of studies by design. \n\n\n\n\n\n\n  \n    \n    \n  \n  \n    \n    \n      Design\n      Studies\n    \n  \n  \n    Randomized Clinical Trial\n27\n    Nonrandomized Trial\n1\n    Prospective Cohort\n3\n    Retrospective Cohort\n9\n    Total\n40\n  \n  \n  \n\n\n\n\n\nDesign, centers, country, and surgery\n Table 6. Study design, enrollment, centers, country, and surgery (see References for citations). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      ID\n      Study\n      Centers\n      Enrolled\n      Countrya\n      Surgery\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    15440\nFazel 2017\n\n1\n60\nIrana\nGI/Abdominal\n    11652\nForsmo 2016\n\n1\n653\nNorway\nGI/Abdominal\n    16559\nGeng 2017\n\n1\n150\nChinaa\nGI/Abdominal\n    16572\nIshii 2016\n\n1\n59\nJapan\nGI/Abdominal\n    17\nLi 2021a\n\n4\n544\nChinaa\nGI/Abdominal\n    385\nNishikawa 2004\n\n1\n50\nJapan\nGI/Abdominal\n    331\nNishikawa 2007a\n\n1\n30\nJapan\nGI/Abdominal\n    16622\nTang 2014\n\n1\n220\nChinaa\nGI/Abdominal\n    13719\nOzer 2017\n\n1\n88\nTurkey\nCardiac\n    285\nTanaka 2017\n\n1\n100\nUSA\nOrtho\n    16557\nEpple 2001\n\n1\n124\nGermany\nOphtho\n    16587\nLuntz 2004\n\n1\n96\nGermany\nOphtho\n    16556\nEgawa 2016\n\n1\n148\nJapan\nThoracic\n    150\nQin 2019\n\n1\n104\nChinaa\nThoracic\n    10\nZhang 2018a\n\n1\n392\nChinaa\nThoracic\n    5915\nJellish 2003\n\n1\n60\nUSA\nHeadneck\n    16726\nLiang 2022\n\n1\n224\nChinaa\nSpine\n    16547\nCelik 2011\n\n1\n100\nTurkey\nUrol\n    534\nCai 2012\n\n1\n2216\nChinaa\nVariousb\n    17101\nCao 2023\n\n14\n1228\nChinaa\nVariousb\n    6506\nDai 2021\n\n1\n164\nChinaa\nVariousb\n    9011\nDing 2021\n\n1\n180\nChinaa\n — \n    447\nLindholm 2013\n\n1\n231\nNorway\n — \n    4033\nQiao 2015\n\n1\n90\nChinaa\n — \n    16931\nQiao 2023\n\n1\n69\nChinaa\n — \n    2794\nRohan 2005\n\n1\n45\nIreland\n — \n    376\nZangrillo 2011\n\n1\n153\nItaly\n — \n    \n      Nonrandomized Trial\n    \n    13116\nZhou 2021\n\n1\n265\nChinaa\nThoracic\n    \n      Prospective Cohort\n    \n    22\nKonishi 2018\n\n1\n300\nJapan\nOrtho\n    17080\nDeiner 2014\n\n1\n76\nUSA\nGeneral|Spine|Thoracic|Urol\n    155\nDeiner 2015\n\n1\n105\nUSA\nGeneral|Thoracic|Urol\n    \n      Retrospective Cohort\n    \n    15331\nKoo 2016\n\n1\n1934\nSouth Africa\nGI/Abdominal\n    14821\nShimizu 2010\n\n1\n265\nJapan\nGI/Abdominal\n    332\nGoins 2018\n\n1\n116\nUSA\nCardiac\n    234\nJakobsen 2007\n\n3\n10535\nDenmark\nCardiac\n    383\nKishimoto 2018\n\n — \n21899\nJapan\nOrtho\n    132\nOh 2019\n\n1\n3084\nSouth Korea\nThoracic\n    6964\nCho 2021\n\n1\n3045\nSouth Korea\nVariousb\n    1134\nPark 2020\n\n1\n1254\nSouth Korea\nVariousb\n    16890\nYoshimura 2022\n\n1730\n738600\nJapan\nVariousb\n  \n  \n  \n    \n       GI: gastrointestinal; Ortho: orthopedic; Ent: ear, nose, and throat; Neuro: neurological; Oralmax: oral maxillofacial; Vasc: vascular.\n    \n    \n      a Non very-high Human Development Index country.\n    \n    \n      b Described as various or more than 4 different types of surgery.\n    \n  \n\n\n\n\n\n\nCountry Summary\n Table 7. Summary of studies by country where conducted. \n\n\n\n\n\n\n  \n    \n    \n      \n      N = 40a\n    \n  \n  \n    Country\n\n        China\n13 (33%)\n        Japan\n8 (20%)\n        USA\n5 (13%)\n        South Korea\n3 (7.5%)\n        Germany\n2 (5.0%)\n        Norway\n2 (5.0%)\n        Turkey\n2 (5.0%)\n        Denmark\n1 (2.5%)\n        Iran\n1 (2.5%)\n        Ireland\n1 (2.5%)\n        Italy\n1 (2.5%)\n        South Africa\n1 (2.5%)\n  \n  \n  \n    \n      a n (%)"
  },
  {
    "objectID": "kq4.html#comparators",
    "href": "kq4.html#comparators",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Comparators",
    "text": "Comparators\n\nRandomized\n Table 8. Selected characteristics of randomized clinical trials comparing TIVA with inhaled maintenance anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N \n      Comparator\n      \n        ASA\n      \n          Agea\n      MMSEa\n      \n        Inhaled\n      \n      \n        TIVA\n      \n    \n    \n      PS\n      Des\n      Iso\n      Sev\n      Oth\n      Fen\n      Pro\n      Rem\n      Oth\n    \n  \n  \n    \n      Gastrointestinal/Abdominal\n    \n    Nishikawa 2004\n\n25\nInhaled\n12  \n71.0 (7.0)\n\n\n\n\n✓\n\n\n\n\n\n    \n25\nTIVA\n12  \n71.0 (8.0)\n\n\n\n\n\n\n\n●\n\n\n    Nishikawa 2007a\n\n15\nInhaled\n12  \n70.9 (6.5)\n\n\n\n\n✓\n\n\n\n\n\n    \n15\nTIVA\n12  \n71.2 (5.3)\n\n\n\n\n\n\n\n\n\n●b\n    Tang 2014\n\n99\nInhaled\nNR\n70.0 (4.3)\n\n25.0 (1.7)\n\n\n\n✓\n\n○\n\n\n\n    \n101\nTIVA\nNR\n69.6 (4.8)\n\n24.6 (1.7)\n\n\n\n\n\n\n●\n\n\n    Forsmo 2016\n\n153\nInhaled\n123 \n66.0 [19-93]\n\n\n\n✓c\n✓c\n\n○\n○\n\n\n    \n154\nTIVA\n123 \n65.0 [23-89]\n\n\n\n\n\n\n\n●\n●\n\n    Ishii 2016\n\n30\nInhaled\nNR\n76.5 (4.5)\n\n\n\n\n✓\n\n\n\n\n\n    \n29\nTIVA\nNR\n77.3 (4.6)\n\n\n\n\n\n\n\n●\n\n\n    Fazel 2017\n\n30\nInhaled\nNR\n71.0 (2.6)\n\n27.3 (1.9)\n\n\n\n✓\n\n\n\n\n\n    \n30\nTIVA\nNR\n73.0 (3.2)\n\n27.2 (2.4)\n\n\n\n\n\n\n●\n\n\n    Geng 2017\n\n50\nInhaled\n 23 \n\n28.9 (1.4)\n\n\n\n✓\n\n\n\n\n\n    \n50\nInhaled\n 23 \n\n29.4 (1.9)\n\n\n✓\n\n\n\n\n\n\n    \n50\nTIVA\n 23 \n\n29.2 (1.5)\n\n\n\n\n\n\n●\n\n\n    Li 2021a\n\n272\nInhaled\nNR\n65.0 {62-69}\n\n29 {28-30}\n\n\n\n✓\n\n\n\n○\n\n    \n272\nTIVA\nNR\n64.0 {62-68}\n\n29 {28-30}\n\n\n\n\n\n\n●\n●\n\n    \n      Various\n    \n    Ding 2021\n\n90\nInhaled\n12  \n71.3 (5.6)\n\n27.0 (2.7)\n\n\n\n✓\n\n\n\n\n\n    \n90\nTIVA\n12  \n70.2 (4.3)\n\n26.0 (2.5)\n\n\n\n\n\n\n●\n\n\n    Rohan 2005\n\n15\nInhaled\nNR\n73.8 [67-86]\n\n28.0 [25-30]\n\n\n\n✓\n\n○\n\n\n\n    \n15\nTIVA\nNR\n72.9 [65-83]\n\n27.0 [25-30]\n\n\n\n\n\n●\n●\n\n\n    Zangrillo 2011\n\n44\nInhaled\n1234\n65.0 (11.8)\n\n\n\n\n✓\n\n○\n\n\n\n    \n44\nTIVA\n1234\n64.0 (12.2)\n\n\n\n\n\n\n\n●\n\n\n    Cai 2012\n\n1000\nInhaled\nNR\n69.3 (5.1)\n\n27.4 (1.1)\n\n\n✓\n\n\n○\n○\n\n\n    \n1000\nTIVA\nNR\n71.2 (3.8)\n\n27.2 (1.1)\n\n\n\n\n\n●\n●\n\n\n    Dai 2021\n\n81\nInhaled\n 234\n72.0 (7.0)\n\n\n\n\n✓\n\n\n\n\n\n    \n83\nTIVA\n 234\n73.0 (8.0)\n\n\n\n\n\n\n\n●\n●\n\n    Cao 2023\n\n597\nInhaled\n123 \n71.0 [65-88]\n\n28 {26-30}\n\n\n\n✓\n\n\n\n\n\n    \n598\nTIVA\n123 \n72.0 [65-88]\n\n28 {26-30}\n\n\n\n\n\n\n●\n\n\n    \n      Thoracic\n    \n    Egawa 2016\n\n72\nInhaled\n123 \n72.0 {63-72}\n\n30 {28-30}\n\n\n\n✓\n\n\n\n\n\n    \n72\nTIVA\n123 \n69.0 {63-73}\n\n30 {29-30}\n\n\n\n\n\n\n●\n\n\n    Zhang 2018a\n\n190\nInhaled\n123 \n72.4 (5.6)\n\n28.3 (1.7)\n\n\n\n✓\n\n\n\n\n\n    \n189\nTIVA\n123 \n72.8 (5.5)\n\n28.2 (1.7)\n\n\n\n\n\n\n●\n\n\n    Qin 2019\n\n52\nInhaled\nNR\n\n28.6 (1.0)\n\n\n\n✓\n\n\n\n\n\n    \n52\nTIVA\nNR\n\n28.8 (1.0)\n\n\n\n\n\n\n●\n\n\n    \n      Ophthalmologic\n    \n    Epple 2001\n\n62\nInhaled\n123 \n76.0 (6.0)\n\n\n\n✓\n\n✓\n○\n\n\n\n    \n62\nTIVA\n123 \n77.0 (6.0)\n\n\n\n\n\n\n\n●\n●\n\n    Luntz 2004\n\n32\nInhaled\n123 \n77.0 (7.0)\n\n\n\n\n✓d\n\n\n\n\n\n    \n32\nInhaled\n123 \n76.0 (6.0)\n\n\n\n\n✓\n\n\n○\n\n\n    \n32\nTIVA\n123 \n74.0 (7.0)\n\n\n\n\n\n\n\n●\n\n\n    \n      Otolaryngological\n    \n    Qiao 2015\n\n30\nInhaled\nNR\n68.0 (3.0)\n\n27.8 (1.8)\n\n\n\n✓\n\n\n\n\n\n    \n30\nTIVA\nNR\n68.0 (2.0)\n\n28.6 (1.1)\n\n\n\n\n\n\n●\n\n\n    Qiao 2023\n\n31\nInhaled\n12  \n66.7 (7.2)\n\n27 {26-29}\n\n✓\n\n\n\n\n\n○\n\n    \n32\nTIVA\n12  \n63.9 (5.3)\n\n28 {26-28}\n\n\n\n\n\n\n●\n●\n\n    \n      Orthopedic\n    \n    Tanaka 2017\n\n45\nInhaled\n123 \n69.8 (4.3)\n\n\n✓\n\n\n\n○\n○\n\n\n    \n45\nTIVA\n123 \n70.6 (5.0)\n\n\n\n\n\n\n\n●\n\n\n    \n      Cardiac\n    \n    Ozer 2017\n\n40\nInhaled\nNR\n69.0 (3.0)\n\n28.7 (1.3)\n\n\n✓\n\n\n○\n\n\n\n    \n40\nTIVA\nNR\n66.0 (4.0)\n\n28.8 (1.3)\n\n\n\n\n\n\n●\n●\n\n    \n      Urologic\n    \n    Celik 2011\n\n50\nInhaled\n123 \n69.8 (3.9)\n\n\n\n\n✓\n\n\n\n○\n\n    \n50\nTIVA\n123 \n69.2 (4.8)\n\n\n\n\n\n\n\n●\n●\n\n    \n      Head & Neck\n    \n    Jellish 2003\n\n29\nInhaled\n  3 \n69.2 (1.7)\n\n\n\n✓\n\n\n○\n○\n\n\n    \n30\nTIVA\n  3 \n72.1 (1.5)\n\n\n\n\n\n\n\n●\n●\n\n    \n      Vascular\n    \n    Lindholm 2013\n\n97\nInhaled\n 234\n69.0 (9.0)\n\n\n\n\n✓\n\n○\n\n\n\n    \n96\nTIVA\n 234\n67.0 (9.0)\n\n\n\n\n\n\n\n●\n●\n\n    \n      Spine\n    \n    Liang 2022\n\n70\nInhaled\n 23 \n70.1 (3.5)\n\n\n\n\n✓\n\n\n\n\n\n    \n70\nTIVA\n 23 \n69.5 (3.3)\n\n\n\n\n\n\n\n●\n\n\n  \n  \n  \n    \n       TIVA: total intravenous anesthesia; NR: not reported; ASA PS: ASA Physical Status; MMSE: Mini-Mental State Exam; Des: desflurane; Hal: halothane; Iso: isoflurane; Sev: sevoflurane; Fen: fentanyl; Pro: propofol; Rem: remifentanil; Oth: other.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Thimylal\n    \n    \n      c Induction with sevoflurane; either inhalant used.\n    \n    \n      d Induction with sevoflurane.\n    \n  \n\n\n\n\n\n\nNonrandomized\n Table 9. Selected characteristics of nonrandomized studies comparing TIVA with inhaled maintenance anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N \n      Comparator\n      \n        ASA\n      \n          Agea\n      MMSEa\n      \n        Inhaled\n      \n      \n        TIVA\n      \n    \n    \n      PS\n      Des\n      Iso\n      Sev\n      Fen\n      Pro\n      Rem\n      Suf\n    \n  \n  \n    \n      Cardiac - Retrospective Cohort\n    \n    Jakobsen 2007\n\n5,325\nInhaled\nNR\n64.9\n\n\n\n\n✓\n\n\n\n\n    \n5,210\nTIVA\nNR\n64.7\n\n\n\n\n\n\n●\n\n●\n    Goins 2018\n\n32\nInhaled\nNR\n78.3 (9.0)\n\n\n✓b\n✓\nb\n\n\n○\n\n    \n84\nTIVA\nNR\n79.6 (8.7)\n\n\n\n\n\n\n●\n●\n\n    \n      Various - Retrospective Cohort\n    \n    Park 2020\n\n386\nInhaled\n1234\n65.5 (14.8)\n\n\nc\nc\nc\n\n\n\n\n    \n100\nTIVA\n1234\n65.6 (14.9)\n\n\n\n\n\n\n●\n●\n\n    Cho 2021\n\n1,202\nInhaled\n  34\n62.7 (13.7)\n\n\n✓b\n\n✓b\n\n\n\n\n    \n1,374\nTIVA\n  34\n65.6 (12.8)\n\n\n\n\n\n\n●\n●\n\n    Yoshimura 2022\n\n427,695\nInhaled\nNR\n\n\n✓d\n✓d\n✓d\n\n\n\n\n    \n142,565\nTIVA\nNR\n\n\n\n\n\n\n●\n\n\n    \n      GI/Abdominal - Retrospective Cohort\n    \n    Shimizu 2010\n\n84\nInhaled\n123 \n67.9 (13.6)\n\n\n\n\n✓\n\n\n\n\n    \n84\nTIVA\n123 \n68.1 (14.0)\n\n\n\n\n\n\n●\n\n\n    Koo 2016\n\n390\nInhaled\n1234\n61.7 (13.4)\n\n\n✓b\n\n✓b\n\n\n\n\n    \n390\nTIVA\n1234\n61.5 (12.4)\n\n\n\n\n\n\n●\n●\n\n    \n      General|Spine|Thoracic|Urol - Prospective Cohort\n    \n    Deiner 2014\n\n36\nInhaled\n1234\n76.3 (5.8)\n\n27 {26-30}\n\n\n\n✓\n\n\n\n\n    \n40\nTIVA\n1234\n73.5 (5.0)\n\n29 {28-30}\n\n\n\n\n\n●\n\n\n    \n      General|Thoracic|Urol - Prospective Cohort\n    \n    Deiner 2015\n\n34\nInhaled\nNR\n73.8\n\n\n\n\n✓\n\n\n\n\n    \n43\nTIVA\nNR\n73.8\n\n\n\n\n\n\n●\n\n\n    \n      Ortho - Prospective Cohort\n    \n    Konishi 2018\n\n121\nInhaled\nNR\n69.9 (6.3)\n\n28.1 (1.2)\n\n\n\n✓\n\n\n\n\n    \n171\nTIVA\nNR\n70.1 (6.7)\n\n28.2 (1.3)\n\n\n\n\n\n●\n\n\n    \n      Ortho - Retrospective Cohort\n    \n    Kishimoto 2018\n\n5,140\nInhaled\nNR\n74.4 (7.4)\n\n\n\n\n✓\n\n\n\n\n    \n5,140\nTIVA\nNR\n74.5 (7.2)\n\n\n\n\n\n\n●\n\n\n    \n      Thoracic - Retrospective Cohort\n    \n    Oh 2019\n\n1,477\nInhaled\n123 \n65.0 (10.4)\n\n\n\n\n✓\n\n○\n○\n\n    \n1,395\nTIVA\n123 \n65.0 (10.0)\n\n\n\n\n\n\n●\n●\n\n    \n      Thoracic - Nonrandomized Trial\n    \n    Zhou 2021\n\n116\nInhaled\n12  \n63.4 (17.1)\n\n25.9 (1.2)\n\n\n\n✓\n\n\n\n\n    \n149\nTIVA\n12  \n67.2 (15.1)\n\n26.1 (1.4)\n\n\n\n\n\n●\n\n\n  \n  \n  \n    \n       TIVA: total intravenous anesthesia; NR: not reported; ASA PS: ASA Physical Status; MMSE: Mini-Mental State Exam; Des: desflurane; Iso: isoflurane; Sev: sevoflurane; Fen: fentanyl; Pro: propofol; Rem: remifentanil; Suf: sufentanil.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Either of the two inhalent agents used.\n    \n    \n      c Agent used not specified.\n    \n    \n      d Any agent used."
  },
  {
    "objectID": "kq4.html#delirium-incidence",
    "href": "kq4.html#delirium-incidence",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Delirium Incidence",
    "text": "Delirium Incidence\n Table 10. Delirium incidence and days of ascertainment during hospitalization in randomized clinical trials comparing TIVA with inhaled anesthetics. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR OR (95% CI)\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      GI/Abd – Randomized Clinical Trial\n    \n    Nishikawa 2004\n\n25\nInhaled\nDRS\n3\n     0 (0.0)\n\n\n\n    \n25\nTIVA\n\n\n     4 (16.0)\n\n\n\n    Nishikawa 2007a\n\n15\nInhaled\nDRS\n3\n     2 (13.3)\n\n\n—\n\n    \n15\nTIVA\n\n\n     3 (20.0)\n\n\n1.50 (0.29-7.73)\n\n    Ishii 2016\n\n30\nInhaled\nCAM\nStay\n     8 (26.7)\n\n\n—\n\n    \n29\nTIVA\n\n\n     2 (6.9)\n\n\n0.26 (0.06-1.12)\n\n    \n      Ortho – Randomized Clinical Trial\n    \n    Tanaka 2017\n\n45\nInhaled\nCAM\n2\n     0 (0.0)\n\n\n\n    \n45\nTIVA\n\n\n     1 (2.2)\n\n\n\n    \n      Various – Randomized Clinical Trial\n    \n    Dai 2021\n\n81\nInhaled\nNS\nStay\n    36 (44.4)\n\n\n—\n\n    \n83\nTIVA\n\n\n    35 (42.2)\n\n\n0.95 (0.67-1.35)\n\n    Cao 2023\n\n597\nInhaled\nCAM\n7\n    74 (12.4)\n\n\n—\n\n    \n598\nTIVA\n\n\n    50 (8.4)\n\n\n0.67 (0.48-0.95)\n\n    \n      Cardiac – Retrospective Cohort\n    \n    Goins 2018\n\n32\nInhaled\nCAM\n2\n    11 (34.4)\n\n\n—\n\n    \n84\nTIVA\n\n\n    12 (14.3)\n\n\n0.22 (0.06-0.79)b\n    \n      Various – Prospective Cohort\n    \n    Deiner 2014\n\n36\nInhaled\nCAM\n3\n     8 (22.2)\n\n\n—\n\n    \n40\nTIVA\n\n\n     6 (15.0)\n\n\n0.62 (0.19-1.99)\n\n    \n      Various – Retrospective Cohort\n    \n    Yoshimura 2022\n\n427,695\nInhaled\nICD codes\nStay\n32,912 (7.7)\n\n\n—\n\n    \n142,565\nTIVA\n\n\n10,269 (7.2)\n\n\n0.93 (0.91-0.95)c\n  \n  \n  \n    \n       RR: risk ratio; OR: odds ratio; DRS: Delirium Rating Scale; CAM: Confusion Assessment Method; NS: not specified.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n    \n      b Adjusted from multivariable model.\n    \n    \n      c Propensity score matched.\n    \n  \n\n\n\n\n\nPooled\n Figure 1. Delirium incidence (TIVA versus inhaled; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – .  Hartung-Knapp adjustment not applied. Continuity correction of 0.5 added to studies arms with no events. Too few studies to examine small study effects. \n\n Figure 2. TIVA compared with inhaled anesthetic (nonrandomized designs). \n\n\n\n\n\n\n\n\n\n D1: Bias due to confounding; D2: Bias in selection of participants into the study; D3: Bias in classification of interventions; D4: Bias due to deviations from intended interventions; D5: Bias due to missing data; D6: Bias in measurement of outcomes; D7: Bias in selection of reported results; All: overall risk of bias. Risk of bias ratings: low ++, moderate +, serious -, critical - - ; NI: no information; NA: not applicable.  Note: pooling of adjusted odds ratios from Yoshimura 2022 (propensity matching) and Goins 2018 (multivariable adjustment)."
  },
  {
    "objectID": "kq4.html#delayed-neurocognitive-recovery",
    "href": "kq4.html#delayed-neurocognitive-recovery",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Delayed Neurocognitive Recovery",
    "text": "Delayed Neurocognitive Recovery\n Table 11. Delayed neurocognitive recovery incidence and ascertainment (TIVA versus inhaled; randomized and nonrandomized designs). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Drug\n      \n        Preop\n      \n      \n        Instrument\n      \n      Dayb\n      \n        Delayed Neurocognitive Recovery\n      \n    \n    \n      MMSEa\n      MMSE\n      DST\n      MoCA\n      Other\n      N (%)\n      0 — 100%\n      RR (95% CI)\n    \n  \n  \n    \n      Randomized Clinical Trial — Gastrointestinal/Abdominal\n    \n    Tang 2014\n\n99\nInhaled\n25.0 (1.7)\n\n✓c\n\n\n\n7\n33 (33.3)\n\n\n—\n    \n101\nTIVA\n24.6 (1.7)\n\n\n\n\n\n\n30 (29.7)\n\n\n0.89 (0.59-1.34)\n    Geng 2017\n\n50\nInhaled\n28.9 (1.4)\n\n✓d\n✓\n\n\n✓e\n3\n10 (20.0)\n\n\n—\n    \n50\nInhaled\n29.4 (1.9)\n\n\n\n\n\n\n15 (30.0)\n\n\n1.50 (0.75-3.01)\n    \n50\nTIVA\n29.2 (1.5)\n\n\n\n\n\n\n 2 (4.0)\n\n\n0.20 (0.05-0.87)\n    Li 2021a\n\n272\nInhaled\n29 {28-30}\n\n✓c\n\n\n\n7\n51 (18.8)\n\n\n—\n    \n272\nTIVA\n29 {28-30}\n\n\n\n\n\n\n41 (15.1)\n\n\n0.80 (0.55-1.17)\n    \n      Randomized Clinical Trial — Thoracic\n    \n    Egawa 2016\n\n72\nInhaled\n30 {28-30}\n\n✓d\n\n\nf\n5\n24 (33.3)\n\n\n—\n    \n72\nTIVA\n30 {29-30}\n\n\n\n\nf\n\n16 (22.2)\n\n\n0.67 (0.39-1.15)\n    Zhang 2018a\n\n190\nInhaled\n28.3 (1.7)\n\n✓c\n\n\n\n7\n44 (23.2)\n\n\n—\n    \n189\nTIVA\n28.2 (1.7)\n\n\n\n\n\n\n28 (14.8)\n\n\n0.64 (0.42-0.98)\n    \n      Randomized Clinical Trial — Otolaryngological\n    \n    Qiao 2023\n\n31\nInhaled\n27 {26-29}\n\n✓g\n\n\n\n1\n 3 (9.7)\n\n\n—\n    \n32\nTIVA\n28 {26-28}\n\n\n\n\n\n\n 1 (3.1)\n\n\n0.32 (0.04-2.94)\n    \n      Randomized Clinical Trial — Spine\n    \n    Liang 2022\n\n70\nInhaled\n\n\n\n\n\n7\n23 (32.9)\n\n\n—\n    \n70\nTIVA\n\n\n\n\n\n\n10 (14.3)\n\n\n0.43 (0.22-0.84)\n    \n      Randomized Clinical Trial — Various\n    \n    Rohan 2005\n\n15\nInhaled\n28.0 [25-30]\n\n✓c\n\n\n\n2\n 7 (46.7)\n\n\n—\n    \n15\nTIVA\n27.0 [25-30]\n\n\n\n\n\n\n 7 (46.7)\n\n\n1.00 (0.47-2.15)\n    \n      Randomized Clinical Trial — Vascular\n    \n    Lindholm 2013\n\n97\nInhaled\n\n\n\n\n\n30\n 6 (6.2)\n\n\n—\n    \n96\nTIVA\n\n\n\n\n\n\n 4 (4.2)\n\n\n0.67 (0.20-2.31)\n    \n      Prospective Cohort — Orthopedic\n    \n    Konishi 2018\n\n119\nInhaled\n28.1 (1.2)\n\n✓c\n\n\n\n7\n24 (20.2)\n\n\n—\n    \n160\nTIVA\n28.2 (1.3)\n\n\n\n\n\n\n24 (15.0)\n\n\n0.74 (0.44-1.24)\n    \n      Nonrandomized Trial — Thoracic\n    \n    Zhou 2021\n\n116\nInhaled\n25.9 (1.2)\n\n✓\n\n\n\n\n1\n11 (9.5)\n\n\n—\n    \n149\nTIVA\n26.1 (1.4)\n\n\n\n\n\n\n 4 (2.7)\n\n\n0.28 (0.09-0.87)\n  \n  \n  \n    \n       Mini-Mental State Exam; DST: Digit Span Test; MoCA: Montreal Cognitive Assessment; RR: risk ratio.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Day of assessment.\n    \n    \n      c Z ≥1.96.\n    \n    \n      d Difference from baseline &gt;20%.\n    \n    \n      e Included Digit Symbol Substitution Test; Cumulative Test; Trail Making Test; Rey Auditory Verbal Learning Test; Grooved Pegboard Test.\n    \n    \n      f Trail Making Test Part A, Trail Making Test Part B, Digit Span Forward, Digit Span Backward, Pegboard (dominant hand), Pegboard (non-dominant hand).\n    \n    \n      g Difference from baseline &gt;2 pts.\n    \n  \n\n\n\n\n\nPooled\n Figure 3. Delayed neurocognitive recovery assessed postoperative day 3 or later (TIVA versus inhaled; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – . Five trials conducted in China and 1 each in Norway and Japan."
  },
  {
    "objectID": "kq4.html#neurocognitive-disorder",
    "href": "kq4.html#neurocognitive-disorder",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Neurocognitive Disorder",
    "text": "Neurocognitive Disorder\n Table 12. Cognitive dysfunction &gt; 30 days and ascertainment (TIVA versus inhaled; prospective cohort studies). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Comparator\n      \n        Preop\n      \n      \n        Instrument\n      \n      Dayb\n      \n        Neurocognitive Disorder\n      \n    \n    \n      MMSEa\n      MMSE\n      DST\n      MoCA\n      Other\n      N (%)\n      0 — 100%\n      RR (95% CI)\n    \n  \n  \n    \n      Prospective Cohort\n    \n    Deiner 2015\n\n34\nInhaled\n\n\n\n\n✓c\n90\n 9 (26.5)\n\n\n—\n    \n43\nTIVA\n\n\n\n\n\n\n12 (27.9)\n\n\n1.05 (0.50-2.21)\n    Konishi 2018\n\n119\nInhaled\n28.1 (1.2)\n\n✓\n\n\n\n\n90\n10 (8.4)\n\n\n—\n    \n160\nTIVA\n28.2 (1.3)\n\n\n\n\n\n\n17 (10.6)\n\n\n1.26 (0.60-2.66)\n  \n  \n  \n    \n       Mini-Mental State Exam; DST: Digit Span Test; MoCA: Montreal Cognitive Assessment; RR: risk ratio.\n    \n    \n       Pooled RR 1.15 (95% CI, 0.68–1.95)\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Day of assessment.\n    \n    \n      c Uniform Data Set Battery"
  },
  {
    "objectID": "kq4.html#complications",
    "href": "kq4.html#complications",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Complications",
    "text": "Complications\n Table 13. Reported complications in TIVA versus inhaled anesthesia — cardiac, pulmonary, and renal (TIVA versus inhaled; randomized and nonrandomized designs). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n          Agea\n      Surgery\n      N (%)\n      0 – 100%\n      RD OR (95% CI)b\n    \n  \n  \n    \n      MI – Randomized Clinical Trial\n    \n    Zangrillo 2011\n\n44\nInhaled\n65.0 (11.8)\n\nVarious\n    0 (0.0)\n\n\n—\n\n    \n44\nTIVA\n64.0 (12.2)\n\n\n    0 (0.0)\n\n\n0.0% (-4.3, 4.3)\n\n    Lindholm 2013\n\n97\nInhaled\n69.0 (9.0)\n\nVascular\n    5 (5.2)\n\n\n—\n\n    \n96\nTIVA\n67.0 (9.0)\n\n\n    3 (3.1)\n\n\n-2.0% (-7.6, 3.6)\n\n    \n      MI – Retrospective Cohort\n    \n    Jakobsen 2007\n\n5,325\nInhaled\n64.9\n\nCardiac\n2,076 (39.0)\n\n\n—\n\n    \n5,210\nTIVA\n64.7\n\n\n1,891 (36.3)\n\n\n-2.7% (-4.5, -0.8)\n\n    Cho 2021\n\n1,202\nInhaled\n62.7 (13.7)\n\nVarious\n   15 (1.2)\n\n\n—\n\n    \n1,374\nTIVA\n65.6 (12.8)\n\n\n    6 (0.4)\n\n\n-0.8% (-1.5, -0.1)\n\n    Yoshimura 2022\n\n427,695\nInhaled\n\nVarious\n6,717 (1.6)\n\n\n—\n\n    \n142,565\nTIVA\n\n\n2,039 (1.4)\n\n\n0.91 (0.87-0.96)\n\n    \n      Cardiac Arrest – Retrospective Cohort\n    \n    Cho 2021\n\n1,202\nInhaled\n62.7 (13.7)\n\nVarious\n    0 (0.0)\n\n\n—\n\n    \n1,374\nTIVA\n65.6 (12.8)\n\n\n    2 (0.1)\n\n\n0.1% (-0.1, 0.4)\n\n    \n      Other Cardiac – Randomized Clinical Trial\n    \n    Luntz 2004c\n32\nInhaled\n77.0 (7.0)\n\nOphtho\n    1 (3.1)\n\n\n—\n\n    \n32\nInhaled\n76.0 (6.0)\n\n\n    4 (12.5)\n\n\n—\n\n    \n32\nTIVA\n74.0 (7.0)\n\n\n    8 (25.0)\n\n\n17.2% (0.8, 33.6)d\n    Nishikawa 2007ac\n15\nInhaled\n70.9 (6.5)\n\nGI/Abd\n    2 (13.3)\n\n\n—\n\n    \n15\nTIVA\n71.2 (5.3)\n\n\n    0 (0.0)\n\n\n-13.3% (-33.1, 6.4)\n\n    Zangrillo 2011e\n44\nInhaled\n65.0 (11.8)\n\nVarious\n    1 (2.3)\n\n\n—\n\n    \n44\nTIVA\n64.0 (12.2)\n\n\n    1 (2.3)\n\n\n0.0% (-6.2, 6.2)\n\n    Zhang 2018ac\n190\nInhaled\n72.4 (5.6)\n\nThoracic\n    8 (4.2)\n\n\n—\n\n    \n189\nTIVA\n72.8 (5.5)\n\n\n    6 (3.2)\n\n\n-1.0% (-4.8, 2.8)\n\n    Dai 2021f\n81\nInhaled\n72.0 (7.0)\n\nVarious\n    2 (2.5)\n\n\n—\n\n    \n83\nTIVA\n73.0 (8.0)\n\n\n    2 (2.4)\n\n\n-0.1% (-4.8, 4.7)\n\n    \n      Pneumonia – Randomized Clinical Trial\n    \n    Lindholm 2013\n\n97\nInhaled\n69.0 (9.0)\n\nVascular\n   13 (13.4)\n\n\n—\n\n    \n96\nTIVA\n67.0 (9.0)\n\n\n    9 (9.4)\n\n\n-4.0% (-13.0, 4.9)\n\n    Forsmo 2016\n\n153\nInhaled\n66.0 [19-93]\n\nGI/Abd\n    8 (5.2)\n\n\n—\n\n    \n154\nTIVA\n65.0 [23-89]\n\n\n    7 (4.5)\n\n\n-0.7% (-5.5, 4.1)\n\n    Li 2021a\n\n272\nInhaled\n65.0 {62-69}\n\nGI/Abd\n    1 (0.4)\n\n\n—\n\n    \n272\nTIVA\n64.0 {62-68}\n\n\n    0 (0.0)\n\n\n-0.4% (-1.4, 0.6)\n\n    \n      Respiratory Failure – Randomized Clinical Trial\n    \n    Lindholm 2013\n\n97\nInhaled\n69.0 (9.0)\n\nVascular\n    9 (9.3)\n\n\n—\n\n    \n96\nTIVA\n67.0 (9.0)\n\n\n    6 (6.2)\n\n\n-3.0% (-10.6, 4.5)\n\n    Cao 2023\n\n597\nInhaled\n71.0 [65-88]\n\nVarious\n    6 (1.0)\n\n\n—\n\n    \n598\nTIVA\n72.0 [65-88]\n\n\n    8 (1.3)\n\n\n0.3% (-0.9, 1.6)\n\n    \n      Respiratory Failure – Retrospective Cohort\n    \n    Yoshimura 2022\n\n427,695\nInhaled\n\nVarious\n1,487 (0.3)\n\n\n—\n\n    \n142,565\nTIVA\n\n\n  420 (0.3)\n\n\n0.85 (0.76-0.94)\n\n    \n      PE – Randomized Clinical Trial\n    \n    Forsmo 2016\n\n153\nInhaled\n66.0 [19-93]\n\nGI/Abd\n    0 (0.0)\n\n\n—\n\n    \n154\nTIVA\n65.0 [23-89]\n\n\n    2 (1.3)\n\n\n1.3% (-0.9, 3.5)\n\n    Cao 2023\n\n597\nInhaled\n71.0 [65-88]\n\nVarious\n    1 (0.2)\n\n\n—\n\n    \n598\nTIVA\n72.0 [65-88]\n\n\n    1 (0.2)\n\n\n-0.0% (-0.5, 0.5)\n\n    \n      PE – Retrospective Cohort\n    \n    Cho 2021\n\n1,202\nInhaled\n62.7 (13.7)\n\nVarious\n    0 (0.0)\n\n\n—\n\n    \n1,374\nTIVA\n65.6 (12.8)\n\n\n    2 (0.1)\n\n\n0.1% (-0.1, 0.4)\n\n    Yoshimura 2022\n\n427,695\nInhaled\n\nVarious\n  432 (0.1)\n\n\n—\n\n    \n142,565\nTIVA\n\n\n  185 (0.1)\n\n\n1.29 (1.08-1.53)\n\n    \n      Pulmonary Congestion – Retrospective Cohort\n    \n    Cho 2021\n\n1,202\nInhaled\n62.7 (13.7)\n\nVarious\n    3 (0.2)\n\n\n—\n\n    \n1,374\nTIVA\n65.6 (12.8)\n\n\n    0 (0.0)\n\n\n-0.2% (-0.6, 0.1)\n\n    Yoshimura 2022\n\n427,695\nInhaled\n\nVarious\n    0 (0.0)\n\n\n—\n\n    \n142,565\nTIVA\n\n\n    0 (0.0)\n\n\n—\n\n    \n      AKI – Retrospective Cohort\n    \n    Oh 2019\n\n1,477\nInhaled\n65.0 (10.4)\n\nThoracic\n   71 (4.8)\n\n\n—\n\n    \n1,395\nTIVA\n65.0 (10.0)\n\n\n   69 (4.9)\n\n\n1.03 (0.73-1.45)\n\n    Park 2020\n\n386\nInhaled\n65.5 (14.8)\n\nVarious\n   47 (12.2)\n\n\n—\n\n    \n100\nTIVA\n65.6 (14.9)\n\n\n    7 (7.0)\n\n\n0.54 (0.24-1.24)\n\n    Yoshimura 2022\n\n427,695\nInhaled\n\nVarious\n2,123 (0.5)\n\n\n—\n\n    \n142,565\nTIVA\n\n\n  706 (0.5)\n\n\n1.00 (0.92-1.09)\n\n    \n      Other Cardiac – Nonrandomized Trial\n    \n    Zhou 2021\n\n116\nInhaled\n63.4 (17.1)\n\nThoracic\n    1 (0.9)\n\n\n—\n\n    \n149\nTIVA\n67.2 (15.1)\n\n\n    5 (3.4)\n\n\n2.5% (-0.9, 5.8)\n\n    \n      Cardiac Arrest – Randomized Clinical Trial\n    \n    Cao 2023\n\n597\nInhaled\n71.0 [65-88]\n\nVarious\n    1 (0.2)\n\n\n—\n\n    \n598\nTIVA\n72.0 [65-88]\n\n\n    3 (0.5)\n\n\n0.3% (-0.3, 1.0)\n\n    \n      AKI – Randomized Clinical Trial\n    \n    Cao 2023\n\n597\nInhaled\n71.0 [65-88]\n\nVarious\n   36 (6.0)\n\n\n—\n\n    \n598\nTIVA\n72.0 [65-88]\n\n\n   38 (6.4)\n\n\n0.3% (-2.4, 3.1)\n\n    \n      Pneumothorax – Randomized Clinical Trial\n    \n    Cao 2023\n\n597\nInhaled\n71.0 [65-88]\n\nVarious\n    3 (0.5)\n\n\n—\n\n    \n598\nTIVA\n72.0 [65-88]\n\n\n    6 (1.0)\n\n\n0.5% (-0.5, 1.5)\n\n    \n      Stroke – Randomized Clinical Trial\n    \n    Cao 2023\n\n597\nInhaled\n71.0 [65-88]\n\nVarious\n    3 (0.5)\n\n\n—\n\n    \n598\nTIVA\n72.0 [65-88]\n\n\n    3 (0.5)\n\n\n-0.0% (-0.8, 0.8)\n\n  \n  \n  \n    \n       RD: risk difference; OR: odds ratio; Ophtho: ophthalmologic; GI: gastointestinal; Abd: abdominal.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Odds ratios reported for propensity-matched studies (risk difference with 95% CI reported accounting for matching were not reported).\n    \n    \n      c Bradycardia.\n    \n    \n      d Compared with combined inhalation arms — differed only in induction agents.\n    \n    \n      e Atrial fibrillation.\n    \n    \n      f Cardiac dysfunction.\n    \n  \n\n\n\n\n\nPooled\n\n\n\n\n\n\n\n\nMyocardial Infarction\n Figure 4. Risk ratio for myocardial infarction (TIVA versus inhaled anesthesia; randomized and nonrandomized studies). \n\n\n\n\n\n\n\n\n\n RR: risk ratio. Similar arms combined for Liang 2017. \n\n\nStroke\nNot reported in included studies.\n\n\nRenal\n Figure 5. Risk ratio for renal complications (TIVA versus inhaled anesthesia; nonrandomized studies). \n\n\n\n\n\n\n\n\n\n RR: risk ratio. \n\n\nPulmonary\nComplications categorized as “pulmonary” not reported in included studies.\n\n\nPneumonia\n Figure 6. Risk ratio for pneumonia (regional versus general anesthesia; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n RR: risk ratio; ; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – . \n\n\nPulmonary Embolism\n Figure 7. Risk ratio for pulmonary embolism (regional versus general anesthesia; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n RR: risk ratio. Similar arms combined for Liang 2017."
  },
  {
    "objectID": "kq4.html#patient-satisfaction",
    "href": "kq4.html#patient-satisfaction",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Patient Satisfaction",
    "text": "Patient Satisfaction\n Table 14. Patient satisfaction according to TIVA or inhalation anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Anesth\n      Surgery\n      \n        ASA\n      \n      Agea\n           N (%)\n      0 – 100%\n      RD (95% CI)\n    \n    \n      PS\n    \n  \n  \n    Epple 2001\n\n62\nInhaled\nOphthalmologic\n123 \n76.0 (6.0)\n\n41 (66.1)b\n\n\n—\n    \n62\nTIVA\n\n\n77.0 (6.0)\n\n58 (93.5)b\n\n\n27.4% (14.1, 40.7)\n    Luntz 2004\n\n64c\nInhaled\nOphthalmologic\n123 \n77.0 (7.0)\n\n15 (46.9)d\n\n\n—\n    \n32\nTIVA\n\n\n74.0 (7.0)\n\n23 (71.9)d\n\n\n17.2% (-2.6, 37.0)\n    Nishikawa 2007a\n\n15\nInhaled\nGI/Abdominal\n12  \n70.9 (6.5)\n\n 6 (40.0)e\n\n\n—\n    \n15\nTIVA\n\n\n71.2 (5.3)\n\n 9 (60.0)e\n\n\n20.0% (-15.1, 55.1)\n  \n  \n  \n    \n       TIVA: total intravenous anesthesia; ASA PS: ASA Physical Status; RD: risk difference.\n    \n    \n      a Mean (SD).\n    \n    \n      b Completely satisfied.\n    \n    \n      c Inhaled arms combined.\n    \n    \n      d Highly satisfied.\n    \n    \n      e Very satisfied.\n    \n  \n\n\n\n\n\nPooled\n Figure 8. Risk ratio in patient satisfaction (TIVA versus inhaled; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n RD: risk difference; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – . Similar/Inhaled arms combined for Luntz 2004."
  },
  {
    "objectID": "kq4.html#length-of-stay",
    "href": "kq4.html#length-of-stay",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Length of Stay",
    "text": "Length of Stay\n Table 15. Length of stay according to procedure classification and comparator. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Anesth\n      PSa\n          Ageb\n          LOSb\n      0 – 35 days\n      Country\n    \n  \n  \n    \n      Randomized Clinical Trial - Gastrointestinal/Abdominal\n    \n    Forsmo 2016\n\n153\nInhaled\n123 \n66.0 [19-93]\n\n8.0 [2-48]\n\n\n\nNorway\n    \n154\nTIVA\n123 \n65.0 [23-89]\n\n5.0 [2-50]\n\n\n\n\n    Li 2021a\n\n272\nInhaled\nNR\n65.0 {62-69}\n\n14.0 {11-16}\n\n\n\nChina\n    \n272\nTIVA\nNR\n64.0 {62-68}\n\n15.0 {12-17}\n\n\n\n\n    \n      Randomized Clinical Trial - Thoracic\n    \n    Zhang 2018a\n\n190\nInhaled\n123 \n72.4 (5.6)\n\n8.0 {6-11}\n\n\n\nChina\n    \n189\nTIVA\n123 \n72.8 (5.5)\n\n9.0 {6-13}\n\n\n\n\n    \n      Randomized Clinical Trial - Various\n    \n    Dai 2021\n\n81\nInhaled\n 234\n72.0 (7.0)\n\n8.0 (9.9)\n\n\n\nChina\n    \n83\nTIVA\n 234\n73.0 (8.0)\n\n9.0 (10.8)\n\n\n\n\n    Cao 2023\n\n597\nInhaled\n123 \n71.0 [65-88]\n\n10.0 {7-14}\n\n\n\nChina\n    \n598\nTIVA\n123 \n72.0 [65-88]\n\n10.0 {7-14}\n\n\n\n\n    \n      Retrospective Cohort - Cardiac\n    \n    Goins 2018\n\n32\nInhaled\nNR\n78.3 (9.0)\n\n5.9 (3.3)\n\n\n\nUSA\n    \n84\nTIVA\nNR\n79.6 (8.7)\n\n3.8 (3.3)\n\n\n\n\n    \n      Retrospective Cohort - Orthopedic\n    \n    Kishimoto 2018\n\n5,140\nInhaled\nNR\n74.4 (7.4)\n\n31.4 (14.4)\n\n\n\nJapan\n    \n5,140\nTIVA\nNR\n74.5 (7.2)\n\n32.5 (18.4)\n\n\n\n\n    \n      Retrospective Cohort - Various\n    \n    Yoshimura 2022\n\n427,695\nInhaled\nNR\n\n21.0 (21.0)\n\n\n\nJapan\n    \n142,565\nTIVA\nNR\n\n21.0 (21.8)\n\n\n\n\n  \n  \n  \n    \n       NR: not reported\n    \n    \n      a ASA Physical Status.\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n  \n\n\n\n\n\nPooled\n Figure 9. Mean difference in lengths of stay (TIVA versus inhaled; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – . When the mean or standard deviation were not reported, they were imputed from from the median, interquartile range, and/or range. \n Figure 10. Mean difference in lengths of stay (TIVA versus inhaled; nonrandomized designs). \n\n\n\n\n\n\n\n\n\n D1: Bias due to confounding; D2: Bias in selection of participants into the study; D3: Bias in classification of interventions; D4: Bias due to deviations from intended interventions; D5: Bias due to missing data; D6: Bias in measurement of outcomes; D7: Bias in selection of reported results; All: overall risk of bias. Risk of bias ratings: low ++, moderate +, serious -, critical - - ; NI: no information; NA: not applicable.  When the mean or standard deviation were not reported, they were imputed from from the median, interquartile range, and/or range."
  },
  {
    "objectID": "kq4.html#discharge-location",
    "href": "kq4.html#discharge-location",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Discharge Location",
    "text": "Discharge Location\nNo studies reported"
  },
  {
    "objectID": "kq4.html#mortality",
    "href": "kq4.html#mortality",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Mortality",
    "text": "Mortality\n Table 16. Reported in-hospital, 30-day, and 1-year mortality from randomized clinical trials.\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N  \n      Arm\n      Surgery\n      \n        ASA\n      \n      Agea\n      \n        Mortality\n      \n      RD (95% CI)\n    \n    \n      PS\n      N (%)\n      0 - 100%\n    \n  \n  \n    \n      Hospital\n    \n    Dai 2021\n\n81\nInhaled\nVarious\n 234\n72.0 (7.0)\n\n2 (2.5)\n\n\n—\n    \n83\nTIVA\n\n\n73.0 (8.0)\n\n1 (1.2)\n\n\n-1.3% (-5.4, 2.9)\n    \n      30-day\n    \n    Zangrillo 2011\n\n44\nInhaled\nVarious\n1234\n65.0 (11.8)\n\n0 (0.0)\n\n\n—\n    \n44\nTIVA\n\n\n64.0 (12.2)\n\n1 (2.3)\n\n\n2.3% (-3.8, 8.3)\n    Lindholm 2013\n\n97\nInhaled\nVasc\n 234\n69.0 (9.0)\n\n4 (4.1)\n\n\n—\n    \n96\nTIVA\n\n\n67.0 (9.0)\n\n4 (4.2)\n\n\n0.0% (-5.6, 5.7)\n    Forsmo 2016\n\n153\nInhaled\nGI/Abd\n123 \n66.0 [19-93]\n\n0 (0.0)\n\n\n—\n    \n154\nTIVA\n\n\n65.0 [23-89]\n\n3 (1.9)\n\n\n1.9% (-0.6, 4.5)\n    Zhang 2018a\n\n190\nInhaled\nThoracic\n123 \n72.4 (5.6)\n\n0 (0.0)\n\n\n—\n    \n189\nTIVA\n\n\n72.8 (5.5)\n\n0 (0.0)\n\n\n0.0% (-1.0, 1.0)\n    Dai 2021\n\n81\nInhaled\nVarious\n 234\n72.0 (7.0)\n\n4 (4.9)\n\n\n—\n    \n83\nTIVA\n\n\n73.0 (8.0)\n\n3 (3.6)\n\n\n-1.3% (-7.5, 4.9)\n    \n      1-year\n    \n    Zangrillo 2011\n\n44\nInhaled\nVarious\n1234\n65.0 (11.8)\n\n1 (2.3)\n\n\n2.3% (-3.8, 8.3)\n    \n44\nTIVA\n\n\n64.0 (12.2)\n\n2 (4.5)\n\n\n4.5% (-2.8, 11.9)\n  \n  \n  \n    \n       ASA PS: American Society of Anesthesiologists Physical Status; RD: risk difference; NR: not reported.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n  \n\n\n\n\n Table 17. Reported in-hospital and 30-day mortality from nonrandomized designs (all retrospective cohort studies).\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N    \n      Arm\n      Surgery\n      \n        ASA\n      \n      Agea\n      \n        Mortality\n      \n      RD (95% CI)\n    \n    \n      PS\n      N (%)\n      0 - 100%\n    \n  \n  \n    \n      Hospital\n    \n    Jakobsen 2007\n\n5,325\nInhaled\nCardiac\nNR\n64.9\n\n  116 (2.2)\n\n\n—\n    \n5,210\nTIVA\n\n\n64.7\n\n  172 (3.3)\n\n\n1.1% (0.5, 1.7)\n    Park 2020\n\n386\nInhaled\nVarious\n1234\n65.5 (14.8)\n\n   52 (13.5)\n\n\n—\n    \n100\nTIVA\n\n\n65.6 (14.9)\n\n   22 (22.0)\n\n\n8.5% (-0.3, 17.3)\n    Yoshimura 2022\n\n427,695\nInhaled\nVarious\nNR\n\n4,936 (1.2)\n\n\n—\n    \n142,565\nTIVA\n\n\n\n1,665 (1.2)\n\n\n0.0% (-0.1, 0.1)\n    \n      30-day\n    \n    Jakobsen 2007\n\n5,325\nInhaled\nCardiac\nNR\n64.9\n\n  151 (2.8)\n\n\n0.7% (0.1, 1.3)\n    \n5,210\nTIVA\n\n\n64.7\n\n  172 (3.3)\n\n\n1.1% (0.5, 1.7)\n    Goins 2018\n\n32\nInhaled\nCardiac\nNR\n78.3 (9.0)\n\n    2 (6.2)\n\n\n—\n    \n84\nTIVA\n\n\n79.6 (8.7)\n\n    0 (0.0)\n\n\n-6.2% (-15.4, 2.9)\n    Park 2020\n\n386\nInhaled\nVarious\n1234\n65.5 (14.8)\n\n   35 (9.1)\n\n\n—\n    \n100\nTIVA\n\n\n65.6 (14.9)\n\n   17 (17.0)\n\n\n7.9% (0.0, 15.8)\n    Cho 2021\n\n1,202\nInhaled\nVarious\n  34\n62.7 (13.7)\n\n   51 (4.2)\n\n\n—\n    \n1,374\nTIVA\n\n\n65.6 (12.8)\n\n   22 (1.6)\n\n\n-2.6% (-4.0, -1.3)\n  \n  \n  \n    \n       ASA PS: American Society of Anesthesiologists Physical Status; RD: risk difference; GI: gastrointestinal; Abd: abdominal (includes hepatic); Various: more that one procedure category.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n  \n\n\n\n\n\nPooled\n Figure 11. Risk ratio for hospital or 30-day mortality (TIVA versus inhaled; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – .\n\n Figure 12. Risk ratio for hospital or 30-day mortality (TIVA versus inhaled; nonrandomized designs). \n\n\n\n\n\n\n\n\n\n D1: Bias due to confounding; D2: Bias in selection of participants into the study; D3: Bias in classification of interventions; D4: Bias due to deviations from intended interventions; D5: Bias due to missing data; D6: Bias in measurement of outcomes; D7: Bias in selection of reported results; All: overall risk of bias. Risk of bias ratings: low ++, moderate +, serious -, critical - - ; NI: no information; NA: not applicable. Note for Yoshimura 2022 naïve risk ratio, but identical to odds ratio reported respecting propensity matching."
  },
  {
    "objectID": "kq4.html#risk-of-bias",
    "href": "kq4.html#risk-of-bias",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Risk of Bias",
    "text": "Risk of Bias\n\nRandomized\n Figure 13. Summary risk of bias assessment for randomized clinical trials. \n\n\n\n\n\n Figure 14. Risk of bias assessments for randomized clinical trials. \n\n\n\n\n\n\n\nNonrandomized\n Figure 15. Summary risk of bias assessment for nonrandomized studies. \n\n\n\n\n\n Figure 16. Risk of bias assessments for nonrandomized studies."
  },
  {
    "objectID": "kq1.html",
    "href": "kq1.html",
    "title": "Expanded Preoperative Evaluation",
    "section": "",
    "text": "Among older patients anticipating surgery and anesthesia, does expanded preoperative evaluation (e.g., for frailty, cognitive impairment, functional status, or psychosocial issues) lead to improved postoperative outcomes?"
  },
  {
    "objectID": "kq1.html#key-question",
    "href": "kq1.html#key-question",
    "title": "Expanded Preoperative Evaluation",
    "section": "",
    "text": "Among older patients anticipating surgery and anesthesia, does expanded preoperative evaluation (e.g., for frailty, cognitive impairment, functional status, or psychosocial issues) lead to improved postoperative outcomes?"
  },
  {
    "objectID": "kq1.html#outcome-importance-rankings",
    "href": "kq1.html#outcome-importance-rankings",
    "title": "Expanded Preoperative Evaluation",
    "section": "Outcome Importance Rankings",
    "text": "Outcome Importance Rankings\n\nExpanded Preoperative Evaluation\n Table 1. Rankings of the 5 most important outcomes (11 respondents)."
  },
  {
    "objectID": "kq1.html#outcomes-reported",
    "href": "kq1.html#outcomes-reported",
    "title": "Expanded Preoperative Evaluation",
    "section": "Outcomes Reported",
    "text": "Outcomes Reported\n Table 2. Dichotomous or count outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 11\n      NR Trial, N = 1\n      Quasi-exp, N = 15\n      Prosp Coh, N = 1\n      Retro Coh, N = 1\n    \n  \n  \n    ADL\n1 (9.1%)\n—\n—\n—\n—\n    Complications\n5 (45%)\n—\n9 (60%)\n1 (100%)\n1 (100%)\n    DNCR/PND\n—\n—\n1 (6.7%)\n—\n—\n    Delirium\n6 (55%)\n—\n6 (40%)\n—\n1 (100%)\n    Delirium duration\n—\n—\n—\n—\n—\n    Discharge location\n4 (36%)\n1 (100%)\n4 (27%)\n—\n—\n    Mortality\n7 (64%)\n1 (100%)\n10 (67%)\n1 (100%)\n1 (100%)\n    Opioid use\n—\n—\n—\n—\n—\n    Pain\n1 (9.1%)\n—\n1 (6.7%)\n—\n—\n    QoR\n—\n—\n—\n—\n—\n    Readmission\n5 (45%)\n—\n8 (53%)\n—\n1 (100%)\n    Satisfaction\n—\n—\n1 (6.7%)\n—\n—\n  \n  \n  \n    \n       ADL: activities of daily living; NCR: neurocognitive recovery; POCD: postoperative neurocognitive disorder; QoR: quality of recovery; RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort.\n    \n  \n\n\n\n\n Table 3. Continuous outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 11\n      NR Trial, N = 1\n      Quasi-exp, N = 15\n      Prosp Coh, N = 1\n      Retro Coh, N = 1\n    \n  \n  \n    Delirium duration\n2 (18%)\n—\n—\n—\n—\n    Length of stay\n10 (91%)\n1 (100%)\n9 (60%)\n1 (100%)\n1 (100%)\n    Opioid use\n—\n—\n—\n—\n—\n  \n  \n  \n    \n       RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort.\n    \n  \n\n\n\n\n Table 4. Likert or ordinal outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 11\n      NR Trial, N = 1\n      Quasi-exp, N = 15\n      Prosp Coh, N = 1\n      Retro Coh, N = 1\n    \n  \n  \n    ADL\n6 (55%)\n1 (100%)\n2 (13%)\n—\n—\n    DNCR/PNCD\n3 (27%)\n—\n—\n—\n—\n    Delirium\n1 (9.1%)\n—\n—\n—\n—\n    Complications\n—\n—\n—\n—\n—\n    Pain\n—\n—\n—\n—\n—\n    Quality of life\n1 (9.1%)\n—\n2 (13%)\n—\n—\n    QoR\n—\n—\n—\n—\n—\n    Satisfaction\n—\n—\n—\n—\n—\n  \n  \n  \n    \n       ADL: activities of daily living; NCR: neurocognitive recovery; POCD: postoperative neurocognitive disorder; QoR: quality of recovery; RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort."
  },
  {
    "objectID": "kq1.html#included-studies",
    "href": "kq1.html#included-studies",
    "title": "Expanded Preoperative Evaluation",
    "section": "Included Studies",
    "text": "Included Studies\n Table 5. Number of studies by design. \n\n\n\n\n\n\n  \n    \n    \n  \n  \n    \n    \n      Design\n      Studies\n    \n  \n  \n    Randomized Clinical Trial\n10\n    Nonrandomized Trial\n1\n    Before-After/Time Series\n14\n    Prospective Cohort\n1\n    Retrospective Cohort\n1\n    Total\n27\n  \n  \n  \n    \n       Studies with multiple publications counted only once (applies to 2 studies with 2 publications).\n    \n  \n\n\n\n\n\nDesign, centers, country, and surgery\n Table 6. Study design, enrollment, centers, country, and surgery (see References for citations). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      ID\n      Study\n      Centers\n      Enrolled\n      Countrya\n      Surgery\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    741\nMarcantonio 2001\n\n1\n126\nUSA\nHipFx\n    16608\nPrestmo 2015\n\n1\n397\nNorway\nHipFx\n    17156\nShyu 2005\n\n1\n159\nTaiwana\nHipFx\n    17155\nShyu 2008\n\n1\n162\nTaiwana\nHipFx\n    16628\nVidan 2005\n\n1\n321\nSpain\nHipFx\n    1201\nWatne 2014\n\n1\n329\nNorway\nHipFx\n    16739\nZhu 2022\n\n1\n155\nChinaa\nHipFx\n    555\nOmmundsen 2018\n\n2\n122\nNorway\nGI/Abd\n    760\nHempenius 2013 (Hempenius 2016)\n\n3\n297\nNetherlands\nVariousb\n    1263\nHempenius 2016 (Hempenius 2013)\n\n3\n297\nNetherlands\nVariousb\n    16605\nPartridge 2017\n\n1\n201\nUK\nVariousb\n    \n      Nonrandomized Trial\n    \n    17087\nDeschodt 2011\n\n1\n171\nBelgium\nHipFx\n    \n      Before-After/Time Series\n    \n    16544\nBjorkelund 2010\n\n1\n276\nSweden\nHipFx\n    16629\nVochteloo 2011\n\n1\n1056\nNetherlands\nHipFx\n    16601\nOlsson 2014\n\n2\n266\nSweden\nOther Ortho\n    13133\nRomano 2021\n\n1\n181\nItaly\nOther Ortho\n    16846\nGiannotti 2022\n\n1\n207\nItaly\nGI/Abd\n    149\nIndrakusuma 2015\n\n1\n443\nNetherlands\nGI/Abd\n    6017\nSouwer 2018\n\n1\n149\nNetherlands\nGI/Abd\n    16539\nBakker 2014\n\n1\n241\nNetherlands\nVariousb\n    2736\nErnst 2014 (Hall 2017)\n\n1\n310\nUSA\nVariousb\n    1313\nHall 2017 (Ernst 2014)\n\n1\n9153\nUSA\nVariousb\n    11264\nLester 2022\n\n1\n492\nUSA\nVariousb\n    16591\nMcDonald 2018\n\n1\n326\nUSA\nVariousb\n    1294\nRichter 2005\n\n1\n62\nUSA\nVariousb\n    2108\nBraude 2017\n\n1\n242\nUK\nUrol\n    1189\nAdogwa 2017\n\n1\n125\nUSA\nNeuro\n    \n      Prospective Cohort\n    \n    17128\nJones 2021\n\n1\n466\nUSA\nVariousb\n    \n      Retrospective Cohort\n    \n    16623\nTarazona-Santabalbina 2019\n\n1\n310\nSpain\nGI/Abd\n  \n  \n  \n    \n       GI: gastrointestinal; Ortho: orthopedic; Neuro: neurological; Oralmax: oral maxillofacial; Vasc: vascular.\n    \n    \n      a Non very-high Human Development Index country.\n    \n    \n      b Described as various or more than 4 different types of surgery.\n    \n  \n\n\n\n\n\nCountry Summary\n Table 7. Summary of studies by country where conducted. \n\n\n\n\n\n\n  \n    \n    \n      \n      N = 27a\n    \n  \n  \n    Country\n\n        USA\n7 (26%)b\n        Netherlands\n5 (19%)b\n        Norway\n3 (11%)\n        Italy\n2 (7.4%)\n        Spain\n2 (7.4%)\n        Sweden\n2 (7.4%)\n        Taiwan\n2 (7.4%)\n        UK\n2 (7.4%)\n        Belgium\n1 (3.7%)\n        China\n1 (3.7%)\n  \n  \n  \n    \n      a n (%)\n    \n    \n      b Studies with more that one publications considered once."
  },
  {
    "objectID": "kq1.html#comparators",
    "href": "kq1.html#comparators",
    "title": "Expanded Preoperative Evaluation",
    "section": "Comparators",
    "text": "Comparators\n\nStudy Characteristics\n Table 8. Selected characteristic of included studies. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N \n      Arm\n      ASA PSa\n         Ageb\n         MMSEb\n    \n  \n  \n    \n      GI/Abd — Before-After/Time Series\n    \n    Indrakusuma 2015\n\n222\nStd\nNR\n77.0 {73-81}\n\n\n    \n221\nExp\nNR\n77.0 {74-82}\n\n\n    Souwer 2018\n\n63\nStd\n1234\n81.4 {74-89}\n\n\n    \n86\nExp\n1234\n80.6 {74-87}\n\n\n    Giannotti 2022\n\n117\nStd\nNR\n82.0 {78-85}\n\n28 {26-29}\n\n    \n90\nExp\nNR\n79.0 {76-83}\n\n27 {25-29}\n\n    \n      GI/Abd — Randomized Clinical Trial\n    \n    Ommundsen 2018\n\n63\nStd\nNR\n78.8 (7.8)\n\n\n    \n53\nExp\nNR\n78.2 (7.4)\n\n\n    \n      GI/Abd — Retrospective Cohort\n    \n    T-Santabalbina 2019\n\n107\nStd\n1234\n75.3 (5.1)\n\n\n    \n203\nExp\n1234\n77.5 (4.8)\n\n\n    \n      HipFx — Before-After/Time Series\n    \n    Bjorkelund 2010\n\n132\nStd\n1234\n82.0 (7.6)\n\n\n    \n131\nExp\n1234\n81.1 (7.5)\n\n\n    Vochteloo 2011\n\n\nStd\nNR\n\n\n    \n378\nExp\nNR\n83.7\n\n\n    \n      HipFx — Nonrandomized Trial\n    \n    Deschodt 2011\n\n77\nStd\nNR\n81.1 (7.2)\n\n7.2 (3.9)\n\n    \n94\nExp\nNR\n80.4 (7.0)\n\n7.3 (3.9)\n\n    \n      HipFx — Randomized Clinical Trial\n    \n    Marcantonio 2001\n\n64\nStd\nNR\n80.0 (8.0)\n\n\n    \n62\nExp\nNR\n78.0 (8.0)\n\n\n    Shyu 2005\n\n69\nStd\nNR\n77.7 (7.1)\n\n\n    \n68\nExp\nNR\n77.6 (8.3)\n\n\n    Vidan 2005\n\n164\nStd\nNR\n82.6 (7.4)\n\n\n    \n155\nExp\nNR\n81.1 (7.8)\n\n\n    Shyu 2008\n\n82\nStd\nNR\n78.9 (7.3)\n\n\n    \n80\nExp\nNR\n77.4 (8.2)\n\n\n    Watne 2014\n\n166\nStd\nNR\n85.0 {46-101}\n\n\n    \n163\nExp\nNR\n84.0 {55-99}\n\n\n    Prestmo 2015\n\n199\nStd\nNR\n83.2 (6.4)\n\n\n    \n198\nExp\nNR\n83.4 (5.4)\n\n\n    Zhu 2022\n\n85\nStd\n1234\n81.8\n\n\n    \n70\nExp\n1234\n79.5\n\n\n    \n      Neuro — Before-After/Time Series\n    \n    Adogwa 2017\n\n25\nStd\nNR\n73.0 (4.9)\n\n\n    \n100\nExp\nNR\n73.6 (6.0)\n\n\n    \n      Other Ortho — Before-After/Time Series\n    \n    Olsson 2014\n\n138\nStd\n123 \n66.0 (13.9)\n\n\n    \n128\nExp\n123 \n68.0 (12.0)\n\n\n    Romano 2021\n\n59\nStd\n123 \n73.0 {68-77}\n\n\n    \n122\nExp\n123 \n70.0 {64-77}\n\n\n    \n      Urol — Before-After/Time Series\n    \n    Braude 2017\n\n101\nStd\nNR\n\n\n    \n124\nExp\nNR\n\n\n    \n      Various — Before-After/Time Series\n    \n    Richter 2005\n\n30\nStd\n123 \n72.6 (8.3)\n\n\n    \n32\nExp\n123 \n70.9 (6.3)\n\n\n    Bakker 2014\n\n120\nStd\nNR\n76.5 (4.9)\n\n26.6 (3.7)\n\n    \n121\nExp\nNR\n76.0 (5.1)\n\n27.3 (2.6)\n\n    Ernst 2014\n\n160\nStd\nNR\n68.3 (11.2)\n\n\n    \n150\nExp\nNR\n71.3 (10.6)\n\n\n    Hall 2017\n\n5275\nStd\n1234\n60.3 (13.4)\n\n\n    \n3878\nExp\n1234\n60.3 (13.7)\n\n\n    McDonald 2018\n\n143\nStd\nNR\n71.9 (6.4)\n\n\n    \n183\nExp\nNR\n75.6 (6.8)\n\n\n    Lester 2022\n\n250\nStd\nNR\n82.7 {78-87}\n\n\n    \n242\nExp\nNR\n81.1 {78-86}\n\n\n    \n      Various — Prospective Cohort\n    \n    Jones 2021\n\n308\nStd\n 234\n80.0 (5.0)\n\n\n    \n158\nExp\n 234\n80.0 (5.0)\n\n\n    \n      Various — Randomized Clinical Trial\n    \n    Hempenius 2013\n\n149\nStd\nNR\n77.6 (7.7)\n\n26.3 (3.9)\n\n    \n148\nExp\nNR\n77.5 (6.7)\n\n26.7 (3.0)\n\n    Hempenius 2016\n\n133\nStd\nNR\n77.4 (7.7)\n\n\n    \n127\nExp\nNR\n77.4 (6.9)\n\n\n    Partridge 2017\n\n105\nStd\nNR\n75.5 (6.3)\n\n\n    \n104\nExp\nNR\n75.5 (6.6)\n\n\n  \n  \n  \n    \n       Exp: expanded preoperative evaluation; Std: standard preoperative evaluation; NR: not reported.\n    \n    \n      a ASA Physical Status.\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n  \n\n\n\n\n\n\nEvaluation Components\n Table 9. Components of expanded preoperative evaluation and interventions prompted. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      \n      \n        Assessments\n      \n      \n        Interventions\n      \n    \n    \n      Study\n      ERAS\n      \n        General\n      \n      \n        Targeted\n      \n      \n        Patient Education\n      \n      \n        Staff\n      \n    \n    \n      CGA\n      Multidisciplinary\n      Meds/Comorbidity\n      Nutrition\n      Other\n      Frailty\n      Cognitive\n      Physical Function\n      Psychosocial\n      Nutrition\n      Physical activity\n      Procedure\n      Social Ties\n      Other\n      Rx/comorbidities\n      Deprescribing\n      Geriatric Visits\n      Multidisciplinary\n      Nutritional Suppl\n      Treatment Plan\n      Other\n      Active Delirium Screen\n    \n  \n  \n    \n      HipFx — Randomized Clinical Trial\n    \n    Marcantonio 2001\n\n\n ●a\n\n\n\n\n\n\n\n\n\n ●\n\n\n\n\n ●\n ●\n ￭\n ●\n ●\n ●\n ●\n    Shyu 2005\n\n\n ●a\n\n\n\n\n\n\n\n\n\n ○\n\n\n\n\n\n ●\n ●\n\n ●\n\n\n    Vidan 2005\n\n\n ●a\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n ●\n ●\n\n\n\n\n    Shyu 2008\n\n\n ●a\n\n\n\n\n\n\n\n\n\n ○\n\n\n\n\n\n ●\n ●\n\n ●\n\n\n    Watne 2014\n\n\n ●a\n\n\n\n\n\n\n\n\n ●\n ￭\n\n ●\n\n\n\n\n ●\n ●\n ●\n\n\n    Prestmo 2015\n\n\n ●a\n\n\n\n\n\n\n\n\n ●\n ●\n\n ●\n\n ●\n\n\n ●\n\n ●\n\n\n    Zhu 2022\n\n\n ●a\n\n\n\n\n\n\n\n\n ●\n ●\n\n ●\n\n ●\n\n\n\n\n\n\n\n    \n      HipFx — Before-After/Time Series\n    \n    Bjorkelund 2010\n\n\n\n\n\n\n\n\n ●\n\n\n\n\n\n\n\n\n ●\n ●\n ●\n ●\n\n ●\n ●\n    Vochteloo 2011\n\n\n\n\n\n\n\n\n ●\n\n\n\n\n\n\n\n\n\n\n\n\n\n ●\n ●\n    \n      Other Ortho — Before-After/Time Series\n    \n    Olsson 2014\n\n\n\n\n\n\n\n\n\n ●\n ●\n\n ●\n ￭\n ●\n\n\n\n\n\n\n ●\n\n\n    Romano 2021\n\n  x\n\n ●\n ￭\n ●\n\n\n\n\n ●\n ●\n ●\n\n ●\n\n ●\n\n\n ●\n\n ●\n\n\n    \n      GI/Abd — Randomized Clinical Trial\n    \n    Ommundsen 2018\n\n  x\n ●a\n\n\n\n\n ○\n\n\n\n ●\n ●\n\n ●\n\n ●\n ●\n\n ●\n ●\n ●\n\n\n    \n      GI/Abd — Before-After/Time Series\n    \n    Indrakusuma 2015\n\n\n\n\n\n\n ●\n\n ●\n ●\n\n\n\n\n\n\n\n\n ●\n ●\n ●\n ●\n ●\n\n    Souwer 2018\n\n  x\n\n ●\n ￭\n ￭\n\n ￭\n ￭\n ●\n ●\n ●\n ●\n\n\n\n ●\n\n\n ●\n\n ●\n\n\n    Giannotti 2022\n\n  x\n ￭a,b\n\n\n\n\n\n\n\n\n ●\n ●\n\n\n\n ●\n\n ●\n ￭\n\n\n\n\n    \n      GI/Abd — Retrospective Cohort\n    \n    T-Santabalbina 2019\n\n\n ●a\n\n\n\n\n\n\n\n\n\n\n\n ●\n\n\n ●\n\n ￭\n ●\n ●\n\n ●\n    \n      Various — Randomized Clinical Trial\n    \n    Hempenius 2013\n\n\n ●a\n\n\n\n\n ○\n\n\n\n\n\n\n\n\n\n\n ￭\n ●\n\n ●\n\n\n    Hempenius 2016\n\n\n ●a\n\n\n\n\n ○\n\n\n\n\n\n\n\n\n\n\n ●\n ●\n\n ●\n\n\n    Partridge 2017\n\n\n ●a\n\n ○\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n ●\n\n ●\n\n\n    \n      Various — Before-After/Time Series\n    \n    Richter 2005\n\n\n\n\n ○\n ●\n\n\n ●\n ￭\n ￭\n\n\n\n\n\n\n\n\n\n\n ●\n\n\n    Bakker 2014\n\n\n ●a\n\n\n\n\n\n\n\n\n ●\n ●\n\n ●\n\n\n ●\n ●\n ●\n\n ●\n\n\n    Ernst 2014\n\n\n\n\n\n\n ●\n ●\n\n\n\n\n\n\n\n ●\n\n\n\n ●\n\n ●\n\n\n    Hall 2017\n\n\n\n\n\n\n\n ●\n\n\n\n\n\n ●\n\n ●\n\n\n\n ●\n\n ●\n\n\n    McDonald 2018\n\n  x\n\n\n ●\n ●\n ●\n\n ●\n ●\n ●\n ●\n ●\n\n ●\n\n ●\n ●\n ●\n ●\n\n ●\n\n\n    Lester 2022\n\n\n\n ●\n ●\n ●\n ●\n\n ●\n ●\n\n ●\n\n\n\n\n\n ●\n ●\n ●\n\n ●\n\n\n    \n      Various — Prospective Cohort\n    \n    Jones 2021\n\n\n\n\n\n ●\n ●\n ●\n ●\n ●\n\n\n ●\n\n\n\n\n ●\n\n ●\n\n ●\n ●\n\n    \n      Neuro — Before-After/Time Series\n    \n    Adogwa 2017\n\n\n\n ●\n ●\n\n\n\n\n\n\n\n\n\n\n\n ●\n\n ●\n ●\n\n\n\n\n    \n      Urol — Before-After/Time Series\n    \n    Braude 2017\n\n\n ●a\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n ●\n\n ●\n\n\n    \n      HipFx — Nonrandomized Trial\n    \n    Deschodt 2011\n\n\n ●a\n\n\n\n\n\n ○\n ○\n ○\n\n\n\n\n\n\n ●\n\n ●\n ●\n\n ￭\n\n  \n  \n  \n    \n       ERAS: enhanced recovery after surgery; CGA: comprehensive geriatric assessment; GI: gastrointestinal; Abd: abdominal; Suppl: supplement;  ● expanded evaluation only; ￭ in expanded and standard evaluation arms; ◦ in standard evaluation arms only\n    \n    \n      a When a comprehensive geriatric assessment (CGA) was conducted, all components were presumed included. \n    \n    \n      b Selective comprehensive geriatric assessment in standard arm."
  },
  {
    "objectID": "kq1.html#delirium-incidence",
    "href": "kq1.html#delirium-incidence",
    "title": "Expanded Preoperative Evaluation",
    "section": "Delirium Incidence",
    "text": "Delirium Incidence\n Table 10. Delirium incidence with expanded versus standard preoperative evaluation. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n      MMSE   (preop)a\n      Scale\n      Day(s)b\n      Surgery\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Marcantonio 2001\n\n64\nStd\n\nCAM\nStay\nHipFx\n 32 (50.0)\n\n\n—\n    \n62\nExp\n\n\n\n\n 20 (32.3)\n\n\n0.65 (0.42-1.00)\n    Vidan 2005\n\n164\nStd\n\nCAM\nStay\nHipFx\n 67 (40.9)\n\n\n—\n    \n155\nExp\n\n\n\n\n 53 (34.2)\n\n\n0.84 (0.63-1.11)\n    Watne 2014\n\n166\nStd\n\nCAM\n10\nHipFx\n 86 (51.8)\n\n\n—\n    \n163\nExp\n\n\n\n\n 80 (49.1)\n\n\n0.95 (0.76-1.17)\n    Zhu 2022\n\n85\nStd\n\nDSM\nStay\nHipFx\n 27 (31.8)\n\n\n—\n    \n70\nExp\n\n\n\n\n 15 (21.4)\n\n\n0.67 (0.39-1.16)\n    Hempenius 2013\n\n133\nStd\n26.3 (3.9)\n\nDOS/DSM\n10\nVarious\n 19 (14.3)\n\n\n—\n    \n127\nExp\n26.7 (3.0)\n\n\n\n\n 12 (9.4)\n\n\n0.66 (0.33-1.31)\n    Partridge 2017\n\n91\nStd\n\nNR\nStay\nVarious\n 22 (24.2)\n\n\n—\n    \n85\nExp\n\n\n\n\n  9 (10.6)\n\n\n0.44 (0.21-0.90)\n    \n      Before-After/Time Series\n    \n    Bjorkelund 2010\n\n132\nStd\n\nDSM/other\nStay\nHipFx\n 45 (34.1)\n\n\n—\n    \n131\nExp\n\n\n\n\n 29 (22.1)\n\n\n0.65 (0.44-0.97)\n    Vochteloo 2011\n\nc \nStdd\n\nDSM\nStay\nHipFx\n(29.0)\n\n\n—\n    \nc \nStde\n\n\n\n\n(23.9)\n\n\n—\n    \nc \nStdf\n\n\n\n\n(27.8)\n\n\n—\n    \n378\nExp\n\n\n\n\n102 (27.0)\n\n\n—\n    Indrakusuma 2015\n\n222\nStd\n\nDOS/other\nStay\nGI/Abd\n 27 (12.2)\n\n\n—\n    \n221\nExp\n\n\n\n\n 22 (10.0)\n\n\n0.82 (0.48-1.39)\n    Bakker 2014\n\n120\nStd\n26.6 (3.7)\n\nCAM\n30\nVarious\n 16 (13.3)\n\n\n—\n    \n121\nExp\n27.3 (2.6)\n\n\n\n\n 15 (12.4)\n\n\n0.93 (0.48-1.79)\n    Lester 2022\n\n210\nStd\n\nCAM\nStay\nVarious\n 25 (11.9)\n\n\n—\n    \n182\nExp\n\n\n\n\n 12 (6.6)\n\n\n0.55 (0.29-1.07)\n    Adogwa 2017\n\n25\nStd\n\nNR\nStay\nNeuro\n  4 (16.0)\n\n\n—\n    \n100\nExp\n\n\n\n\n 18 (18.0)\n\n\n1.12 (0.42-3.03)\n    \n      Retrospective Cohort\n    \n    T-Santabalbina 2019\n\n107\nStd\n\nCAM\nStay\nGI/Abd\n 31 (29.0)\n\n\n—\n    \n203\nExp\n\n\n\n\n 23 (11.3)\n\n\n0.39 (0.24-0.64)\n  \n  \n  \n    \n       RR: risk ratio; MMSE: Mini-Mental State Examination; CAM: Confusion Assessment Method; DI: Delirium Index; DRS: Delirium Rating Scale; DOS: delirium observation screening; DSM: Diagnostic and Statistical Manual of Mental Disorders; NR: not reported; HipFx: hip fracture; GI/Abd: gastrointestinal or abdominal.\n    \n    \n      a Mean Med (SD) [Range] {IQR}.\n    \n    \n      b Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n    \n      c N = 611 for the 3 years of standard evaluation (2005-2007); outcomes reported by year separately.\n    \n    \n      d 2005.\n    \n    \n      e 2006.\n    \n    \n      f 2007.\n    \n  \n\n\n\n\n\nPooled\n Figure 1. Expanded versus standard preoperative evaluation (delirium incidence; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – .\n\n Figure 2. Expanded versus standard preoperative evaluation (delirium incidence; nonrandomized designs). \n\n\n\n\n\n\n\n\n\n RR: risk ratio; D1: Bias due to confounding; D2: Bias in selection of participants into the study; D3: Bias in classification of interventions; D4: Bias due to deviations from intended interventions; D5: Bias due to missing data; D6: Bias in measurement of outcomes; D7: Bias in selection of reported results; All: overall risk of bias. Risk of bias ratings: low ++, moderate +, serious -, critical - - ; NI: no information; NA: not applicable. Sensitivity analysis including Vochteloo 2011 assuming effectively equal numbers of participants studied each year, obtained RR 0.68 (95% CI, 0.50–0.92; I 2 = 64%). \n\n\nExploratory NMA\n\n\n\n\n\n\n Exploratory component network meta-analysis including all designs. Assumes that a comprehensive geriatric assessment incorporates all components. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Exploratory component network meta-analysis including all designs. Assumes that a comprehensive geriatric assessment incorporates all components."
  },
  {
    "objectID": "kq1.html#delayed-neurocognitive-recovery",
    "href": "kq1.html#delayed-neurocognitive-recovery",
    "title": "Expanded Preoperative Evaluation",
    "section": "Delayed Neurocognitive Recovery",
    "text": "Delayed Neurocognitive Recovery\n Table 11. Delayed neurocognitive recovery incidence and ascertainment (expanded versus standard preoperative evaluation; randomized and nonrandomized designs). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Drug\n      \n        Preop\n      \n      \n        Instrument\n      \n      \n        Delayed Neurocognitive Recovery\n      \n    \n    \n      MMSE\n      MMSE\n      DST\n      MoCA\n      Other\n      N (%)\n      0 — 100%\n      RR (95% CI)\n    \n  \n  \n    \n      Before-After/Time Series — Various Procedures\n    \n    Bakker 2014\n\n84\nStd\n26.6 (3.7)\n\n✓\n\n\n\n\n16 (19.0)\n\n\n—\n    \n96\nExp\n27.3 (2.6)\n\n\n\n\n\n13 (13.5)\n\n\n0.71 (0.36-1.39)\n  \n  \n  \n    \n       Mini-Mental State Exam; DST: Digit Span Test; MoCA: Montreal Cognitive Assessment; RR: risk ratio."
  },
  {
    "objectID": "kq1.html#physical-function",
    "href": "kq1.html#physical-function",
    "title": "Expanded Preoperative Evaluation",
    "section": "Physical Function",
    "text": "Physical Function\n Table 12. Physical functional status for expanded versus standard preoperative evaluation (randomized* and nonrandomized designs). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N\n      Arm\n          Agea\n      Scale\n      Range\n      Days\n      Ratinga\n      SMD (95% CI)\n      Surgery\n    \n  \n  \n    \n      &lt;30 days\n    \n    Deschodt 2011\n\n77\nStd\n81.1 (7.2)\n\nKatz Index\n0→18\n8\n12.9 (2.5)\n\n\nHipFx\n    \n94\nExp\n80.4 (7.0)\n\n\n\n\n12.0 (2.7)\n\n-0.34 (-0.65 to -0.04)\n\n    Zhu 2022*\n\n85\nStd\n81.8\n\nBarthel Index\n0→100\n21\n51.7\n\n\nHipFx\n    \n70\nExp\n79.5\n\n\n\n\n50.5\n\n-0.10 (-0.42 to 0.22)\n\n    Bakker 2014\n\n80\nStd\n76.5 (4.9)\n\nGARS\n44→11\n8\nb\n\nVarious\n    \n98\nExp\n76.0 (5.1)\n\n\n\n\nb\n0.29 (-0.01 to 0.59)c\n\n    Hempenius 2016*\n\n133\nStd\n77.4 (7.7)\n\nSF-36 physical\n0→100\n10\n49.3 (7.0)\n\n\nVarious\n    \n127\nExp\n77.4 (6.9)\n\n\n\n\n48.4 (9.1)\n\n-0.12 (-0.36 to 0.13)\n\n    \n      30-90 days\n    \n    Prestmo 2015*\n\n169\nStd\n83.2 (6.4)\n\nBarthel Index\n0→20\n30\n14.2 (3.8)\n\n\nHipFx\n    \n179\nExp\n83.4 (5.4)\n\n\n\n\n14.5 (3.7)\n\n0.08 (-0.13 to 0.29)\n\n    Shyu 2005*\n\n68\nStd\n77.7 (7.1)\n\nSF-36 physical\n\n30\n73.8 (19.3)\n\n\nHipFx\n    \n66\nExp\n77.6 (8.3)\n\n\n\n\n81.4 (14.4)\n\n0.44 (0.10 to 0.79)\n\n    Shyu 2005*\n\n63\nStd\n77.7 (7.1)\n\nSF-36 physical\n\n90\n79.3 (21.3)\n\n\nHipFx\n    \n63\nExp\n77.6 (8.3)\n\n\n\n\n89.8 (12.9)\n\n0.59 (0.24 to 0.95)\n\n    Shyu 2008*\n\n76\nStd\n78.9 (7.3)\n\n\n\n30\n72.9 (19.8)\n\n\nHipFx\n    \n71\nExp\n77.4 (8.2)\n\n\n\n\n81.2 (15.5)\n\n0.46 (0.14 to 0.79)\n\n    Shyu 2008*\n\n70\nStd\n78.9 (7.3)\n\n\n\n90\n79.9 (20.0)\n\n\nHipFx\n    \n67\nExp\n77.4 (8.2)\n\n\n\n\n88.8 (13.4)\n\n0.52 (0.18 to 0.86)\n\n    Bakker 2014\n\n62\nStd\n76.5 (4.9)\n\nGARS\n44→11\n90\nb\n\nVarious\n    \n81\nExp\n76.0 (5.1)\n\n\n\n\nb\n-0.36 (-0.69 to -0.03)c\n\n    Richter 2005\n\n30\nStd\n72.6 (8.3)\n\nSF-36 physical\n0→100\n42\n37.6 (7.5)\n\n\nVarious\n    \n32\nExp\n70.9 (6.3)\n\n\n\n\n39.0 (8.3)\n\n0.17 (-0.32 to 0.67)\n\n    \n      &gt;90 days\n    \n    Prestmo 2015*\n\n165\nStd\n83.2 (6.4)\n\nBarthel Index\n0→20\n120\n15.3 (3.7)\n\n\nHipFx\n    \n168\nExp\n83.4 (5.4)\n\n\n\n\n16.3 (3.7)\n\n0.27 (0.05 to 0.49)\n\n    Watne 2014*\n\n120\nStd\n85.0 {46-101}\n\nBarthel Index\n0→20\n120\n16 [12-20]\n\n\nHipFx\n    \n119\nExp\n84.0 {55-99}\n\n\n\n\n17 [10-20]\n\n-0.09 (-0.34 to 0.16)\n\n    Watne 2014*\n\n93\nStd\n85.0 {46-101}\n\nBarthel Index\n0→20\n365\n16 [11-19]\n\n\nHipFx\n    \n97\nExp\n84.0 {55-99}\n\n\n\n\n17 [10-19]\n\n-0.06 (-0.34 to 0.23)\n\n    Richter 2005\n\n30\nStd\n72.6 (8.3)\n\nSF-36 physical\n0→100\n180\n49.2 (10.4)\n\n\nVarious\n    \n32\nExp\n70.9 (6.3)\n\n\n\n\n45.3 (10.9)\n\n-0.36 (-0.86 to 0.14)\n\n  \n  \n  \n    \n       SMD: standardized mean difference; GARS: Groningen Activity Restriction Scale.\n    \n    \n       * Randomized clinical trial.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Study reported only difference scores.\n    \n    \n      c For scale reverse to be consistent with other studies.\n    \n  \n\n\n\n\n\nPooled\n Figure 3. Pooled results for physical functional status for expanded versus standard preoperative evaluation (higher is better; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n Multilevel model fitted accounting for study reporting at more than one time point. \n\n Figure 4. Pooled results for physical functional status for expanded versus standard preoperative evaluation (higher is better; before-after studies). \n\n\n\n\n\n\n\n\n\n Multilevel model fitted accounting for reporting at more than one time point."
  },
  {
    "objectID": "kq1.html#complications",
    "href": "kq1.html#complications",
    "title": "Expanded Preoperative Evaluation",
    "section": "Complications",
    "text": "Complications\n Table 13. Reported complications in expanded versus standard preoperative evaluation — cardiac, pulmonary, and acute kidney injury (randomized and nonrandomized designs). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n          Agea\n      N (%)\n      0 – 100%\n      RD (95% CI)\n      Surgery\n    \n  \n  \n    \n      Cardiac Arrest – Randomized Clinical Trial\n    \n    Partridge 2017\n\n91\nStd\n75.5 (6.3)\n\n 5 (5.5)\n\n\n—\nVarious\n    \n85\nExp\n75.5 (6.6)\n\n 1 (1.2)\n\n\n-4.3% (-9.5, 0.9)\n\n    \n      Cardiac Arrest – Before-After/Time Series\n    \n    McDonald 2018\n\n143\nStd\n71.9 (6.4)\n\n 2 (1.4)\n\n\n—\nVarious\n    \n183\nExp\n75.6 (6.8)\n\n 1 (0.5)\n\n\n-0.9% (-3.1, 1.3)\n\n    \n      MI – Randomized Clinical Trial\n    \n    Vidan 2005\n\n164\nStd\n82.6 (7.4)\n\n 1 (0.6)\n\n\n—\nHipFx\n    \n155\nExp\n81.1 (7.8)\n\n 0 (0.0)\n\n\n-0.6% (-2.3, 1.1)\n\n    \n      MI – Before-After/Time Series\n    \n    Bjorkelund 2010\n\n132\nStd\n82.0 (7.6)\n\n 5 (3.8)\n\n\n—\nHipFx\n    \n131\nExp\n81.1 (7.5)\n\n 3 (2.3)\n\n\n-1.5% (-5.6, 2.6)\n\n    Adogwa 2017\n\n25\nStd\n73.0 (4.9)\n\n 1 (4.0)\n\n\n—\nNeuro\n    \n100\nExp\n73.6 (6.0)\n\n 1 (1.0)\n\n\n-3.0% (-10.9, 4.9)\n\n    Lester 2022\n\n250\nStd\n82.7 {78-87}\n\n 0 (0.0)\n\n\n—\nVarious\n    \n242\nExp\n81.1 {78-86}\n\n 2 (0.8)\n\n\n0.8% (-0.6, 2.2)\n\n    McDonald 2018\n\n143\nStd\n71.9 (6.4)\n\n 5 (3.5)\n\n\n—\nVarious\n    \n183\nExp\n75.6 (6.8)\n\n 3 (1.6)\n\n\n-1.9% (-5.4, 1.7)\n\n    \n      Other Cardiac – Randomized Clinical Trial\n    \n    Watne 2014b\n166\nStd\n85.0 {46-101}\n\n19 (11.4)\n\n\n—\nHipFx\n    \n163\nExp\n84.0 {55-99}\n\n22 (13.5)\n\n\n2.1% (-5.1, 9.2)\n\n    Hempenius 2013c\n133\nStd\n77.6 (7.7)\n\n37 (27.8)\n\n\n—\nVarious\n    \n127\nExp\n77.5 (6.7)\n\n40 (31.5)\n\n\n3.7% (-7.4, 14.8)\n\n    Partridge 2017d\n91\nStd\n75.5 (6.3)\n\n25 (27.5)\n\n\n—\nVarious\n    \n85\nExp\n75.5 (6.6)\n\n 7 (8.2)\n\n\n-19.2% (-30.1, -8.4)\n\n    \n      Other Cardiac – Before-After/Time Series\n    \n    Giannotti 2022b\n117\nStd\n82.0 {78-85}\n\n25 (21.4)\n\n\n—\nGI/Abd\n    \n90\nExp\n79.0 {76-83}\n\n16 (17.8)\n\n\n-3.6% (-14.4, 7.3)\n\n    Indrakusuma 2015b\n222\nStd\n77.0 {73-81}\n\n28 (12.6)\n\n\n—\nGI/Abd\n    \n221\nExp\n77.0 {74-82}\n\n32 (14.5)\n\n\n1.9% (-4.5, 8.2)\n\n    Souwer 2018b\n63\nStd\n81.4 {74-89}\n\n 5 (7.9)\n\n\n—\nGI/Abd\n    \n86\nExp\n80.6 {74-87}\n\n 0 (0.0)\n\n\n-7.9% (-15.0, -0.9)\n\n    Bjorkelund 2010e\n132\nStd\n82.0 (7.6)\n\n11 (8.3)\n\n\n—\nHipFx\n    \n131\nExp\n81.1 (7.5)\n\n 7 (5.3)\n\n\n-3.0% (-9.1, 3.1)\n\n    McDonald 2018f\n143\nStd\n71.9 (6.4)\n\n45 (31.5)\n\n\n—\nVarious\n    \n183\nExp\n75.6 (6.8)\n\n40 (21.9)\n\n\n-9.6% (-19.3, 0.1)\n\n    \n      Pulmonary – Randomized Clinical Trial\n    \n    Watne 2014b\n166\nStd\n85.0 {46-101}\n\n13 (7.8)\n\n\n—\nHipFx\n    \n163\nExp\n84.0 {55-99}\n\n21 (12.9)\n\n\n5.1% (-1.5, 11.6)\n\n    Hempenius 2013b\n133\nStd\n77.6 (7.7)\n\n27 (20.3)\n\n\n—\nVarious\n    \n127\nExp\n77.5 (6.7)\n\n31 (24.4)\n\n\n4.1% (-6.0, 14.2)\n\n    Partridge 2017g\n91\nStd\n75.5 (6.3)\n\n13 (14.3)\n\n\n—\nVarious\n    \n85\nExp\n75.5 (6.6)\n\n 8 (9.4)\n\n\n-4.9% (-14.4, 4.6)\n\n    \n      Pneumonia – Randomized Clinical Trial\n    \n    Vidan 2005\n\n164\nStd\n82.6 (7.4)\n\n 6 (3.7)\n\n\n—\nHipFx\n    \n155\nExp\n81.1 (7.8)\n\n 6 (3.9)\n\n\n0.2% (-4.0, 4.4)\n\n    Partridge 2017\n\n91\nStd\n75.5 (6.3)\n\n12 (13.2)\n\n\n—\nVarious\n    \n85\nExp\n75.5 (6.6)\n\n 8 (9.4)\n\n\n-3.8% (-13.1, 5.5)\n\n    \n      Pneumonia – Before-After/Time Series\n    \n    Giannotti 2022\n\n117\nStd\n82.0 {78-85}\n\n26 (22.2)\n\n\n—\nGI/Abd\n    \n90\nExp\n79.0 {76-83}\n\n10 (11.1)\n\n\n-11.1% (-21.1, -1.2)\n\n    Indrakusuma 2015\n\n222\nStd\n77.0 {73-81}\n\n31 (14.0)\n\n\n—\nGI/Abd\n    \n221\nExp\n77.0 {74-82}\n\n37 (16.7)\n\n\n2.8% (-3.9, 9.5)\n\n    Bjorkelund 2010\n\n132\nStd\n82.0 (7.6)\n\n 3 (2.3)\n\n\n—\nHipFx\n    \n131\nExp\n81.1 (7.5)\n\n 6 (4.6)\n\n\n2.3% (-2.1, 6.7)\n\n    Adogwa 2017\n\n25\nStd\n73.0 (4.9)\n\n 1 (4.0)\n\n\n—\nNeuro\n    \n100\nExp\n73.6 (6.0)\n\n 5 (5.0)\n\n\n1.0% (-7.8, 9.8)\n\n    Lester 2022\n\n250\nStd\n82.7 {78-87}\n\n 2 (0.8)\n\n\n—\nVarious\n    \n242\nExp\n81.1 {78-86}\n\n 1 (0.4)\n\n\n-0.4% (-1.8, 1.0)\n\n    McDonald 2018\n\n143\nStd\n71.9 (6.4)\n\n 2 (1.4)\n\n\n—\nVarious\n    \n183\nExp\n75.6 (6.8)\n\n 3 (1.6)\n\n\n0.2% (-2.4, 2.9)\n\n    \n      Respiratory Failure – Before-After/Time Series\n    \n    McDonald 2018\n\n143\nStd\n71.9 (6.4)\n\n21 (14.7)\n\n\n—\nVarious\n    \n183\nExp\n75.6 (6.8)\n\n16 (8.7)\n\n\n-5.9% (-13.0, 1.2)\n\n    \n      Ventilator &gt;48hr – Before-After/Time Series\n    \n    McDonald 2018\n\n143\nStd\n71.9 (6.4)\n\n 2 (1.4)\n\n\n—\nVarious\n    \n183\nExp\n75.6 (6.8)\n\n 0 (0.0)\n\n\n-1.4% (-3.7, 0.9)\n\n    \n      PE – Before-After/Time Series\n    \n    Bjorkelund 2010\n\n132\nStd\n82.0 (7.6)\n\n 2 (1.5)\n\n\n—\nHipFx\n    \n131\nExp\n81.1 (7.5)\n\n 2 (1.5)\n\n\n0.0% (-2.9, 3.0)\n\n    Adogwa 2017\n\n25\nStd\n73.0 (4.9)\n\n 0 (0.0)\n\n\n—\nNeuro\n    \n100\nExp\n73.6 (6.0)\n\n 2 (2.0)\n\n\n2.0% (-4.1, 8.1)\n\n    McDonald 2018\n\n143\nStd\n71.9 (6.4)\n\n 1 (0.7)\n\n\n—\nVarious\n    \n183\nExp\n75.6 (6.8)\n\n 2 (1.1)\n\n\n0.4% (-1.6, 2.4)\n\n    \n      Renal – Randomized Clinical Trial\n    \n    Watne 2014\n\n166\nStd\n85.0 {46-101}\n\n 2 (1.2)\n\n\n—\nHipFx\n    \n163\nExp\n84.0 {55-99}\n\n 6 (3.7)\n\n\n2.5% (-0.9, 5.8)\n\n    Hempenius 2013\n\n133\nStd\n77.6 (7.7)\n\n 2 (1.5)\n\n\n—\nVarious\n    \n127\nExp\n77.5 (6.7)\n\n 5 (3.9)\n\n\n2.4% (-1.5, 6.4)\n\n    \n      Renal – Before-After/Time Series\n    \n    Giannotti 2022\n\n117\nStd\n82.0 {78-85}\n\n41 (35.0)\n\n\n—\nGI/Abd\n    \n90\nExp\n79.0 {76-83}\n\n25 (27.8)\n\n\n-7.3% (-19.9, 5.4)\n\n    Bjorkelund 2010\n\n132\nStd\n82.0 (7.6)\n\n 2 (1.5)\n\n\n—\nHipFx\n    \n131\nExp\n81.1 (7.5)\n\n 1 (0.8)\n\n\n-0.8% (-3.3, 1.8)\n\n    McDonald 2018\n\n143\nStd\n71.9 (6.4)\n\n13 (9.1)\n\n\n—\nVarious\n    \n183\nExp\n75.6 (6.8)\n\n15 (8.2)\n\n\n-0.9% (-7.1, 5.3)\n\n  \n  \n  \n    \n       RD: risk difference; GI: gastrointestinal; Abd: abdominal; Ortho: orthopedic; Neuro: neurologic.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Unspecified.\n    \n    \n      c Arrhythmia, cardiac failure.\n    \n    \n      d Acute coronary syndrome, heart failure, tachyarrhythmia, or bradyarrhythmia.\n    \n    \n      e Cardiac failure.\n    \n    \n      f MI, cardiac arrest, ventricular fibrillation, dysrhythmia, or heart failure.\n    \n    \n      g Pneumonia, infectious exacerbation of chronic obstructive pulmonary disease (COPD).\n    \n  \n\n\n\n\n\nPooled\n\nMyocardial Infarction\n Figure 5. Risk ratio for myocardial infarction (expanded versus standard preoperative evaluation; nonrandomized designs). \n\n\n\n\n\n\n\n\n\n\n\nPulmonary\n Figure 6. Risk ratio for complications reported as “pulmonary” (expanded versus standard preoperative evaluation; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n Hempenius 2013 and Watne 2014 unspecified; Partidge 2017 pneumonia, infectious exacerbation of chronic obstructive pulmonary disease (COPD). \n\n\n\nPneumonia\n Figure 7. Risk ratio for pneumonia (expanded versus standard preoperative evaluation; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n\n Figure 8. Risk ratio for pneumonia (expanded versus standard preoperative evaluation; nonrandomized designs). \n\n\n\n\n\n\n\n\n\n\n\n\nPulmonary Embolism\n Figure 9. Risk ratio for pneumonia (expanded versus standard preoperative evaluation; nonrandomized designs). \n\n\n\n\n\n\n\n\n\n\n\n\nRenal\n Figure 10. Risk ratio for renal complications (expanded versus standard preoperative evaluation; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n Figure 11. Risk ratio for renal complications (expanded versus standard preoperative evaluation; nonrandomized designs)."
  },
  {
    "objectID": "kq1.html#length-of-stay",
    "href": "kq1.html#length-of-stay",
    "title": "Expanded Preoperative Evaluation",
    "section": "Length of Stay",
    "text": "Length of Stay\n Table 15. Length of stay according to procedure classification and type of preoperative evaluation. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n      PSa\n          Ageb\n          LOSb\n      0 – 25 days\n      Country\n    \n  \n  \n    \n      Randomized Clinical Trial - HipFx\n    \n    Marcantonio 2001\n\n64\nStd\nNR\n80.0 (8.0)\n\n5.0 {3-7}\n\n\n\nUSA\n    \n62\nExp\nNR\n78.0 (8.0)\n\n5.0 {3-7}\n\n\n\n\n    Shyu 2005\n\n69\nStd\nNR\n77.7 (7.1)\n\n10.2 (6.5)\n\n\n\nTaiwan\n    \n68\nExp\nNR\n77.6 (8.3)\n\n10.1 (3.7)\n\n\n\n\n    Vidan 2005\n\n164\nStd\nNR\n82.6 (7.4)\n\n18.0 {13-24}\n\n\n\nSpain\n    \n155\nExp\nNR\n81.1 (7.8)\n\n16.0 {13-19}\n\n\n\n\n    Shyu 2008\n\n82\nStd\nNR\n78.9 (7.3)\n\n9.7 (5.0)\n\n\n\nTaiwan\n    \n80\nExp\nNR\n77.4 (8.2)\n\n10.1 (3.7)\n\n\n\n\n    Watne 2014\n\n166\nStd\nNR\n85.0 {46-101}\n\n8.0 {5-11}\n\n\n\nNorway\n    \n163\nExp\nNR\n84.0 {55-99}\n\n11.0 {8-15}\n\n\n\n\n    Prestmo 2015\n\n199\nStd\nNR\n83.2 (6.4)\n\n11.0 (0.5)\n\n\n\nNorway\n    \n198\nExp\nNR\n83.4 (5.4)\n\n12.6 (0.4)\n\n\n\n\n    Zhu 2022\n\n85\nStd\n1234\n81.8\n\n23.6\n\n\n\nChina\n    \n70\nExp\n1234\n79.5\n\n20.8\n\n\n\n\n    \n      Randomized Clinical Trial - GI/Abd\n    \n    Ommundsen 2018\n\n63\nStd\nNR\n78.8 (7.8)\n\n8.0\n\n\n\nNorway\n    \n53\nExp\nNR\n78.2 (7.4)\n\n8.0\n\n\n\n\n    \n      Before-After/Time Series - GI/Abd\n    \n    Indrakusuma 2015\n\n222\nStd\nNR\n77.0 {73-81}\n\n9.0 {7-14}\n\n\n\nNetherlands\n    \n221\nExp\nNR\n77.0 {74-82}\n\n7.0 {5-12}\n\n\n\n\n    Giannotti 2022\n\n117\nStd\nNR\n82.0 {78-85}\n\n9.0 {8-14}\n\n\n\nItaly\n    \n90\nExp\nNR\n79.0 {76-83}\n\n9.0 {7-14}\n\n\n\n\n    \n      Retrospective Cohort - GI/Abd\n    \n    T-Santabalbina 2019\n\n107\nStd\n1234\n75.3 (5.1)\n\n9.0 {8-13}\n\n\n\nSpain\n    \n203\nExp\n1234\n77.5 (4.8)\n\n11.0 {9-17}\n\n\n\n\n    \n      Randomized Clinical Trial - Various\n    \n    Hempenius 2013\n\n149\nStd\nNR\n77.6 (7.7)\n\n8.0 [1-44]\n\n\n\nNetherlands\n    \n148\nExp\nNR\n77.5 (6.7)\n\n8.0 [1-135]\n\n\n\n\n    Partridge 2017\n\n105\nStd\nNR\n75.5 (6.3)\n\n5.5c\n\n\nUK\n    \n104\nExp\nNR\n75.5 (6.6)\n\n3.3c\n\n\n\n    \n      Before-After/Time Series - Various\n    \n    Bakker 2014\n\n120\nStd\nNR\n76.5 (4.9)\n\n8.3 (8.4)\n\n\n\nNetherlands\n    \n121\nExp\nNR\n76.0 (5.1)\n\n8.3 (7.0)\n\n\n\n\n    McDonald 2018\n\n143\nStd\nNR\n71.9 (6.4)\n\n6.0 [1-60]\n\n\n\nUSA\n    \n183\nExp\nNR\n75.6 (6.8)\n\n4.0 [1-75]\n\n\n\n\n    Lester 2022\n\n250\nStd\nNR\n82.7 {78-87}\n\n3.0 {2-6}\n\n\n\nUSA\n    \n242\nExp\nNR\n81.1 {78-86}\n\n3.0 {2-6}\n\n\n\n\n    \n      Prospective Cohort - Various\n    \n    Jones 2021\n\n308\nStd\n 234\n80.0 (5.0)\n\n8.8 (11.8)\n\n\n\nUSA\n    \n158\nExp\n 234\n80.0 (5.0)\n\n5.4 (4.8)\n\n\n\n\n    \n      Before-After/Time Series - Other Ortho\n    \n    Olsson 2014\n\n138\nStd\n123 \n66.0 (13.9)\n\n5.3 (2.2)\n\n\n\nSweden\n    \n128\nExp\n123 \n68.0 (12.0)\n\n7.0 (5.0)\n\n\n\n\n    Romano 2021\n\n59\nStd\n123 \n73.0 {68-77}\n\n8.0 {8-10}\n\n\n\nItaly\n    \n122\nExp\n123 \n70.0 {64-77}\n\n5.0 {4-6}\n\n\n\n\n    \n      Before-After/Time Series - Neuro\n    \n    Adogwa 2017\n\n25\nStd\nNR\n73.0 (4.9)\n\n8.7 (6.1)\n\n\n\nUSA\n    \n100\nExp\nNR\n73.6 (6.0)\n\n6.1 (5.7)\n\n\n\n\n    \n      Before-After/Time Series - Urol\n    \n    Braude 2017\n\n101\nStd\nNR\n\n4.9 (4.4)\n\n\n\nUK\n    \n124\nExp\nNR\n\n4.0 (3.5)\n\n\n\n\n    \n      Nonrandomized Trial - HipFx\n    \n    Deschodt 2011\n\n77\nStd\nNR\n81.1 (7.2)\n\n12.4 (8.5)\n\n\n\nBelgium\n    \n94\nExp\nNR\n80.4 (7.0)\n\n11.1 (5.1)\n\n\n\n\n  \n  \n  \n    \n       NR: not reported\n    \n    \n      a ASA Physical Status.\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n    \n      c Geometric mean.\n    \n  \n\n\n\n\n\nPooled\n Figure 12. Mean difference in lengths of stay (expanded versus standard preoperative evaluation; randomized clinical trials). \n\n\n\n\n\n\n\n\n\nPartridge 2017 geometric means reported. Ommundsen 2018 reported only median and between-group p-value and was excluded. \n\n Figure 13. Mean difference in lengths of stay (expanded versus standard preoperative evaluation; nonrandomized designs). \n\n\n\n\n\n\n\n\n\n When the mean or standard deviation were not reported, they were imputed from from the median, interquartile range, and/or range."
  },
  {
    "objectID": "kq1.html#discharge-location",
    "href": "kq1.html#discharge-location",
    "title": "Expanded Preoperative Evaluation",
    "section": "Discharge Location",
    "text": "Discharge Location\n Table 16. Discharge location in studies comparing expanded with standard preoperative assessments. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n         Agea\n      Country\n      \n        Discharge to Institution\n      \n      RR (95% CI)\n    \n    \n      N (%)\n      0 — 100%\n    \n  \n  \n    \n      Randomized Clinical Trial — HipFx\n    \n    Marcantonio 2001\n\n64\nStd\n80.0 (8.0)\n\nUSA\n 56 (87.5)\n\n\n\n    \n62\nExp\n78.0 (8.0)\n\n\n 57 (91.9)\n\n\n1.05 (0.93-1.18)\n    Prestmo 2015\n\n187\nStd\n83.2 (6.4)\n\nNorway\n167 (89.3)\n\n\n\n    \n191\nExp\n83.4 (5.4)\n\n\n143 (74.9)\n\n\n0.84 (0.76-0.92)\n    \n      Randomized Clinical Trial — Various\n    \n    Hempenius 2013\n\n110\nStd\n77.6 (7.7)\n\nNetherlands\n 23 (20.9)\n\n\n\n    \n113\nExp\n77.5 (6.7)\n\n\n 37 (32.7)\n\n\n1.57 (1.00-2.45)\n    \n      Before-After/Time Series — Various\n    \n    Lester 2022\n\n250\nStd\n82.7 {78-87}\n\nUSA\n104 (41.6)\n\n\n\n    \n242\nExp\n81.1 {78-86}\n\n\n 98 (40.5)\n\n\n0.97 (0.79-1.20)\n    McDonald 2018\n\n143\nStd\n71.9 (6.4)\n\nUSA\n 70 (49.0)\n\n\n\n    \n183\nExp\n75.6 (6.8)\n\n\n 69 (37.7)\n\n\n0.77 (0.60-0.99)\n    \n      Randomized Clinical Trial — GI/Abd\n    \n    Ommundsen 2018\n\n63\nStd\n78.8 (7.8)\n\nNorway\n 25 (39.7)\n\n\n\n    \n53\nExp\n78.2 (7.4)\n\n\n 15 (28.3)\n\n\n0.71 (0.42-1.21)\n    \n      Before-After/Time Series — Neuro\n    \n    Adogwa 2017\n\n25\nStd\n73.0 (4.9)\n\nUSA\n 19 (76.0)\n\n\n\n    \n100\nExp\n73.6 (6.0)\n\n\n 46 (46.0)\n\n\n0.61 (0.45-0.82)\n    \n      Before-After/Time Series — Other Ortho\n    \n    Romano 2021\n\n59\nStd\n73.0 {68-77}\n\nItaly\n 57 (96.6)\n\n\n\n    \n122\nExp\n70.0 {64-77}\n\n\n 45 (36.9)\n\n\n0.38 (0.30-0.48)\n    \n      Nonrandomized Trial — HipFx\n    \n    Deschodt 2011\n\n77\nStd\n81.1 (7.2)\n\nBelgium\n 26 (33.8)\n\n\n\n    \n94\nExp\n80.4 (7.0)\n\n\n 30 (31.9)\n\n\n0.95 (0.61-1.45)\n  \n  \n  \n    \n       Exp: expanded preoperative evaluation; Std: standard preoperative evaluation; RR: risk ratio; Various: more that one procedure category.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n  \n\n\n\n\n\nPooled\n Figure 14. Pooled comparison of discharge location in studies comparing expanded with standard preoperative assessments (randomized clinical trials). \n\n\n\n\n\n\n\n\n\n\n Figure 15. Pooled comparison of discharge location in studies comparing expanded with standard preoperative assessments (nonrandomized designs)."
  },
  {
    "objectID": "kq1.html#mortality",
    "href": "kq1.html#mortality",
    "title": "Expanded Preoperative Evaluation",
    "section": "Mortality",
    "text": "Mortality\n Table 17. Reported mortality in randomized clinical trials.\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N  \n      Arm\n      Surgery\n      \n        ASA\n      \n      Agea\n      \n        Mortality\n      \n      RD (95% CI)\n    \n    \n      PS\n      N (%)\n      0 - 100%\n    \n  \n  \n    \n      Hospital\n    \n    Vidan 2005\n\n164\nStd\nHipFx\nNR\n82.6 (7.4)\n\n 9 (5.5)\n\n\n—\n    \n155\nExp\n\n\n81.1 (7.8)\n\n 1 (0.6)\n\n\n-4.8% (-8.5, -1.1)\n    Watne 2014\n\n166\nStd\nHipFx\nNR\n85.0 {46-101}\n\n 3 (1.8)\n\n\n—\n    \n163\nExp\n\n\n84.0 {55-99}\n\n 6 (3.7)\n\n\n1.9% (-1.7, 5.4)\n    Hempenius 2013\n\n133\nStd\nVarious\nNR\n77.6 (7.7)\n\n 4 (3.0)\n\n\n—\n    \n127\nExp\n\n\n77.5 (6.7)\n\n10 (7.9)\n\n\n4.9% (-0.6, 10.4)\n    \n      30-day\n    \n    Shyu 2005\n\n63\nStd\nHipFx\nNR\n77.7 (7.1)\n\n 0 (0.0)\n\n\n—\n    \n63\nExp\n\n\n77.6 (8.3)\n\n 0 (0.0)\n\n\n0.0% (-3.1, 3.1)\n    Shyu 2008\n\n76\nStd\nHipFx\nNR\n78.9 (7.3)\n\n 0 (0.0)\n\n\n—\n    \n71\nExp\n\n\n77.4 (8.2)\n\n 0 (0.0)\n\n\n0.0% (-2.6, 2.6)\n    Ommundsen 2018\n\n63\nStd\nGI/Abd\nNR\n78.8 (7.8)\n\n 3 (4.8)\n\n\n—\n    \n53\nExp\n\n\n78.2 (7.4)\n\n 2 (3.8)\n\n\n-1.0% (-8.3, 6.4)\n    \n      90-day\n    \n    Shyu 2005\n\n63\nStd\nHipFx\nNR\n77.7 (7.1)\n\n 1 (1.6)\n\n\n—\n    \n63\nExp\n\n\n77.6 (8.3)\n\n 0 (0.0)\n\n\n-1.6% (-5.9, 2.7)\n    Ommundsen 2018\n\n63\nStd\nGI/Abd\nNR\n78.8 (7.8)\n\n 4 (6.3)\n\n\n—\n    \n53\nExp\n\n\n78.2 (7.4)\n\n 3 (5.7)\n\n\n-0.7% (-9.3, 8.0)\n    Hempenius 2016\n\n133\nStd\nVarious\nNR\n77.4 (7.7)\n\n 9 (6.8)\n\n\n—\n    \n127\nExp\n\n\n77.4 (6.9)\n\n17 (13.4)\n\n\n6.6% (-0.7, 13.9)\n    \n      1-year\n    \n    Vidan 2005\n\n164\nStd\nHipFx\nNR\n82.6 (7.4)\n\n42 (25.6)\n\n\n—\n    \n155\nExp\n\n\n81.1 (7.8)\n\n29 (18.7)\n\n\n-6.9% (-16.0, 2.2)\n    Shyu 2008\n\n76\nStd\nHipFx\nNR\n78.9 (7.3)\n\n15 (19.7)\n\n\n—\n    \n71\nExp\n\n\n77.4 (8.2)\n\n13 (18.3)\n\n\n-1.4% (-14.1, 11.3)\n  \n  \n  \n    \n       ASA PS: American Society of Anesthesiologists Physical Status; NR: not reported; RD: risk difference; GI: gastrointestinal; Abd: abdominal (includes hepatic); Various: more that one procedure category.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n  \n\n\n\n\n\n Table 18. Reported mortality in nonrandomized designs (all retrospective cohort studies).\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N    \n      Arm\n      Surgery\n      \n        ASA\n      \n      Agea\n      \n        Mortality\n      \n      RD (95% CI)\n    \n    \n      PS\n      N (%)\n      0 - 100%\n    \n  \n  \n    \n      Hospital\n    \n    Deschodt 2011\n\n77\nStd\nHipFx\nNR\n81.1 (7.2)\n\n  0 (0.0)\n\n\n—\n    \n94\nExp\n\n\n80.4 (7.0)\n\n  1 (1.1)\n\n\n1.1% (-2.0, 4.1)\n    T-Santabalbina 2019\n\n107\nStd\nGI/Abd\n1234\n75.3 (5.1)\n\n  4 (3.7)\n\n\n—\n    \n203\nExp\n\n\n77.5 (4.8)\n\n  8 (3.9)\n\n\n0.2% (-4.3, 4.7)\n    McDonald 2018\n\n143\nStd\nVarious\nNR\n71.9 (6.4)\n\n  0 (0.0)\n\n\n—\n    \n183\nExp\n\n\n75.6 (6.8)\n\n  1 (0.5)\n\n\n0.5% (-1.1, 2.2)\n    \n      30-day\n    \n    Bjorkelund 2010\n\n132\nStd\nHipFx\n1234\n82.0 (7.6)\n\n  6 (4.5)\n\n\n—\n    \n131\nExp\n\n\n81.1 (7.5)\n\n  5 (3.8)\n\n\n-0.7% (-5.6, 4.1)\n    Indrakusuma 2015\n\n222\nStd\nGI/Abd\nNR\n77.0 {73-81}\n\n 17 (7.7)\n\n\n—\n    \n221\nExp\n\n\n77.0 {74-82}\n\n 14 (6.3)\n\n\n-1.3% (-6.1, 3.4)\n    Souwer 2018\n\n63\nStd\nGI/Abd\n1234\n81.4 {74-89}\n\n  2 (3.2)\n\n\n—\n    \n86\nExp\n\n\n80.6 {74-87}\n\n  2 (2.3)\n\n\n-0.8% (-6.2, 4.5)\n    T-Santabalbina 2019\n\n107\nStd\nGI/Abd\n1234\n75.3 (5.1)\n\n  5 (4.7)\n\n\n—\n    \n203\nExp\n\n\n77.5 (4.8)\n\n  9 (4.4)\n\n\n-0.2% (-5.1, 4.7)\n    Giannotti 2022\n\n117\nStd\nGI/Abd\nNR\n82.0 {78-85}\n\n  9 (7.7)\n\n\n—\n    \n90\nExp\n\n\n79.0 {76-83}\n\n  3 (3.3)\n\n\n-4.4% (-10.4, 1.7)\n    Ernst 2014\n\n160\nStd\nVarious\nNR\n68.3 (11.2)\n\n 51 (31.9)\n\n\n—\n    \n150\nExp\n\n\n71.3 (10.6)\n\n 32 (21.3)\n\n\n-10.5% (-20.3, -0.8)\n    Hall 2017\n\n5,275\nStd\nVarious\n1234\n60.3 (13.4)\n\n 84 (1.6)\n\n\n—\n    \n3,878\nExp\n\n\n60.3 (13.7)\n\n 26 (0.7)\n\n\n-0.9% (-1.3, -0.5)\n    Jones 2021\n\n308\nStd\nVarious\n 234\n80.0 (5.0)\n\n 12 (3.9)\n\n\n—\n    \n158\nExp\n\n\n80.0 (5.0)\n\n  4 (2.5)\n\n\n-1.4% (-4.6, 1.9)\n    Lester 2022\n\n250\nStd\nVarious\nNR\n82.7 {78-87}\n\n  6 (2.4)\n\n\n—\n    \n242\nExp\n\n\n81.1 {78-86}\n\n 10 (4.1)\n\n\n1.7% (-1.4, 4.9)\n    Braude 2017\n\n101\nStd\nUrol\nNR\n\n  3 (3.0)\n\n\n—\n    \n124\nExp\n\n\n\n  0 (0.0)\n\n\n-3.0% (-6.7, 0.7)\n    Adogwa 2017\n\n25\nStd\nNeuro\nNR\n73.0 (4.9)\n\n  0 (0.0)\n\n\n—\n    \n100\nExp\n\n\n73.6 (6.0)\n\n  0 (0.0)\n\n\n0.0% (-5.5, 5.5)\n    \n      90-day\n    \n    Giannotti 2022\n\n117\nStd\nGI/Abd\nNR\n82.0 {78-85}\n\n 12 (10.3)\n\n\n—\n    \n90\nExp\n\n\n79.0 {76-83}\n\n  9 (10.0)\n\n\n-0.3% (-8.5, 8.0)\n    \n      1-year\n    \n    Souwer 2018\n\n63\nStd\nGI/Abd\n1234\n81.4 {74-89}\n\n  7 (11.1)\n\n\n—\n    \n86\nExp\n\n\n80.6 {74-87}\n\n  3 (3.5)\n\n\n-7.6% (-16.3, 1.1)\n    T-Santabalbina 2019\n\n107\nStd\nGI/Abd\n1234\n75.3 (5.1)\n\n 10 (9.3)\n\n\n—\n    \n203\nExp\n\n\n77.5 (4.8)\n\n 23 (11.3)\n\n\n2.0% (-5.0, 9.0)\n    Giannotti 2022\n\n117\nStd\nGI/Abd\nNR\n82.0 {78-85}\n\n 16 (13.7)\n\n\n—\n    \n90\nExp\n\n\n79.0 {76-83}\n\n 17 (18.9)\n\n\n5.2% (-5.0, 15.4)\n    Ernst 2014\n\n160\nStd\nVarious\nNR\n68.3 (11.2)\n\n126 (78.8)\n\n\n—\n    \n150\nExp\n\n\n71.3 (10.6)\n\n 99 (66.0)\n\n\n-12.7% (-22.6, -2.9)\n    Hall 2017\n\n5,275\nStd\nVarious\n1234\n60.3 (13.4)\n\n320 (6.1)\n\n\n—\n    \n3,878\nExp\n\n\n60.3 (13.7)\n\n 78 (2.0)\n\n\n-4.1% (-4.8, -3.3)\n  \n  \n  \n    \n       ASA PS: American Society of Anesthesiologists Physical Status; RD: risk difference; GI: gastrointestinal; Abd: abdominal (includes hepatic); Various: more that one procedure category.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n  \n\n\n\n\n\nPooled\n Figure 16. Risk ratio for hospital or 30-day mortality (expanded preoperative evaluation versus standard; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n\n Figure 17. Risk ratio for hospital or 30-day mortality (expanded preoperative evaluation versus standard; nonrandomized designs). \n\n\n\n\n\n\n\n\n\n\n Figure 18. Risk ratio for 1-year mortality (expanded preoperative evaluation versus standard; nonrandomized designs)."
  },
  {
    "objectID": "kq1.html#risk-of-bias",
    "href": "kq1.html#risk-of-bias",
    "title": "Expanded Preoperative Evaluation",
    "section": "Risk of Bias",
    "text": "Risk of Bias\n\nRandomized\n Figure 19. Summary risk of bias assessment for randomized clinical trials (expanded preoperative evaluation). \n\n\n\n\n\n Figure 20. Risk of bias assessments for randomized clinical trials (expanded preoperative evaluation). \n\n\n\n\n\n\n\nNonrandomized\n Figure 21. Summary risk of bias assessment for nonrandomized studies (expanded preoperative evaluation). \n\n\n\n\n\n Figure 22. Risk of bias assessments for nonrandomized studies (expanded preoperative evaluation)."
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "About this site (tbd)"
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Geriatrics Evidence Synthesis",
    "section": "",
    "text": "Key Questions \nExpanded Preoperative Evaluation\nPrehabilitation\nRegional versus General Anesthesia\nTIVA versus Inhaled Anesthesia\nPotentially Inappropriate Medications\nDelirium Prophylaxis\n\n Strength of Evidence and Summary of Findings \nGRADE\nBalance Tables\n\n Other \nDraft Protocol\nStudy-level evidence tables\nOutcome Importance Rankings\n\nDraft materials (not to be cited).\nPlease send corrections, suggestions, or comments to Mark Grant."
  },
  {
    "objectID": "outcome_rankings.html",
    "href": "outcome_rankings.html",
    "title": "Outcome Priority Rankings",
    "section": "",
    "text": "Table 1.  Rankings for the 5 most important outcomes across 7 key questions (11 respondents; maximum 77 for each outcome rank or any top 5 ranking).\n\n\n\n\n\n\n\n\n\n Table 2. Dichotomous or count outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 188\n      NR Trial, N = 4\n      Quasi-exp, N = 22\n      Prosp Coh, N = 9\n      Retro Coh, N = 14\n      Case-Cont, N = 2\n    \n  \n  \n    ADL\n5 (2.7%)\n—\n—\n—\n—\n—\n    Complications\n83 (44%)\n2 (50%)\n14 (64%)\n1 (11%)\n9 (64%)\n1 (50%)\n    Delayed NCR/NCD\n44 (23%)\n2 (50%)\n1 (4.5%)\n2 (22%)\n—\n—\n    Delirium\n91 (48%)\n1 (25%)\n12 (55%)\n6 (67%)\n6 (43%)\n2 (100%)\n    Delirium duration\n3 (1.6%)\n—\n1 (4.5%)\n—\n—\n—\n    Depression\n1 (0.5%)\n—\n—\n—\n—\n—\n    Discharge location\n6 (3.2%)\n—\n4 (18%)\n—\n1 (7.1%)\n—\n    Mortality\n50 (27%)\n—\n13 (59%)\n1 (11%)\n6 (43%)\n1 (50%)\n    Opioid use\n5 (2.7%)\n—\n—\n—\n—\n—\n    Pain\n8 (4.3%)\n—\n1 (4.5%)\n—\n—\n—\n    QoR\n1 (0.5%)\n—\n—\n—\n—\n—\n    Readmission\n9 (4.8%)\n—\n8 (36%)\n—\n1 (7.1%)\n—\n    Satisfaction\n13 (6.9%)\n—\n1 (4.5%)\n—\n—\n—\n  \n  \n  \n    \n       RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort; Case-Cont: case-control.\n    \n  \n\n\n\n\n Table 3. Continuous outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 188\n      NR Trial, N = 4\n      Quasi-exp, N = 22\n      Prosp Coh, N = 9\n      Retro Coh, N = 14\n      Case-Cont, N = 2\n    \n  \n  \n    6-minute walk\n—\n—\n—\n—\n—\n—\n    Delirium duration\n23 (12%)\n—\n1 (4.5%)\n1 (11%)\n—\n—\n    Grip strength\n—\n—\n—\n—\n—\n—\n    Length of stay\n64 (34%)\n—\n14 (64%)\n2 (22%)\n5 (36%)\n1 (50%)\n    Opioid use\n23 (12%)\n—\n—\n—\n—\n—\n    Pulmonary function\n1 (0.5%)\n—\n—\n—\n—\n—\n  \n  \n  \n    \n       RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort; Case-Cont: case-control.\n    \n  \n\n\n\n\n Table 4. Likert or ordinal outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 188\n      NR Trial, N = 4\n      Quasi-exp, N = 22\n      Prosp Coh, N = 9\n      Retro Coh, N = 14\n      Case-Cont, N = 2\n    \n  \n  \n    ADL\n12 (6.4%)\n—\n2 (9.1%)\n—\n—\n—\n    Delayed NCR/NCD\n69 (37%)\n3 (75%)\n—\n—\n—\n—\n    Delirium\n14 (7.4%)\n—\n1 (4.5%)\n—\n—\n—\n    Complications\n1 (0.5%)\n—\n—\n—\n—\n—\n    Depression/anxiety\n15 (8.0%)\n—\n1 (4.5%)\n—\n—\n—\n    Pain\n42 (22%)\n—\n—\n—\n—\n—\n    Quality of life\n3 (1.6%)\n—\n2 (9.1%)\n—\n—\n—\n    QoR\n3 (1.6%)\n—\n—\n—\n—\n—\n    Satisfaction\n3 (1.6%)\n—\n—\n—\n—\n—\n  \n  \n  \n    \n       RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort; Case-Cont: case-control."
  },
  {
    "objectID": "outcome_rankings.html#for-all-included-key-questions",
    "href": "outcome_rankings.html#for-all-included-key-questions",
    "title": "Outcome Priority Rankings",
    "section": "",
    "text": "Table 1.  Rankings for the 5 most important outcomes across 7 key questions (11 respondents; maximum 77 for each outcome rank or any top 5 ranking).\n\n\n\n\n\n\n\n\n\n Table 2. Dichotomous or count outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 188\n      NR Trial, N = 4\n      Quasi-exp, N = 22\n      Prosp Coh, N = 9\n      Retro Coh, N = 14\n      Case-Cont, N = 2\n    \n  \n  \n    ADL\n5 (2.7%)\n—\n—\n—\n—\n—\n    Complications\n83 (44%)\n2 (50%)\n14 (64%)\n1 (11%)\n9 (64%)\n1 (50%)\n    Delayed NCR/NCD\n44 (23%)\n2 (50%)\n1 (4.5%)\n2 (22%)\n—\n—\n    Delirium\n91 (48%)\n1 (25%)\n12 (55%)\n6 (67%)\n6 (43%)\n2 (100%)\n    Delirium duration\n3 (1.6%)\n—\n1 (4.5%)\n—\n—\n—\n    Depression\n1 (0.5%)\n—\n—\n—\n—\n—\n    Discharge location\n6 (3.2%)\n—\n4 (18%)\n—\n1 (7.1%)\n—\n    Mortality\n50 (27%)\n—\n13 (59%)\n1 (11%)\n6 (43%)\n1 (50%)\n    Opioid use\n5 (2.7%)\n—\n—\n—\n—\n—\n    Pain\n8 (4.3%)\n—\n1 (4.5%)\n—\n—\n—\n    QoR\n1 (0.5%)\n—\n—\n—\n—\n—\n    Readmission\n9 (4.8%)\n—\n8 (36%)\n—\n1 (7.1%)\n—\n    Satisfaction\n13 (6.9%)\n—\n1 (4.5%)\n—\n—\n—\n  \n  \n  \n    \n       RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort; Case-Cont: case-control.\n    \n  \n\n\n\n\n Table 3. Continuous outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 188\n      NR Trial, N = 4\n      Quasi-exp, N = 22\n      Prosp Coh, N = 9\n      Retro Coh, N = 14\n      Case-Cont, N = 2\n    \n  \n  \n    6-minute walk\n—\n—\n—\n—\n—\n—\n    Delirium duration\n23 (12%)\n—\n1 (4.5%)\n1 (11%)\n—\n—\n    Grip strength\n—\n—\n—\n—\n—\n—\n    Length of stay\n64 (34%)\n—\n14 (64%)\n2 (22%)\n5 (36%)\n1 (50%)\n    Opioid use\n23 (12%)\n—\n—\n—\n—\n—\n    Pulmonary function\n1 (0.5%)\n—\n—\n—\n—\n—\n  \n  \n  \n    \n       RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort; Case-Cont: case-control.\n    \n  \n\n\n\n\n Table 4. Likert or ordinal outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 188\n      NR Trial, N = 4\n      Quasi-exp, N = 22\n      Prosp Coh, N = 9\n      Retro Coh, N = 14\n      Case-Cont, N = 2\n    \n  \n  \n    ADL\n12 (6.4%)\n—\n2 (9.1%)\n—\n—\n—\n    Delayed NCR/NCD\n69 (37%)\n3 (75%)\n—\n—\n—\n—\n    Delirium\n14 (7.4%)\n—\n1 (4.5%)\n—\n—\n—\n    Complications\n1 (0.5%)\n—\n—\n—\n—\n—\n    Depression/anxiety\n15 (8.0%)\n—\n1 (4.5%)\n—\n—\n—\n    Pain\n42 (22%)\n—\n—\n—\n—\n—\n    Quality of life\n3 (1.6%)\n—\n2 (9.1%)\n—\n—\n—\n    QoR\n3 (1.6%)\n—\n—\n—\n—\n—\n    Satisfaction\n3 (1.6%)\n—\n—\n—\n—\n—\n  \n  \n  \n    \n       RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort; Case-Cont: case-control."
  },
  {
    "objectID": "outcome_rankings.html#by-key-question",
    "href": "outcome_rankings.html#by-key-question",
    "title": "Outcome Priority Rankings",
    "section": "By key question",
    "text": "By key question\nRankings of the 5 most important outcomes (11 respondents).\n\nKQ 1 Expanded Preoperative Evaluation\n Table 5. Among older patients anticipating surgery and anesthesia, does expanded preoperative evaluation (e.g., for frailty, cognitive impairment, functional status, or psychosocial issues) lead to improved postoperative outcomes? \n\n\n\n\n\n\n\n\n\nKQ 2 Prehabilitation\n Table 6. Among older patients anticipating surgery and anesthesia, do interventions targeted at improving physical function, cognition, and nutritional status before surgery (“prehabilitation”) improve postoperative outcomes? \n\n\n\n\n\n\n\n\n\nKQ 3 Regional vs. General Anesthesia\n Table 7. Among older patients undergoing surgery, does regional anesthesia as the primary anesthetic technique improve postoperative outcomes compared with general anesthesia? \n\n\n\n\n\n\n\n\n\nKQ 4 Intravenous vs. Inhaled Anesthesia\n Table 8. Among older patients undergoing surgery with general anesthesia, does the use of intravenous agents for maintenance of anesthesia improve postoperative outcomes compared with inhaled agents? \n\n\n\n\n\n\n\n\n\nKQ 5 Potentially Inappropriate Medications\n Table 9. Among older patients undergoing surgery and anesthesia, do commonly used potentially inappropriate medications administered during the perioperative period increase the risk of postoperative delirium or other adverse outcomes? \n\n\n\n\n\n\n\n\n\nKQ 6 Delirium Prophylaxis\n Table 10. Among older patients undergoing surgery and anesthesia, do dexmedetomidine, ketamine, ramelteon, or melatonin administered during the perioperative period decrease the risk of postoperative delirium or other adverse cognitive outcomes? \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKQ 8 Delirium Screening\n Table 12. Does screening older patients for postoperative delirium in the post anesthesia care unit improve postoperative outcomes?"
  },
  {
    "objectID": "summary_kq4.html",
    "href": "summary_kq4.html",
    "title": "Study/Patient Characteristics TIVA vs. Inhaled",
    "section": "",
    "text": "Randomized Trial Characteristics\n Table 1. Characteristics of randomized controlled trials. \n\n\n\n\n\n\n  \n    \n    \n  \n  \n    \n    \n      Characteristic\n      N (%)\n    \n  \n  \n    Number of Trials\n26\n    Patients Enrolled (N)\n \n      Mean\n244\n      Median\n114\n      Range\n(30-2216)\n    Arms\n \n      Two\n20\n      Multi\n5\n      Mean \n2.2\n      Median \n2\n      Range \n(2-3)\n    Pilot Study\n0 (0.0)\n    Ambulatory\n0 (0.0)\n    Centers\n \n      Single Center\n25 (96.2)\n      Multicenter\n1 (3.8)\n    Volatile Anesthetic\n0 (0.0)\n    Country\n \n      China\n11 (42.3)\n      Japan\n4 (15.4)\n      Germany\n2 (7.7)\n      Norway\n2 (7.7)\n      Turkey\n2 (7.7)\n      United States\n2 (7.7)\n      Iran\n1 (3.8)\n      Ireland\n1 (3.8)\n      Italy\n1 (3.8)\n    Non-very-high HDI Countryª\n12 (46.2)\n    Funding\n \n      Industry\n5 (19.2)\n      Public/Industry\n2 (7.7)\n      Public\n8 (30.8)\n      Not Reported\n8 (30.8)\n    Author COI\n1 (3.8)\n    Registered\n12 (46.2)\n  \n  \n  \n\n\n\n\n\n\n\nPatient Charcteristics\n\n Table 2. Patient characteristics in randomized controlled trials. \n\n\n\n\n\n\n  \n    \n    \n  \n  \n    \n    \n      Characteristic\n      N (%) or Value\n    \n  \n  \n    Age (average of mean or med, range)\n0 (Inf--Inf)\n    Female (%, range)\nNaN (Inf--Inf)\n    ASA Physical Status (%)\n \n      I-II\nNA\n      I-III\nNA\n      I-IV\nNA\n      II-IV\nNA\n      II-III\nNA\n      III\nNA\n      III-IV\nNA\n      NR\nNA\n    BMI (average of mean or med, range)\n0 (Inf--Inf)\n    BMI (mean or med ≥ 30), (%)\n(NaN)\n    Surgery, N (%)\n\n      Ortho\n65 (27.2)\n      Various (&gt;3)\n46 (19.2)\n      Cardiac\n39 (16.3)\n      GI/Abd\n39 (16.3)\n      Thoracic\n15 (6.3)\n      Urol\n10 (4.2)\n      Neuro\n4 (1.7)\n      Ophtho\n4 (1.7)\n      Ent\n3 (1.3)\n      Headneck\n3 (1.3)\n      Oralmax\n3 (1.3)\n      Spine\n3 (1.3)\n      Other\n2 (0.8)\n      Vasc\n2 (0.8)\n      Gyn\n1 (0.4)"
  },
  {
    "objectID": "evidence_tables.html#randomized-clinical-trials",
    "href": "evidence_tables.html#randomized-clinical-trials",
    "title": "Evidence Tables",
    "section": "Randomized Clinical Trials",
    "text": "Randomized Clinical Trials\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      Enrolled\n      Inclusion/Exclusion Criteria\n      Results\n      Note\n    \n  \n  \n    Aasbo2002\n\n60\nInclude: Patients aged 18-80 years; ASA physical status I-III.Exclude: Known allergy or contraindications to any of the study drugs; history of psychiatric disease.\n\nPatients in the regional anesthesia had less pain postop at 1 h (Regional M=0.41, SD = 0.50 vs General M=1.37, SD=0.85; P = &lt;0.001), 2 h (Regional M=0.53, SD = 0.51 vs General M=1.0, SD=0.5; P = 0.02), 24 h rest (Regional M=0.17, SD = 0.46 vs General M = 0.50, SD = 0.63; P = 0.01), 48 h rest (Regional M=0.07, SD = 0.25 vs General M = 0.29, SD=0.46; P = &lt;0.001), 48 h activity (Regional M = 0.73, SD = 0.74 vs General M = 1.24, SD = 0.74; P = 0.01), 7 days rest (Regional M = 0.07, SD = 0.37 vs General M = 0.25, SD = 0.44; P = 0.005). Patients in the regional anesthesia also had lower analgesic consumption postop for codeine 6-24 h (Regional M = 60, SD = 57 vs General M = 90, SD = 57; P = &lt;0.05), codeine 24-48 h (Regional M = 18, SD = 23 vs General M = 43.4, SD = 49.8; P = &lt;0.03), codeine 48h-7 days (Regional M = 26.9, SD = 58 vs General M = 61.3, SD = 101; P = &lt;0.007), and Ketobemidone total (Regional M = 0.03, SD = 0.18 vs General M = 2.57, SD = 3.9; P = &lt;0.001). Lastly, patients in the regional group had higher patient satisfaction postop at 48h (Regional M=3.0, SD = 0 vs General M=2.68, SD=0.48; P = &lt;0.001) and 7 days (Regional M=2.96, SD = 0.19 vs General M=2.46, SD=0.59; P = &lt;0.001).\n\nAssumed to be single center\n\n    Aizawa2002\n\n42\nInclude: Age 70-86 yrs.Exclude: Liver cirrhosis; liver dysfunction; respiratory disturbance; metal disorder; visual impairment; emergency surgery.\n\nThe incidence of postoperative delirium, measured using DSM-IV criteria, was (35.0%) in the non delirium prevention protocol group and (5.0%) in the delirium prevention protocol group (p = 0.023).\n\n\n    Aksoy2013\n\n36\nInclude: Patients with stage IV knees according to the Kellgren-Lawrence score (0-4) were included in the study.Exclude: Patients with severe systemic and psychiatric diseases were not included.\n\nNo statistically significant differences were found between the SA group and GA groups in terms of HAD (hospital anxiety and depression) scores. No significant differences were found between the mean postoperative VAS scores of the groups. A statistically significant difference was found between the two groups for the physicians score for patients postoperative anxiety.\n\n\n    Alas2020\n\n61\nInclude: Women age 40 years or older scheduled for pelvic organ prolapse, ASA I-II, and BMI &lt; 40.Exclude: Neurological diseases that can interfere with spinal anesthesia, anticoagulation therapy within a week of surgery, evidence of voiding dysfunction or urinary retention, and history of back deformity.\n\nPostoperative urinary retention rates between spinal and general anesthesia were 92.9% vs 78.6%, p= 0.2516. There was also no difference in the QoR-15 scores between the two types of anesthesia (p= 0.467).\n\n\n    Apan2016\n\n52\nInclude: Patients aged between 18 to 85 years; scheduled for elective single-level percutaneous kyphoplasty.Exclude: Cognitive disorders preventing cooperation; ASA IV; pathology in cervical vertebra; history of allergy to the study drugs; contraindication to epidural anesthesia; pregnancy; severe systemic disease such as myelomatous disease; requiring surgical intervention at more than one level.\n\nVAS scores were lower in the epidural group compared to the general group at the first 4 hours postoperative (P &lt; 0.05). Postoperative analgesic requirement was higher for those in the general group (16%) compared to the epidural group (8%); P &lt; 0.667.\n\n\n    Avidan2017\n\n672\nInclude: Age &gt;60; undergoing major open cardiac; undergoing non-cardiac surgeries; under general anaesthesia.Exclude: Dx of delirium prior to surgery; allergy to ketamine; those for whom a significant elevation of blood pressure would constitute a serious hazard; hx of drug misuse; pts currently taking anti-psychotic medications; pts with a weight outside the range of 50 kg - 200 kg.\n\nThere was no difference in postoperative delirium incidence between those in the combined ketamine groups and those who received the placebo (19.45% vs 19.82%, respectively; absolute difference, 0.36%; 95% CI, -6.07% to 7.38%, p=0.92).\n\n\n    Azeem2018\n\n70\nInclude: Age ≥60; ASA I-II; 70-100kg body weight; height 160-180 cm; undergoing elective cardiac surgery under general anesthesia.Exclude: Allergy to any drugs of the study; hx of drug abuse; hx of alcohol abuse; hx of uncontrolled diabetes; hx of hypertension; hx of chronic pain; daily intake of analgesics within 24 h before surgery; impaired kidney function; impaired liver function.\n\nDifferences were not detected in delirium following cardiac surgery between the Dexmedetomidine group and the midazolam with morphine group (3.33%, n=1 vs 6.67%, n=2, respectively; p=1).\n\nNote that what is written in the abstract box is opposite to what the results section notes (i.e., abstract box notes significance where results notes no difference being detected).\n\n    Bielka2021\n\n90\nInclude: Patients age &gt;18; planned osteosynthesis of the proximal femur.Exclude: Pregnancy and lactation; opiate addiction history; traumatic brain injury; acute stroke; dementia; acute cerebrovascular accident; chronic heart failure (NYHA class III-IV); respiratory failure; renal failure (creatinine clearance &lt;30 ml/min/1.73 m2); hepatic insufficiency (Child-Pugh class C).\n\nIn patients undergoing osteosynthesis of the proximal femur, patients receiving psoas compartment block had less opioid use 24 h postsurgery compared with patients receiving spinal anesthesia and patients receiving general anesthesia, median (IQR): 0 (0-5) vs 15 (10-20) and 20 (15-25)mg, respectively, p&lt;0.001. Patients receiving psoas compartment block also reported less severe pain within 48 h postsurgery compared with the other 2 groups, p&lt;0.05.\n\n\n    Bornemann-Cimenti2016\n\n60\nInclude: Patients age &gt;18 years; ASA status I-III; weight between 40-120 kg; elective major open abdominal (colorectal and hepatic) surgery.Exclude: Acute or chronic pain treated with opioid therapy; severe kidney or liver dysfunction; alcohol or opioid addiction; present or past psychotic disorders.\n\nIn patients undergoing open abdominal surgery, patients receiving low-dose S-ketamine experienced higher delirium compared with patients receiving minimal-dose S-ketamine or placebo (p=0.007). Patients receiving low-dose and minimal-dose S-ketamine used less opioid compared with patients receiving placebo (p&lt;0.05). Opioid use did not differ between the low-dose and minimal-dose S-ketamine groups (p=0.59).\n\n\n    Brown2021\n\n219\nInclude: Patients age ≥65; undergoing lumbar spine fusion; expected surgery duration &lt;3 h.Exclude: Contraindiations to spina anesthesia (eg, severe aortic stenosis, anticoagulant therapy); BMI &gt;40 kg/m2; previous L2-L5 full lumbar fusion; baseline dementia or MMSE &lt;24; psychiatric disease precluding cooperation with seation; surgeon or anesthesiologist preference for either anesthetic approach.\n\nIn patients undergoing lumbar spine fusion, a difference was not detected in postoperative delirium in patients receiving spinal anesthesia with targeted sedation compared with patients receiving general anesthesia with masked BIS values, 28/111 (25%) vs 20/106 (19%), RR (95% CI): 1.22 (0.85-1.76), p=0.259.\n\n\n    Cai2012\n\n2216\nInclude: Patients undergoing surgery in the Second Affiliated Hospital.Exclude: Requiring post-operative intensive care; post-operative sedation; did not consent to the study; severe lung disease or hepatic or renal dysfunction;.\n\nMMSE score in inhalation group was lower at day 3 after surgery compared with the intravenous anesthesia group (mean score 20.8 vs 26.9, p&lt;0.01).\n\n\n    Cao2023\n\n1228\nInclude: Patients aged ≥ 65 years old and &lt; 90; who were thought to have primary solid organ non-neurological cancer; had not been previously treated with either radiation or chemotherapy; were undergoing primary cancer surgery that was expected to last ≥ 2 hours.Exclude: Patients with ASA physical status ≥ 4; history of schizophrenia; history of epilepsy; history of Parkinson’s disease; history of myasthenia gravis; inability to communicate in the preoperative period due to coma, profound dementia, language barrier, or incapacity from severe disease; severe hepatic dysfunction (Child-Pugh Class C); required preoperative dialysis.\n\nDelirium occured in 8.4% (50/597) of subjects given propofol-based anesthesia vs 12.4% (74/597) of subjects given sevoflurane-based anesthesia (RR 0.68[95% CI: 0.48–0.95]; P=0.023; adjusted RR 0.59 [95% CI: 0.39–0.90]; P=0.014). Delirium reduction mainly occurred on the first day after surgery, with a prevalence of 5.4% (32/597) with propofol anesthesia vs 10.7% (64/597) with sevoflurane anesthesia (RR 0.50 [95% CI: 0.33–0.75]; P=0.001). Secondary endpoints, including ICU admission, postoperative duration of hospitalization, major complications within 30 days, cognitive function at 30 days and 3 year, and safety outcomes, did not differ between groups.\n\nNote that the Chinese Clinical Trial Registry was done 4/7/2015 but the study was not registered into the ClinicalTrials.gov until 4/18/22\n\n    Carron2007\n\n40\nInclude: Patients ASA status ≤3; age ≥18 and ≤85 years old, life expectancy ≥3months; S-creatine &lt;220 umol/L; S-bilirubin total &lt;68 umol/L; WBCc ≥3109/L; PLTc &gt;75109/L; Hemoglobin &gt;85g/L; PT ≥60%; aPTT ≥22s; no chemotherapy in the last month.Exclude:  Not specified.\n\nGA and SA did not differ in times to achieve home readiness or patient satisfaction. Compared with GA, SA significantly (P&lt;0.05) reduced anesthesia times, postoperative VAS scored for pain and nausea, and the number of admissions ti the postanesthesia care unit.\n\nInclusion criteria from other article (Subarachnoid anesthesia for loco-regional antiblastic perfusion with circulatory block (stop-flow perfusion))\n\n    Casati2003\n\n30\nInclude: Elderly patients ASA II-III; undergoing hemiarthroplasty of the hip for repair of fractured femur.Exclude: Patients with contraindications to spinal anesthesia or laryngeal mask placement; those with severe and uncompensated cardiovascular or pulmonary disease; and psychiatric pathology.\n\nCognitive decline (MMSE test decreased &gt;=2 points from baseline) was seen in 8 patients in the spinal group (53%) and 9 patients in the general group (60%; P = n.s.). 24h post surgery. Seven days postop confusion was still present in 1 patient in the regional group (6%) and in 3 patients in the general group (20%; P = n.s.).\n\n\n    Celik2011\n\n100\nInclude: Patients age 65-80; ASA physical status I-III; elective urological surgery lasting &gt;1.5 hrs.Exclude: Routine use of sedative drugs; dialysis; emergency surgery; cardiac or repiratory failure.\n\nIn patients undergoing urologic surgery, patients receiving propofol had improved cognitive scores compared with patients receiving sevoflurane (p&lt;0.05) at 30 minutes postoperation. Differences in cognition were not detected between the groups at 60 and 90 minutes postoperation.\n\n\n    Chawdhary2020\n\n87\nInclude: Age ≥55 yrs; ASA I-III.Exclude: MMSE ≤23; any cognitive impairment; substance abuse; cardiac co-morbidity; stroke or seizures.\n\nPOCD on postoperative day 3 in the dexmedetomidine group was 32.5% compared to the propofol group 22.5% (p=0.31).\n\n\n    Chen2020\n\n88\nInclude: Patients age ≥60; ASA physical status I-II; MMSE ≥25; normal kidney and liver function.Exclude: Hypertension, heart disease, diabetes history; cerebral hemorrhage, brain trauma, or cerrebral infarction history; mental illness or mental abnormality; alcohol or drug abusedeath during the study; significant abnormalities in study measures; serious adverse reactions during operation (difficult intubation, major bleeding, anaphylactic shock).\n\nIn patients undergoing radical resection for colorectal cancer, patients receiving dexmedetomidine (n=43) experienced higher MMSE scores compared with patients in the control group (n=45) on postoperative days 1 and 3, p&lt;0.05 on both days. MMSE scores for the dexmedetomidine group were 27.3 +/- 0.8 and 28.8 +/- 0.9 on days 1 and 3 respectively, and the control group’s scores were 21.1 +/- 0.5 and 22.5 +/- 0.8.\n\n\n    Chen2013\n\n126\nInclude: Age 60-75 yrs.Exclude: Hx of mental illness; hypotension; bradycardia; CNS disease.\n\nSevere cognitive impairment was not seen in either dexmedetomidine or control groups 24 hour after surgery. Moderate cognitive impairment was seen in 1.7% of patients in the dexmedetomidine group and 3.2% in the control (p=0.598). In patients older than 65 years, mean MMSE was 27.9+-1.3 in the dexmedetomidine group and 28.2+-0.9 in the control group one month after surgery.\n\n\n    Chitnis2022\n\n70\nInclude: Age &gt; 75; undergoing CABG or aortic valve replacement (AVR) surgery on cardiopulmonary bypass.Exclude: Dx of moderate dementia MMSE score &lt; 20; hx of hypersensitivity to any medication in the study protocol.\n\nThere was no significant difference in QoR-40 scores (95% CI, -7.6 to 11.0; P= 1.0), the incidence of delirium (group Propofol, 42.4% vs group Dexmedetomidine, 24.2%, P=0.19) or mean duration of delirium (95% CI, -5.5 to 1.5; P=0.30).\n\n\n    Chu2006\n\n60\nInclude: Patients having primary total knee replacement.Exclude: Bilateral knee arthroplasty; revision knee arthroplasty; patient refusal; abnormal coagulation profile; systemic or local infection; allergy to study drugs; abnormal mental status; and physical disability to operate the PCA device.\n\nPostoperative median pain scores were lower at 1 (P&lt;0.0001), 6 (P=0.08), 12 (P=0.003), 24 (P=0.14), and 48 hours (P=0.007) in those given regional anesthesia. Complications were also lower in this group (P=0.503). Patients with regional aesthesia also showed a trend towards earlier hospital discharge (P=0.32).\n\n\n    Dai2021\n\n164\nInclude: Patients had a known diagnosis of CAD confirmed by prior AMI or coronary angiography, or the occurrence of representative angina pectoris, and at least 2 of the following risk factors: age &gt;65, active smoking, hypertension, hyperlipidemia, and diabetes mellitus; patient was scheduled for major noncardiac surgery; percutaneous coronary intervention within 2 months.Exclude: Signs of acute cardiac failure; unstable angina; recent onset (&lt; 6 months) myocardial infarction; percutaneous coronary intervention within 2 months; emergency surgery; combined or repeated procedures; participation in other research that might interfere with the current study endpoint.\n\nOccurrence of delirium did not differ between the sevoflurane and propofol groups.\n\n\n    Deiner2017\n\n429\nInclude: &gt;68; major elective noncardiac surgery.Exclude: MMSE &lt;20; dementia; emergency surgery; intracardiac or intracranial surgery; planned postop intubation; severe visual or auditory handicap; illiteracy; parkinsons disease; life expectancy &lt;6months; renal failure requiring dialysis; sick sinus syndrome; second or third-degree heart block or clinically significant sinus bradycardia; contraindication for use of an a2-adrenic agonist; ASA class IV or V; hepatic dysfunction.\n\nNo difference in postop delirium delirium between the dexmedetomidine and placebo groups. After adjusting for age and education, there was no difference in postop cognitive performance between treatment groups at 3 and 6 months. Adverse events were comparably distributed between the two groups.\n\nThe study was stopped for futility in accord with the DSMB in January 2014 based on a planned interim analysis in the spring of 2013. The conditional power for concluding efficacy under the original assumption of treatment effect was 3% and under the observed trend and a null trend was less than 1% for both. The conditional power for concluding harm was less than 25% under the 3 different assumptions.\n\n    Dianatkhah2015\n\n145\nInclude: Patients undergoing elective coronary artery bypass graft.Exclude: Use of psychiatric medications, central nervous system depressants, or hypnotic drugs; history of sleep disorder.\n\nIn patients undergoing coronary artery bypass graft, patients receiving melatonin experienced less delirium compared with patients receiving a benzodiazepine, 4/66 (6%) vs 9/71 (13%), p=0.187.\n\n\n    Dieleman2012\n\n4494\nInclude: Age &gt; 18 yrs.Exclude: Emergent or off-pump procedure; life expectancy &lt; 6 mo.\n\nPostoperative delirium was seen in 9.2% dexamethasone group and 11.7% in the placebo group (RR 0.79, 95% CI: 0.66-0.94, p=0.006).\n\nLarge multicenter clinical trial on dexamethasone. There were two substudies from this trial (Sauer 2014 and Ottens 2014) that focused on delirium and cognitive decline.\n\n    Ding2021\n\n180\nInclude: Scheduled to undergo non-cardiac surgery.Exclude: Severe lung or heart diseases; renal or hepatic dysfunction;.\n\nFor older patients, intravenous anesthesia was a better anesthesia method because it has no distinct effect on the cognitive function of people after surgery.\n\n\n    Ding2022\n\n40\nInclude: Patients age 65-80; ASA I -III; BMI 18-25 kg/m2; undergoing laparoscopic colorectal tumor resection.Exclude: Long-term use of NSAIDs, opioids, or tranquilizers; mental diseases or neurological or muscular endocrine lesions; heart rate &lt;50 BPM and with myocardial conduction function and arrhythmia; anaphylaxis to alpha2 adrenergic receptor agonists; difficulty in cognitive assessment; Hasegawa’s dementia scale score &lt;20.\n\nIn patients undergoing laparoscopic colorectal tumor resection, patients receiving dexmedetomidine experienced less POCD by day 5 compared with control patients, 1/20 (5%) vs 5/20 (25%), p&lt;0.05.\n\n\n    Ding2015\n\n40\nInclude: Age 45-80 yrs; ASA I-III; BMI 18-25 kg/m2;.Exclude: Cardiovascular disease; hepatic or renal dysfunction; COPD; endocrine and metabolic disease; CNS disease; acute upepr respiratory infection.\n\nPOCD was seen in 15% of patients in the dexmedetomidine group compared to 35% in the control group 1 day after surgery, and 5% vs 20% 5 days after surgery respectively.\n\n\n    Djainai2016\n\n185\nInclude: Age &gt;60 undergoing elective complex cardiac surgery; AND age &gt;70 undergoing either isolated coronary revascularization or single-valve repair/replacement surgery with the use of cardiopulmonary bypass (CPB).Exclude: Hx of serious mental illness; hx of delirium; hx of severe dementia; currently undergoing emergency procedures.\n\nPOD was present in 16 of 91 (17.5%) and 29 of 92 (31.5%) of patients in dexmedetomidine and propofol groups, respectively (odds ratio, 0.46; 95% CI, 0.23 to 0.92; P= 0.028). Duration of POD 2 days (1 to 4 days) versus 3 days (1 to 5 days), P=0.04, in dexmedetomidine and propofol groups, respectively.  The absolute risk reduction for POD was 14% with a number needed to treat of 7.1.\n\n\n    Du2019\n\n87\nInclude: Age ≥ 65; ASA I-II;.Exclude: Dxof cognitive dysfunction; dxof psychosis; dxof severe cardiac disease; dx of lung disease; dx of liver disease; dx of renal disease; dx of any other system disease; surgery time &gt;1h; surgery could not be accomplished successfully and turned into laparotomy operation.\n\nPostoperative cognitive dysfunction was greater in the control group compared to the dexmedetomidine group. MMSE scores were lower in the control group compared to the dexmedetomidine group at 12h (19.4±1.8 vs 22.4±1.9), 24h (22.3±1.4 vs 23.7±1.3), and 48h (24.1±1.1 vs 25.0±1.5) postop (P&lt;0.05).\n\n\n    Edipoglu2019\n\n80\nInclude: Patients age &lt; 90 years, BMI &lt; 40, and MMSE &gt; 15.Exclude: Emergent trauma cases, patients with prior psychiatric or neurologic disorders, patients using steroids or NSAID, and patients with uncontrolled diabetes were excluded.\n\nPatients who received regional anesthesia showed higher Mini-Mental State Examination (MMSE) scored compared with the general anesthesia at POD 7 (22.58 vs 20.27 p = 0.037).\n\n\n    Egawa2016\n\n148\nInclude: Patients scheduled for elective lung surgery; age 20-85l ASA physical status I-III; fluency in Japanese; ability to read; absence of serious hearing or visual impairments that would preclude neuropsychological testing.Exclude: Patients with interstitial lung disease or lung fibrosis; pregnancy or possibility of pregnancy; history of neurological or mental illness; baseline MMSE score below 24; renal insufficiency (serum creatine in excess of 1.5 mg.dL-1); active liver disease (aspartate aminotransferase in excess of 40 U.dL-1); documented coagulopathy.\n\nRates of POCD did not differ statistically between groups five days postoperatively or three months postoperatively. Multivariable regression analysis revealed older age as an independent predictor of POCD.\n\n\n    El-Naggar2018\n\n50\nInclude: Patients age ≥60 years; ASA III-IV; elective coronary artery bypass graft, 2 or 3 vessel grafts.Exclude: Emergency surgery; ejection fraction &lt;40%; MMSE ≤24; history of neuropsychiatric disorders; liver cirrhosis; renal failure; chronic pulmonary disease; uncontrolled systemic disease such as diabetes or hypertension; serious perioperative or postoperative complications causing unexpected morbidity; prolonged ventilation &gt;8 h; history of choni sedative hypnotic use &gt;3/week in month prior to surgery; study drug allergy.\n\nIn patients undergoing coronary artery bypass graft, patients receiving melatonin experienced less delirium compared with patients receiving placebo, 2/25 (8%) vs 7/25 (28%), p=0.046.\n\n\n    Epple2001\n\n124\nInclude: Patients age &gt;65; ASA physical status I, II, III; scheduled for elective cataract surgery under general anesthesia.Exclude: Patients with a history of allergic reaction to one of the drugs used in the study.\n\nIn the propofol and remifentanil group, more patients were satisfied and would accept the same anesthetic again.\n\n\n    Esmaeii2022\n\n150\nInclude: Age over 65 years.Exclude: History of depression, dementia, cerebral trauma, cerebral tumor, cerebral infarction, suffering from common endocrine disorders such as hyperthyroidism and hypothyroidism, chronic metabolic disorders, head and neck radiation therapy, heavy metal and carbon monoxide poisoning, chronic liver diseases, chronic kidney diseases, infectious diseases, fluid and electrolyte disturbance. In addition, alcohol use for more than a year, regular use of psychiatric drugs and hypnotics, the Abbreviated Mental Test (AMT) score &lt; 8 and systolic blood pressure less than 100 mmHg were other exclusion criteria.\n\nThere was a higher incidence of delirium on postoperative day 3 in the melatonin group compared to controls (4.1% (2/49) vs 2.1% (1/48), p=0.355) when assessed using MMSE.\n\n\n    Fan2017a\n\n148\nInclude: Age &gt; 65 yrs; ASA I-III.Exclude: MMSE &lt; 23; allergy to melatonin; chronic sleep disorder; alcoholism; drug abuse; psychiatric or neurological diseases.\n\nMMSE score in the melatonin group remained unchanged during the 7 days of postoperative monitoring compared to control group (p &lt;0.05).\n\n\n    Fan2017b\n\n76\nInclude: Not stated.Exclude: Not stated.\n\nIncidence of delirium was greater in the control group compared to the observation group, 6/38 (16%) vs 1/38 (3%), respectively.\n\n\n    Fazel2017\n\n60\nInclude: Patients &gt;65 years; ASA class I, II, III.Exclude: Patients with MMSE &lt;23; inadequate education to complete the neuropsychological test; severe visual and hearing impairment; a history of known psychological disorders; consumption of antipsychotic, anti-anxiety, and anti-depression medications; consumption of alcohol; a history of mental illness, addictions, sensitivity to anesthetic medications or unwillingness to cooperate.\n\nPostoperative cognitive function in the sevoflurane group was significantly better than the propofol group in the 6-12 and 12-24 hours after surgery, but the assessment of the two groups in 24-48 hours after surgery showed similar conditions.\n\nThe registration says the age range is 55-65, but the article says 65+\n\n    Fazel2022\n\n80\nInclude: Patients ≥60 years of age; Abbreviated Mental Test (AMT) &gt;8; undergoing hip, femur, or knee surgery.Exclude: Patient diagnosed with dementia; history of substance abuse; history of psychotropic medications; sensory disorders including blindness and hearing loss; cognitive disorders; severe underlying diseases including severe infection, severe anemia, seizures, stroke, and cerebral hemorrhage; heart disease including acute myocardial infarction, congestive heart failure, and arrhythmia, and currently taking medications including anticonvulsants, antihistamines, and psychotropic drugs.\n\nOn the first day after the surgery, the incidence of delirium was significantly lower in the melatonin group compared to the placebo group (22.2% vs 44.4%, p = 0.046). On the second and third days after the surgery, the levels of delirium in the melatonin group was also significantly lower than that in the placebo group. The generalized estimating equations model (GEE) showed a significant interaction between time and treatment groups.\n\n\n    Ford2020\n\n210\nInclude: Patients age ≥50; elective cardiac surgery (coronary artery bypass graft or valve replacement).Exclude: Emergency surgery; contraindication to melatonin or already taking melatonin; dementia; Modified Telephone Interview for Cognitive Status score ≤19; Alcohol Use Disorders Identification Test score ≥15.\n\nIn patients undergoing cardiac surgery, a difference in postoperative delirium was not detected in patients receiving melatonin for 7 days (starting 2 days before surgery) compared with patients receiving placebo, 21/98 (21%) vs 21/104 (20%), adjusted OR (95% CI): 0.78 (0.35-1.75). Differences in delirium duration, delirium severity, cognitive function, anxiety and depression were also not detected between the groups.\n\n\n    Forsmo2016\n\n653\nInclude: Patients &gt;18 years; scheduled for elective open or laparoscopic colorectal surgery for malignant or benign diseases, with or without stoma; rectal cancer who had pelvic radiation.Exclude: Patients with a planned multivisceral resection; ASA class IV; pregnancy; emergency operations; impaired mental capacity.\n\nTotal hospital stay was significantly shorter among patients randomized to ERAS than among the standard group.  The two treatment groups exhibited similar outcomes regarding overall major and minor morbidity, reoperation date, readmission rate, and 30-day mortality.\n\n\n    Fukata2014\n\n121\nInclude: Patients age ≥75 years; elective abdominal surgery under general anesthesia; elective orthopedic surgery under general/spinal anesthesia.Exclude: Emergency surgery; preop NEECHAM &lt;20; periodic dosing with new or switched antipsychotics, antidepressants, hypnotics, or anti-Parkinson agents within 2 wks of surgery; previous treatment with haloperidol for delirium after surgery.\n\nAmong patients undergoing abdominal or orthopedic surgery, 25/59  (42%) patients receiving 2.5 mg haloperidol on days 1-3 postoperatively experienced delirium compared with 20/60 (33%) patients receiving no treatment, [adjusted OR (95% CI): 1.30 (0.54-3.17), p=0.558].\n\n\n    Fukata2017\n\n201\nInclude: Patients age ≥75 years; elective abdominal surgery under general anesthesia or elective orthopedic surgery under general/spinal anesthesia.Exclude: Emergency surgery; preop NEECHAM &lt;20; use of new antipsychotics, antidepressants, hypnotics, or anti-Parkinson agents 2 wks before surgery.\n\nAmong patients undergoing abdominal or orthopedic surgery, patients receiving 5 mg haloperidol (n=99) postoperatively, experienced less delirium on postoperative day 1 compared with patients receiving no treatment (n=100), 3% vs 13%, respectively, p=0.017. Adjusting for age, sex, preoperative cognition, and type of surgery, the risk (OR, 95% CI) of developing severe postoperative delirium in patients receiving haloperidol compared with no treatment was 0.31, 0.13-0.66.\n\n\n    Gao2021\n\n40\nInclude: Age 65-77 yrs; ASA II-III; weight 56-75 kg; HYHA II-III;.Exclude: Dementia and mental history; cerebrovascular disease; acid-base imbalance; electrolyte disturbance; abnormal liver and kidney function; MI; brain trauma; diabetes.\n\nThe incidence of postoperative cognitive dysfunction (POCD) in the Dexmedetomidine group was significantly lower than that in the control group at postoperative 7 days and postoperative 30 days (10% vs 40%; 0% vs 20%, p &lt; .05).\n\n\n    Gao2020\n\n60\nInclude: Age 65-75; ASA II-III; NYHA grade II-III; Body Weight 55-85 kg;.Exclude: Mental illness; Previous acute myocardial infarction; previous diagnosis of heart failure; diabetes; brain trauma; cerebrovascular accident; left ventricular ejection fraction &gt;40%; abnormal liver and kidney function; sedatives or antidepressants intake; history of drug abuse; sick sinus syndrome;.\n\nAt 72 h and 7d after operation, incidence of cognitive dysfunction in the dexmedetomidine group was lower compared with the placebo group (P &lt;0.05).\n\n\n    Ge2016\n\n50\nInclude: Diagnosis of carotid stenosis of ≥70% with or without symptoms; no prior hx of undergoing carotid surgery.Exclude: MMSE score &lt;20; pt undergoing emergency surgery; pt refusal to general anesthetic; pt undergoing treatment with psychiatric drugs;.\n\nMMSE scores were lower POD1 compared to 1 day prior to surgery for both groups (Control 25.80 vs 26.88; Dexmedetomidine 26.09 vs 27.18; p&lt;=0.001. MMSE scores were higher in the dexmedetomidine group at 48 hours and 72 hours post-op compared to the control group (26.72 vs 25.87; p=0.025 and 27.10 vs 26.39; p=0.03, respectively).\n\n\n    Geng2017\n\n150\nInclude: Patients age≥65; with ASA score II-III; sufficient level of education to be capable of completing neuropsychological tests.Exclude: Mini Mental State Examination score ≤26; preexisting diagnosis of schizophrenia; preexisting diagnosis of dementia; known disorder affecting cognition; mental dysfunction; history of cerebral surgery; severe anxiety; recent history of alcohol abuse; history of chronic opioid or other psychotropic drug use; history of allergy to anesthetics; dialysis-dependent renal failure; liver transaminase level &lt;1.5 times the normal value; recent stroke.\n\nThe incidence of POCD was lower in the propofol group compared to the isoflurane and sevoflurange group at postoperative day 1 (D1) and postoperative day 3 (D3) (propofol vs isoflurane: D1 and D3, P &lt;0.001; propofol vs sevoflurane: D1, P = 0.012; D3, P = 0.013). The incidence of POCD was lower in the sevoflurane group compared to the isoflurane group at D1 (P = 0.041), but not at D3.\n\n\n    Glumac2017\n\n169\nInclude: Patients age 41-84 years; elective coronary artery bypass graft, heart valve, or combined surgery with or without cardiopulmonary bypass.Exclude: Cerebrovascular incident past 3 yrs; mental illness; visual, hearing, or motor impairment interfering with cognitive assessment; left ventricular ejection fraction &lt;35%; adrenal gland disease requiring steroids &gt;7 days in past yr; alcohol (&gt;50 g/day or &gt;500 g/wk) or substance abuse; MMSE &lt;26; BDI-II &gt;19; preop CRP &gt;5 mg/L; preop WBC &lt;4 or &gt;10 x10(ninth)/L; stroke; additional corticosteroid during study period.\n\nPatients undergoing cardiac surgery who received dexamethasone (n=80) experienced less postoperative cognitive decline compared with patients who received placebo (n=81), RR (95% CI): 0.43 (0.21-0.89). Subgroup analysis by age shows patients &gt;=65 experience less cognitive decline when receiving dexamethasone (RR, 95% CI: 0.22, 0.05-0.94), while no difference is detected among patients &lt;65 (RR, 95% CI: 0.59, 0.26-1.36).\n\n\n    Gu2021\n\n94\nInclude: ASA I-III hip fracture patients.Exclude: Patients with hemorrhagic diathesis, peripheral neuropathies, allergy to amide local anesthetics, mental disorders, and BMI over 35 kg·m-2 were excluded.\n\nEarly severe delirium (24 h postoperatively) was higher with general anesthesia 15% (7/45) than with regional 9% (4/42) p&lt; 0.05.\n\n\n    Guo2015\n\n184\nInclude: Age 65-80 yrs; ASA I-III;.Exclude: Dementia or MMSE &lt; 24; hx of CNS injury; hypotension; endocrine/metabolic disorders; inflammatory diseases; alcohol or drug dependence;.\n\nMean MMSE on postoperative day 3 was higher in the dexmedetomidine group compared to placebo (27.1 +- 2.0 vs 25.8 +- 2.7, p=0.001). Quality of recovery score was higher in the dexmedetomidine group compared to placebo in all three postoperative days compared to placebo (Day 1: 146.8 +- 24.2 vs 129.5 +- 22.5; Day 2: 155.3 +- 26.4 vs 136.9 +- 21.1; Day 3: 163.1 +- 25.3 vs 145.6 +- 28.6, p&lt;0.001).\n\n\n    Gupta2019\n\n100\nInclude: Age ≥ 65 yrs; ASA I-II.Exclude: Dementia; severe infection; intracranial bleed; acute cardia event.\n\nThe incidence of delirium in Ramelteon group was lower in comparison with placebo group (4% vs 12%).\n\n\n    Haghighi2017\n\n100\nInclude: Patients aged &gt;60 years; ASA class I-III; undergoing hip fracture fixation.Exclude: Dementia; cognitive disorders; history of opioid use; hepatorenal diseases; pulmonary diseases; sensitivity to anesthetic agents; coagulopathies; neurologic disease; inability to give accurate responses to questions; high intra-cerebral pressure; infection at site of injection; massive hemorrhage during surgery; low blood pressure during surgery.\n\nPain and opioid consumption were lower in the spinal anesthesia group compared to the general anesthesia group (M=2.36, SD=1.85 vs M=4.86, SD=1.75; P=0.001 and M=0.86, SD=1.52 vs M=2.66, SD=1.63; P=0.001, respectively).\n\n\n    Hakim2012\n\n101\nInclude: Age &gt; 65 yrs.Exclude: Hx of neuropsychiatric disorders, alcoholism; intake of psychotropic mediations.\n\nIncidence of postoperative delirium was lower in the risperidone group compared to placebo (13.7% vs 34%, p=0.031) when given post-operatively.\n\n\n    Harsten2013\n\n124\nInclude: ASA I-III; able to understand given information; age &gt; 45 years and &lt; 85 years; signed informed consent;.Exclude: Previous major knee surgery to the same knee; obesity (BMI &gt; 35); rheumatoid arthritis; immunological depression; allergy to any of the drugs used in this study; taking opioids or steroids; history of stroke or psychiatric disease that could affect perception of pain.\n\nThe median (IQR) 24 h postoperative consumption of morphine was 19 mg (11–28) in the general anesthesia group and 54 mg (37–78) in the regional anesthesia group (p&lt; 0.001).\n\n\n    Harsten2015\n\n120\nInclude: Patients age 46-84; ASA I-III; elective total hip arthroplasty.Exclude: Previous surgery to same hip; BMI &gt;35; rheumatoid arthritis; immunological depression; allergy to study drugs; taking opioids or steroids; history of stroke or psychiatric disease that could affect pain perception.\n\nIn patients undergoing total hip arthroplasty, patients receiving regional anesthesia had longer length of stay (p=0.004), less pain at 2 h (p&lt;0.001), more pain at &gt;6 h (p&lt;0.05) and requested a change in anesthesia method more often (0.022) compared with patients receiving general anesthesia.\n\n\n    He2018\n\n90\nInclude: Age 75-90; ASA grade I-III; receiving selective operation; dx of thoracic or lumbar vertebral fractures.Exclude: Pts gaining ≤23 points in the MMSE; taking sedatives; taking antipsychotics; dx of mental illness; dx of central nervous system illness; unable to effectively communicate; dx of severe heart disease; dx of severe lung disease; dx of severe brain disease; dx of severe liver disease; dx of severe kidney disease; dx of severe disease to any other important organ; dx of severe vision impairment; dx of severe hearing impairment; allergies to the drugs used in the study; those not suitable for this study.\n\nThe incidence rate of POD in the dexmedetomidine group was apparently lower than those in both the midazolam and control groups (F=38.731; p&lt;0.001); the incidence rate of POD at 1-2 days after operation in the midazolam group was higher than the control group (F=26.759; p=0.003 vs F=17.685; p=0.031); there was no significant difference in the incidence rate of POD at 3-5 days after operation between the midazolam and control group (F=4.716; p=0.528 vs F=3.681; p=0.815; vs F=6.257; p=0.482).\n\n\n    Hempenius2013\n\n297\nInclude: Patients age &gt;65; elective surgery for solid tumor; frail (defined as Groningen Frailty Indicator [screening instrument with 4 domains - physical, cognitive, social, psychological] score &gt;3).Exclude: Non-frail; unable to complete questionnaires.\n\nIn frail patients undergoing elective surgery for solid tumors, a difference in delirium was not detected in patients receiving geriatric liaison interventions compared with patients receiving standard care, 12/127 (9.4%) vs 19/133 (14.3%), OR (95% CI): 0.63 (0.29-1.35). Differences in complications, and physical and mental scores, were also not detected between the groups.\n\nTen day results (SF-36, MMSE) and 30-day results (mortality, readmission) reported in Hempenius 2016.\n\n    Hempenius2016\n\n297\nInclude: Age &gt; 65 yrs with Groningen Frailty Indicator &gt; 3 (frail).Exclude: Unable to fill out questionnaires or comply with follow-up visits.\n\nOverall incidence of postoperative delirium in this clinical trial was 11.5% (26/227). There was no difference in the MMSE score at discharge between the standard care group and multicomponent preoperative assessment group (26.5 vs 26.9, p=0.97). The Short Form-36 physical component measure were similar in both groups, respectively (49.3 vs 48.4, p=0.17).\n\nLiaison Intervention in Frail Elderly (LIFE), was a multicenter, randomized clinical trial in the Netherlands. Primary outcome of postoperative delirium is not reported by study groups but by mortality.\n\n    Hestin2022\n\n60\nInclude: Patients aged ≥18; admitted with chronic subdural hematoma requiring surgical evacuation (according to neurosurgical decision).Exclude: Pre-operative agitation precluding regional anesthesia; history of disability with a modified Rankin score &gt;2; pregnant; breastfeeding; associated intracranial lesions on cerebral CT scan; allergy to local anesthetics.\n\nConfusion, as assessed by CAM, was seen in 6/30 (20%) participants in the general anesthesia group and in 7/30 (23.3%) participants in the regional anesthesia group (Percent difference = -3%; 95% CI = -24 to 17).\n\nStudy notes on pg 548 that the study was registered before patient enrollment, but does not state where or provide the trial number. Found NCT based on search terms, verify that it is the correct trial protocol.\n\n    Hollinger2021\n\n143\nInclude: Aged ≥65 years and scheduled for visceral, orthopaedic, vascular, gynaecological, cardiac, or thoracic surgery.Exclude: Delirium at admission; MMSE score &lt; 24; DOS ≥ 3; dementia; known ICU admission; haloperidol or ketamine intolerance; communication issues; QT interval prolongation; Parkinson’s disease; epilepsy; body weight &gt; 100 kg; intake of dopaminergic drugs.\n\nDelirium was seen in 6.4% of patients in the ketamine group, 11.1% with haloperidol, and 9.1 % with placebo (p=0.16).\n\nBaden PRIDe Trial was an investigator-initiated, phase IV, two-centre, randomised, placebo-controlled, double-blind clinical trial. The purpose of this study was to identify within a cohort of ICU patients admitted for severe illness those who are at risk of death in the year following the discharge from ICU. Eleven other articles have indexed this trial.\n\n    Hong2021\n\n712\nInclude: Age 65-90 yrs; ASA I-III.Exclude: Hx of schizophrenia, epilepsy, parkinsons, or myasthenia gravis; dementia; sick sinus syndrome, severe bradycardia; sleep apnea; hepatic dysfuncion; renal failure;.\n\nThe incidence of postoperative delirium was 7.3% with placebo and 4.8% with dexmedetomidine (RR 0.65, 95% CI 0.36 to 1.18; p=0.151).\n\n\n    Hongyu2019\n\n90\nInclude: Age 65-80 years; tumor grade I-III; BMI 18.5-23.9; lung cancer.Exclude: Patients with glaucoma, cataract and other eye diseases; patients with central nervous system and psychiatric disorders, linguistically ineffective communication with psychologists; mini-mental state examination (MMSE) scores ≤23 points.\n\nMean MMSE score in elderly patients given penehyclidine hydrochloride was higher on POD 1 (24.7 vs 23.8; p&lt;0.05) and lower POD 4 compared to controls (16.7 vs 23.5; p&lt;0.001). Postoperative delirium was seen in 10% of PHH patients on POD 1 and 26.7% on POD 4 compared to 13.3% in controls.\n\n\n    Hu2021\n\n177\nInclude: Patients age 60-80 years; ASA status I-III; open transthoracic oesophagectomy under general endotracheal anesthesia.Exclude: BMI &gt;30 kg/m2; severe pulmonary, cardiac, renal, hepatic, cerebrovascular comorbidities; chronic pain or substance abuse; dementia or treatment with antipsychotic drugs; dexmedetomidine allergy; life expectancy &lt;6 months.\n\nIn patients undergoing open transthoracic oesophagectomy under general endotracheal anesthesia, patients receiving dexmedetomidine experienced less postoperative delirium compared with patients receiving saline, 15/90 (16.7%) vs 32/87 (36.8%), RR (95% CI): 0.45 (0.26-0.78).\n\n\n    Hudetz2009b\n\n58\nInclude: Patients age ≥55; elective coronary artery bypass graft surgery and/or valve replacement/repair procedures with a cardiopulmonary bypass.Exclude: Cerebrovascular accident within 3 y; permanent ventricular pacing; previously documented cognifive deficits; hepatic impairment (aspartate aminotransferase or alanine aminotransferase greater than twice upper normal limit); chronic renal insufficiency (creatinine &gt;2 mg/dL); increased risk of perioperative complications; use of psychoactive drugs for psychosis.\n\nIn patients undergoing surgeries requiring cardiopulmonary bypass, patients receiving ketamine experienced less postoperative delirium compared with patients receiving a placebo, 1/29 (3%) vs 9/29 (31%) within 5 days postsurgery, p=0.01.\n\nDelirium defined as ICDSC &gt;=4.\n\n    Hudetz2009a\n\n78\nInclude: Patients age ≥55; elective coronary artery bypass graft surgery and/or valve replacement/repair procedures with a cardiopulmonary bypass.Exclude: Cerebrovascular accident within 3 y; permanent ventricular pacing; previously documented cognifive deficits; hepatic impairment (aspartate aminotransferase or alanine aminotransferase greater than twice upper normal limit); chronic renal insufficiency (creatinine &gt;2 mg/dL).\n\nIn patients undergoing surgeries requiring cardiopulmonary bypass, patients receiving ketamine experienced less of a decrease in cognitive performance (at least 2 standard deviations) compared with patients receiving a placebo, 7/26 (27%) vs 21/26 (81%), p&lt;0.001 at 1 week postsurgery.\n\nTests used: Repeatable Battery for the Assessment of Neuropsychological Status subtests; Brief Visual Memory Test Revised; Backward Digit Span; Semantic Fluency; Phonemic Fluency\n\n    Huyan2019\n\n360\nInclude: Age ≥ 65 yrs; ASA II-III; BMI 18-25 kg/m3; forced vital capacity &gt; 80%; 1st second forced expiration &gt; 70%;.Exclude: Hx of metabolic disorder (diabetes); discharge to ICU after surgery; preop delirium; new atrial fibrillation; cardiac arrest; stock blood infusion; hypoxemia (SpO2 &lt; 90%, &gt; 1 min).\n\nPostoperative delirium was seen 15.6% of patients receiving dexmedetomidine compared to 27.2% in the control group on postoperative day 1 and 0% on postoperative day 7 in both groups.\n\n\n    Ishii2016\n\n59\nInclude: All patients scheduled to undergo elective gastrectomy, colectomy, or rectectomy under general anesthesia combined with epidural anesthesia.Exclude: Patients with a history of dementia, depression, alcoholism, and liver cirrhosis; a history of using benzodiazepine, major tranquilizers, or steroids; an ineffective postoperative analgesia via epidural anesthesia; and allergic reactions to local anesthetics.\n\nThe incidence of POD in the propofol anesthesia group (6.9%) was significantly less than that observed in the sevoflurane anesthesia group (26.7%).\n\n\n    Jaiswal2019\n\n120\nInclude: Patients age ≥18; elective pulmonary thromboendarterectomy.Exclude: Pregnancy; cirrhosis; use of fluvoxamine.\n\nIn patients undergoing pulmonary thromboendarterectomy, a difference in postop delirium was not detected between patients receiving ramelteon 8 mg the night before surgery through maximum 6 nights compared with patients receiving placebo, 19/59 (32%) vs 22/58 (38%), RR 0.8, 95% CI (0.5-1.4). Differences in delirium duration and in-hospital mortality were also not detected.\n\n\n    Javaherforoosh2021\n\n60\nInclude: ≥30 years; elective on-pump CABG; ASA class II-III; minimum ejection fraction of 30%;.Exclude: Presence of melatonin contraindications; allergy to the drug; chronic or recent use of melatonin or hypnotic drugs; receiving barbiturates or or antipsychotics; a history of kidney or liver disease or chronic pulmonary disease; history of neurological or psychological diseases; alcohol consumption; inability to communicate verbally; occurrence of serious and like threatening events during or after.\n\nMelatonin may be effective in reducing the severity of delirium after cardiac surgery. The effect of melatonin asa delirium prevention agent should be considered in patients admitted in the cardiovascular intensive care.\n\n\n    Jellish2003\n\n60\nInclude: Isolated unilateral endarterectomies by the same surgeon.Exclude: Patients undergoing emergency procedures; atrial fibrillation; significant renal or hepatic disease.\n\nPostoperative variables were similar except that patients who received iso/fen had lower Stewart recovery scores during the first 15 minutes after post anesthesia care unit admission and a higher incidence of nausea and vomiting the day after surgery, whereas patients receiving remi/prop had discharge delays secondary to hypertension. ICU admittance, time to first void, oral intake, and time to hospital discharge were similar between the groups.\n\nNo COI, funding, or registration number reported. No age criteria\n\n    Jia2014\n\n240\nInclude: Patients with age ranging from 70 to 88 years with colorectal carcinoma.Exclude: Patients with a history of dementia, Parkinson’s disease, alcohol intake of ≥250 g/day, long-term use of sleeping pills or anxiolytics, and those who received anesthesia within the past 30 days were excluded.\n\nThe incidence of postoperative delirium was significantly lower in patients with epidural anesthesia (4/117, 3.4 %) than with general (15/116, 12.9 %; p =0.008).\n\n\n    Kalisvaart2005\n\n430\nInclude: Patients age ≥70 years; acute or elective hip surgery; at intermediate (1-2 risk factors) or high risk (3-4 risk factors) for postop delirium out of following: 1) visual impairment (worse than 20/70 after correction), 2) APACHE II ≥16, 3) MMSE ≤24, and 4) index of dehydration (blood urea nitrogen/creatinine ratio ≥18).Exclude: Delirium at admission; no risk factors for postop delirium; haloperidol allergy history; cholinesterase inhibitor use; parkinsonism; epilepsy; levodopa treatment; inability to participate in interviews (profound dementia, language barrier, intubation, respiratory isolation, aphasia, coma, terminal illness); surgery delay &gt;72 h after admission; prolonged QTc interval &gt;460 ms (males) or &gt;470 ms (females).\n\nIn patients undergoing hip arthroplasty or hip fracture surgery, delirium incidence was 15.1% (32/212) among patients receiving haloperidol (1.5 mg daily from admission to 3 days postop) and 16.5% (36/218) among patients receiving placebo, (RR, 95% CI: 0.91, 0.59-1.44). Delirium severity (Delirium Rating Scale mean difference, 4.0 [95% CI: 2.0-5.8]) and delirium duration (mean difference in days, 6.4 [95% CI: 4.0-8.0]) were lower in the haloperidol group compared with the placebo group.\n\n\n    Kasprzak2006\n\n186\nInclude: Patients between 45 and 89 years of age with symptomatic ICA-Stenosis &gt; 70% or asymptomatic ICA-Stenosis &gt; 80% and begun therapy with oral platelet aggregation inhibitor one weak prior to surgery.Exclude: Patients who’ve had recent stroke, MI within the last 6 months, unstable angina, aortic stenosis, hypertrophic cardiomyopathy, left bundle brunch block, taking digoxin, untreated hypertension, with cardiac pacemaker, hyperthyroidism, hemodialysis, renal insufficiency, anemia, thrombocytopenia, and contraindication for regional anesthesia method.\n\nTransient ischemic attack was seen in 1% of patients in both general and regional anesthesia group. Cardiopulmonary complications was higher in the general anesthesia group (4/95) 4% vs regional anesthesia (1/91) 1% (p&gt; 0.05). One patient died in the general anesthesia group.\n\n\n    Larsen2010\n\n495\nInclude: Age &lt;65 with with a history of post op delirium; age≥65, elective TKR or THR.Exclude: Diagnosis of dementia; active alcohol use; history of alcohol abuse; allergy olanzapine; current use of antipsychotic.\n\nThe incidence of delirium was significantly lower in the olanzapine group than in the placebo group (14.3% vs 40.2%, Adjusted OR:0.2, CI: 0.1-0.4, p&lt;0.001). However, delirium lasted longer in the olanzapine group (2.2 [SD\u00031.3] versus 1.6 [SD\u00030.7] days; p=0.02). The severity of delirium was also greater in the olanzapine-treated group than in the placebo group (16.44 [SD: 3.7] vs 14.5 [SD: 2.7]; p=0.02).\n\nHigh dropout rate, patients stratified by complexity of surgery\n\n    Lee2018a\n\n354\nInclude: Age &gt;65 years; ASA I-III; scheduled for laparoscopic major non-cardiac surgery under general anesthesia.Exclude: History of kidney or liver disease; allergy to the drug; cognitive impairment; use of antipsychotic alpha-2 agonists or antagonist meds; use of anti-inflammatory drugs.\n\nDexmedetomidine group 1 (1 ug/kg bolus followed by 0.2-0.7 ug/kg infusion) reduced incidence and duration of delirium compared to control (9.5% vs 24.8%, p=0.017). Dexmedetomidine group 2 (1 ug/kg bolus only) decreased its duration in patients with delirium compared to control (18.4% vs 24.8%). Dose and timing of dexmedetomidine appeared to be important in preventing delirium.\n\n\n    Lee2018b\n\n132\nInclude: Patients age 18-75 years; ASA physical class I-II; elective TKA or THA under spinal anesthesia.Exclude: Allergy and/or contraindication to study drugs; clinically significant medical or psychiatric conditions; pregnancy; alcohol or drug abuse; use of opioids and/or study drugs for chronic pain; significant cardiac, hepatic, or renal disease.\n\nIn patients undergoing TKA or THA, patients receiving dexmedetomidine experienced less postoperative delirium compared with patients receiving placebo or pregabalin, 3/31 (9.7%) vs 11/31 (35.5%) or 14/33 (42.4%), p&lt;0.05. A difference was not detected in postoperative delirium in patients receiving dexmedetomidine compared with patients receiving pregabalin plus dexmedetomidine.\n\nDexmedetomidine was more effective than pregablin for clinically relevant pain. Differences were not detected in pain or morphine use in patients receiving dexmedetomidine compared with patients receiving pregabalin plus dexmedetomidine.\n\n    Lee2015\n\n56\nInclude: Age &gt;60; ASA I-III; undergoing orthopedic surgery (duration of anesthesia &gt; 2 hours).Exclude: Dementia; Hx of CNS-related diseases; medication with tranquilizers; medication with antidepressants; inability to perform neurocognitive function tests; severe visual or auditory dysfunction; hx of alcohol abuse; hx of drug dependence; hx of a cerebrovascular accident within the previous 3 years.\n\nThere was a difference between the trail-making test scores in which the saline group had increased scores than the ketamine group at POD 1 (52.5 vs 13 points, respectively; p=0.047). There was no difference detected in the mini-mental status examination at either POD 1 (p=0.98) or POD 6 (p=0.33) and the digit substitution test at either POD 1 (p=0.39) or POD 6 (p=0.81). There was no difference in the MMSE (p=0.19), trail making test (p=0.08) and digit substitution test socres (p=0.28) between the two groups throughut the time.\n\n\n    Lewis2008\n\n3526\nInclude: Patients with symptomatic or asymptomatic internal carotid stenosis requiring endarterectomy with either local or general anestheia.Exclude: Simultaneous bilateral carotid endarterectomy; carotid endarterectomy combined with another operative procedure such as coronary artery bypass graft; unfit for general or local aesthesia; randomized into trial previously.\n\nIn patients undergoing cartotid endarterectomy, a difference was not detected in the primary composite outcome (stroke, myocardial infarction, or death) in patients receiving local anesthesia compared with patients receiving general anesthesia, 80/1771 (4.5%) vs 84/1752 (4.5%), RR (95% CI): 0.94 (0.70-1.27).\n\n\n    Li2022\n\n950\nInclude: Patients ≥65 years with a fragility hip fracture; ASA I-IV; scheduled for surgical repair.Exclude: Patients with multiple trauma or fractures; contraindications for regional or general anesthesia; malignant hyperthermia; enrolled in another RCT.\n\nPostoperative delirium occurred in 29 (6.2%) in the regional anesthesia group vs 24 (5.1%) in the general anesthesia group (unadjusted risk difference, -1.1) Regional anesthesia without sedation did not significantly reduce the incidence of postoperative delirium compared with general anesthesia.\n\n\n    Li2021a\n\n544\nInclude: Major elective gastrointestinal, gynecological, prostate, or bladder surgery patients who are ≥ 60 years old; laparoscopic surgery that is expected to last for ≥ 2hours under general anesthesia and the patient will be hospitalized for at least 7 days after surgery; lack of serious hearing and vision impairment.Exclude: Life expectancy less than 3 months; MMSE score ≤23; history of dementia, psychiatric illness or any diseases of the central nervous system; current use of sedatives or antidepressants; alcoholism or drug dependence; patients previously included in this study; uncontrolled hypertension (&gt;180/100mmHg).\n\n46 patients in the sevoflurane group and 38 patients in the propofol met the criteria for delayed neurocognitive recovery (OR:0.77, 95%CI: 0.48, 1.24). Anesthetic choice did not appear to affect the incidence of delayed neurocognitive recovery.\n\n\n    Li2019\n\n164\nInclude: Patients age ≥65; ASA physical status I-III; elective unilateral total hip replacement or total knee replacement.Exclude: Contraindications to spinal surgery (eg, aortic stenosis, coagulopathy, anticoagulant use, spinal cord disease, refusal of spinal anesthesia); severe hepatic or renal insufficiency; stroke or transient ischemic attack in 1 month; difficulty with neuropsychological assessment (&lt;9 yr education or existing mental disorder).\n\nAmong patients undergoing THA or TKA with spinal anesthesia, patients receiving midazolam experienced more postoperative cognitive dysfunction at day 7 compared with patients receiving propofol,  28/54 (52%) v 10/55 (18%), p&lt;0.001. A difference in cognitive dysfunction was not detected between patients receiving midazolam compared with dexmedetomidine, 28/54 (52%) vs 22/55 (40%), p=0.214. Differences were not detected in cognitive function among any of the groups at 1 year followup.\n\n\n    Li2017\n\n285\nInclude: Age ≥60; scheduled to undergo elective coronary artery bypass graft and/or valve replacement surgery.Exclude: History of schizophrenia; history of epilepsy; diagnosis of Parkinson disease; diagnosis of severe dementia; inability to communicate because of severe visual/auditory dysfunction or language barrier; history of functional neurosurgery or brain injury; diagnosis of preoperative sick sinus syndrome; diagnosis of severe bradycardia (heart rate &lt;50); diagnosis of second-degree or above atrioventricular block without pacemaker; diagnosis of severe hepatic insufficiency (Child-Pugh grades C); diagnosis of severe renal insufficiency (requirement of renal replacement therapy); patient refused to participate in the study.\n\nDexmedetomidine administered during anesthesia and early postoperative period did not decrease the incidence of delirium (4.9% [7/142] in the DEX group vs 7.7% [11/143] in the CTRL group; OR 0.62, 95% CI 0.23 to 1.65, p = 0.341) in elderly patients undergoing elective cardiac surgery.\n\n\n    Li2021b\n\n120\nInclude: Age 65-90 yrs undergoing laparoscopic abdominal surgery likely &gt; 2 h.Exclude: MMSE &lt; 24; mental and neurological disease; hepatic or renal disease; bradycardia or hypotension.\n\nIncidence of POCD was 40% in the control group and 6.7% in patients given highest dose of dexmedetomidine.\n\nThree doses of dexmedetomidine compared to placebo to determine occurrence of POCD.\n\n    Li2015\n\n100\nInclude: ASA I-III; age &gt;60 yrs;.Exclude: Age &gt; 75 yrs; stroke; stupor; dementia; hepatic or renal dysfunction; bradycardia; hypotension.\n\nModerate cognitive impairment (MMSE 9-21) 24 hour after surgery was seen in 2% patients in dexmedetomidine group and 4% in the control group. No patients developed severe cognitive impairment (MMSE &lt;9) 24 hour surgery.\n\n\n    Liang2017\n\n198\nInclude: Patients with ASA I-III.Exclude: Patients with history of nervous system or cardiac surgery, mental disorder, defective vision, and neurological disorders.\n\nPatients in the general anesthesia group higher rates of pulmonary embolism 3% (2/66) when compared to epidural alone 0% and combined spinal epidural 1.5% (1/66). MMSE score was higher in patients given epidural anesthesia than general or combined spinal epidural (m=24.46 vs 22.45 vs 22.48, p&lt; 0.05).\n\n\n    Liang2022\n\n224\nInclude: Patients aged 65–80 years and scheduled for spinal surgery.Exclude: Preoperative neurological diseases (such as vascular dementia), severe liver and renal insufficiency, autoimmune diseases, recent use of sedatives, antidepressants, or immunosuppressive drugs, traumatic brain injury or history of alcoholism.\n\nThe incidence of neurocognitive dysfunction was higher in the sevoflurane group compared to TIVA with propofol 33% (23/70) vs 14% (10/70) p&lt; 0.05.\n\n\n    Lindholm2013\n\n231\nInclude: Patients who were scheduled for open, elective abdominal aortic aneurysm surgery; ASA class I-IV.Exclude: Patients &lt;18 years old; included in other pharmaceutical studies; history of opioids, bensodiazepins, antiepileptic drugs, alcohol, and a2-agonist abuse; pregnant and breastfeeding women; family history of malignant hyperthermia; hypersensitivity to opioids, propofol or volatile anesthetics; considerable arrhythmia; uncontrolled hypertension, or serious psychiatric disease; unstable angina pectoris or myocardial infarction last month before inclusion; acute abdominal aortic surgery; acute dissection or rupture; planned laparoscopic abdominal aortic aneurysm surgery.\n\nAlthough underpowered, the authors found no differences in postoperative complications, nonfatal coronary events, or mortality between groups.\n\n\n    Liu2016\n\n200\nInclude: Age 65-80; ASA II-III; total hip arthroplasty or total knee arthroplasty.Exclude: Neurological diseases that may affect cognitive function (subdural hematoma, vascular dementia, B12 deficiency, encephalitis); hypoxic pulmonary disease; perioperative serious cardiopulmonary complications.\n\nIn patients with amnestic mild cognitive impairment (aMCI) undergoing THA or TKA, patients administered dexmedetomidine experienced less postoperative delirium compared with patients receiving placebo, 10/39 (26%) vs 25/40 (63%), p&lt;0.01. In patients without aMCI, patients administered dexmedetomidine experienced less postoperative delirium compared with patients receiving placebo, 5/60 (8%) vs 18/58 (31%), p&lt;0.01.\n\nA subgroup analysis on age showed increased risk in patients aged &gt;=75 with aMCI who were not treated with dexmedetomidine.\n\n    Liu2022a\n\n60\nInclude: Patients age 45-70; ASA I-II; elective video-assisted thoracoscopic lobectomy.Exclude: Cardiovascular or cerebrovascular disease; arrhythmia; sinus bradycardia; ischemic heart disease; obstructive sleep apnea; dexmedetomidine allergy; education below junior high school; on medication for mental disorders; previous neurological disease; memory impairment; abnormal coagulation function, puncture site infection, or perioperative blood transfusion; spinal surgery; chronic pain or oral analgesics prior to surgery; complications leading to secondary surgery; converted to pneumonectomy; catheter prolapse; use of 2-adenoceptor agonist in past week.\n\nIn patients undergoing  video-assisted thoracoscopic lobectomy, patients receiving dexmedetomidine experienced higher MoCA scores compared with patients receiving placebo on days 1 and 3 postsurgery, mean (SD): 26.4 (0.7) vs 25.5 (1.0), p&lt;0.001 on day 1, and 27.1 (0.8) vs 26.6 (0.8), p=0.032 on day 3. Differences in MoCA were not detected on postoperative day 7.\n\n\n    Liu2022b\n\n120\nInclude: Age greater than and equal to 65 years, ASA I-II, preop MMSE &gt; 24.Exclude: Dementia, combined neuropsychiatric system diseases, emergency surgery, bradycardia (HR &lt;50 beats/min), pathological sinus syndrome, heart block, serious cardiovascular and cerebrovascular diseases (Heart failure, myocardial infarction, cerebral infarction, cerebral hemorrhage), liver and kidney insufficiency, coagulation dysfunction and other systemic diseases, preoperative lesions with infection, and drug allergy.\n\nPostoperative delirium developed in 13.3% (8/60) of patients in the control group and 8.3% (5/60) in the dexmedetomidine group (p=0.378).\n\n\n    Lu2021\n\n808\nInclude: ≥60; elective abdominal surgery; expected surgical duration of 1-6 hours.Exclude: Gastrointestinal motility disorders; previous abdominal surgery; severe hepatic or kidney dysfunction; second or third-degree heart blockage; bradyarrhythmia with a baseline rate lower than 50 beats/minute; mental disorders; history of difficult airway or delayed extubation; opioid medication misuse; allergy to dexmedetomidine or other anesthetics; preop gastrointestinal hemorrhage; emergency reoperations; ASA class IV or V.\n\nThe dexmedetomidine group had a significantly shorter time to first flatus. The incidence of delirium was comparable between the dexmedetomidine and control groups in the first 3 postoperative days.\n\n\n    Lu2017\n\n152\nInclude: Patients age ≥60 years; ASA status II-III; elective shoulder arthroscopy.Exclude: History of neurological or psychiatric disorders; psychotropic drugs; alcohol or drug dependence; use of pain medications; use of opioid or dexmedetomidine for allergies; MMSE &lt;23; COPD; history of heart block or sinus bradycardia.\n\nIn patients undergoing shoulder arthroscopy, patients receiving dexmedetomidine pre- and post-operatively experienced higher MMSE scores on day 1 (p=0.003), day 2 (p=0.002), and day 7 (p=0.001) following surgery compared with patients receiving dexmedetomidine only pre-operatively.\n\n\n    Luntz2004\n\n96\nInclude: Patients age ≥65; ASA physical status I-III; elective unilateral ophthalmic surgery.Exclude: Cardiovascular complaints (New York Heart Association III-IV); adverse reaction to study drug; general anesthesia in past 3 months; &lt;60% vision in contralateral eye.\n\nIn patients undergoing opthalmic surgery, patients receiving sevoflurane alone reported less satisfaction with anesthesia induction compared with patients receiving propofol or propofol with sevoflurane (p&lt;0.05). Differences in satisfaction with awakening and with anesthesia in general were not detected between the groups.\n\n\n    Lv2022\n\n327\nInclude: Patients &gt;60; undergoing surgery with general anesthesia and admitted to ICU postsurgery.Exclude: Unsalvageable at admission; diabetes combined with high cholesterol; history of brain injury, neurosurgery, severe sinus bradycardia, neurological disease, rhabdomyolysis, myopathy, mental illness, epilepsy, severe lung disease, multiple organ dysfunction.\n\nIn patients undergoing various surgeries under general anesthesia, patients receiving dexmedetomidine experienced less delirium compared to patients receiving placebo, 21/152 (14% vs 46/152 (29%), p&lt;0.01. Differences were not detected between the groups in 30-day mortality.\n\n\n    Mahrose2021\n\n110\nInclude: Patients of both sexes above age 60; written informed consent.Exclude: Preoperative mental illness; emergency procedures; preoperative renal failure; diagnosis of chronic liver disease; diagnosis by carotid duplex to have carotid disease; prolonged postoperative intubation and re-exploration.\n\nIncidence of delirium was lower, onset was more delayed, and duration was shorter in the dexmedetomidine + oral melatonin group (group -DM) compared to the dexmedetomidine alone group (group-D).\n\n\n    Mandal2011\n\n60\nInclude: Adult patients with ASA I-II scheduled for hip and knee surgery.Exclude: MMSE score ≤ 23, patients with diseases of the central nervous system, patients with history of consumption of tranquilizers or antidepressants, patients with severe visual or auditory handicap,\npatients currently diagnosed with alcoholism or drug dependence, history of previous neuropsychological testing, and those having a geriatric depression score ≥21.\n\nPostoperative MMSE score between the general and regional anesthesia groups were 25.16 vs 26.83 p= 0.0051.\n\n\n    Mansouri2019\n\n150\nInclude: &gt; 65 years of age; ASA I and II characteristics; No history of sensitivity to anesthetics; No history of moderate to severe mental disorders;.Exclude: Occurrence of severe hemodynamic disorder during the surgery leading to a change in anesthesia; extended surgery duration for &gt;1 hour; Sensitivity to the anesthetics.\n\nNo statistically significant difference between the midazolam and dexmedetomidine groups in the MMSE score 24 hours after surgery (14% vs 12%, respectively) and 1 week postop (8% vs 12%, respectively; P &gt; 0.05). However, there was a significant difference between these two groups and the control  (8% for Midazolam, 12% for Dexmedetomidine vs 20% Control; P &lt; 0.05).\n\n\n    Marcantonio2001\n\n126\nInclude: Patients age ≥65; surgical repair of hip fracture.Exclude: Metastatic cancer or other comorbid illness reducing life expectancy &lt;6 months.\n\nIn patients undergoing emergency hip fracture repair, a difference was not detected in postoperative delirium in patients receiving daily proactive geriatrics consultation compared with patients receiving usual care, when adjusting for prefracture dementia and ADL impairment, OR=0.6 (95% CI: 0.3-1.3). A difference in severe postoperative delirium was also not detected when adjusting for prefracture dementia and ADL impairment, OR=0.4 (95% CI: 0.1-1.2).\n\n\n    Mardani2013\n\n110\nInclude: Did not specify.Exclude: Illiteracy; prolonged intubation; &gt;3hrs of CPB; &gt;80 yrs; EF lower than 20% hemodynamic instability; hx of delirium; Emergency Operation; &gt;24hr intubation postoperatively.\n\nDelirium and hospital length of stay significantly decreased in the dexamethasone group compared to the placebo in the first postoperative day (4 [9.3%] vs. 13 [26%], p=0.03; 12.93 ± 1.03 vs 13.64 ± 1.75 days, p=0.02, respectively).\n\n\n    Mazul-Sunko2010\n\n57\nInclude: Patients undergoing elective carotid endarterectomy.Exclude: None described.\n\nIn patients undergoing carotid endarterectomy, differences were not detected in cognitive outcomes (perceptual speed, attention, working memory, spatial working memory, or verbal fluency) in patients receiving general anesthesia compared with patients receiving regional anesthesia.\n\n\n    Mei2018\n\n336\nInclude: Age &gt;65 yrs; ASA I-IV.Exclude: Contradictions to lumbosacral plexus and T12 paravertebral block (ie coagulopathy, infection at puncture site, and refusal); patients with mental or language barriers; patients anesthetized within the past 30 days; severe congestive heart failure/severe chronic obstructive pulmonary disease; sinus sick syndrome; severe sinus bradycardia; second or greater atrioventricular block without pacemaker; cognitive impairment (MMSE &lt;24)/preop delirium(CAM).\n\nThe patients sedated with dexmedetomidine had lower incidences of POD and POCD and were out of bed and discharged sooner than the patients sedated with propofol. There was no difference in complications between the two groups.\n\n\n    Mei2020\n\n415\nInclude: Age ≥65; undergoing total knee arthroplasty; ASA I to IV.Exclude: Contraindications to spinal anesthesia (i.e., coagulopathy, infection at puncture site, and refusal of spinal anesthesia); having a mental or language barrier; patients with infections; patients who had been anesthetized within the past 30 days; history of congestive heart failure (New York Heart Association, class IV); and/or severe chronic obstructive pulmonary disease (Global Initiative for Chronic Obstructive Lung Disease Guidelines, stages III to IV); diagnosis of sick sinus syndrome; severe sinus bradycardia (&lt;50 beats/min); and second or greater atrioventricular block without pacemaker; patients exhibiting cognitive impairment (i.e., a MMSE score &lt;24) and/or perioperative delirium (i.e., CAM result).\n\nPts who received dexmedetomidine sedation had lower incidences of POD (odds ratio: 0.54; 95%CI: 0.31-0.92; P=0.032). In addition they had better postoperative cognitive function than patients sedated with Propofol on the third (24.3 ± 3.9 vs 22.1 ± 4.3; P&lt;0.001, respectively) and seventh (25.6 ± 4.8 vs23.3 ± 3.3; P&lt;0.001, respectively) day postoperatively.\n\nFigure 1 shows the flowchart for the patient enrollment and randomization, but does not specify which groups is the control and which is the intervention.\n\n    Meuret2018\n\n40\nInclude: Patients &gt; 75 years of age undergoing emergent hip fracture repair with ASA I-III.Exclude: Contraindication to spinal anesthesia and consent refusal.\n\nExcellent patient satisfaction was reported by 53% (10/19) in the regional groups and 23% (5/21) in the general anesthesia group.\n\n\n    Mohamed2014\n\n58\nInclude: &gt;60; ASA class I to III; elective abdominal surgery expected to be longer than 2 hours; hospital stay &gt;48hrs; educable.Exclude: High vagal tone (heart rate &lt;60); arrhythmic disorders; severe ventricular dysfunction (EF &lt;35%); hypovolemic patients; any psychological disorders; preexisting cognitive impairment; alcohol or drug abuse; preexisting CNS deficit; neurological symptomatic disorder confirmed by MRI.\n\nThe use of Dexmedetomidine as an adjuvant during Sevoflurane anesthesia did not have significant effect on protection against POCD in one day and one week postoperatively. The anesthetic and analgesic sparing effect of Dexmedetomidine was significantly proved by lower Sevoflurane need and significant lesser amount of total 24 hours postoperative Fentanyl requirements, but with significant prolonged extubation and orientation times in Dexmedetomidine group than placebo group.\n\n\n    Mohamed2022\n\n80\nInclude: Patients ≥65 years old; ASA physical status I-III; operations done in the morning; upper limb (accompanied or not with lower limb) orthopedic trauma; receiving perioperative opioids to alleviate trauma pain; surgeries under general anesthesia;.Exclude: ASA physical status ≥IV; allergy to the study medications; patients with Abbreviated Mental Test score of &lt;8; preoperative sedation score &gt;3; alcohol abuse; lost vision or hearing; hematocrit &lt;27%; cerebral insults (stroke, hemorrhage, infection); fluids and electrolyte abnormalities; acute cardiac problems (infarction, heart failure, dysrhythmias); acute respiratory events (asthma or chronic obstructive lung disease exacerbation, pulmonary embolism, hypoxemia, hypercarbia); drugs (anticonvulsants, antidepressants, antihistamines, anti-parkinsonism agents, antipsychotics, melatonin); history of chronic sedative-hypnotic use &gt;3 times per week during a month before the surgery.\n\nThe incidence of delirium was lower postoperatively in those who received melatonin (25%) compared to those who did not receive melatonin (52.5%; p&lt;0.001; OR=2.3; 95%CI=-0.44 to 1.23).\n\n\n    Momeni2021\n\n420\nInclude: Patients age ≥60; cardiac surgery with cardiopulmonary bypass.Exclude: Hepatic dysfunction (liver enzyme 3x upper normal limit with serum albumin below normal limit); preop delirium; surgery without cardiopulmonary bypass; emergency surgery; chronic renal replacement therapy.\n\nIn patients undergoing cardiac surgery with cardiopulmonary bypass, a difference was not detected in postoperative delirium during the hospital stay, among patients receiving postoperative dexmedetomidine vs saline, 31/177 (18%) and 33/172 (19%), OR (95% CI): 0.89 (0.52-1.54). Patients receiving dexmedetomidine experienced shorter duration of delirium compared with patients receiving saline, p=0.026.\n\n\n    Nesek-Adam2012\n\n40\nInclude: Patients scheduled for peripheral vascular surgery; ASA physical status II-III.Exclude: Allergy to local anesthetics; severe spinal deformity; coagulopathy; failed or inadequate spinal anesthesia; alcohol or narcotic substance abuse; psychiatric history.\n\nIn patients undergoing peripheral vascular surgery, patients receiving spinal anesthesia report less pain in the first 4 hours postsurgery (p&lt;0.05) and more overall satisfaction (p=0.028) compared with patients receiving general anesthesia.\n\n\n    Neuman2021\n\n1600\nInclude: Patients aged &gt; 50 years; undergoing surgery for hip fracture; ability to walk 10 feet or across a room without human assistance before fracture.Exclude: Planned concurrent surgery not amenable to spinal anesthesia; absolute contraindications to spinal anesthesia; periprosthetic fracture; patient at risk for malignant hyperthermia; previous participation in the trial; unable to walk approximately 10 ft or across a room without the assistance of another person before the fracture (as reported by the patient or by a proxy), and if considered to be unsuitable for randomization by the surgeon or anesthesiologists on the basis of the physician’s clinical assessment.\n\nPrimary outcome (composite of death or an inability to walk approximately 10ft independently or with a walker/cane at 60 days) occured in 132 of 712 patients (18.5%) in the spinal anesthesia group and 132 of 733 (18.0%) in the general anesthesia group (RR = 1.03, 95% CI = 0.84 to 1.27; P=0.83). Delirium occured in 130 of 633 patients (20.5%) in the spinal anesthesia group and in 124 of 629 (19.7%) in the general anesthesia group (RR=1.04; 95% CI=0.84 to 1.30).\n\n\n    Neuman2016\n\n12\nInclude: Patients aged &gt;18 with a acute femoral neck or pertrochanteric hip fracture\nThree (50%) participants in the general anesthesia arm and four in the spinal anesthesia arm had femoral neck fractures; three (50%) in the general anesthesia arm and two (33%) in the spinal anesthesia arm had pertrochanteric factures.Exclude: Montreal Cognitive Assessment score less than 16;  delirium at time of screening; Pathological or periprosthetic fracture; concurrent conditions requiring surgery (e.g., multitrauma, acute cholecystitis); Known contraindications to spinal anesthesia or volatile general anesthetics; and pregnancy.\n\nPostoperative delirium occurred in two (33%) participants randomized to receive general anesthesia and none randomized to receive spinal anesthesia (P = 0.45).\n\n\n    Neuman2022\n\n1600\nInclude: Adults aged 50 years or older who were scheduled to undergo surgical repair of a clinically or radiographically diagnosed femoral neck, intertrochanteric, or subtrochanteric hip fracture.Exclude: Inability to walk approximately 10 feet or across a room without human assistance before fracture, need for a concurrent procedure not amenable to spinal anesthesia, periprosthetic fracture, and contraindications to spinal anesthesia (coagulopathy, anticoagulant medications, critical or severe aortic stenosis, infection at the injection site, and elevated intracranial pressure).\n\nNA\nThere was no difference detected in patient satisfaction between general and regional anesthesia methods (85.3% vs. 86.9%, RR: 0.89 (0.68-1.17).\n\n    Nishikawa2007a\n\n30\nInclude: Patients age &gt;65; undergoing laparoscopic cholecystectomy; ASA physical status I-II.Exclude: Contraindications for epidural anesthesia; previous or current neurologic disease; abnormal mental status (Abbreviated Mental Test score &lt;8).\n\nIn patients undergoing laparoscopic cholecystectomy, a difference in postoperative delirium and opioid use was not detected in patients receiving inhaled anesthesia compared with patients receiving IV-based anesthesia. Patients receiving inhaled anesthesia reported less satisfaction compared with patients receiving IV-based anesthesia (p=0.024).\n\nPatients receiving inhaled anesthesia received epidural-based analgesia and cited anxiety or discomfort with epidural analgesia, resulting in lower satisfaction ratings. IV patients received analgesia through the IV.\n\n    Nishikawa2007b\n\n80\nInclude: Patients age 65-80; ASA physical status I-II; elective outpatient prostate biopsy.Exclude: Clinically significant cardiovascular, respiratory, renal/hepatic, or metabolic disease; mental dysfunction or inability to give accurate responses.\n\nAmong patients undergoing prostate biopsy, differences were not detected in complications or satisfaction in patients receiving spinal anesthesia compared with patients receiving general anesthesia.\n\n\n    Nishikawa2004\n\n50\nInclude: Patients in ASA class I or II; age &gt;65; scheduled for elective laparoscope-assisted surgical procedures which would last more than 3 hours under combined general and epidural anesthesia.Exclude: Patients with anticoagulation; symptomatic coronary artery disease; cardiac valvular regurgitation or stenosis; central nervous system or neuromuscular disorders; major or minor tranquilizer medication; psychotic symptoms; and neurocognitive impairment as judged by a psychiatrist were excluded.\n\nThere was no significant difference between the incidences of POD in the two groups during the first 3 days after surgery. The scored for DRS on day 2 and 3 after surgery, however, were significantly higher in group propofol than in group servoflurane (p&lt;0.01).\n\nNo registration, dates, funding, or COI info included. Searched all 3 databases by title but could not find the study on any registration site.\n\n    Oh2021\n\n80\nInclude: Planned orthopedic surgery (elective primary or revision join, hip or knee, replacement) and inpatient stay following surgery; age &gt;65 years; MMSE &gt;15 before surgery; ability to understand, speak, read, and write English.Exclude: Diagnosis of delirium by CAM prior to surgery; inability to give informed consent due to cognitive impairment and a suitable Legally Authorized Representative cannot be identified; declines participation; currently taking ramelteon, melatonin, and medications that will alter systemic ramelteon levels including fluvoxamine, rifampin, ketoconazole, or fluconazole; history of ramelteon or riboflavin intolerance; heavy daily alcohol intake by medical record or history; current moderate to severe liver failure (as defined by Charlson criteria); evidence of Systemic Inflammatory Response Syndrome (SIRS) as measured by &gt;2 criteria; or presence of a condition that in the opinion of the Principle Investigator might compromise patient safety if enrolled in the study.\n\nDelirium incidence during the two days following surgery was 7% (5/71), with no difference detected between the ramelteon versus placebo: 9% (3/33) and 5% (2/38), respectively. The adjusted odds ratio for postoperative delirium as a function of assignment to the ramelteon treatment arm was 1.28 (95% CI 0.21-7.93; p = 0.79). Adverse events were similar between the two groups.\n\n\n    Ommundsen2018\n\n122\nInclude: Patients age &gt;65; meeting one or more frailty criteria - 1) Vulnerable Elders Survey score &gt;2, 2) severe comorbidity (eg, heart failure, COPD, renal failure), 3) cognitive impairment (eg, dementia), 4) malnutrition (BMI &lt;20 kg/m2 or weight loss &gt;5% last 6 months), and 5) polypharmacy (&gt;5 daily medications); elective resection of adenocarcinoma in colon and/or rectum.Exclude: Emergency surgery.\n\nIn frail patients undergoing resection of adenocarcinoma in colon or rectum, differences were not detected in patients receiving tailored interventions based on preoperative geriatric assessments compared with patients receiving usual care in Grade II-V complications (68% vs 75%, p=0.43), reoperation (19% vs 11%, p=0.24), length of stay (8 days both groups), readmission (16% vs 6%, p-0.12), or 30 day survival (4% vs 5%, p=0.79).\n\nA model including study group, Vulnerable Elders Survey score, and TNM stage showed patients receiving tailored interventions experienced fewer Grade I-V complications compared with the control patients, OR=0.33 (95% CI, 0.11-0.95).\n\n    Ornek2010\n\n60\nInclude: Patients ages 65 yrs or older and ASA II-III were enrolled.Exclude: Patients with BMI &gt; 32 and having allergy to study medications.\n\nPACU length of stay was shorter in patients given general anesthesia compared to spinal (m=21.7 vs 23.3, p=0.970). Patient satisfaction was higher in the general anesthesia group (85.2% vs 75%).\n\n\n    Ottens2014\n\n291\nInclude: Age &gt; 18 yrs;.Exclude: Vision impairments; hearing or motor impairment; mental illness.\n\nAt 1-month follow-up, 13.6% in the dexamethasone group 7.2% in the placebo group were diagnosed with POCD (relative risk, 1.87; 95% CI, 0.90 to 3.88; P = 0.09). At 12-month follow-up, 7.0% in the dexamethasone group and 3.5% in the placebo group had POCD (relative risk, 1.98; 95% CI, 0.61 to 6.40; P = 0.24).\n\n\n    Ozer2017\n\n88\nInclude: Age &gt;64; elective OPCAB surgery.Exclude: More than 50% carotid artery stenosis; severe chronic obstructive pulmonary disease (COPD) requiring daily therapy with steroids or bronchodilators; renal insufficiency (creatine concentration &gt;150 mmol liter 1); severe liver disease (alanine aminotransferase or aspartate aminotransferase &gt;75 IU liter-1); a history of allergy to propofol; a history of seizure or stroke; preoperative MMSE score of &gt;23.\n\nWe believe that well-performed hemodynamic stability with either intravenous or general anesthesia may offer a well-controlled mental function in elderly patients undergoing off-pump CABG surgery.\n\nNo registration or dates provided.\n\n    Papaiannou2005\n\n50\nInclude: Patients aged greater than or equal to 60 years.Exclude: Illiteracy, severe auditory or visual disturbances, central nervous system disorders, alcoholism or drug dependence, treatment with tranquillizers or antidepressants, Parkinson’s disease and a preoperative MMSE score &lt;23 points.\n\nPostoperative delirium was diagnosed in 21% (6/28) of patients in the general anesthesia group and 16% (3/19) in the spinal anesthesia group.\n\n\n    Parker2015\n\n322\nInclude: Patients over 49 years of age with an acute hip fracture.Exclude: Patients who expressed a preference to a particular method of anesthesia were excluded at their request. In addition those patients in whom either the attending anesthetist or surgeon felt either technique was more appropriate were also excluded.\n\n30-day mortality was marginally reduced for spinal anesthesia 7/164(4.3%) compared to general 5/158(3.2%) (p = 0.57). Postoperative delirium was seen in 3/164 (1.8%) in the spinal anesthesia group compared to 0 with general (p=0.25).\n\n\n    Partridge2017\n\n201\nInclude: Age ≥ 65 years  scheduled for elective endovascular/open aortic aneurysm repair or lower-limb arterial bypass surgery.Exclude: Admitted directly to the ward from surgical clinic or emergency department.\n\nThere was a lower incidence of postoperative delirium (11% vs 24%, p=0.018), cardiac complications (8% vs 27%, p=0.001), and length of stay (3.32 vs 5.53 days, p&lt;0.001) in patients receiving a CGA compared to standard preoperative care.\n\n\n    Prakanrattana2007\n\n126\nInclude: Patients age &gt;40; elective cardiac surgery with cardiopulmonary bypass.Exclude: Emergency surgery; patients admitted to ICU; tracheal intubation prior to operating room arrival; preoperative delirium; history of psychiatric problems.\n\nIn patients undergoing cardiac surgery requiring cardiopulmonary bypass, patients receiving sublingual risperidone postoperatively experienced less postoperative delirium compared with patients receiving placebo, 7/63 (11%) vs 20/63 (32%), RR (95% CI): 0.35 (0.16-0.77).\n\n\n    Prestmo2015\n\n397\nInclude: Home-dwelling people aged 70 years or older who had been able to walk 10 m before the fracture were eligible.Exclude: Pathological fractures, multiple traumas, short life expectancy, or nursing home resident.\n\nMobility measured by SPPB index at 4 months postoperative was better in the CGA group compared to usual care with mean difference of 0.74 (95% CI: 0.18, 1.30; p=0.10).\n\n\n    Purwar2015\n\n60\nInclude: Patients undergoing vaginal prolapse or incontinence surgical procedures.Exclude: ASA &gt;III; contraindication to spinal anesthesia.\n\nIn a feasibility study of patients undergoing vaginal surgery for pelvic floor disorders, differences were not detected in pain, quality of life, or functional outcomes in patients receiving spinal anesthesia (n=31) compared with patients receiving general anesthesia (n=28).\n\nProportion converting from spinal anesthesia to general anesthesia: 8/31 (26%). Four due to inadequate analgesia, 2 changed their mind after allocation, 1 inability to insert spinal, and 1 undocumented reason.\n\n    Qiao2023\n\n69\nInclude: Patients age ≥65; ASA I-II; undergoing elective laser laryngeal surgery under general anesthesia.Exclude: Uncontrolled hypertension or diabetes; untreated cardiac or pulmonary disease; hepatic or renal failure; epilepsy; using drugs affecting central nervous system; preexisting mental status alterations; MMSE ≤23.\n\nIn patients undergoing laser laryngeal surgery, a difference in cognitive impairment was not detected in patients receiving propofol compared with patients receiving desflurane, 1/32 (3%) vs 3/31 (10%), p=0.583.\n\n\n    Qiao2015\n\n90\nInclude: Patients in ASA status I, II, or III; preoperative MMSE score ≥23; no evidence of cardiovascular, respiratory or central nervous system disease; normal renal and hepatic function; no serious hearing or visual impairment; absence of a history of benzodiazepine or antidepressant use, alcohol or cigarette misuse or drug dependence.Exclude: Alzheimer’s disease; a family history of mental illness or mental illness; a cognitive impairment of the disease; a history of alcohol and drug dependence.\n\nThe MMSE and MoCA scored were significantly lower in the sevoflurane group than in the propofol control group on the first, third, and seventh postoperative days (p&lt;0.05).\n\nOnly abstracted propofol vs sevoflurane, the article provided a separate p-value\n\n    Qin2019\n\n104\nInclude: Patients who met lung cancer diagnostic criteria; age ≥ 60; no contraindications to surgery and anesthesia; gave informed consent; &gt;9 years of education in China;.Exclude: Patients with cardio-cerebrovascular diseases; abnormal lung function; cognitive disorders; history of drug dependence;.\n\nAt postoperative day 1, MMSE scores were higher in the sevoflurane group than in the propofol group (m=28.87 +- 0.54 vs 27.54 +- 0.89, p=0.002).\n\n\n    Qu2023\n\n469\nInclude: Age &gt; 60 years undergoing cardiac surgical procedure with scheduled ICU admission.Exclude: Allergy to dexmedetomidine, renal or liver failure, were on chronic benzodiazepine or antipsychotic therapy, had severe deficit(s) due to structural or anoxic brain damage, or were SARS-CoV-2 positive or symptomatic.\n\nPostoperative delirium occurred in 5 of 175 patients (2.9%) in the dexmedetomidine group and 16 of 189 patients (8.5%) in the placebo group (OR 0.32, 95% CI: 0.10–0.83; p = 0.029) on the first postoperative day.  A higher proportion of participants experienced delirium within three days postoperatively in the placebo group (25/177; 14.1%) compared to the dexmedetomidine group (14/160; 8.8%; OR 0.58; 95% CI, 0.28–1.15).\n\nMINDSS is a single-center placebo-controlled superiority trial studying the effect of nighttime administration of dexmedetomidine on the incidence of delirium in elderly patients undergoing cardiac surgery.\n\n    Rascon-Martinez2016\n\n80\nInclude: Patients age ≥60; ASA I-III; vitrectomy or cataract surgery involving retrobulbar block.Exclude: History of psychosis, schizophrenia, nephropathy; difficult to control arterial blood pressure; uncontrolled hepatic disorders; ketamine allergy; moderate to severe depression; postop depression; required medications other than study drugs.\n\nIn patients undergoing opthalmic surgeries, more patients receiving ketamine during surgery experienced improved cognitive scores 2 h postsurgery compared with patients receiving a placebo, mean change in error score of -1.0 (1.1) vs -0.2 (0.9), p=0.001.\n\nShort Portable Mental Status Questionnaire used, scoring is 0-2 errors=intact cognition; 3-4 errors=mild cognitive deterioration; 5-7 errors=moderate deterioration; and 8-10 errors=severe deterioration.\n\n    Rasmussen2003\n\n428\nInclude: Patients aged 60 years or older.Exclude: Disease of the central nervous system.\n\nAt 7 days, POCD was found in 37/188 patients (19.7%, [14.3—26.1%]) after general anesthesia and in 22/176 (12.5%, [8.0—18.3%]) after regional anesthesia, p=0.06. After 3 months, POCD was present in 25/175 patients (14.3%, [9.5—20.4%]) after general anesthesia vs. 23/165 (13.9%, [9.0—20.2%]) after regional anesthesia, p=0.93.\n\n\n    Remerand2009\n\n160\nInclude: All adult patients undergoing total hip arthroplasty.Exclude: Patient refusal, inability to use PCA device or NRS, chronic treatment with gabapentin and clonazepam, chronic morphine or fentanyl intake, contraindication to NSAIDs, paracetamol, or ketamine, history of gastric ulcers, allergy, porphyries, hepatic, renal, or coagulation disorders.\n\nPatients given Ketamine used post-operatively had less morphine consumption at 24 h compared with placebo (19+-12 mg to 14+-13 mg, p=0.004). Lower incidence of hallucinations was observed with Ketamine compared to placebo (10.1% (8/79) vs 14.7 (11/75), p=0.51). Length of stay was similar in both groups (8.8 vs 8.3 days, p=0.20).\n\n\n    Ren2021\n\n281\nInclude: Patients aged 65-79 years; undergoing proximal femoral fracture surgery.Exclude: Current diagnosis of CNS diseases (i.e., dementia and Parkinson’s disease) and currently undergoing antidepressant therapy.\n\nNo difference detected between both groups for the development of postoperative delirium (P&gt;0.05). Cognitive impairment, as measured with the trail making test, showed an increase in both groups. However, overall there was no difference between the groups ( P &gt;0.05).\n\nStudy notes there was no significant difference in the number of patients who developed postoperative delirium with a p value of &gt;0.05, but don’t provide any data. Also, no valid scale was used to detect delirium. Study noted that it was an assessment for confusion in which there was dichotomous outcomes (absence or presence based on definition they provided).\n\n    Rohan2005\n\n45\nInclude: Age above 65; presenting for urological and gynecological surgery; requiring general anesthesia; anticipated hospital stay of on night postoperatively;.Exclude: Diseases of the central nervous system including pre-existing cognitive dysfunction; consumption of phenothiazines or antidepressants; cardiac or neurosurgery; previous neuropsychological testing; poor comprehension of the language used in processing the study tests; patients with alcoholism or addictive drug dependence.\n\nIncidence of post-operative cognitive dysfunction (POCD) in elderly patients on the first day after minor surgery was similar in patients given sevoflurane than TIVA with propofol 47% (7/15) vs 47% (7/15) p= 0.003.\n\n\n    Royse2017\n\n555\nInclude: Enrolled in SIRS (Whitlock 2015): age ≥18 years; EuroSCORE ≥6; cardiac surgery requiring cardiopulmonary bypass.Exclude: Known cognitive impairment or psychiatric illness; (from Whitlock 2015: taking or expected to take steroids immediately postop; bacterial or fungal infection preceding 30 days; steroid intolerance or allergy; expected to receive aprotonin).\n\nIn a substudy of patients undergoing cardiac surgery requiring cardiopulmonary bypass, a difference was not detected in overall quality of recovery at 6 months in patients receiving methylprednisolone compared with patients receiving placebo, odds ratios over time 0.39 to 1.45 (95% CI, 0.08-2.04 to 0.40-5.27). Differences were not detected in the subcategories of the recovery scale (cognitive, anxiety and depression, activities of daily living) between the study groups.\n\n\n    Salonia2004\n\n72\nInclude: Patients undergoing radical retropubic prostatectomy with pelvic lymphadenectomy.Exclude: None described.\n\nIn patients undergoing radical retropubic prostatectomy, patients receiving spinal anesthesia experienced more mobilization on postoperative day 1 compared with patients receiving general anesthesia, 17/36 (47%) vs 6/34 (18%), p=0.02. Differences were not detected in pain or in willingness to receive the same anesthesia in subsequent surgeries between the two groups.\n\n\n    Salonia2006\n\n121\nInclude: Patients undergoing radical retropubic prostatectomy.Exclude: None described.\n\nIn patients undergoing radical retropubic prostatectomy, patients receiving general anesthesia experienced more postoperative holding area pain compared with patients receiving spinal anesthesia combined with diazepam, propofol, or midazolam (p&lt;0.0004). Patients receiving spinal anesthesia combined with midazolam reported the lowest pain scores in the holding area. Patients receiving spinal anesthesia combined with either diazepam or propofol reported the lowest pain scores on postoperative day 1 (p=0.007).\n\n\n    Sauer2014\n\n737\nInclude: Age &gt;18 yrs; undergoing cardiopulmonary bypass.Exclude: Emergency surgery; scheduled for an off-pump technique; patients with a life expectancy of &lt;6months.\n\nThe intraoperative admin of dexamethasone did not reduce the incidence or duration of delirium in the first 4 days after cardiac surgery.\n\nA substudy of DECS trial\n\n    Sellbrant2021\n\n90\nInclude: Patients age 19-86 years; ASA status 1-3; ≤ days from trauma and scheduled for operative fixation with a volar locked plate; maximum surgery length &lt;90min.Exclude: Multifractures; pre-trauma inflammatory diseases; dementia; severe psychiatric disorder or cognitive dysfunction; ongoing drug/alcohol use; known local anesthetic allergy; and pregnancy.\n\nMean pain (NRS) at 24h was significantly lower for the regional+mepivacaine group compared to the regional+ropivicaine group during the first three days after surgery [1 IQR(0.3-33), 2.7 IQR(1.3-4.3),p=0.017].\n\nRetrospectively registered\n\n    Shehabi2009\n\n306\nInclude: Patients age ≥60 years; undergoing pump cardiac surgery.Exclude: Allergy to study drugs; using other alpha2 agonists (clonidine or psychoactive agents other than night time hypnotics); heart rate &lt;55 beats/min and/or systolic bp &lt;90 mmHg; weight &gt;150 kg; preop creatinine &gt;1.6 mg/dL or creatinine clearance &lt;50 ml/min; preop dementia, Parkinson disease, recent seizures.\n\nIn patients undergoing cardiac surgery, a difference was not detected in postoperative delirium in patients receiving dexmedetomidine versus morphine postoperatively, 13 (9%) vs 22 (15.%), risk ratio (95% CI): 0.57 (0.26-1.10), p=0.09. However, patients receiving dexmedetomidine experienced shorter delirium duration, 2 (IQR, 1-7) vs 5 (IQR, 2-12) days, p=0.03.\n\nIn small subgrp of patients requiring intraaortic balloon pump, patients receiving dexmedetomidine experienced less postoperative delirium compared with patients receiving morphine, 3/20 (15%) vs 9/25 (36%), RR 0.42 (95% CI, 0.15-0.64).\n\n    Shi2021\n\n297\nInclude: Age &gt; 60 yrs; ICU admission.Exclude: Mental illness and epilepsy; neurologic disease; brain injury or neurosurgery; high cholesterol with diabetes.\n\nThe incidence of postoperative delirium was significantly lower in the melatonin group than in the placebo group (27.0% vs. 39.6%, respectively, p = 0.02). No difference was detected in 30-day all-cause mortality (12.2% vs. 14.1%, p = 0.62).\n\n\n    Shi2020\n\n106\nInclude: MMSE &gt;24; ≥65; male; scheduled for thoracoscopic lobectomy with OLV; expected surgery time between 2 and 4 hr; general anesthesia.Exclude: Not allowed to smoke for at least 14 days prior; systolic bp ≥ 180 or &lt;90 mmHg; diastolic bp ≥110 or &lt;60 mmHg; serious heart, liver, kidney, lung, endocrine, nervous system, or severe infection; administration of sedatives or antidepressants; abnormal results of preop MMSE, MoCA, or CAM; contradictions regarding epidural anesthesia, epidural puncture failure; severe vision disorder; allergies to study drugs; sleep disorders; history of: perioperative severe cardiovascular disease, respiratory complications, inability to complete thoracoscopic lobectomy incompatibility with the neurologic scale assessments and other unpredictable adverse events.\n\nAt 6 h and on the first day postoperatively, the MoCA score in the DEX group was significantly higher than that in the saline group. The incidence of POCD and POD in the DEX group was 13.2 and 7.5%, respectively, while that in the saline group\nwas 35.8 and 11.3%, respectively. There was a significant difference in the incidence of POCD between the two groups (P&lt;0.01). In the DEX group, mean sleep quality was increased, whereas the mean VAS was decreased compared with the corresponding values in the saline group. In conclusion, elderly male patients who underwent thoracoscopic lobectomy under continuous infusion of DEX exhibited a reduced incidence of POCD during the first 7 postoperative days as compared with the placebo group.\n\nonly male ??\n\n    Shin2023\n\n748\nInclude: Patients ASA I-II and age 65 years or older undergoing orthopedic surgery under spinal anesthesia.Exclude: Patients who refused intraoperative sedation, and those with visual, cognitive, language, or speech impairment, neuropsychiatric diseases including dementia, Parkinson’s disease, or cerebrovascular accidents were excluded.\n\nThe delirium incidence was lower in the dexmedetomidine group than in the propofol group (11 [3.0%] vs. 24 [6.6%]; OR, 0.42; 95% CI, 0.201 to 0.86; p = 0.036).\n\n\n    Shin2020\n\n186\nInclude: Patients over the age of 65 years that received daytime hip fracture surgery.Exclude: Patients with absolute contraindications to spinal anesthesia, known allergies to propofol, and altered mental status due to intracranial lesions were excluded.\n\nPostoperative delirium rates were similar between regional, TIVA, and general groups (13.8% vs 13.8% vs 15.0%, p= 0.977). There was no in-hospital mortality in the TIVA group, 3.4% in the regional, and 1.7% in the general group.\n\n\n    Shyu2008\n\n162\nInclude: Patients ≥60 years; accidental single-side hip fracture; undergoing hip arthroplasty or internal fixation; able to perform full range of motion against gravity and against some or full resistance; prefracture Chinese Barthel Index &gt;70.Exclude: Severe cognitive impairment; Chinese MMSE &lt;10; terminally ill.\n\nPatients receiving expanded preoperative evaluations and postoperative gerontological visits experienced improved self-care ability and less depression compared to patients receiving standard care.\n\n\n    Shyu2005\n\n159\nInclude: Patients ≥60 years; accidental single-side hip fracture; undergoing hip arthroplasty or internal fixation; able to perform full range of motion against gravity and against some or full resistance; prefracture Chinese Barthel Index &gt;70.Exclude: Severe cognitive impairment; Chinese MMSE &lt;10; terminally ill.\n\nPatients receiving expanded preoperative evaluations and postoperative gerontological visits experienced improved activities of daily living at 1 and 3 months, and mental and physical function at 3 months compared to patients receiving standard care. No difference was detected in Geriatric Depression Scale scores at 1 month; however, at 3 months, the patients receiving expanded care experienced less depression.\n\n\n    Silbert2014\n\n98\nInclude: Patients aged ≥ 55 years.Exclude: Pre-existing neurological disease, MMSE score ≤ 25, anticipated difficulty with neuropsychological assessment, contraindications to general or spinal anesthesia.\n\nAt 7 days after operation, the incidence of POCD was 4.1% (95% CI: 0.5–14%) in the general anaesthesia group and 11.9% (95% CI: 4.0–26.6%) in the spinal group (p=0.16). At 3 months, POCD was detected in 6.8% (95% CI: 1.4–18.7%) of patients in the general anaesthesia group and 19.6% (95% CI: 9.4–33.9%) in the spinal group (p=0.07).\n\n\n    Siripoonyothai2021\n\n75\nInclude: Age &gt;65 yrs; Euroscore &lt;4.Exclude: Dementia; cognitive impairment; psychiatric or mental disorder; positive on CAM; cerebrovascular disease; carotid disease;.\n\nPostoperative delirium was detected in 31% of patients in the ketamine group and 56% in the Propofol group.\n\n\n    Subramaniam2019\n\n140\nInclude: Patients &gt;60 years having coronary artery bypass graft surgery with or without aortic and/or mitral value replacement.Exclude: Preoperative left ventricular ejection fraction of less than 30%; preexisting cognitive impairment; alzheimer disease; parkinson disease; medications for cognitive decline; history of recent seizures; serum creatine levels above 2ml/dL; liver dysfunction; recent history of alcohol misuse; hypersensitivity to study medications.\n\nDelirium was seen in 21% (13/61) of patients receiving propofol for sedation and in 17% (10/59) in patients given dexmedetomidine.\n\n4 arms: dex-placebo, propofol-placebo, dex-acetaminophen, propofol-acetaminophen\nonly extracted placebo arms as of now.\n\n    Sultan2010\n\n152\nInclude: Age &gt; 65 yrs; ASA I-III.Exclude: Dementia; alcohol abuse; blind/deaf; severe infection; severe anemia; stroke; fluid or electrolyte imbalance; acute cardiac event; acute pulmonary events; on anticonvulsants, antidepressants, antihistamines, antiparkinsonians, antipsychotics, benzodiazepines.\n\nPostoperative delirium was seen in 9.4% of patients given melatonin compared to 32.6% in the control group. This study also compared patients given midazolam (44%) and clonidine (37.2%) preoperatively.\n\n\n    Sun2019\n\n618\nInclude: Age &gt;65; ASA I to III; scheduled to undergo major elective noncardiac surgery under general anesthesia without a planned ICU stay; MMSE ≥20; agree to use of patient-controlled intravenous analgesia pump.Exclude: Hx of schizophrenia; hx of epilepsy; emergency surgery; intracardiac surgery; intracranial surgery; sick sinus syndrome; clinically significant sinus bradycardia; second-degree or higher heart block in the absence of a pacemaker; serious liver dysfunction (Child-Pugh class C); serious kidney failure (requiring dialysis); hx of Parkinson’s disease; hx of myasthenia gravis; allergy to alpha2-adrenergic agonist; allergy to opioids; prior recruitment in other clinical trials.\n\nThe incidence of POD had no difference between he dexmedetomidine and placebo groups (11.7% [33 of 281] vs 13.8% [38 of 276], P=0.47).\n\n\n    Tan2022\n\n99\nInclude: Age &gt;60; undergoing upper GI endoscopy; ASA I-II.Exclude: Clinically significant cardiorespiratory instability; clinically significant renal or hepatic dysfunction; history of drug/alcohol abuse, neurological disease, auditory, or visual disturbances; pre-existing memory or cognitive impairment; and allergy to anesthetics.\n\nThe addition of 0.1 mg/kg of Remimazolam tosilate as an adjunct to opiate sedation not only achieves more stable perioperative hemodynamics, but also achieves acceptable neuropsychiatric function in elderly patients.\n\n\n    Tanaka2017\n\n100\nInclude: Age &gt;65 years old; BMI &gt;30kg/m2; undergoing primary knee arthroplasty surgery; ASA class II-III.Exclude: Failure of regional block; preexisting neurocognitive disorders.\n\nFound a low incidence of delirium, but significant cognitive decline in the first 48 hours after surgery.  There was no difference in the incidence of postoperative delirium between the two groups.\n\n\n    Tang2014\n\n220\nInclude: Memory complaints documented by the patient and a collateral informant; Montreal Cognitive Assessment test score 15-24; MMSE&lt; 27; Activities of Daily Living score &lt;22; no evidence of dementia.Exclude: Current diagnosis of dementia (preoperative MMSE score &lt;23); current or past psychiatric illness; current use of antidepressant or antianxiety medication; history of drug dependence or alcohol abuse; history of coronary artery, peripheral arterial or cerebrovascular disease; severe visual, auditory, or motor handicap; acute infection; preoperative hemoglobin &lt; 85 g/L.\n\nAt 7 days after surgery, the incidence of POCD was 29.7% in the propofol group and 33.3% in the sevoflurane group. Sevoflurane anesthesia had a more severe impact on cognitive function than propofol anesthesia.\n\n\n    Tang2021\n\n100\nInclude: Patients age 60-85 years; ASA status I-II; laparoscopic radical resection of rectal cancer.Exclude: History of neurological or mental illness; drug allergy; alcoholism; use of anticoagulants, NSAIDS, or hormones 3 months prior; blood loss during operation &gt;20% basal blood volume; intractable hypotension; anaphylactic shock.\n\nIn patients undergoing laparoscopic radical resection of rectal cancer, patients recevieving dexmedetomidine experienced higher cognitive scores through 48 h postsurgery compared with patients receiving placebo (p&lt;0.05).\n\n\n    Tanifuji2022\n\n112\nInclude: Patients age &gt;65; elective liver, biliary system, or pancreas open abdominal surgery under general anesthesia, with exception of laparoscopic surgery and exploratory surgery.Exclude: Study drug allergy; severe hepatic dysfunction (Child-Pugh 10-15); use of ≥3 hypnotics; use of antidepressants or antipsychotics; history of delirium; &lt;2 wks administration time before surgery; sedation after surgery.\n\nIn patients undergoing hepatic, biliary, or pancreatic surgery, a difference was not detected in delirium among patients receiving ramelteon compared with patients receiving placebo, 1/23 (4%) vs 4/19 (21%), RR=0.21 (95% CI, 0.03-1.70).\n\n\n    Tu2021\n\n80\nInclude: Patients age ≥60 years; ASA status I-III.Exclude: Hepatic and renal dysfunction; coagulation dysfunction; infectious disease; blood system diseases; increased blood lactic acid or metabolic diseases; end-stage chronic diseases; active bleeding; severe pulmonary hypertension, heart failure and acute myocardial infarction; surgical contraindications; anesthesia contraindications; severe infections; functional abnormality of important organs; mental disorders or psychological illness.\n\nIn patients undergoing spinal surgery, patients induced with propofol and esketamine experienced higher neurocognitive scores (Montreal Cognitive Assessment) at 24 h postop compared with patients induced with propofol and sufentanil, mean (SD) of 21.8 (1.5) vs 17.4 (0.9), p&lt;0.05.\n\nThis study administered esketamine (not ketamine).\n\n    Turan2020\n\n798\nInclude: Age 18-85 yrs.Exclude: Sick-sinus or Wolff-Parkinson-White syndrome; allergy to dexmedetomidine; hepatic disease; atrial fibrillation; permanent pacemaker; MI within 7 days; severe heart failure; BMI &gt;+ 40 kg/m2; clonidine within 48 hours.\n\nThe incidence of delirium was higher in patients given dexmedetomidine compared with placebo (12% vs 17%; RR 1.48, 97.8% CI: 0·99–2·23). Atrial arrhythmia was also higher in patients given a placebo (30% vs 34%; RR 0.91, 97.8% CI: 0.72-1.15).\n\nDECADE is a multi-center randomized controlled trial across 6 academic medical centers in the USA and funded by Hospira Pharmaceuticals.\n\n    Tzimas2018\n\n72\nInclude: Patients over 65 years of age with hip fracture, spoke Greek, and have at least elementary level of education.Exclude: Patients with central nervous system disease, dementia, alcoholism, on anti-depressants, previous neurophysiological testing, severe visual or auditory disorder, or debilitating previous cerebral vascular event.\n\nThe results of neuropsychological testing showed that there were no significant differences between general and spinal anesthesia groups in eight out of ten neurocognitive tests at baseline and 30 days after surgery. There was a significant decline of the Instrumental Activities of Daily Living Scale score in spinal group compared with general anesthesia on the 30th postoperative day (p = 0.043).\n\n\n    Vidan2005\n\n321\nInclude: Patients aged 65 years or older admitted for acute hip fracture surgery.Exclude: Inability to walk before fracture and dependency in all basic ADLs, pathological hip fracture, and know terminal illness.\n\nMedian length of stay was 16 days in the geriatric intervention group and 18 days in the usual care group (p=0.06). There was a lower mortality rate in the intervention group (0.6% vs 5.8%, p=0.03) and major medical complications (45.2% vs 61.7%, p=0.003).\n\n\n    Wang2017\n\n80\nInclude: Patients aged ≥ 60 years, with ASA I-II and TNM stage II/III tumors were recruited.Exclude: None of the patients had any significant cardiovascular disease, and their pulmonary function test results were normal. No patient had a history of central nervous system disease, serious hearing or visual impairment, or any communication impediment, any history of antipsychotic drug administration within 6 months.\n\nPatients in the ulinastatin group had a lower incidence of POCD than control group (23.7% versus 45.9%, p = 0.043).\n\n\n    Wang2022b\n\n100\nInclude: Patients age 65-80 years; ASA I-III; normal preoperative coagulation; no analgesia or sedatives 1 day before surgery; no study drug allergy; education junior high or above; MoCA ≥23; MMSE ≥23.Exclude: Neurological or psychiatric disease; using drugs affecting nervous or mental systems; severe vision, hearing, speech dysfunction; severe heart, lung, brain, liver, kidney diseases.\n\nIn patients undergoing various surgeries under general anesthesia, patients receiving dexmedetomidine experienced higher MMSE and MoCA scores at 24 and 72 h postsurgery compared with patients receiving placebo.\n\n\n    Wang2012\n\n457\nInclude: Patients age ≥65 years; noncardiac surgery admitted to ICU.Exclude: Schizophrenia; epilepsy; parkinsonism; cholinesterase inhibitor use; levodopa treatment; inability to communicate (coma, profound dementia, language barrier); haloperidol or other neuroleptic use during or after anesthesia; neurosurgery; unlikely survival &gt;24 hrs; prolonged corrected QT ≥460 for men or ≥470 for women at baseline.\n\nAmong patients undergoing non-cardiac surgery, 35/229  (15%) patients receiving 5 mg haloperidol IV over 12 h postoperatively experienced delirium during the first 7 days post-surgery compared with 53/228 (23%) patients receiving no treatment, OR (95% CI): 0.57 (0.35-0.94), p=0.026. A difference was not detected in 28-day mortality between the haloperidol group (0.9%) and the control group (2.6%), p=0.175.\n\n\n    Wang2020a\n\n44\nInclude: Currently using a nasal tracheal duct in ICU postop; required sedative treatment; age ≥ 18; ASA I or II.Exclude: Dx liver dysfunction; dx of kidney dysfunction; ALT exceeding 3x the upper limit of normal as indicator of liver damage; Serum creatinine and urea nitrogen exceeding the upper limit of normal as indicator of impaired renal function; acute myocardial infarction or severe heart failure; drug dependence; alcoholism’ hx of psychological illness; severe cognitive dysfunction; currently pregnant or lactating; allergic to midazolam; allergic to dexmedetomidine.\n\nThe incidence of delirium in the dexmedetomidine group was significantly lower than in the midazolam group (1 (1.5%) vs 9 (45%), respectively; P=0.003).\n\nAuthors were emailed to inquire what scale was used to measure delirium.\n\n    Wang2020b\n\n25\nInclude: Patients were (1) a diagnosis with malignant bone tumor around the knee by preoperative biopsy; (2) no distant metastasis upon clinical examination; (3) Enneking staging IA, IB, IIA and IIB with good response to chemotherapy; and (4) tumors with no main blood vessel invasion, no nerve invasion, and no pathological fractures and diffuse skin infiltration.Exclude: Patients had (1) coagulopathy, (2) local skin infection, (3) peripheral neuropathy, (4) mental retardation, (5) mental illness, and (6) rheumatoid knee arthritis.\n\nThere were no statistical differences in pre- and postoperative WOMAC indexes (49.89 ± 7.9, 25.12 ± 6.2 vs. 51.3 ± 8.3, 23.15 ± 5.3) between the general and spinal anesthesia groups (p &gt; 0.05).\n\n\n    Wang2022a\n\n125\nInclude: Age 60-75 yrs; ASA I-II.Exclude: Cognitive dysfunction; adverse response to propofol, remifentanil, dexmedetomidine; cardiovascular disease; endocrine disease; liver or kidney dysfunction; alcohol, sedatives, or opioid use.\n\nThe mean MMSE score was similar between the dexmedetomidine and placebo groups on postoperative days 2 and 3 (25.2 vs 25.1, p=0.66; 25.4 vs 25.3, p=0.76).\n\n\n    Wang2016\n\n206\nInclude: Patients over 66 years old undergoing non-cardiac surgery below the abdomen.Exclude: Patients who had heart associated disease; were allergic to the anesthetic and analgesic drugs or had allergic constitution; had other surgical contraindication or were unwilling to participate in the research.\n\nOn the 7th dat after surgery, incidence of cognition impairment in observation group and control group was 48.5% and 44.7%, but there was no statistical significance between the two groups. VAS score in the regional group was much lower than in the general group (p&lt;0.05).\n\n\n    Wang2019\n\n198\nInclude: ≥ 65 years of age; ASA status of I, II, or III; operative time of about 2-4 hours, with the ability to complete MMSE; preoperative MMSE score &gt;15; no significant evidence of serious central nervous, cardiovascular, respiratory, etc; no contraindications to dexmedetomidine or midazolam; no history of  antidepressant usage, benzodiazepine, alcohol, cigarette misuse, drug dependence;.Exclude: Preoperative bradyarrhythmia (HR &lt; 50 bpm); central nervous system or mental disease; use of sedatives or analgesics recently; renal and/or hepatic dysfunction; chronic alcohol or drug abuse; life expectancy of less than three months; massive blood loss (&gt;1500 mL); MMSE score &lt;15 before surgery; refusal to participate in study;.\n\nIncidence of POCD 5-7 days postoperative was higher in the midazolam group compared to dexmedetomidine 28% (28/100) vs 24.5% (24/98) p= 0.575.\n\n\n    Watne2014\n\n329\nInclude: All patients admitted with a hip fracture.Exclude: Moribund on admission or patients with high energy trauma.\n\nThere was no difference in cognitive function four months after surgery between patients in the comprehensive geriatrics assessment group and standard care group (Clinical Dementia Rating Scale 54.7 versus 52.9, 95% CI: −5.9 to 9.5; p=0.65). Postoperative delirium was seen in 49% in the intervention group and 53% in the standard care group (p=0.51).\n\n\n    Weaver2003\n\n136\nInclude: Medicare eligible; lived within geographic catchment area; scheduled for THR or TKR.Exclude:  Not specified.\n\nThere were no differences between the treatment and control groups in functional status (Barthel score; 96.7 vs 96.6, p=0.940), 8 health-related quality of life, or lower extremity functioning (WOMAC index; 4.2 vs 4.2, p=0.789) by group at 1 follow-up.\n\n\n    Weber2009\n\n40\nInclude: Patients undergoing carotid endarterectomy suitable for either local or general anesthesia; symptomatic or asymptomatic internal carotid stenosis for whom surgery advised.Exclude: Unfit for general or local anesthesia; unlikely to cooperate with awake testing during local anesthesia; requiring simultaneous bilateral carotid endarterectomy; combination with other procedure (eg, coronary artery bypass surgery).\n\nIn patients undergoing carotid endarterectomy, patients receiving regional anesthesia were able to complete the Trail Making Test in a shorter time at 5 h and 1 day post-surgery compared with patients receiving general anesthesia, p&lt;0.05. By 3 days post-surgery, a difference was not detected in Trail Making Test times.\n\n\n    Whitlock2015\n\n7507\nInclude: Patients age ≥18 years; EuroSCORE ≥6 (Jul 2011, China and India included EuroSCORE≥4); cardiac surgery requiring cardiopulmonary bypass.Exclude: Taking or expected to receive systemic steroids immediately postoperation; history of bacterial or fungal infection in past 30 days; allergy or intolerance to steroids; expected to receive aprotinin.\n\nDifferences were not detected in 30-day mortality between patients receiving methylprednisolone (154/3755, 4%) compared with patients receiving placebo (177/3752, 5%), RR, 95% CI: 0.87, 0.70-1.07. Differences were not detected in delirium by day 3 between patients receiving methylprednisolone (295/3755, 8%) compared with patients receiving placebo (289/3752, 8%), RR, 95% CI: 1.02, 0.87-1.19.\n\n\n    Wongyingsinn2020\n\n54\nInclude: Patients age &gt; 18 years and ASA I-III scheduled for elective unilateral inguinal hernia repair.Exclude: Patients were excluded due to allergy to any study medications, femoral hernia, recurrent hernia, bilateral hernia, bleeding abnormalities, severe hepatic/renal/cardiovascular disease, chronic use of opioids, or history of NSAID use.\n\nThere were no significant differences between regional and general anesthesia for postoperative pain at rest or on mobilization at 8 and 24 hours after surgery.\n\n\n    Wu2020\n\n80\nInclude: Age 40-75 yrs; ASA II-III; carotid stenosis.Exclude: Cognitive dysfunction; mental disorders; cerebral infarction or intracranial hemorrhage.\n\nThe MMSE scores in both groups increased at 1 and 7 days postoperatively; although the increase in the dexmedetomidine group was sharper, there was no significant difference.\n\n\n    Xiang2022\n\n174\nInclude: Age 65-80 years; ASA II-III.Exclude: Dementia; unstable mental status or illness; hx of stroke; hx of gastric ulcer.\n\nCompared with placebo, methylprednisolone greatly reduced the incidence of delirium at 72 hours following surgery (9 [10.7%] vs 20 [23.8%], p = .03, OR = 2.22 [95% CI 1.05–4.59]).\n\n\n    Xin2021\n\n60\nInclude: &gt;65; laparoscopic cholecystectomy; patients with mild cognitive impairment (MoCA 15-24, MMSE &lt;27, CDR 0.5, daily living score &lt;26).Exclude: Preoperative delirium; preop neurological diseases affecting cognitive function; severe liver and renal insufficiency; autoimmune diseases; recent use of sedatives; antidepressants or immunosuppressive drugs; traumatic brain injury; history of alcoholism.\n\nPOD occurred in 10/30 patients in the control group, and 3/30 patients in the dexmedetomidine group. Dex can alleviate POD in elderly patients with MCI.\n\n\n    Xing2021\n\n110\nInclude: Age ≥ 60 yrs; ASA I-II.Exclude: Cognitive dysfunction; cardiopulmonary abnormalities; coagulation disorders; concomitant immune system and endocrine system disease.\n\nThe incidence of delirium 24 hours post operation was lower in the dexmedetomidine group compared to controls (3.6% vs 14.5%, p&lt;0.05).\n\n\n    Xu2020\n\n240\nInclude: Patients &gt;65 years old and undergoing primary hip replacement.Exclude: Patients with severe hypertension (systolic pressure ≥ 180 mmHg or diastolic pressure ≥ mmHg); long-term administration of non-steroidal anti-inflammatory drugs (NSAIDs); coagulation disorders, such as abnormal prothrombin time, activated partial prothrombin time, and thrombin time; low platelet count (&lt;100x10^9/L); history of deep vein thrombosis or pulmonary embolism; hematological disorder; peripheral vascular disease, such as Klippel-Trenaunay syndrome and anemia; and ankylosing spondylitis.\n\nSingle subarachnoid anesthesia combines with propofol TCI seems to perform better than CSEA and GA for posterior THA in elderly patients, with less blood loss and peri-operative transfusion, higher patients satisfaction degree and fewer complications.\n\n\n    Yan2021\n\n100\nInclude: Age 60-85 yrs; ASA I-II.Exclude: Dementia, schizophrenia, or depression; use of psychotropic drugs; stroke; alcohol abuse; smoking.\n\nThe incidence of postoperative delirium in the dexmedetomidine group was lower than that in control group (10% vs 26%; p=0.037). The duration of delirium (1.3 6 0.6 days) was shorter in the dexmedetomidine group compared to controls (1.3 vs 3.0 days; p=0.000).\n\n\n    Yu2017\n\n92\nInclude: Age &gt;60 yrs; ASA I-II.Exclude: Senile dementia; coronary heart disease; hypertension; severe hepatic and renal dysfunction; other disease.\n\nPostoperative delirium occurrence rate of 6.52% in dexmedetomidine group was significantly lower than that in the control group, and the difference between the two groups had statistical significance (p &lt;0.05).\n\n\n    Zangrillo2011\n\n153\nInclude: Over age of 18; signed written informed consent; planned for general anesthesia;.Exclude: Previous unusual response to anesthetic use of sulfonylurea, theophylline, or allopurinol;.\n\nThere were no cardiac events 30 days post operation in either the sevoflurane or TIVA groups.\n\n\n    Zhang2018a\n\n392\nInclude: Age ≥65 and &lt;90 years; primary cancer without any radio- or chemotherapy before surgery; scheduled to undergo surgery for cancer with an expected duration ≥2hrs under general anesthesia.Exclude: History of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis; inability to communicate in the preoperative period because of coma, profound dementia, language barrier, or incapacity from severe disease; critical illness (ASA status &gt;III), severe hepatic dysfunction (Child-Pugh class C), or severe renal dysfunction (undergoing dialysis before surgery); or neurosurgery.\n\nThe incidence of delayed neurocognitive recovery at 1 week was lower in the propofol group [14.8%(28/189)] than in the sevoflurane group [23.2%(44/190)]; OR=0.58 (95% CI: 0.34-0.98).\n\n“[P]respecified analysis of one center” from 17 participating centers\n\n    Zhang2021\n\n174\nInclude: Age 18-79 yrs; ASA I-III.Exclude: Dementia; psychosis; cerebrovascular disease; acid-base imbalance, electrolyte imbalance; diabetes.\n\nIncidence of POCD was calculated in both dexmedetomidine and control groups as 9.20% and 21.31% (p=0.038), respectively.\n\n\n    Zhang2019\n\n80\nInclude: Patients with normal consciousness before surgery, age &gt;60 years, and &gt;9 years of education in China.Exclude: Patients with neurological diseases, cognitive disorders, history of long-term administration of\nsedatives and those with malignant tumors.\n\nAt 24h after surgery, the number of cases suffering postoperative cognitive dysfunction (POCD) after spinal anesthesia was lower than that of the general anesthesia (15% vs 35%, p=0.039).\n\n\n    Zhang2018c\n\n60\nInclude: Patients between 65-85 years old with ASA I-II.Exclude: MMSE score ≤ 23, acute or chronic infectious diseases or trauma, tumor, taking anti-inflammatory drugs or immunosuppressants, a stroke in the prior 6 months or any other central nervous system diseases, lower digestive diseases, severe deafness or vision problems, illiteracy, and/or communication difficulties related to pronunciation or dialect and postoperative delirium, and refusal or unexpected discharge.\n\nUlinastatin infusion reduced the incidence of POCD in elderly patients undergoing spine surgery compared to controls (16% vs. 43%, χ 2 = 5.079, p = 0.024, p &lt; 0.05).\n\n\n    Zhang2020\n\n240\nInclude: Age 65-90 yrs; ASA I-III.Exclude: Hx psychosis, long-term use of psychotropic medication; alcohol abuse; MMSE ≤23; illiterate; stroke; TIA; communication barriers.\n\nDexmedetomidine decreased POD incidence on first day after surgery compared to placebo (18.2 vs. 30.6%, P = 0.033).\n\n\n    Zhang2018b\n\n120\nInclude: 65-75; underwent esophageal carcinoma; level of education that is capable of completing the neuropsychological teats; preop MMSE score ≥23; no central nervous system lesions; no tranquilizers or antidepressants; no history of cardiovascular or respiratory disease; no history of alcohol or cigarette abuse or drug dependence; no obvious or abnormal renal or hepatic functions; no serious hearing or vision impairments; no anaphylactic reactions to anesthetics.Exclude: &lt;65, &gt;75; see inclusion.\n\nCompared with Group M+S, the MMSE and MoCA scores were significantly higher in group D+S at the 1st, 3rd, and 7th postoperative days.\n\n\n    Zhao2020\n\n432\nInclude: Age &gt; 65; ASA I-III; scheduled to undergo non-cardiac major surgery.Exclude: MMSE scores of less than 17 in illiterate (uneducated) patients; MMSE score less than 20 for pts with elementary education (education of ≤6 years); MMSE scores less than 24 for patients with secondary education or higher (education &gt; 6 years);  inability to communicate during the preoperative period (owing to coma, profound dementia, or a language barrier); regular use of opioids; use of sedatives; use of antidepressants; use of anxiolytic drugs; hx of drug addiction; severe visual or hearing disorders; preoperative hx of schizophrenia; hx of epilepsy; hx of Parkinsons; Hx of myathenia gravis; brain injury; hx of neurosurgery; serious hepatic dysfunction (Child-Pugh class C); serious renal dysfunction (undergoing dialysis before surgery); a preoperative left ventricular ejection fraction less than 50%; sick sinus syndrome; severe sinus bradycardia (&lt;50/min); second degree or greater atrioventricular block without a pacemaker; allergy to sufentanil; allergy to dexmedetomidine.\n\nThe overall incidence rates of POD and early POCD 7 days after surgery were lower in the dexmedetomidine 200 mcg and 400 mcg groups than in the dexmedetomidine 0 mcg and 100 mcg groups (p &lt;0.05). Compared with dexmedetomidine 200 mcg, dexmedetomidine 400 mcg reduced early POCD in patients who underwent open surgery (P &gt;0.05).\n\n\n    Zhou2019b\n\n156\nInclude: Patients age 60-80 years; ASA status I-III; heart valve replacement surgery.Exclude: MMSE ≤23; acute or chronic infectious disease; use of infammatory  drugs or immunosuppressants; stroke in past 6 months or other central nervou system disease; ICU ≥3 days; BMI &gt;35; severe deafness or vision problems; communication difficulties; postoperative delirium.\n\nIn patients undergoing heart valve replacement surgery, patients receiving ulinastatin alone (n=39), dexmedetomidine alone (n=38), and ulinastatin plus dexmedetomidine (n=39 ), experienced less postoperative cognitive dysfunction after 7 days of followup compared with patients receiving saline (n=38), incidences of 18%, 16%, and 10% vs 32%, respectively, p&lt;0.05.\n\n\n    Zhou2019a\n\n180\nInclude: Patients age &gt;70 years; ASA status I-II; hip arthroplasty surgery.Exclude: History of gastric ulcer or duodenal ulcer; flurbiprofen allergy; severe hepatic or renal disorders; ischemic heart disease; general or local infections.\n\nAmong patients undergoing hip arthroplasty surgery, patients receiving 50 mg flurbiprofen preoperatively (n=60) experienced higher MMSE scores compared with patients receiving nothing (n=60, p&lt;0.01) and patients receiving 50 mg flurbiprofen intraoperatively (n=60, p&lt;0.05) at 3, 12, and 24 h postsurgery. Patients receiving flurbiprofen intraoperatively experienced higher MMSE scores compared to patients receiving nothing, p&lt;0.05.\n\n\n    Zhu2022\n\n155\nInclude: Age greater than 65 years with hip, neck, femur, or lesser trochanter fractures.Exclude: Pathological fracture, old fracture, or multiple fractures.\n\nIncidence of postoperative delirium was higher in the standard care group when compared to the CGA group (21.4% vs 31.8%, p&lt;= 0.001). The ADL score was similar in both groups (m=50.5 vs 51.7, p=0.522) respectively.\n\n\n    Zhu2018\n\n178\nInclude: Patients age 65-75 years; elective total knee arthroplasty under general anesthesia.Exclude: MMSE &lt;23; peptic ulcer disease; cardiac-cerebral vascular disease; chronic obstructive pulmonary disease; neurological or psychiatric disorders; NSAIDS allergy; drug or alcohol abuse; hepatic and/or kidney dysfunction; BMI &gt;35; inability to communicate.\n\nIn patients undergoing total knee arthroplasty, at 7 days follow-up, 10/81 (12.3%) patients receiving celecoxib (200 mg, twice daily, 7 days preop) experienced postoperative cognitive dysfunction compared with 28/82 (34.1%) patients receiving placebo, p&lt;0.05. A difference in cognitive function was not detected at the 3-month followup (9% vs 10%).\n\n\n    Zhu2021\n\n187\nInclude: Age ≥ 65 yrs; ASA II-III; no anesthesia contraindications.Exclude: Mental illness; MoCA score ≤ 26; coronary heart disease; diabetes; hypertension; liver malfunction; renal failure; coagulation dysfunction; use of antidepressants or beta blockers.\n\nMean MMSE score 48 hours post operation in the dexmedetomidine group was higher (27.15±1.17) compared to control group (23.11±0.83, p&lt;0.05).\n\n\n    de Jonghe2014\n\n452\nInclude: Patients aged ≥ 65; acute admission for surgical repair of hip-fracture; enrolment within 24 hours of admission.Exclude: Transferred for surgical repair from another hospital; concomitant use of melatonin and prior participation in this study.\n\nDid not observe an effect of melatonin on the incidence of delirium, 55/186 (29.5%) in the melatonin group vs 49/192 (25.5%) in the placebo group; difference 4.1 (95% CI -0.05 to 13.1) percentage points. There were no between-group differences in mortality or in cognitive functional outcomes at 3-months follow-up.\n\n\n    van Norden2021\n\n63\nInclude: Age &gt;60 yrs; major elective cardiac or major abdominal surgery.Exclude: Known drug intolerance or allergy to dexmedetomidine; unable to provide written consent; history of major neurocognitive disorder (MMSE&lt; 24); severe audiovisual impairment; traumatic brain injury; intracranial bleeding &lt; 1 y before the inclusion date; psychiatric illness; history of alcohol or drug abuse; pregnancy; haemodynamic dysfunction (severe hypotension, defined as a mean arterial pressure &lt; 55 mmHg despite optimal preload and vasopressor therapy); second- or third-degree atrioventricular heart block; severe sinus bradycardia (&lt; 50 bpm at rest); spinal injury with autonomic dysfunction; pre-operative cerebrovascular accident with residual neurological deficit; Child C liver cirrhosis; intra-operative use of remifentanil or clonidine; additional administration of dexmedetomidine within 3 months after inclusion; and planned postoperative deep sedation Richmond Agitation Sedation Scale (RASS) &lt; 4.\n\nDexmedetomidine was associated with a reduced incidence of postop delirium within the first 5 preop days compared to placebo, 43.8% vs. 17.9%, p = 0.038.\n\n\n    Spence2020\n\n800\nInclude: All adult patients who underwent cardiac surgery at each site when the study was being conducted were included.Exclude: None.\n\nIn patients with restricted benzodiazepine administration, delirium was assessed in 17.5% (72/411) compared to 14.1% (55/389) in patients with liberal benzodiazepines."
  },
  {
    "objectID": "evidence_tables.html#nonrandomized-trials",
    "href": "evidence_tables.html#nonrandomized-trials",
    "title": "Evidence Tables",
    "section": "Nonrandomized Trials",
    "text": "Nonrandomized Trials\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      Enrolled\n      Inclusion/Exclusion Criteria\n      Results\n      Note\n    \n  \n  \n    Bao2020\n\n178\nInclude: Patients undergoing laparoscopic colorectal cancer surgery; no previous chemical or radiation therapy; no major organ dysfunction; complete clinical general data.Exclude: Withdrawing from study; not cooperating with treatment; severe mental illness leading to poor treatment compliance; infection history prior to surgery; drugs in 6 months prior affecting study indicators; lost to followup.\n\nIn patients undergoing laparoscopic colorectal cancer surgery, patients receiving ulinastatin and dexmedetomidine experienced less POCD compared with patients receiving dexmedetomidine alone, 8/95 (8%) vs 19/83 (23%), p=0.007.\n\n\n    Deschodt2011\n\n171\nInclude: Verbally competent individuals aged 65 and older consecutively admitted to the emergency department with a traumatic hip fracture.Exclude: Multiple trauma or metastatic cancer or other known comorbidity expected to reduce the individuals’ life expectancy to less than 6 months.\n\nThere was no difference in the mean length of stay between the expanded evaluation and standard care group (11.1 vs 12.4 days, p=0.24).\n\n\n    Li2020\n\n87\nInclude: Patients with lung cancer diagnosis willing to receive surgical resection.Exclude: Received prior radiotherapy or chemotherapy; other malignant tumors; liver or kidney dysfunction; communicative or cognitive impairment.\n\nIn patients undergoing lung resection, a difference was not detected in neurocognitive scores among patients receiving dexmedetomidine with conventional anesthesia intraoperatively (n=41) compared with patients receiving conventional anesthesia alone (n=46) (MMSE scores: 27.3 +/- 2.5 vs 27.2 +/- 3.1, p=0.8).\n\n\n    Van Grootven2016\n\n86\nInclude: Patients age &gt;65 yrs; non-pathological hip fracture.Exclude: Polytrauma; life expectency &lt;6 months; not admitted on traumatology wards for postop care; missed premorbid assessment.\n\nA univariate logistic regression of predictors of postoperative delirium reported an OR (95% CI) for benzodiazepine use: 1.44 (0.52-3.99). The purpose of this analysis was to investigate preoperative anxiety and postoperative delirium.\n\n\n    Wang2020c\n\n110\nInclude: Diagnosed with gastric cancer and consented to surgical resections; no radiotherapy, chemotherapy, or comorbidity with other malignant tumors.Exclude: Liver and renal disfunction; communication and cognitive dysfunction.\n\nThe number of postoperative cognitive dysfunction of patients in the experimental group was lower than that of patients in the control group (P&lt;0.05). The total number of adverse reactions in the control group was higher than that of patients in the experimental group (P&lt;0.05). The MMSE scores of the two groups were decreased at 1 day after operation and were significantly lower in the control group than in the experimental group (P&lt;0.05).\n\nText says a total of 100 patients, but there are 60 in the experimental group and 50 in the control?\n\n    Zhou2021\n\n265\nInclude: Patients diagnosed with lung cancer; undergoing thoracoscopy surgery; and had ASA scores I or II.Exclude: Patients with MMSE score &lt;24 before induction of anesthesia.\n\nResults obtained in the study showed that intravenous Propofol improved cognitive function compared to patients receiving sevoflurane (p &lt;0.05)."
  },
  {
    "objectID": "evidence_tables.html#before-after-time-series",
    "href": "evidence_tables.html#before-after-time-series",
    "title": "Evidence Tables",
    "section": "Before-after & Time Series",
    "text": "Before-after & Time Series\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      Enrolled\n      Inclusion/Exclusion Criteria\n      Results\n      Note\n    \n  \n  \n    Adogwa2017\n\n125\nInclude: Patients age ≥65; elective lumbar decompression and fusion surgery; back pain and/or radiculopathy; radiographic evidence of thoracolumbar deformity; prior failed nonsurgical treatment; underwent multilevel lumbar decompression and fusion.Exclude: Severe coexisting pathology that would confound outcomes; nonambulatory.\n\nIn patients undergoing lumbar decompression and fusion surgery, differences were not detected in complications or postoperative delirium in patients receiving additional care from a geriatrician compared with patients receiving standard care. More patients in the intervention group were discharged to home compared with the standard care group, 54% vs 24%, p=0.01.\n\n\n    Bakker2014\n\n241\nInclude: Patients age ≥70; expected length of stay &gt;48 h.Exclude: Contagious disease; terminally ill; treatment by medical specialist from department outside of study.\n\nDifferences were not detected in delirium, neurocognitive delay, or 30-day readmission in patients receiving care after CareWell in Hospital program implementation compared with patients receiving care before implementation of the program.\n\n\n    Bjorkelund2010\n\n276\nInclude: Patients age ≥65 years; hip fracture; cognitively intact based on Short Portable Mental Status Questionnaire (≥8 correct answers).Exclude: History of cognitive impairment; multi-trauma.\n\nIn patients undergoing hip fracture surgery, patients receiving care within a multi-factorial intervention program experienced lower postoperative delirium rates compared with patients receiving care prior to the program implementation, 29/131 (22%) vs 45/132 (34%), p=0.031. Difference in 30-day mortality was not detected between the groups.\n\n\n    Braude2017\n\n242\nInclude: Patients age ≥65; elective or emergency urological surgery.Exclude: None described.\n\nIn patients undergoing urologic surgery, patients receiving geriatric liaison services experienced fewer medical and surgical complications compared with patients receiving usual care, medical OR (95% CI): 0.26 (0.10-0.54) and surgical OR (95% CI): 0.16 (0.05-0.49). Differences were not detected in unplanned readmissions between the groups.\n\nStudy included patients undergoing non-surgical procedures (15 in each arm) and emergency admissions (32 in control group and 41 in intervention group).\n\n    Ernst2014\n\n310\nInclude: Patients undergoing elective surgery; surgical palliative care consultations.Exclude: None described.\n\nIn a large Veterans Affairs hospital, overall 30-day mortality in patients receiving palliative care consultations decreased from 32% (51/160) to 21% (32/150) after the Frailty Screening Initiative was implemented, p&lt;0.05. Six month and 1 year mortality rates also decreased following the screening initiative, both p&lt;0.05. After initiation of the screening program, palliative care consultations were more often ordered prior to surgery (52% vs 26.%, p&lt;0.05) and mortality rates were reduced when palliative care was ordered prior to surgery (adjusted OR [95% CI]: 0.5 [0.3-0.9], p=0.02).\n\nAll intervention patients were assessed for frailty with Risk Analysis Index, and approximately 10% were identified as frail. Those who were deemed frail received additional review by chief of surgery and were strongly encouraged to undergo preoperative palliative care consultation.\n\n    Giannotti2022\n\n207\nInclude: Patients aged 70 or older admitted for elective GI cancer surgery or palliative treatments and required a hospital stay of at least 1 day.Exclude: Any clinical instability needing acute surgery, or if they were admitted for secondary surgeries.\n\nIn the geriatric co-management group, a reduction in complications (adjusted OR 0.29; 95% CI: 0.21-0.40); p&lt; .001) and in 1-year readmissions (adjusted HR 0.53; 95% CI: 0.28-0.98; p&lt; .044) was observed.\n\n\n    Hall2017\n\n9153\nInclude: Patients presenting for major elective surgical procedures.Exclude: Cardiac surgery.\n\nIn a large Veterans Affairs hospital, overall 30-day mortality decreased from 1.6% (84/5275) to 0.7% (26/3878) after the Frailty Screening Initiative was implemented, adjusted OR (95% CI): 3.5 (1.8-7.0). Six month and 1 year mortality rates also decreased following the screening initiative, OR (95% CI): 2.9 (2.0-4.2) and 3.0 (2.1-4.2), respectively. The multivariate models controlled for age, frailty, and predicted mortality.\n\nImprovement in mortality rates was greatest among frail patients (12.2% [24/197] to 3.8% [16/424]), though mortality rates also decreased among robust patients (1.2% [60/5078] to 0.3% [10/3454]).\nAll intervention patients were assessed for frailty with Risk Analysis Index, and 6.8% were identified as frail. Those who were deemed frail received additional review by chief of surgery in regards to surgical decision making.\n\n    Hokuto2020\n\n309\nInclude: Patients who underwent liver resection at Nara Medical University (Nara, Japan) from January 2014 to August 2018 were retrieved (from registration).Exclude: Patients who underwent biliary reconstruction; patients who could not take water or medicine on POD 1 were excluded (from registration).\n\nThe incidence of postoperative delirium was significantly lower in the ramelteon group compared to controls (5.8% vs. 15.1%, p = 0.035).\n\n\n    Indrakusuma2015\n\n443\nInclude: Patients age ≥70; colorectal carcinoma undergoing elective resection.Exclude: Acute operation; transanal endoscopic microsurgery.\n\nIn patients undergoing colorectal carcinoma resection, differences were not detected in 30-day mortality or postoperative delirium in patients screened with the Identification of Seniors at Risk questionnaire compared with patients receiving standard preoperative care (mortality: 14/221 [6%] vs 17/222 [8%], p=0.71; delirium: 22/221 [10%] vs 27/222 [12%], p=0.55).\n\nOf the 221 patients screened preoperatively, 50 (23%) were referred for a Geriatric Daycare Examination by an in-house geriatrician. The assessment included a full medical history, full physical exam, lab tests, MMSE, Geriatric Depression Scale, and Mini Nutritional Assessment. Geriatricians may then advise interventions (eg, haloperidol prophylaxis, blood transfusions, supplements). A case-control analysis compared the 50 patients referred for the additional assessment with patients who did not need the additional assessment. Differences in mortality and delirium were not detected.\n\n    Lester2022\n\n492\nInclude: Patients age ≥75; elective general, gynecologic-oncology, or orthopedic surgery.Exclude: None described.\n\nIn patients undergoing general, gynecologic-oncology, or orthopedic surgeries, differences were not detected in postoperative delirium, discharge location, 30-day readmission, or 30-day mortality in patients receiving expanded comprehensive interdisciplinary preoperative assessments compared with patients receiving usual care.\n\nResults are from 1 center of 11 sites involved in the American College of Surgeons’ Geriatric Surgery Quality Program during the Alpha pilot.\n\n    McDonald2018\n\n326\nInclude: Patients age 65-84 years; elective abdominal surgery; having one of the following conditions: prior diagnosis of cognitive disorder, weight loss &gt;4.54 kg in past year, multimorbidity (2 or more chronic medical conditions), polypharmacy (&gt;5 prescription medications), visual or hearing impairment, or surgeon perceives increased risk.Exclude: None listed.\n\nIn patients undergoing abdominal surgery, patients receiving care under the Perioperative Optimization of Senior Health (POSH) initiative had higher rates of documented delirium compared with patients prior to POSH, 52/183 (28%) vs 8/143 (6%), p&lt;0.001. Patients in the POSH group experienced lower 30-day readmission rates, 14/180 (3%) vs 26/142 (18%), p=0.004, and were more likely to be discharged to home with self-care, 114/183 (62%) vs 73/143 (51%), p=0.04.\n\nA proportion of patients in each study arm had qualified to be part of the ERAS program simultaneously (control - 47% and POSH - 57%). Regression modeling including age, comorbidities, surgical approach, and ERAS enrollment did not change comparison results of POSH vs pre-POSH in length of stay or readmission (regression results not reported).\n\n    Miyata2017\n\n82\nInclude: Age &gt; 70 yrs; undergoing lung resection.Exclude:  Not specified.\n\nThere were no incidence of postoperative delirium in patients taking ramelteon compared to 9% of controls.\n\n\n    Olsson2014\n\n266\nInclude: Patients undergoing total hip arthroplasty; ability to complete study instruments.Exclude: Cognitive impairment.\n\nIn patients undergoing total hip arthroplasty, differences were not detected in physical functioning and health-related quality of life in patients receiving comprehensive patient-centered care compared with patients receiving standard care. Length of stay was shorter in patients receiving the patient-centered care compared with patients receiving standard care, mean (SD) 5.3 (2.2) vs 7 (5.0), p&lt;0.0005.\n\n\n    Richter2005\n\n62\nInclude: Patients age &gt;60; undergoing pelvic floor surgery.Exclude: None described.\n\nIn women undergoing pelvic floor surgery, differences in SF-36 physical and mental scores were not detected at 6-week followup in patients receiving enhanced preoperative assessment compared with patients receiving usual care (6-week physical: 39.0 +/- 8.3 vs 37.6 +/- 7.5; 6-week mental: 55.5 +/- 9.5 vs 53.7 +/- 8.6). Differences in SF-36 scores were not detected in 6-month followup between the groups (6-month physical: 45.3 +/- 10.9 vs 49.2 +/- 10.4; 6-month mental: 56.3 +/- 7.3 vs 53.9 +/- 10.8).\n\n\n    Romano2021\n\n181\nInclude: Patients undergoing elective hip or knee arthroplasty replacement.Exclude: None described.\n\nIn patients undergoing total hip or knee arthroplasty, patients receiving care under a fast-track recovery system experienced higher rates of home discharge compared with patients prior to the fast-track system, adjusted OR (95% CI): 41.9 (12.1-144.9) and shorter length of stay, p&lt;0.01.\n\nComplications also reported, but all of the following combined: pain, range of motion, infections, surgical wound, hypotonus, tendonitis, hematoma, joint effusion, periprosthetic joint infection, and thromboembolioc events. No differences in complications detected at 1 month; intervention group experiencing lower rate of complications at 6-, 12-, 24-, and 36-months followup compared with control group.\n\n    Souwer2018\n\n149\nInclude: Patients age ≥75; surgical resection for colorectal cancer.Exclude: None described.\n\nIn patients undergoing resection for colorectal cancer, patients receiving a multidisciplinary preoperative assessment experienced fewer cardiac complications (p=0.01) and shorter length of stay (p=0.047) compared with patients receiving usual care. Differences were not detected between the groups in 30-day mortality, 1-year mortality, readmission, or surgical complications.\n\n\n    Ushida2009\n\n122\nInclude: Patients age &gt;50 years; cervical decompression surgery.Exclude: Pre-existence of dementia or other psychological disorder.\n\nPatients undergoing cervical decompression surgery following a change in protocol (reduction in methylprednisolone dose and encouragement of free body movement) experienced lower incidence of postoperative delirium compared with patients prior to protocol changes [3/41 (7%) vs 23/81 (28%), p=0.009]. During the first period found increased incidence of delirium with high-dose (≥1000mg cumulative, anything &gt;500mg administered postoperative days 1 or 23). Noted that under the modified protocol (second period) methylprednisolone use was “reduced or avoided”, but did not report by how much.\nmodified protocol, we reduced or avoided using methyl-.\n\n\n    Vochteloo2011\n\n1056\nInclude: Patients age ≥65; hip fracture due to low energy trauma, non-pathologic origin.Exclude: None mentioned.\n\nIn patients undergoing hip fracture surgery, a difference in delirium incidence was not detected in patients assessed by the Risk Model for Delirium compared with patients receiving usual care. Delirium incidence in intervention group was 27% compared with 3 pre-intervention years of 29%, 24%, and 28%.\n\n\n    Yamasaki2019\n\n21\nInclude: Patients age ≥65 years; hepatectomy.Exclude: Laparoscopic hepatectomy; ICU admission following hepatectomy.\n\nIn patients undergoing hepatectomy, patients receiving omeprazole experienced less postoperative delirium compared with patients receiving famotidine, 3/11 ((27%) vs 9/10 (90%), p&lt;0.01."
  },
  {
    "objectID": "evidence_tables.html#observational",
    "href": "evidence_tables.html#observational",
    "title": "Evidence Tables",
    "section": "Observational",
    "text": "Observational\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      Enrolled\n      Inclusion/Exclusion Criteria\n      Results\n      Note\n    \n  \n  \n    Aoki2023\n\n222\nInclude: ≥ 65 years; underwent elective cardiovascular surgery; admitted to the ICU postoperatively.Exclude: No written informed consent; undergoing second elective surgery during the same hospitalization; come and seizures after surgery; alcohol withdrawal patients; patients with an MMSE of ≤23 preoperative; surgery was cancelled after inclusion; could not be admitted to the ICU postoperatively; refused to continue after surgery; had to be reoperated within 5 days postoperatively.\n\n30.3% of the remimazolam group patients and 26.6% of the control group patients developed delirium within 5 days (risk diference, 3.8%; 95% confdence interval−11.5% to 19.1%; p=0.63). Remimazolam was not signifcantly associated with postoperative delirium when compared with other anesthetic agents.\n\n\n    Barreto Chang2022\n\n98\nInclude: Age ≥ 65 yrs.Exclude: Inability to read, understand, or speak English.\n\nIncidence of postoperative delirium occurred in 32% of patients in the ketamine group and 18% of patients in the control group.\n\n\n    Deiner2015\n\n105\nInclude: Patients older than 68 years.Exclude: Intracranial surgery, cardiac surgery, pre-existing neuropsychiatric disease, history of cerebrovascular accident with residual deficits, baseline Mini Mental State Examination (MMSE) score &lt;20, unable to consent for study participation, or unable to speak English.\n\nPostoperative cognitive dysfunction was detected in 26.4% (9/34) in the sevoflurane group compared to 27.9% (12/43) in the TIVA group.\n\n\n    Deiner2014\n\n76\nInclude: Age 68 years or older scheduled for major noncardiac surgery.Exclude: Intracranial surgery, cardiac surgery, preexisting neuropsychiatric disease, history of cerebrovascular accident (CVA, stroke) with residual deficits, baseline Mini-Mental State Exam (MMSE) score &lt;20 or unable to consent to study participation, and/or unable to speak English.\n\nThe incidence of postoperative delirium seen in the PACU was 3.2% (1/36) in the volatile group and 7.5% (3/36) in the TIVA group with p=0.622.\n\n\n    Duprey2022\n\n566\nInclude: Age 70 years or older English speaking (English need not be first language) Scheduled for eligible high-risk surgery: Orthopedic (total hip or knee replacement; lumbar, cervical, or sacral laminectomy)\nVascular (lower extremity arterial bypass surgery; open abdominal aortic aneurysm repair;\nlower extremity amputation)\nGeneral (open or laparoscopic colectomy)\nPlanned general or regional anesthesia Scheduled at least 6 days before surgery to allow adequate time for the baseline assessment Planned admission to the hospital for at least 2 days Living within 40 miles from study hospitals Exclusion criteria\nActive delirium.Exclude: Active delirium Dementia (dementia diagnosis or score &lt;69 or education-adjusted equivalent on baseline 3MS\ncognitive test)\nHospitalization within 3 months before enrollment to minimize risk of recent delirium Terminal condition with life expectancy &lt; 6 months (eg, metastatic cancer, pancreatic cancer,\nor receiving palliative care)\nInability to perform cognitive tests because of legal blindness or severe deafness.\n\n134 (24%) developed delirium during hospitalization.\nPreoperative medication associations with delirium:\nbenzodiazepines (RR, 1.44; 95% CI, 0.85–2.44)\nbeta-blocker (RR, 1.38; 95% CI, 0.94–2.05)\nNSAID (RR, 1.12; 95% CI, 0.77–1.62)\nopioid (RR, 1.22; 95% CI, 0.82–1.82)\nstatin (RR, 1.34; 95% CI, 0.92–1.95)\nPostoperative medication associations with delirium (before delirium):\nbenzodiazepine (aHR, 3.23; 95% CI, 2.10–4.99)\nantipsychotic (aHR, 1.48; 95% CI, 0.74–2.94)\nopioid (aHR, 0.82; 95% CI, 0.62–1.11)\nAntipsychotic use (either presurgery or postsurgery) was associated with a 0.34 point (standard error, 0.16) decrease in general cognitive performance at 1 month through its effect on delirium (P = .03), despite no total effect being observed.\n\n\n    Jones2021\n\n466\nInclude: Patients age ≥75 years; inpatient operations (elective, urgent, emergent) across all subspecialties.Exclude: Outpatient surgery; &lt;24 h admission.\n\nDifferences in complication occurrence and 30-day mortality were not detected in patients receiving care under the Geriatric Surgery Verification Program (GSV) compared with matched controls from the Veterans Affairs Surgical Quality Improvement Program. Length of stay was reduced in patients in the GSV program (median 4 days, range 1-31) compared with the controls (median 5 days, range 1-86).\n\n\n    Juliebo2009\n\n187\nInclude: Age greater than 65 years, spoke Norwegian, no severe aphasia, head injury, or terminal illness undergoing hip fracture surgery.Exclude: Patients with delirium.\n\nThere was a higher incidence of delirium in patients given ketamine intraoperatively compared to no ketamine (44% (30/68) vs 32% (38/119), p=0.10).\n\n\n    Ke2022b\n\n98\nInclude: Patients aged 65 years and above presenting for noncardiac surgery that was expected to last longer than 2 hours.Exclude: Neurosurgical procedures and those undergoing surgery performed under local anesthesia.\n\nNo delirium was reported in patients receiving dexmedetomidine intraoperatively compared to no dexmedetomidine (0% (0/1) vs 11% (11/91), p&gt;0.999).\n\n\n    Ke2022c\n\n98\nInclude: Patients aged 65 years and above presenting for noncardiac surgery that was expected to last longer than 2 hours.Exclude: Neurosurgical procedures and those undergoing surgery performed under local anesthesia.\n\nA higher incidence of delirium was reported in patients receiving ketamine intraoperatively compared to no ketamine (16.7% (⅙) vs 10.9% (10/92), p=0.671).\n\n\n    Ke2022a\n\n98\nInclude: Patients aged 65 years and above presenting for noncardiac surgery that was expected to last longer than 2 hours.Exclude: Neurosurgical procedures and those undergoing surgery performed under local anesthesia.\n\nThere was a higher incidence of delirium in patients receiving midazolam intraoperatively compared to no midazolam (14% (¼) vs 10% (10/91), p=0.790).\n\n\n    Konishi2018\n\n300\nInclude: Age 60 or older, elective first-time total hip replacement for osteoarthritis; living within reasonable proximity to the hospital to allow investigators to travel to participant’s homes for cognitive testing.Exclude: Pre-existing neurological or clinically evident neurovascular disease; MMSE score less than 26; Clinical Dementia Rating Scale more than 1; anticipated difficulty with neuropsychological assessment; poor English; ability to perform neuropsychological testing; blindness; deafness; critical medical problems such as ASA physical status IV or higher;.\n\nThere was no difference between the incidence of POCD (MMSE score) at postoperative day 7 with sevoflurane compared to propofol (20.2% vs 15.0%, p=0.26).\n\n\n    Leigheb2022\n\n83\nInclude: Patients age ≥65; undergoing femur fracture osteosynthesis or total hip arthroplasty.Exclude: Delirium at admission.\n\nIn patients undergoing hip fracture or THA, patients receiving preoperative midazolam experienced more postoperative delirium (12/47, 36%) compared with patients not receiving midazolam (5/36, 14%), p=0.000.\n\n\n    Pipanmekaporn2021\n\n429\nInclude: Patients aged 60 years or older; undergoing noncardiac surgery.Exclude: Patients with severe visual and auditory impairment; preoperative delirium; death upon the first 24 hours after surgery.\n\nNo difference in the incidence of delirium was detected in those not receiving preoperative benzodiazepine (6.9%) compared to those receiving preoperative benzodiazepine (4.3%; p=0.390).\n\n\n    Wang2021\n\n1266\nInclude: Age 65-85 years, English fluency.Exclude: Brain or cardiac surgery, no written consent.\n\nFrom a secondary analysis of three studies (1 prospective cohort and 2 RCTs ), results were inconclusive concerning midazolam premedication and delirium incidence — 23% on the first postoperative day in older patients undergoing major noncardiac surgery compared with 25% for those not receiving midazolam (OR = 0.91; 95% CI, 0.65-1.29; p=0.67).\n\n\n    Burfeind2022\n\n1627\nInclude: Patients age ≥65; undergoing inpatient elective non-cardiac surgery; documentation of preoperative Mini-Cog and Edmonton Frail Scale scores (study period began after implementation of cognitive and frailty screening program).Exclude: Cardiac surgery.\n\nIn a retrospective study of elective surgeries, the authors suggested that potentially inappropriate medication (PIM) was associated with longer lengths of stay among cognitively impaired and frail patients. Almost all PIMs were dexamethasone, midazolam, or promethazine; few patients received diphenhydramine, scopolamine, metoclopramide, prochlorperazine, meperidine, and famotidine). Differences in discharge location were not detected.\n\nThe study results are limited. The length of stay result was not adjusted for the type of procedure, and justification for the selection of confounders was not provided. No distinction between the type/class of PIM was examined. The investigators were unable to examine delirium owing to a lack of ascertainment. The authors included 3-way interactions in the multivariable model (PIM, cognitive status, and frailty) yet reported results for frailty and cognition independently. Important outcomes including surgical success, complications, and mortality were not examined.\n\n    Cho2021\n\n3045\nInclude: End-stage renal disease (ESRD) patients on hemodialysis in the institutional database; age 20-80; underwent general anesthesia.Exclude: Patients who had undergone cardiac surgery, cancer surgery, organ transplantation, or emergency surgery; patients who received both forms of anesthesia within the study period, either during the same surgical procedure or for additional procedures.\n\nAfter the multivariate analysis, factors associated with a significantly lower MACE risk included preoperative chloride concentration, baseline SBP, and propofol TIVA.\n\n\n    Fuchita2019b\n\n84\nInclude: Patients aged 18 years or older undergoing esophagectomy.Exclude: A history of severe dementia, alcohol abuse, schizophrenia, Parkinson disease, or neuroleptic malignant syndrome. Patients were also excluded if they were pregnant or nursing, on cholinesterase inhibitors or levodopa, or if they had a corrected QT interval exceeding 500 milliseconds.\n\nNo incidence of postoperative delirium was reported in patients given dexamethasone intraoperatively compared to 35% (27/57) without dexamethasone (p=0.091).\n\nThis is a secondary analysis for the PEPOD placebo-controlled single-center clinical trial comparing scheduled low-dose haloperidol versus placebo for delirium prevention in postoperative noncardiac thoracic surgery patients. This study was not included in our analysis due to younger age in the overall study cohort.\n\n    Fuchita2019c\n\n84\nInclude: Patients aged 18 years or older undergoing esophagectomy.Exclude: A history of severe dementia, alcohol abuse, schizophrenia, Parkinson disease, or neuroleptic malignant syndrome. Patients were also excluded if they were pregnant or nursing, on cholinesterase inhibitors or levodopa, or if they had a corrected QT interval exceeding 500 milliseconds.\n\nPostoperative delirium occurred in 30% (3/10) of patients given ketamine intraoperatively and in 32% (24/74) without ketamine (p=1.00).\n\nThis is a secondary analysis for the PEPOD placebo-controlled single-center clinical trial comparing scheduled low-dose haloperidol versus placebo for delirium prevention in postoperative noncardiac thoracic surgery patients.\n\n    Fuchita2019a\n\n84\nInclude: Patients aged 18 years or older undergoing esophagectomy.Exclude: A history of severe dementia, alcohol abuse, schizophrenia, Parkinson disease, or neuroleptic malignant syndrome. Patients were also excluded if they were pregnant or nursing, on cholinesterase inhibitors or levodopa, or if they had a corrected QT interval exceeding 500 milliseconds.\n\nPostoperative delirium occurred in 32% (26/81) of patients given benzodiazepine intraoperatively and in 33% (⅓) without benzodiazepine (p=1.00).\n\nThis is a secondary analysis for the PEPOD placebo-controlled single-center clinical trial comparing scheduled low-dose haloperidol versus placebo for delirium prevention in postoperative noncardiac thoracic surgery patients.\n\n    Goins2018\n\n116\nInclude: Patients undergoing transcatheter aortic valve replacement; general anesthesia.Exclude:  Not specified.\n\nThe odds of delirium were lower in patients with TIVA compared to volatile anesthesia after adjusting. No significant difference in hospital or intensive care unit length of stay was seen after adjusting for procedural characteristics.\n\n\n    Jakobsen2007\n\n10535\nInclude: All procedures performed since January 1999.Exclude: Reoperations during the same hospitalization; heart transplants where cardioprotection was not relevant; procedures primarily involving surgery on the ascending or descending aorta.\n\nThe 30-day mortality was lower after sevoflurane (2.84%) versus propofol (3.30%) although not significantly. No difference was found in the incidence of postoperative myocardial infarction.\n\n\n    Kishimoto2018\n\n21899\nInclude: Patients who underwent TKA with general anesthesia.Exclude: A history of prior THA within 30 days of surgery; a history of prior contralateral TKA within 30 days of surgery; age &lt;40 years; surgical site infection treatment during the hospitalization with antibiotics other than anti-methicillin- resistant Staphylococcus aureus (MRSA) drugs and aminoglycosides; missing data on hospital characteristics; missing data on duration of anesthesia; missing data on type of intraoperative analgesia; use of ketamine for anesthesia induction; and diagnosis of gout or pseudogout.\n\nPropensity score analysis suggested no significant association between the choice of anesthetic maintenance agent and the occurrence of suspected early-onset periprosthetic joint infection in patients undergoing total knee arthroplasty (1.3% propofol vs 1.7% sevoflurane [relative risk = 0.76; 95% CI = 0.55 to 1.04; P = 0.10]). The mean (SD) length of stay in the propofol group was significantly longer than in the sevoflurane group (32.5 (18.4) days vs 31.4 (14.4) days, respectively [mean difference = 1.1; 95% CI = 0.5 to 1.8; P &lt; 0.001]).\n\n\n    Koch2023\n\n1058\nInclude: Patients age ≥60; surgery lasting ≥60 minutes; general anesthesia.Exclude: History of neurologic deficits; current MMSE &lt;24.\n\nAmong patients undergoing various surgical procedures, a difference was not detected in postoperative delirium incidence in patients receiving preoperative midazolam (14/57, 25%) compared with patients not receiving the drug (184/1001, 18%).\n\nThis is a retrospective secondary analysis of an RCT evaluating surgical depth of anesthesia and cognitive outcomes.\n\n    Koo2016\n\n1934\nInclude: Adult inpatients who underwent elective colorectal surgery under general anesthesia; ICD-9-CM procedure codes: 45.7, 45.8, 46.1, 46.52, 48.5, 48.63, and 17.3.Exclude:  Not specified.\n\nStudy results suggest that intravenous anesthesia may have beneficial effects for reducing surgical site infection in colorectal surgery compared to volatile anesthesia (2 [0.5%] vs 10 [2.6%], OR = 5.0 [95% CI = 1.1-22.8], respectively).\n\nNotes it was registered at ClinicaTrials but no record number provided.\n\n    Liu2023b\n\n195\nInclude: Patients age ≥65; elective urinary calculi surgery.Exclude: Delirium; coma; gout; severe renal insufficiency or renal failure; hospitalization &lt;1 day postop; drugs affecting uric acid level.\n\nAmong patients undergoing urologic procedures, patients receiving intraoperative dexmedetomidine experienced less postoperative delirium (12/160, 7.5%) compared with patients not receiving the drug (7/35, 20%), p=0.024.\n\nThis was a risk factor study for delirium.\n\n    Liu2023a\n\n195\nInclude: Patients age ≥65; elective urinary calculi surgery.Exclude: Delirium; coma; gout; severe renal insufficiency or renal failure; hospitalization &lt;1 day postop; drugs affecting uric acid level.\n\nAmong patients undergoing urologic procedures, a difference was not detected in postoperative delirium incidence in patients receiving intraoperative midazolam (14/145, 9.7%) compared with patients not receiving the drug (5/50, 10%).\n\nThis was a risk factor study for delirium.\n\n    Mangusan2015\n\n656\nInclude: Not specified.Exclude:  Not specified.\n\nPostoperative delirium occurred in 31% patients who took oral benzodiazepines after cardiac surgery and in 19.8% of patients taking Ketorolac.\n\n\n    Memtsoudis2019b\n\n1694795\nInclude: Patients undergoing primary hip or knee arthroplasty.Exclude: Patients undergoing both hip and knee arthroplasty; non-elective procedures; outpatient procedures; surgery at hospital performing &lt;30 procedures/yr.\n\nIn patients undergoing total hip arthroplasty, the OR (95% CI) of delirium after ketamine on day of surgery and/or postop day 1:\n1.06 (0.92-1.24).\n\nDelirium identified by ICD-9 codes and/or billing for antipsychotics (haloperidol, olanzapine, and quetiapine).\n\n    Memtsoudis2019c\n\n564226\nInclude: Patients undergoing primary total hip arthroplasty.Exclude: Patients undergoing both hip and knee arthroplasty; non-elective procedures; outpatient procedures; surgery at hospital performing &lt;30 procedures/yr.\n\nIn patients undergoing total hip arthroplasty, the OR (95% CI) of delirium after corticosteroids on day of surgery and/or postop day 1: 0.95 (0.81-1.11).\n\nDelirium identified by ICD-9 codes and/or billing for antipsychotics (haloperidol, olanzapine, and quetiapine).\n\n    Memtsoudis2019d\n\n564226\nInclude: Patients undergoing primary total hip arthroplasty.Exclude: Patients undergoing both hip and knee arthroplasty; non-elective procedures; outpatient procedures; surgery at hospital performing &lt;30 procedures/yr.\n\nIn patients undergoing total hip arthroplasty, the OR (95% CI) of delirium after NSAIDs on day of surgery and/or postop day 1: 0.85 (0.79-0.91).\n\nDelirium identified by ICD-9 codes and/or billing for antipsychotics (haloperidol, olanzapine, and quetiapine).\n\n    Memtsoudis2019e\n\n564226\nInclude: Patients undergoing primary total hip arthroplasty.Exclude: Patients undergoing both hip and knee arthroplasty; non-elective procedures; outpatient procedures; surgery at hospital performing &lt;30 procedures/yr.\n\nIn patients undergoing total hip arthroplasty, the OR (95% CI) of delirium after cyclooxygenase-2 inhibitors on day of surgery and/or postop day 1: 0.82 (0.77-0.89).\n\nDelirium identified by ICD-9 codes and/or billing for antipsychotics (haloperidol, olanzapine, and quetiapine).\n\n    Memtsoudis2019f\n\n1130569\nInclude: Patients undergoing primary total knee arthroplasty.Exclude: Patients undergoing total knee arthroplasty; non-elective procedures; outpatient procedures; surgery at hospital performing &lt;30 procedures/yr.\n\nIn patients undergoing total knee arthroplasty, the OR (95% CI) of delirium after benzodiazepines on day of surgery and/or postop day 1: short-acting vs none, 0.82 (0.77-0.88); long-acting vs none, 2.24 (2.01-2.49); short- and long-acting vs none, 1.78 (1.64-1.92).\n\nDelirium identified by ICD-9 codes and/or billing for antipsychotics (haloperidol, olanzapine, and quetiapine).\n\n    Memtsoudis2019g\n\n1130569\nInclude: Patients undergoing primary total hip arthroplasty.Exclude: Patients undergoing both hip and knee arthroplasty; non-elective procedures; outpatient procedures; surgery at hospital performing &lt;30 procedures/yr.\n\nIn patients undergoing total knee arthroplasty, the OR (95% CI) of delirium after ketamine on day of surgery and/or postop day 1: 0.99 (0.89-1.11).\n\nDelirium identified by ICD-9 codes and/or billing for antipsychotics (haloperidol, olanzapine, and quetiapine).\n\n    Memtsoudis2019h\n\n1130569\nInclude: Patients undergoing primary total knee arthroplasty.Exclude: Patients undergoing both hip and knee arthroplasty; non-elective procedures; outpatient procedures; surgery at hospital performing &lt;30 procedures/yr.\n\nIn patients undergoing total knee arthroplasty, the OR (95% CI) of delirium after corticosteroids on day of surgery and/or postop day 1: 0.96 (0.86-1.06).\n\nDelirium identified by ICD-9 codes and/or billing for antipsychotics (haloperidol, olanzapine, and quetiapine).\n\n    Memtsoudis2019i\n\n1130569\nInclude: Patients undergoing primary total knee arthroplasty.Exclude: Patients undergoing both hip and knee arthroplasty; non-elective procedures; outpatient procedures; surgery at hospital performing &lt;30 procedures/yr.\n\nIn patients undergoing total knee arthroplasty, the OR (95% CI) of delirium after NSAIDs on day of surgery and/or postop day 1: 0.84 (0.80-0.88).\n\nDelirium identified by ICD-9 codes and/or billing for antipsychotics (haloperidol, olanzapine, and quetiapine).\n\n    Memtsoudis2019j\n\n1130569\nInclude: Patients undergoing primary total knee arthroplasty.Exclude: Patients undergoing both hip and knee arthroplasty; non-elective procedures; outpatient procedures; surgery at hospital performing &lt;30 procedures/yr.\n\nIn patients undergoing total knee arthroplasty, the OR (95% CI) of delirium after COX-2 inhibitors on day of surgery and/or postop day 1: 0.83 (0.79-0.88).\n\nDelirium identified by ICD-9 codes and/or billing for antipsychotics (haloperidol, olanzapine, and quetiapine).\n\n    Memtsoudis2019a\n\n564226\nInclude: Patients undergoing primary hip or knee arthroplasty.Exclude: Patients undergoing both hip and knee arthroplasty; non-elective procedures; outpatient procedures; surgery at hospital performing &lt;30 procedures/yr.\n\nIn patients undergoing total hip arthroplasty, the OR (95% CI) of delirium after benzodiazepine use on day of surgery and/or postop day 1: short-acting vs none, 0.79 (0.72-0.87); long-acting vs none, 2.10 (1.82-2.42); both short- and long-acting vs none, 1.74 (1.56-1.94).\n\nDelirium identified by ICD-9 codes and/or billing for antipsychotics (haloperidol, olanzapine, and quetiapine).\n\n    Mueller2020b\n\n651\nInclude: Patients age ≥65; gastrointestinal, genitourinary, gynecological, or thoracic cancer surgery.Exclude: MMSE &lt;24; ≥2 concurrent carcinomas; emergency surgery; life expectancy &lt;2 months.\n\nIn patients undergoing cancer surgery, a difference was not detected in postoperative delirium in patients receiving prophylactic haloperidol (delirium in 14/92, 15%) compared with patients not receiving the drug (delirium in 51/558, 9%), p=0.09.\n\nThis is a retrospective study of an RCT with goal of empowering patients to be active in postop rehabilitation.\n\n    Mueller2020a\n\n651\nInclude: Patients age ≥65; gastrointestinal, genitourinary, gynecological, or thoracic cancer surgery.Exclude: MMSE &lt;24; ≥2 concurrent carcinomas; emergency surgery; life expectancy &lt;2 months.\n\nIn patients undergoing cancer surgery, a difference was not detected in postoperative delirium incidence in patients receiving preoperative benzodiazepines (51/529, 10%) compared with patients not receiving the drug (11/82, 13%), p=0.32.\n\nThis is a retrospective study of an RCT with goal of empowering patients to be active in postop rehabilitation.\n\n    Oh2019\n\n3084\nInclude: Patients ages &gt;19; underwent curative lung resection surgery for primary nonsmall cell lunch cancer (NSCLC).Exclude: Patients with end stage rental disease; defined as requiring renal replacement therapy or having pre-operative estimated glomerular filtration rate less than 15 ml min -1 1.73 m-2; those with incomplete or missing medical records; those who required repeat lung cancer after surgery during the study period.\n\nNo significant difference was found in the incidence of postoperative AKI after lung resection surgery between patients who received TIVA and sevoflurane.\n\n\n    Park2020\n\n1254\nInclude: Adult patients who underwent non-cardiac surgery under general anesthesia with troponin measurement before surgery and repeated measurement within 7 postoperative days.Exclude:  Not specified.\n\nIn-hospital mortality was higher in the TIVA group than the volatile group (22% vs 13.5%) adjusted HR 1.78, 95% CI: 1.08–2.92 p=0.02. 30 day mortality was higher in the TIVA group than the volatile group (17% vs 9.1%) adjusted HR 2.60, 95% CI: 1.14–5.93 p=0.02.\n\n\n    Shimizu2010\n\n265\nInclude: All adult patients undergoing gastrointestinal surgery.Exclude: Patients aged &lt;20; ASA physical status IV-VI; laparoscopic surgeries.\n\nAfter matching, standardized infection ratio after sevoflurane anesthesia was 1.89, which was significantly lower than after propofol anesthesia.\n\n\n    Slor2011b\n\n526\nInclude: Patients age ≥70; acute or elective hip surgery.Exclude: Delirium at admission; inability to participate in interviews (profound dementia, language barrier, intubation, respiratory isolation, aphasia, coma, terminal illness); surgery delay &gt;72 h after admission; cholinesterase inhibitor use; parkinsonism; levodopa treatment; epilepsy; prolonged QTc interval &gt;460 ms (males) or &gt;470 ms (females) on ECG.\n\nIn this secondary analysis of RCT data, 36/430 (8%) patients receiving benzodiazepines and 24/96 (25%) patients receiving no benzodiazepines developed postoperative delirium (OR, 95% CI: 0.73, 0.35-1.51).\n\n\n    Slor2011c\n\n526\nInclude: Patients age ≥70; acute or elective hip surgery.Exclude: Delirium at admission; inability to participate in interviews (profound dementia, language barrier, intubation, respiratory isolation, aphasia, coma, terminal illness); surgery delay &gt;72 h after admission; cholinesterase inhibitor use; parkinsonism; levodopa treatment; epilepsy; prolonged QTc interval &gt;460 ms (males) or &gt;470 ms (females) on ECG.\n\nIn this secondary analysis of RCT data, 8/46 (17%) patients receiving any anticholinergic and 52/480 (11%) patients receiving no anticholinergics developed postoperative delirium, p=0.18.\n\n\n    Slor2011a\n\n526\nInclude: Patients age ≥70; acute or elective hip surgery.Exclude: Delirium at admission; inability to participate in interviews (profound dementia, language barrier, intubation, respiratory isolation, aphasia, coma, terminal illness); surgery delay &gt;72 h after admission; cholinesterase inhibitor use; parkinsonism; levodopa treatment; epilepsy; prolonged QTc interval &gt;460 ms (males) or &gt;470 ms (females) on ECG.\n\nIn this secondary analysis of RCT data, 18/189 (9.5%) patients receiving general anesthesia and 42/337 (12.5%) patients receiving regional anesthesia developed postoperative delirium (OR, 95% CI: 0.81, 0.43-1.52).\n\nRisk factors for delirium (age, baseline cognitive impairment, haloperidol prophylaxis) did not differ between the general and regional groups.\n\n    Tarazona-Santabalbina2019\n\n310\nInclude: Patients age ≥70 years; elective colorectal cancer surgery. For intervention group: ASA III-IV, previous diagnosis of dementia, history of heart failure, ischemic cardiomyopathy, chronic obstructive pulmonary disease, peripheral artery disease, diabetes, or Barthel score &lt;60.Exclude: Secondary surgeries; life expectancy &lt;6 months.\n\nIn patients undergoing colorectal cancer surgery, patients receiving expanded care from a multidisciplinary team experienced less postoperative delirium compared with patients receiving usual care, 23/203 (11%) vs 31/107 (29%), p&lt;0.001. Differences were not detected in readmissions, or in-hospital and 1-year mortality between the groups.\n\n\n    Weinstein2018b\n\n41766\nInclude: Patients age &gt;18 who had THA or TKA.Exclude: Patients with missing record data.\n\nThe incidence of delirium was lower in those not receiving postoperative benzodiazepine (1.9%) compared to those receiving postoperative benzodiazepine (4.8%; p&lt;0.001).\n\nDelirium was based on ICD-9 codes.\n\n    Weinstein2018c\n\n41766\nInclude: Patients age &gt;18 who had THA or TKA.Exclude: Patients with missing record data.\n\nThe incidence of delirium did not differ in those not receiving intraoperative ketamine (2.2%) compared to those receiving intraoperative ketamine (2.1%; p=0.676).\n\nDelirium was based on ICD-9 codes.\n\n    Weinstein2018d\n\n41766\nInclude: Patients age &gt;18 who had THA or TKA.Exclude: Patients with missing record data.\n\nThe incidence of delirium was higher in those receiving postoperative ketamine (13.1%) compared to those not receiving postoperative ketamine (2.1%; p&lt;0.001).\n\nDelirium was based on ICD-9 codes.\n\n    Weinstein2018a\n\n41766\nInclude: Patients age &gt;18 who had THA or TKA.Exclude: Patients with missing record data.\n\nThe incidence of delirium was higher in those not receiving intraoperative benzodiazepine (6.1%) compared to those receiving intraoperative benzodiazepine (1.9%; p&lt;0.001).\n\nDelirium was based on ICD-9 codes.\n\n    Yoshimura2022\n\n738600\nInclude: Patients older than 65 years.Exclude: Those who underwent surgical procedures under regional anesthesia alone underwent multiple surgical procedures per admission or had preoperative delirium.\n\nThe incidence of postoperative delirium occurred in 8.6% (50827/589060) of patients in the inhalation group and 7.0% (10425/149540) in the TIVA group (OR 0.79; CI 0.78-0.81, p&lt; 0.001).\n\n\n    Choi2019\n\n58\nInclude: Patients with postoperative acute lung injury after lung resection surgery for lung cancer.Exclude: Respiratory distress due to respiratory/systemic infection.\n\nIn a case-control study of patients developing acute lung injury after lung resection surgery, patients administered corticosteroids early (within 72 h) experienced less postoperative delirium compared with patients receiving corticosteroids later  (after 72 h), 10/42 (24%) vs 10/16 (63%), p=0.012. Differences were not detected between the groups in complications or length of stay.\n\nPatients receiving early treatment with corticosteroids had greater improvements in lung injury score (primary outcome) compared with patients receiving later treatment; however, no difference was detected in mechanical ventilation weaning within 7 days (primary outcome).\n\n    Nandi2014\n\n463\nInclude: Patients undergoing primary or revision total hip or knee arthroplasty under general anesthesia.Exclude: Spinal anesthesia; antipsychotic drug use.\n\nA case-control study of patients undergoing THA or TKA, reported an increased risk of postoperative delirium among patients administered benzodiazepines during hospital stay compared with patients not receiving benzodiazepines [adjusted OR (95% CI): 9.68 (4.30-21.79)].\n\nOR adjusted for sex, preop alcohol use, and preop depression."
  },
  {
    "objectID": "summary_kq3.html",
    "href": "summary_kq3.html",
    "title": "Study/Patient Characteristics Regional versus General Anesthesia",
    "section": "",
    "text": "Table 1. Characteristics of included randomized clinical trials. \n\n\n\n\n\n\n  \n    \n    \n  \n  \n    \n    \n      Characteristic\n      N (%)\n    \n  \n  \n    Number of Trials\n45\n    Patients Enrolled (N)\n \n      Mean\n273\n      Median\n80\n      Range\n(25-3526)\n    Arms\n \n      Two\n37\n      Multi\n7\n      Mean \n2.2\n      Median \n2\n      Range \n(2-4)\n    Pilot Study\n3 (6.7)\n    Ambulatory\n1 (2.2)\n    Centers\n \n      Single Center\n40 (88.9)\n      Multicenter\n5 (11.1)\n    Volatile Anesthetic\n8 (17.8)\n    Country\n \n      China\n10 (22.2)\n      Italy\n4 (8.9)\n      Turkey\n4 (8.9)\n      United States\n4 (8.9)\n      Sweden\n3 (6.7)\n      United Kingdom\n3 (6.7)\n      Croatia\n2 (4.4)\n      France\n2 (4.4)\n      Germany\n2 (4.4)\n      Greece\n2 (4.4)\n      Australia\n1 (2.2)\n      Denmark\n1 (2.2)\n      India\n1 (2.2)\n      Iran\n1 (2.2)\n      Japan\n1 (2.2)\n      Norway\n1 (2.2)\n      South Korea\n1 (2.2)\n      Thailand\n1 (2.2)\n      Ukraine\n1 (2.2)\n    Non-very-high HDI Countryª\n12 (26.7)\n    Funding\n \n      Industry\n0 (0.0)\n      Public/Industry\n0 (0.0)\n      Public\n18 (40.0)\n      Not Reported\n19 (42.2)\n    Author COI\n5 (11.1)\n    Registered\n18 (40.0)"
  },
  {
    "objectID": "protocol.html",
    "href": "protocol.html",
    "title": "Protocol",
    "section": "",
    "text": "Between 2019 and 2060, the number of US adults aged 65 years or older will likely increase from 54 to 95 million; the oldest-old (85+ years) will grow from 6.6 to 19 million over the same period.1,2 These demographic shifts carry significant implications for the practice of anesthesiology. In 2007, the elderly (15% of the US population) underwent 35% of inpatient surgeries.3 In 2006, 32% of outpatient surgeries were performed in the elderly.4 Moreover, the risk of postoperative complications increases with age.5,6 Improving the quality of perioperative care for older adults is a major priority for patients, providers, and policy makers.\n\n\n\n\nAmong older patients anticipating surgery and anesthesia, does expanded preoperative evaluation (eg, for frailty, cognitive impairment, functional status, or psychosocial issues) lead to improved postoperative outcomes?\nAmong older patients undergoing surgery, does regional anesthesia as the primary anesthetic technique improve postoperative outcomes compared with general anesthesia?\nAmong older patients undergoing surgery with general anesthesia, does the use of intravenous agents for maintenance of anesthesia improve postoperative outcomes compared with inhaled agents?\nAmong older patients undergoing surgery and anesthesia, do commonly used potentially inappropriate medications administered during the perioperative period increase the risk of postoperative delirium or other adverse outcomes?\nAmong older patients undergoing surgery and anesthesia, do dexmedetomidine, ketamine, ramelteon, or melatonin administered during the perioperative period decrease the risk of postoperative delirium or other adverse cognitive outcomes?\n\n\n\n\n\n\n\nPatients 65 years or older undergoing general anesthesia, sedation, or regional anesthesia for surgical procedures.\nSubgroups\n\nAge\n\n65-74\n75-84\n85+\n\nSex\nRace\nEthnicity\nFrailty\nMild neurocognitive disorder (mild cognitive impairment)\nMajor neurocognitive disorder (dementia)\nElective surgery\nEmergency surgery\nType of procedure\n\n\n\nASA classification\n\nASA I-II\nASA III or higher\n\n\n\n\n\n\n\n\n\nExpanded preoperative evaluation (frailty, cognitive, functional, or psychosocial)\n\nPrimary frailty tools to include (but not limited to)\n\nFried Frailty Index\nFrailty Index\nClinical Frailty Scale\nEdmonton Frail Scale\nRisk Analysis Index\n\n\nPrehabilitation (functional, cognitive, nutritional)\n\n\n\n\n\nRegional anesthesia as the primary anesthetic  \nTIVA\nInhalation agents\nPotentially inappropriate medications\n\nAnticholinergics\nAntipsychotics\nCorticosteroids\nKetorolac and NSAIDs\nH2-receptor antagonists\nBenzodiazepines\nNonbenzodiazepine benzodiazepine receptor agonist hypnotics: eszopiclone, zaleplon, zolpidem\n\nDrugs to prevent delirium (dexmedetomidine, ketamine, ramelteon, or melatonin)\n\n\n\n\n\nPostoperative regional anesthetics for lower limb pain (continuous epidural, nerve block with catheter)\nPACU screening for delirium\n\n\n\n\n\n\n\n\nStandard preoperative evaluation\nNo prehabilitation\n\n\n\n\n\nRegional anesthesia as the primary anesthetic  \nTIVA\nAvoidance of potentially inappropriate medications\nNo drugs to prevent delirium\n\n\nInterventions and corresponding comparators.\n\n\n\n\n\n\n\n\nIntervention(s)\nComparator(s)\n\n\n\n\nPreoperative\nExpanded preoperative evaluation\n(frailty, cognitive, functional, psychosocial)\nStandard preoperative evaluation\n\n\nIntraoperative\nRegional anesthesia as the primary anesthetic\nGeneral anesthesia\n\n\n\nTotal intravenous anesthesia\nVolatile anesthetics\n\n\n\nAnticholinergics\nAntipsychotics\nCorticosteroids\nH2-receptor antagonists\nBenzodiazepines\nNonbenzodiazepine benzodiazepine receptor agonist hypnotics: eszopiclone, zaleplon, zolpidem\nNone\n\n\n\nDrugs to prevent delirium (dexmedetomidine, ketamine, ramelteon, or melatonin)\nNone\n\n\n\n\n\n\n\n\nPostoperative delirium\nDelayed neurocognitive recovery (&lt; 30 days after procedure)\nPostoperative neurocognitive disorder\nStroke\nRecovery (eg, Aldrete and Quality of Recovery scores)\nDepression\nPatient/caregiver/family satisfaction\nValued life activities\nPhysical functional status (independence/disability)\nHealth-related quality of life\nComplications\n\nSurgical site infection\nRespiratory (pneumonia, unplanned intubation, pulmonary embolism, on ventilator &gt; 48 hours)\nUrinary tract infection\nAcute kidney injury\nCentral nervous system (stroke, nerve injury)\nCardiac (MI, arrest)\nDeep venous thrombosis\nSepsis\n\nLength of stay\nDischarge location\n\nHome\nRehab/skilled/short-term, long-term care, or other than primary residence\n\nMortality\n\n\n\n\n\nPerioperative period through 1 year\n\n\n\n\n\nAny surgical\n\n\n\n\n\n\n\n\n\n\n\nThe literature search will include publications from 2000 to present (PubMed, Embase, Scopus, and Cochrane Central).\n\n\n\n\nStudies of older patients. (Studies including younger patients will be considered if a result is judged transportable to the target population).\nPublication Types\n\nPublished journal articles, reports \nLanguage restrictions: English language only\nLimited to humans\nGrey literature\n\nStudy Designs\n\nInclude\n\nRandomized clinical trials\nNon-randomized trials\nQuasi-randomized designs (eg, before-after studies, interrupted time series)\nCohort studies (prospective, retrospective)\nCase-control studies\nOther observational studies (eg, diagnostic accuracy)\n\nExclude\n\nCase reports and case series\nSurveys, questionnaires\nLetters\nEditorials\nConference abstracts\nSystematic reviews and meta-analyses (for reference checking)\n\n\n\n\n\n\n(Separate document)\n\n\n\nTitle/abstract and full-text screening together with data extraction will be performed on the DistillerSR platform.7 All screening will be conducted in duplicate, with disagreements resolved by consensus or a third reviewer as needed.\nAnticipated data extraction includes study characteristics (eg, design, dates, setting, centers, country, funding, registration, subgroups, surgery, and anesthetic), study arms (eg, intervention, participant characteristics, intervention, and outcomes reported), and outcome detail according to type (eg, patient-reported or clinical; continuous, dichotomous [includes relative effects], rating scales [Likert, visual analog, numeric]). As required, figures will be digitized. A single reviewer will extract study data followed by verification.8\n\n\n\nRisk of bias assessment for randomized trials will be conducted using the Cochrane risk of bias tool. 9 Risk of bias assessment of non-randomized studies of interventions (eg, observational studies of interventions including cohort, case-control, and quasi-randomized designs) will utilize the Risk Of Bias In Non-randomised Studies of Interventions tool (ROBINS-I).10 Risk of bias will be assessed independently by two reviewers with discrepancies resolved by discussion, or a third reviewer as needed.\n\n\n\nAs appropriate, based on clinical and methodological heterogeneity, study results will be pooled in either pairwise or network meta-analyses in random effects models (given the goal of estimating unconditional effects not relevant only to the pooled studies).11 Statistical heterogeneity is evaluated using between study variance and I2.12 When there is meaningful heterogeneity and the number of studies sufficient (eg, 10 or more) meta-regression is considered to explain the variability.13 With 10 or more pooled studies, small study effects and the potential for publication bias will be examined in funnel plots, regression-based tests, adjustment methods, and p-curves.14,15\nRelative effects will be pooled as risk ratios for clinical interpretability except when adjusted measures reported as odds are pooled. Continuous measures are pooled as mean differences or standardized mean differences when studies use differing scales. When practicably, standardized mean differences will be re-expressed on the most meaningful scale.16 R (R Foundation for Statistical Computing, Vienna, Austria) will be used for analyses and data made publicly available when the guideline is completed.\n\n\n\nThe strength (certainty) of evidence for important outcomes will be appraised using either GRADE17 and ACCF/AHA18 frameworks.\n\n\n\nTBD\n\n\n\n\n\n\n\n\n\nHistory\n\n\n\n\n\n\n\n\n\n\n\n\n\nDate\nSection\nModification\n\n\n\n\nJuly 2021\nNone\nFirst draft\n\n\nJune 2022\nKey questions\nKey questions removed: EEG monitoring and cognitive function; sedation titration with EEG monitoring; and maintaining intraoperative high blood pressure\n\n\nFebruary 2023\nKey questions\nKQ8 combined with KQ1; KQ2 (prehabilitation) and KQ7 (pain) removed\n\n\nSeptember 2023\nKey questions\nReworded to “older patients”\n\n\n\nPICOTS\nUpdated to be consistent with deleted and combined key questions\n\n\n\nAnalytic framework\nUpdated to be consistent with deleted and combined key questions\n\n\n\n\n\n\n\n\n\n\n1. Administration on Aging: 2020 Profile of Older Americans, 2021\n2. Mather M, Jacobsen L, Kilduff L, Lee A, Pollard K, Scommegna P, Vonorman A: America’s Changing Population. Population Bulletin 2019; 74\n3. Hall MJ, DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A: National Hospital Discharge Survey: 2007 summary. Natl Health Stat Report 2010:1-20, 24\n4. Cullen KA, Hall MJ, Golosinskiy A: Ambulatory surgery in the United States, 2006. Natl Health Stat Report 2009:1-25\n5. Turrentine FE, Wang H, Simpson VB, Jones RS: Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg 2006; 203:865-77\n6. Monk TG, Saini V, Weldon BC, Sigl JC: Anesthetic management and one-year mortality after noncardiac surgery. Anesth Analg 2005; 100:4-10\n7. Evidence Partners: DistillerSR. Ottawa, Canada, 2020\n8. PCORI: Methodology Standards (11: Standards for Systematic Reviews) https://www.pcori.org/research-results/about-our-research/research-methodology/pcori-methodology-standards#Systematic%20Reviews, 2021\n9. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928\n10. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hrobjartsson A, Kirkham J, Juni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schunemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP: ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355:i4919\n11. Hedges LV, Vevea JL: Fixed-and random-effects models in meta-analysis. Psychological Methods 1998; 3:486\n12. Rucker G, Schwarzer G, Carpenter JR, Schumacher M: Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol 2008; 8:79\n13. Thompson SG, Higgins JP: How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21:1559-73\n14. Schwarzer G, Carpenter JR, Rücker G: Meta-analysis with R, Springer, 2015\n15. Simonsohn U, Nelson LD, Simmons JP: p-Curve and Effect Size: Correcting for Publication Bias Using Only Significant Results. Perspect Psychol Sci 2014; 9:666-81\n16. Higgins JPT, Cochrane Collaboration: Cochrane handbook for systematic reviews of interventions, Second edition. edition. Hoboken, NJ, Wiley-Blackwell, 2020\n17. Schunemann H, Brozek J, Guyatt G, Oxman A: GRADE Handbook, 2019\n18. Jacobs AK, Kushner FG, Ettinger SM, Guyton RA, Anderson JL, Ohman EM, Albert NM, Antman EM, Arnett DK, Bertolet M, Bhatt DL, Brindis RG, Creager MA, DeMets DL, Dickersin K, Fonarow GC, Gibbons RJ, Halperin JL, Hochman JS, Koster MA, Normand S-LT, Ortiz E, Peterson ED, Roach JWH, Sacco RL, Smith JSC, Stevenson WG, Tomaselli GF, Yancy CW, Zoghbi WA, Harold JG, He Y, Mangu PB, Qaseem A, Sayre MR, Somerfield MR: ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61:213-65"
  },
  {
    "objectID": "protocol.html#background",
    "href": "protocol.html#background",
    "title": "Protocol",
    "section": "",
    "text": "Between 2019 and 2060, the number of US adults aged 65 years or older will likely increase from 54 to 95 million; the oldest-old (85+ years) will grow from 6.6 to 19 million over the same period.1,2 These demographic shifts carry significant implications for the practice of anesthesiology. In 2007, the elderly (15% of the US population) underwent 35% of inpatient surgeries.3 In 2006, 32% of outpatient surgeries were performed in the elderly.4 Moreover, the risk of postoperative complications increases with age.5,6 Improving the quality of perioperative care for older adults is a major priority for patients, providers, and policy makers."
  },
  {
    "objectID": "protocol.html#systematic-review-questions",
    "href": "protocol.html#systematic-review-questions",
    "title": "Protocol",
    "section": "",
    "text": "Among older patients anticipating surgery and anesthesia, does expanded preoperative evaluation (eg, for frailty, cognitive impairment, functional status, or psychosocial issues) lead to improved postoperative outcomes?\nAmong older patients undergoing surgery, does regional anesthesia as the primary anesthetic technique improve postoperative outcomes compared with general anesthesia?\nAmong older patients undergoing surgery with general anesthesia, does the use of intravenous agents for maintenance of anesthesia improve postoperative outcomes compared with inhaled agents?\nAmong older patients undergoing surgery and anesthesia, do commonly used potentially inappropriate medications administered during the perioperative period increase the risk of postoperative delirium or other adverse outcomes?\nAmong older patients undergoing surgery and anesthesia, do dexmedetomidine, ketamine, ramelteon, or melatonin administered during the perioperative period decrease the risk of postoperative delirium or other adverse cognitive outcomes?"
  },
  {
    "objectID": "protocol.html#picots",
    "href": "protocol.html#picots",
    "title": "Protocol",
    "section": "",
    "text": "Patients 65 years or older undergoing general anesthesia, sedation, or regional anesthesia for surgical procedures.\nSubgroups\n\nAge\n\n65-74\n75-84\n85+\n\nSex\nRace\nEthnicity\nFrailty\nMild neurocognitive disorder (mild cognitive impairment)\nMajor neurocognitive disorder (dementia)\nElective surgery\nEmergency surgery\nType of procedure\n\n\n\nASA classification\n\nASA I-II\nASA III or higher\n\n\n\n\n\n\n\n\n\nExpanded preoperative evaluation (frailty, cognitive, functional, or psychosocial)\n\nPrimary frailty tools to include (but not limited to)\n\nFried Frailty Index\nFrailty Index\nClinical Frailty Scale\nEdmonton Frail Scale\nRisk Analysis Index\n\n\nPrehabilitation (functional, cognitive, nutritional)\n\n\n\n\n\nRegional anesthesia as the primary anesthetic  \nTIVA\nInhalation agents\nPotentially inappropriate medications\n\nAnticholinergics\nAntipsychotics\nCorticosteroids\nKetorolac and NSAIDs\nH2-receptor antagonists\nBenzodiazepines\nNonbenzodiazepine benzodiazepine receptor agonist hypnotics: eszopiclone, zaleplon, zolpidem\n\nDrugs to prevent delirium (dexmedetomidine, ketamine, ramelteon, or melatonin)\n\n\n\n\n\nPostoperative regional anesthetics for lower limb pain (continuous epidural, nerve block with catheter)\nPACU screening for delirium\n\n\n\n\n\n\n\n\nStandard preoperative evaluation\nNo prehabilitation\n\n\n\n\n\nRegional anesthesia as the primary anesthetic  \nTIVA\nAvoidance of potentially inappropriate medications\nNo drugs to prevent delirium\n\n\nInterventions and corresponding comparators.\n\n\n\n\n\n\n\n\nIntervention(s)\nComparator(s)\n\n\n\n\nPreoperative\nExpanded preoperative evaluation\n(frailty, cognitive, functional, psychosocial)\nStandard preoperative evaluation\n\n\nIntraoperative\nRegional anesthesia as the primary anesthetic\nGeneral anesthesia\n\n\n\nTotal intravenous anesthesia\nVolatile anesthetics\n\n\n\nAnticholinergics\nAntipsychotics\nCorticosteroids\nH2-receptor antagonists\nBenzodiazepines\nNonbenzodiazepine benzodiazepine receptor agonist hypnotics: eszopiclone, zaleplon, zolpidem\nNone\n\n\n\nDrugs to prevent delirium (dexmedetomidine, ketamine, ramelteon, or melatonin)\nNone\n\n\n\n\n\n\n\n\nPostoperative delirium\nDelayed neurocognitive recovery (&lt; 30 days after procedure)\nPostoperative neurocognitive disorder\nStroke\nRecovery (eg, Aldrete and Quality of Recovery scores)\nDepression\nPatient/caregiver/family satisfaction\nValued life activities\nPhysical functional status (independence/disability)\nHealth-related quality of life\nComplications\n\nSurgical site infection\nRespiratory (pneumonia, unplanned intubation, pulmonary embolism, on ventilator &gt; 48 hours)\nUrinary tract infection\nAcute kidney injury\nCentral nervous system (stroke, nerve injury)\nCardiac (MI, arrest)\nDeep venous thrombosis\nSepsis\n\nLength of stay\nDischarge location\n\nHome\nRehab/skilled/short-term, long-term care, or other than primary residence\n\nMortality\n\n\n\n\n\nPerioperative period through 1 year\n\n\n\n\n\nAny surgical"
  },
  {
    "objectID": "protocol.html#methods",
    "href": "protocol.html#methods",
    "title": "Protocol",
    "section": "",
    "text": "The literature search will include publications from 2000 to present (PubMed, Embase, Scopus, and Cochrane Central).\n\n\n\n\nStudies of older patients. (Studies including younger patients will be considered if a result is judged transportable to the target population).\nPublication Types\n\nPublished journal articles, reports \nLanguage restrictions: English language only\nLimited to humans\nGrey literature\n\nStudy Designs\n\nInclude\n\nRandomized clinical trials\nNon-randomized trials\nQuasi-randomized designs (eg, before-after studies, interrupted time series)\nCohort studies (prospective, retrospective)\nCase-control studies\nOther observational studies (eg, diagnostic accuracy)\n\nExclude\n\nCase reports and case series\nSurveys, questionnaires\nLetters\nEditorials\nConference abstracts\nSystematic reviews and meta-analyses (for reference checking)\n\n\n\n\n\n\n(Separate document)\n\n\n\nTitle/abstract and full-text screening together with data extraction will be performed on the DistillerSR platform.7 All screening will be conducted in duplicate, with disagreements resolved by consensus or a third reviewer as needed.\nAnticipated data extraction includes study characteristics (eg, design, dates, setting, centers, country, funding, registration, subgroups, surgery, and anesthetic), study arms (eg, intervention, participant characteristics, intervention, and outcomes reported), and outcome detail according to type (eg, patient-reported or clinical; continuous, dichotomous [includes relative effects], rating scales [Likert, visual analog, numeric]). As required, figures will be digitized. A single reviewer will extract study data followed by verification.8\n\n\n\nRisk of bias assessment for randomized trials will be conducted using the Cochrane risk of bias tool. 9 Risk of bias assessment of non-randomized studies of interventions (eg, observational studies of interventions including cohort, case-control, and quasi-randomized designs) will utilize the Risk Of Bias In Non-randomised Studies of Interventions tool (ROBINS-I).10 Risk of bias will be assessed independently by two reviewers with discrepancies resolved by discussion, or a third reviewer as needed.\n\n\n\nAs appropriate, based on clinical and methodological heterogeneity, study results will be pooled in either pairwise or network meta-analyses in random effects models (given the goal of estimating unconditional effects not relevant only to the pooled studies).11 Statistical heterogeneity is evaluated using between study variance and I2.12 When there is meaningful heterogeneity and the number of studies sufficient (eg, 10 or more) meta-regression is considered to explain the variability.13 With 10 or more pooled studies, small study effects and the potential for publication bias will be examined in funnel plots, regression-based tests, adjustment methods, and p-curves.14,15\nRelative effects will be pooled as risk ratios for clinical interpretability except when adjusted measures reported as odds are pooled. Continuous measures are pooled as mean differences or standardized mean differences when studies use differing scales. When practicably, standardized mean differences will be re-expressed on the most meaningful scale.16 R (R Foundation for Statistical Computing, Vienna, Austria) will be used for analyses and data made publicly available when the guideline is completed.\n\n\n\nThe strength (certainty) of evidence for important outcomes will be appraised using either GRADE17 and ACCF/AHA18 frameworks.\n\n\n\nTBD\n\n\n\n\n\n\n\n\n\nHistory\n\n\n\n\n\n\n\n\n\n\n\n\n\nDate\nSection\nModification\n\n\n\n\nJuly 2021\nNone\nFirst draft\n\n\nJune 2022\nKey questions\nKey questions removed: EEG monitoring and cognitive function; sedation titration with EEG monitoring; and maintaining intraoperative high blood pressure\n\n\nFebruary 2023\nKey questions\nKQ8 combined with KQ1; KQ2 (prehabilitation) and KQ7 (pain) removed\n\n\nSeptember 2023\nKey questions\nReworded to “older patients”\n\n\n\nPICOTS\nUpdated to be consistent with deleted and combined key questions\n\n\n\nAnalytic framework\nUpdated to be consistent with deleted and combined key questions"
  },
  {
    "objectID": "protocol.html#references-update",
    "href": "protocol.html#references-update",
    "title": "Protocol",
    "section": "",
    "text": "1. Administration on Aging: 2020 Profile of Older Americans, 2021\n2. Mather M, Jacobsen L, Kilduff L, Lee A, Pollard K, Scommegna P, Vonorman A: America’s Changing Population. Population Bulletin 2019; 74\n3. Hall MJ, DeFrances CJ, Williams SN, Golosinskiy A, Schwartzman A: National Hospital Discharge Survey: 2007 summary. Natl Health Stat Report 2010:1-20, 24\n4. Cullen KA, Hall MJ, Golosinskiy A: Ambulatory surgery in the United States, 2006. Natl Health Stat Report 2009:1-25\n5. Turrentine FE, Wang H, Simpson VB, Jones RS: Surgical risk factors, morbidity, and mortality in elderly patients. J Am Coll Surg 2006; 203:865-77\n6. Monk TG, Saini V, Weldon BC, Sigl JC: Anesthetic management and one-year mortality after noncardiac surgery. Anesth Analg 2005; 100:4-10\n7. Evidence Partners: DistillerSR. Ottawa, Canada, 2020\n8. PCORI: Methodology Standards (11: Standards for Systematic Reviews) https://www.pcori.org/research-results/about-our-research/research-methodology/pcori-methodology-standards#Systematic%20Reviews, 2021\n9. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343:d5928\n10. Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hrobjartsson A, Kirkham J, Juni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schunemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP: ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 2016; 355:i4919\n11. Hedges LV, Vevea JL: Fixed-and random-effects models in meta-analysis. Psychological Methods 1998; 3:486\n12. Rucker G, Schwarzer G, Carpenter JR, Schumacher M: Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol 2008; 8:79\n13. Thompson SG, Higgins JP: How should meta-regression analyses be undertaken and interpreted? Stat Med 2002; 21:1559-73\n14. Schwarzer G, Carpenter JR, Rücker G: Meta-analysis with R, Springer, 2015\n15. Simonsohn U, Nelson LD, Simmons JP: p-Curve and Effect Size: Correcting for Publication Bias Using Only Significant Results. Perspect Psychol Sci 2014; 9:666-81\n16. Higgins JPT, Cochrane Collaboration: Cochrane handbook for systematic reviews of interventions, Second edition. edition. Hoboken, NJ, Wiley-Blackwell, 2020\n17. Schunemann H, Brozek J, Guyatt G, Oxman A: GRADE Handbook, 2019\n18. Jacobs AK, Kushner FG, Ettinger SM, Guyton RA, Anderson JL, Ohman EM, Albert NM, Antman EM, Arnett DK, Bertolet M, Bhatt DL, Brindis RG, Creager MA, DeMets DL, Dickersin K, Fonarow GC, Gibbons RJ, Halperin JL, Hochman JS, Koster MA, Normand S-LT, Ortiz E, Peterson ED, Roach JWH, Sacco RL, Smith JSC, Stevenson WG, Tomaselli GF, Yancy CW, Zoghbi WA, Harold JG, He Y, Mangu PB, Qaseem A, Sayre MR, Somerfield MR: ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61:213-65"
  },
  {
    "objectID": "kq3.html",
    "href": "kq3.html",
    "title": "Regional versus General Anesthesia",
    "section": "",
    "text": "Recent updates (last 2024-01-03)\n\n\n\n\n\n\n\n\nDate               \nModification\n\n\n\n\n2023-11-08\nUpdated to most current included studies. Removed risk of bias tallies from forest plots where not pertinent to outcome. Used weighted risk of bias summary for delirium and added for overall. Added risk differences per 1000 to complications and mortality.\n\n\n2023-11-09\nAdded balance tables (also appear in appendix).\n\n\n2024-01-02\nAdded figure 4 to display potential dependence of effects on baseline (control arm event rate) for delirium. Updated balance tables\n\n\n2024-01-03\nAdded link under included studies section to updated appendix that now includes a primary outcomes table."
  },
  {
    "objectID": "kq3.html#key-question",
    "href": "kq3.html#key-question",
    "title": "Regional versus General Anesthesia",
    "section": "Key Question",
    "text": "Key Question\nAmong older patients undergoing surgery and anesthesia, does regional anesthesia as the primary anesthetic technique improve postoperative outcomes compared with general anesthesia?"
  },
  {
    "objectID": "kq3.html#outcome-importance",
    "href": "kq3.html#outcome-importance",
    "title": "Regional versus General Anesthesia",
    "section": "Outcome Importance",
    "text": "Outcome Importance\n Table 1. Rankings of the 5 most important outcomes (11 respondents)."
  },
  {
    "objectID": "kq3.html#outcomes-reported",
    "href": "kq3.html#outcomes-reported",
    "title": "Regional versus General Anesthesia",
    "section": "Outcomes Reported",
    "text": "Outcomes Reported\n Table 2. Dichotomous or count outcomes. \n\n\n\n\n\n\n  \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 45a\n    \n  \n  \n    ADL\n3 (6.7%)\n    Complications\n22 (49%)\n    DNCR/PND\n5 (11%)\n    Delirium\n12 (27%)\n    Delirium duration\n—\n    Discharge location\n1 (2.2%)\n    Mortality\n11 (24%)\n    Opioid use\n1 (2.2%)\n    Pain\n4 (8.9%)\n    QoR\n—\n    Readmission\n2 (4.4%)\n    Satisfaction\n10 (22%)\n  \n  \n  \n    \n       ADL: activities of daily living; DNCR: delayed neurocognitive recovery; PND: postoperative neurocognitive disorder; QoR: quality of recovery; RCT: randomized clinical trial.\n    \n    \n      a Number or trial publications, not the unique trials (see inlcuded studies below).\n    \n  \n\n\n\n\n Table 3. Continuous outcomes. \n\n\n\n\n\n\n  \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 45a\n    \n  \n  \n    Delirium duration\n1 (2.2%)\n    Length of stay\n14 (31%)\n    Opioid use\n8 (18%)\n  \n  \n  \n    \n       RCT: randomized clinical trial.\n    \n    \n      a Number or trial publications, not the unique trials (see inlcuded studies below).\n    \n  \n\n\n\n\n Table 4. Likert or ordinal outcomes. \n\n\n\n\n\n\n  \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 45a\n    \n  \n  \n    ADL\n1 (2.2%)\n    DNCR/PND\n11 (24%)\n    Delirium\n1 (2.2%)\n    Complications\n1 (2.2%)\n    Pain\n19 (42%)\n    Quality of life\n1 (2.2%)\n    QoR\n1 (2.2%)\n    Satisfaction\n2 (4.4%)\n  \n  \n  \n    \n       ADL: activities of daily living; DNCR: delayed neurocognitive recovery; PND: postoperative neurocognitive disorder; QoR: quality of recovery; RCT: randomized clinical trial.\n    \n    \n      a Number or trial publications, not the unique trials (see inlcuded studies below)."
  },
  {
    "objectID": "kq3.html#included-studies",
    "href": "kq3.html#included-studies",
    "title": "Regional versus General Anesthesia",
    "section": "Included Studies",
    "text": "Included Studies\nSee Appendix for detailed summary study and patient characteristics including primary outcomes.\n Table 5. Number of studies by design. \n\n\n\n\n\n\n  \n    \n    \n  \n  \n    \n    \n      Design\n      Studies\n    \n  \n  \n    Randomized Clinical Trial\n43\n    Total\n43\n  \n  \n  \n    \n       Studies with multiple publications counted only once (applied to 1 trial with 2 publications).\n    \n  \n\n\n\n\n\nDesign, centers, country, and surgery\n Table 6. Enrollment, centers, country, and surgical procedures (see References for citations). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      ID\n      Study\n      Centers\n      Enrolled\n      Country\n      Surgery\n    \n  \n  \n    6540\nBielka 2021\n\n1\n90\nUkrainea\nHip fracture\n    14441\nCasati 2003\n\n1\n30\nItaly\nHip fracture\n    7744\nGu 2021\n\n1\n94\nChina\nHip fracture\n    13669\nHaghighi 2017\n\n1\n100\nIrana\nHip fracture\n    7490\nLi 2022\n\n9\n950\nChina\nHip fracture\n    4782\nLiang 2017\n\n1\n198\nChinaa\nHip fracture\n    6072\nMeuret 2018\n\n1\n40\nFrance\nHip fracture\n    8117\nNeuman 2021 (Neuman 2022)\n\n46\n1600\nUSA\nHip fracture\n    17100\nNeuman 2022 (Neuman 2021)\n\n46\n1600\nUSA\nHip fracture\n    1335\nParker 2015\n\n1\n322\nUK\nHip fracture\n    13141\nRen 2021\n\n1\n281\nChinaa\nHip fracture\n    6109\nShin 2020\n\n1\n186\nSouth Korea\nHip fracture\n    1320\nTzimas 2018\n\n1\n72\nGreece\nHip fracture\n    221\nAksoy 2013\n\n1\n36\nTurkey\nOrtho\n    14566\nChu 2006\n\n1\n60\nChinaa\nOrtho\n    2252\nEdipoglu 2019\n\n1\n80\nTurkey\nOrtho\n    208\nHarsten 2013\n\n1\n124\nSweden\nOrtho\n    269\nHarsten 2015\n\n1\n120\nSweden\nOrtho\n    5894\nMandal 2011\n\n1\n60\nIndiaa\nOrtho\n    6424\nSellbrant 2021\n\n1\n90\nSweden\nOrtho\n    2020\nWang 2020b\n\n1\n25\nChinaa\nOrtho\n    158\nXu 2020\n\n1\n240\nChinaa\nOrtho\n    1489\nZhang 2019\n\n1\n80\nChinaa\nOrtho\n    3218\nAlas 2020\n\n1\n61\nUSA\nUrol\n    397\nNishikawa 2007b\n\n1\n80\nJapan\nUrol\n    737\nOrnek 2010\n\n1\n60\nTurkeya\nUrol\n    296\nSalonia 2004\n\n1\n72\nItaly\nUrol\n    329\nSalonia 2006\n\n1\n121\nItaly\nUrol\n    781\nSilbert 2014\n\n1\n98\nAustralia\nUrol\n    14396\nAasbo 2002\n\n1\n60\nNorway\nGI/Abdominal\n    16573\nJia 2014\n\n1\n240\nChinaa\nGI/Abdominal\n    6132\nWang 2016\n\n1\n206\nChinaa\nGI/Abdominal\n    658\nWongyingsinn 2020\n\n1\n54\nThailand\nGI/Abdominal\n    15278\nApan 2016\n\n1\n52\nTurkey\nNeuro\n    241\nMazul-Sunko 2010\n\n1\n57\nCroatia\nNeuro\n    2592\nLewis 2008 (Weber 2009)\n\n95\n3526\nUK\nNeuro|Vasc\n    315\nWeber 2009 (Lewis 2008)\n\n1\n40\nGermany\nNeuro|Vasc\n    2518\nKasprzak 2006\n\n1\n186\nGermany\nCardiac\n    262\nPurwar 2015\n\n1\n60\nUK\nGyn\n    1400\nPapaiannou 2005\n\n1\n50\nGreece\nGyn|Ortho|Urol|Vasc\n    16379\nHestin 2022\n\n1\n60\nFrance\nHeadneck\n    239\nCarron 2007\n\n1\n40\nItaly\nOther\n    7554\nBrown 2021\n\n1\n219\nUSA\nSpine\n    831\nRasmussen 2003\n\n12\n428\nDenmark\nVariousb\n    307\nNesek-Adam 2012\n\n1\n40\nCroatia\nVasc\n  \n  \n  \n    \n       GI: gastrointestinal; Ortho: orthopedic; Urol: urological; Neuro: neurological; Oralmax: oral maxillofacial; Vasc: vascular; Hip fracture: only hip fracture.\n    \n    \n      a Non very-high Human Development Index country.\n    \n    \n      b Described as various or more than 4 different types of surgery.\n    \n  \n\n\n\n\n\n\nCountry Summary\n Table 7. Summary of trials by country where conducted. \n\n\n\n\n\n\n  \n    \n    \n      \n      N = 43a\n    \n  \n  \n    Country\n\n        China\n10 (23%)\n        Italy\n4 (9.3%)\n        Turkey\n4 (9.3%)\n        Sweden\n3 (7.0%)\n        USA\n3 (7.0%)\n        Croatia\n2 (4.7%)\n        France\n2 (4.7%)\n        Germany\n2 (4.7%)\n        Greece\n2 (4.7%)\n        UK\n2 (4.7%)\n        Australia\n1 (2.3%)\n        Denmark\n1 (2.3%)\n        India\n1 (2.3%)\n        Iran\n1 (2.3%)\n        Japan\n1 (2.3%)\n        Norway\n1 (2.3%)\n        South Korea\n1 (2.3%)\n        Thailand\n1 (2.3%)\n        Ukraine\n1 (2.3%)\n  \n  \n  \n    \n      a n (%)"
  },
  {
    "objectID": "kq3.html#comparators",
    "href": "kq3.html#comparators",
    "title": "Regional versus General Anesthesia",
    "section": "Comparators",
    "text": "Comparators\n Table 8. Selected characteristics of randomized clinical trials comparing regional to general anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      \n      \n        Regional\n      \n    \n    \n      Study\n       N\n      Comparator\n      \n        ASA\n      \n          Agea\n      MMSEa\n      \n        General\n      \n      \n        Neuraxial\n      \n      Block\n    \n    \n      PS\n      Vol\n      TIVA\n      NR\n      Spinal\n      Epid\n      CSE\n    \n  \n  \n    \n      Ortho — HipFx\n    \n    Casati 2003\n\n15\nGen\n 23 \n84.0 [67-88]\n\n29 [24-29]\n\n●\n\n\n\n\n\n\n    \n15\nNeur\n 23 \n84.0 [71-94]\n\n28 [25-30]\n\n\n\n\n●\n\n\n\n    Parker 2015\n\n164\nGen\n1234\n83.0 [59-99]\n\n\n\n\n●\n\n\n\n\n    \n158\nNeur\n1234\n82.9 [25-105]\n\n\n\n\n\n●\n\n\n\n    Haghighi 2017\n\n50\nGen\n123 \n66.0 (4.8)\n\n\n●\n\n\n\n\n\n\n    \n50\nNeur\n123 \n66.2 (5.2)\n\n\n\n\n\n●\n\n\n\n    Liang 2017\n\n66\nGen\n123 \n68.0 (11.0)\n\n26.7 (1.6)\n\n\n●\n\n\n\n\n\n    \n66\nNeur\n123 \n67.0 (12.0)\n\n26.8 (2.0)\n\n\n\n\n\n●\n\n\n    \n66\nNeur\n123 \n66.0 (10.0)\n\n26.6 (1.9)\n\n\n\n\n\n\n●\n\n    Meuret 2018\n\n21\nGen\n123 \n85.0 (5.0)\n\n21 [12-24]\n\n\n●\n\n\n\n\n\n    \n19\nNeur\n123 \n83.0 (6.0)\n\n19 [12-26]\n\n\n\n\n●\n\n\n\n    Tzimas 2018\n\n33\nGen\n123 \n75.1 (6.1)\n\n25.7 (2.9)\n\n●\n\n\n\n\n\n\n    \n37\nNeur\n123 \n77.1 (6.5)\n\n25.3 (0.9)\n\n\n\n\n●\n\n\n\n    Shin 2020\n\n58\nGen\nNR\n80.5 (6.7)\n\n\n\n●\n\n\n\n\n\n    \n60\nGen\nNR\n79.4 (7.7)\n\n\n●\n\n\n\n\n\n\n    \n58\nNeur\nNR\n81.6 (6.7)\n\n\n\n\n\n●\n\n\n\n    Bielka 2021\n\n30\nGen\nNR\n73.0 {72-74}\n\n\n●\n\n\n\n\n\n\n    \n30\nBlock\nNR\n72.0 {68-73}\n\n\n\n\n\n\n\n\n●\n    \n30\nNeur\nNR\n72.0 {70-73}\n\n\n\n\n\n●\n\n\n\n    Gu 2021\n\n45\nGen\n 23 \n69.3 [60-91]\n\n\n●\n\n\n\n\n\n\n    \n42\nBlock\n 23 \n74.5 [60-88]\n\n\n\n\n\n\n\n\n●\n    Neuman 2021\n\n804\nGen\n1234\n78.4 (10.6)\n\n\n●\n\n\n\n\n\n\n    \n795\nNeur\n1234\n77.7 (10.7)\n\n\n\n\n\n●\n\n\n\n    Ren 2021\n\n154\nGen\n123 \n74.1 (4.2)\n\n25.6 (1.4)\n\n\n●\n\n\n\n\n\n    \n127\nNeur\n123 \n73.1 (6.2)\n\n25.7 (1.2)\n\n\n\n\n●\n\n\n\n    Li 2022\n\n471\nGen\n1234\n77.0 {71-82}\n\n20 {15-25}\n\n●\n●\n\n\n\n\n\n    \n471\nNeur\n1234\n77.0 {72-82}\n\n20 {15-24}\n\n\n\n\n●\n●\n●\n\n    Neuman 2022\n\n796\nGen\nNR\n78.0 (11.0)\n\n\n●\n\n\n\n\n\n\n    \n795\nNeur\nNR\n78.0 (11.0)\n\n\n\n\n\n●\n\n\n\n    \n      Ortho — HipFx|Other\n    \n    Zhang 2019\n\n40\nGen\nNR\n69.4 (2.6)\n\n\n\n●\n\n\n\n\n\n    \n40\nNeur\nNR\n69.4 (2.6)\n\n\n\n\n\n●\n\n\n\n    \n      Ortho — TKA|THA|HipFx|Other\n    \n    Mandal 2011\n\n30\nGen\n12  \n67.1 (7.1)\n\n27.3 (1.8)\n\n●\n\n\n\n\n\n\n    \n30\nNeur\n12  \n66.6 (5.6)\n\n28.0 (1.3)\n\n\n\n\n\n●\n\n\n    \n      Ortho — TKA\n    \n    Chu 2006\n\n30\nGen\n123 \n69.0 {62-74}\n\n\n●\n\n\n\n\n\n\n    \n30\nNeur\n123 \n65.0 {62-68}\n\n\n\n\n\n\n\n●\n\n    Aksoy 2013\n\nNR\nGen\nNR\n67.2 [58-78]\n\n\n\n\n●\n\n\n\n\n    \nNR\nNeur\nNR\n67.9 [62-77]\n\n\n\n\n\n●\n\n\n\n    Harsten 2013\n\n60\nGen\n123 \n68.0 (7.0)\n\n\n\n●\n\n\n\n\n\n    \n60\nNeur\n123 \n67.0 (7.0)\n\n\n\n\n\n●\n\n\n\n    Edipoglu 2019\n\n26\nGen\nNR\n68.8 (4.9)\n\n22.6 (3.0)\n\n●\n\n\n\n\n\n\n    \n31\nNeur\nNR\n69.8 (4.4)\n\n22.6 (2.7)\n\n\n\n\n●\n\n\n\n    \n      Ortho — THA\n    \n    Harsten 2015\n\n60\nGen\n123 \n68.0 (9.0)\n\n\n\n●\n\n\n\n\n\n    \n58\nNeur\n123 \n66.0 (7.8)\n\n\n\n\n\n●\n\n\n\n    Xu 2020\n\n80\nGen\nNR\n75.4 (5.6)\n\n\n\n●\n\n\n\n\n\n    \n80\nNeur\nNR\n75.6 (5.5)\n\n\n\n\n\n\n\n●\n\n    \n80\nNeur\nNR\n75.0 (5.2)\n\n\n\n\n\n●\n\n\n\n    \n      Ortho\n    \n    Wang 2020b\n\n13\nGen\nNR\n58.4 (7.3)\n\n\n●\n\n\n\n\n\n\n    \n12\nNeur\nNR\n62.7 (8.7)\n\n\n\n\n\n●\n\n\n\n    Sellbrant 2021\n\n29\nGen\n123 \n57.4 (15.3)\n\n\n●\n\n\n\n\n\n\n    \n28\nBlockb\n123 \n62.3 (13.1)\n\n\n\n\n\n\n\n\n●\n    \n27\nBlockc\n123 \n60.3 (10.4)\n\n\n\n\n\n\n\n\n●\n    \n      Urol\n    \n    Salonia 2004\n\n34\nGen\nNR\n66.0 (6.8)\n\n\n●\n\n\n\n\n\n\n    \n36\nNeur\nNR\n65.3 (6.9)\n\n\n\n\n\n●\n\n\n\n    Salonia 2006\n\n34\nGen\nNR\n66.0 (7.0)\n\n\n●\n\n\n\n\n\n\n    \n30\nNeurd\nNR\n59.5 (10.4)\n\n\n\n\n\n●\n\n\n\n    \n29\nNeure\nNR\n64.1 (8.1)\n\n\n\n\n\n●\n\n\n\n    \n28\nNeurf\nNR\n65.3 (6.3)\n\n\n\n\n\n●\n\n\n\n    Nishikawa 2007b\n\n40\nGen\n12  \n73.0 (6.0)\n\n\n\n●\n\n\n\n\n\n    \n40\nNeur\n12  \n71.0 (6.0)\n\n\n\n\n\n●\n\n\n\n    Ornek 2010\n\n30\nGen\n 23 \n70.0 (9.6)\n\n\n●\n\n\n\n\n\n\n    \n30\nNeur\n 23 \n76.4 (11.8)\n\n\n\n\n\n●\n\n\n\n    Silbert 2014\n\n50\nGen\nNR\n63.9 [55-78]\n\n\n●\n\n\n\n\n\n\n    \n48\nNeur\nNR\n66.9 [56-75]\n\n\n\n\n\n●\n\n\n\n    Alas 2020\n\n29\nGen\nNR\n63.7 (11.4)\n\n\n●\n\n\n\n\n\n\n    \n29\nNeur\nNR\n67.3 (10.9)\n\n\n\n\n\n●\n\n\n\n    \n      GI/Abdominal\n    \n    Aasbo 2002\n\n30\nGen\n123 \n56.0 (17.0)\n\n\n\n●\n\n\n\n\n\n    \n30\nBlock\n123 \n63.0 (13.0)\n\n\n\n\n\n\n\n\n●\n    Jia 2014\n\n116\nGen\nNR\n74.8 (4.0)\n\n\n\n●\n\n\n\n\n\n    \n117\nNeur\nNR\n75.7 (4.2)\n\n\n\n\n\n\n●\n\n\n    Wang 2016\n\n103\nGen\nNR\n71.9 (8.4)\n\n\n\n●\n\n\n\n\n\n    \n103\nNeur\nNR\n71.2 (7.9)\n\n\n\n\n\n\n\n●\n\n    Wongyingsinn 2020\n\n18\nGen\n123 \n67.7 (15.1)\n\n\n●\n\n\n\n\n\n\n    \n18\nNeur\n123 \n64.9 (10.3)\n\n\n\n\n\n●\n\n\n\n    \n      Neuro\n    \n    Mazul-Sunko 2010\n\n28\nGen\nNR\n66.0 (8.7)\n\n\n●\n\n\n\n\n\n\n    \n29\nNeur\nNR\n66.2 (8.3)\n\n\n\n\n\n●\n\n\n\n    Apan 2016\n\n25\nGen\n123 \n62.7 (14.3)\n\n\n●\n\n\n\n\n\n\n    \n25\nNeur\n123 \n67.0 (10.4)\n\n\n\n\n\n\n●\n\n\n    \n      Neuro|Vasc\n    \n    Lewis 2008\n\n1752\nGen\n1234\n70.0 (8.8)\n\n\n\n\n●\n\n\n\n\n    \n1771\nBlock\n1234\n69.0 (8.8)\n\n\n\n\n\n\n\n\n●\n    Weber 2009\n\n23\nGen\nNR\n67.0 (9.0)\n\n\n●\n\n\n\n\n\n\n    \n17\nBlock\nNR\n66.0 (8.0)\n\n\n\n\n\n\n\n\n●\n    \n      Cardiac\n    \n    Kasprzak 2006\n\n95\nGen\nNR\n69.0 (8.0)\n\n\n●\n\n\n\n\n\n\n    \n91\nBlock\nNR\n69.0 (8.0)\n\n\n\n\n\n\n\n\n●\n    \n      Gyn\n    \n    Purwar 2015\n\n28\nGen\n123 \n65.1 (12.5)\n\n\n●\n\n\n\n\n\n\n    \n31\nNeur\n123 \n60.6 (11.5)\n\n\n\n\n\n●\n\n\n\n    \n      Gyn|Ortho|Urol|Vasc\n    \n    Papaiannou 2005\n\n28\nGen\n1234\n≥60\n\n28.1\n\n●\n●\n\n\n\n\n\n    \n19\nNeur\n1234\n≥60\n\n27.6\n\n\n\n\n●\n●\n\n\n    \n      Headneck\n    \n    Hestin 2022\n\n30\nGen\n1234\n75.0 (9.0)\n\n\n\n●\n\n\n\n\n\n    \n30\nBlock\n1234\n76.0 (11.0)\n\n\n\n\n\n\n\n\n●\n    \n      Other\n    \n    Carron 2007\n\n20\nGen\n123 \n62.6 (10.7)\n\n\n●\n\n\n\n\n\n\n    \n20\nNeur\n123 \n65.5 (16.8)\n\n\n\n\n\n●\n\n\n\n    \n      Various TKA|THA|Other\n    \n    Rasmussen 2003\n\n217\nGen\n1234\n70.8 [61-84]\n\n\n\n\n●\n\n\n\n\n    \n211\nNeur\n1234\n71.1 [61-84]\n\n\n\n\n\n●\n●\n\n\n    \n      Vasc\n    \n    Nesek-Adam 2012\n\n20\nGen\n 23 \n61.2 (10.5)\n\n\n●\n\n\n\n\n\n\n    \n20\nNeur\n 23 \n60.6 (9.7)\n\n\n\n\n\n●\n\n\n\n    \n      Spine\n    \n    Brown 2021\n\n106\nGen\nNR\n72.0 {69-76}\n\n28 {27-29}\n\n●\n\n\n\n\n\n\n    \n111\nNeur\nNR\n73.0 {69-78}\n\n29 {27-29}\n\n\n\n\n●\n\n\n\n  \n  \n  \n    \n       Gen: general; Neur: neuraxial; PS: physical stutus; Vol: volatile; TIVA: total intravenous anesthesia; NR: not reported; Epid: epidural; CSE: combined spinal and epidural; Ortho: orthopedic; Urol: urological; GI: gastrointestinal; Neuro: neurologic; Gyn: gynecologic; Vasc: vascular; Ophtho: opthalomogic; Fx: fracture; TKA: total knee arthroplasty; THA: total hip arthroplasty.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Ropivacaine.\n    \n    \n      c Mepivacaine.\n    \n    \n      d Propofol.\n    \n    \n      e Midazolam.\n    \n    \n      f Diazepam."
  },
  {
    "objectID": "kq3.html#delirium-incidence",
    "href": "kq3.html#delirium-incidence",
    "title": "Regional versus General Anesthesia",
    "section": "Delirium Incidence",
    "text": "Delirium Incidence\n Table 9. Delirium incidence and ascertainment during hospitalization in randomized clinical trials comparing regional to general anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n        MMSE(preop)a\n      Scale\n      Day(s)b\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Hip fx\n    \n    Parker 2015\n\n164\nGen\n\nNR\nStay\n  0 (0.0)\n\n\n—\n    \n158\nNeur\n\n\n\n  3 (1.9)\n\n\nNot estimated\n    Tzimas 2018\n\n33\nGen\n25.7 (2.9)\n\nCAM\nStay\n  4 (12.1)\n\n\n—\n    \n37\nNeur\n25.3 (0.9)\n\n\n\n 10 (27.0)\n\n\n2.23 (0.77-6.44)\n    Shin 2020\n\n60\nGen\n\nNR\nStay\n 17 (28.3)\n\n\n—\n    \n58\nNeur\n\n\n\n  8 (13.8)\n\n\n0.49 (0.23-1.04)\n    Bielka 2021\n\n30\nGen\n\nDSM\nStay\n  1 (3.3)\n\n\n—\n    \n60\nNeur/Block\n\n\n\n  1 (1.7)\n\n\n0.50 (0.03-7.72)\n    Gu 2021\n\n45\nGen\n\nDI\nNotec\n  7 (15.6)\n\n\n—\n    \n42\nBlock\n\n\n\n  4 (9.5)\n\n\n0.61 (0.19-1.94)\n    Neuman 2021\n\n629\nGen\n\nCAM\n3\n124 (19.7)\n\n\n—\n    \n633\nNeur\n\n\n\n130 (20.5)\n\n\n1.04 (0.84-1.30)\n    Li 2022\n\n470\nGen\n20 {15-25}\n\nCAM\n7\n 24 (5.1)\n\n\n—\n    \n471\nNeur\n20 {15-24}\n\n\n\n 29 (6.2)\n\n\n1.21 (0.71-2.04)\n    \n      GI/Abd\n    \n    Jia 2014\n\n116\nGen\n\nDRS\nStay\n 15 (12.9)\n\n\n—\n    \n117\nNeur\n\n\n\n  4 (3.4)\n\n\n0.26 (0.09-0.77)\n    \n      Headneck\n    \n    Hestin 2022\n\n30\nGen\n\nCAM\n3\n  6 (20.0)\n\n\n—\n    \n30\nBlock\n\n\n\n  7 (23.3)\n\n\n1.17 (0.44-3.06)\n    \n      Spine\n    \n    Brown 2021\n\n106\nGen\n28 {27-29}\n\nCAM\nStay\n 20 (18.9)\n\n\n—\n    \n111\nNeur\n29 {27-29}\n\n\n\n 28 (25.2)\n\n\n1.34 (0.80-2.22)\n    \n      Various\n    \n    Rasmussen 2003\n\n217\nGen\n\nNR\nStay\n  5 (2.3)\n\n\n—\n    \n211\nNeur\n\n\n\n  4 (1.9)\n\n\n0.82 (0.22-3.02)\n    Papaiannou 2005\n\n28\nGen\n28.1\n\nDSM\n3\n  6 (21.4)\n\n\n—\n    \n19\nNeur\n27.6\n\n\n\n  3 (15.8)\n\n\n0.74 (0.21-2.59)\n  \n  \n  \n    \n       RR: risk ratio; MMSE: Mini-Mental State Examination; CAM: Confusion Assessment Method; DI: Delirium Index; DRS: Delirium Rating Scale; DSM: Diagnostic and Statistical Manual of Mental Disorders; NR: not reported.\n    \n    \n       Gen: general anesthesia; Neur: neuraxial; RR: risk ratio; MMSE: Mini-Mental State Examination; DRS: Delirium Rating Scale; DSM: Diagnostic and Statistical Manual of Mental Disorders; CAM: Confusion Assessment Method; DI: Delirium Index.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n    \n      c Maximum of reported daily incidence.\n    \n  \n\n\n\n\n\nPooled\n Figure 1. Regional versus general anesthesia (randomized clinical trials). \n\nRR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – .  In hip fracture subgroup not applying the Hartung-Knapp adjustment — RR 1.03 (95% CI, 0.85–1.24); random effects pooled estimate dominated by Neuman 2021 (74.1%) and Li 2022 (13.0%). Harbord test for small study effects P = 0.72. Delirium was designated a primary or secondary outcome in 33.3% and 16.7%, respectively.\n\n\n\n\n\n\n Figure 2. Regional versus general anesthesia cumulative meta-analysis by study size. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Figure 3. Regional versus general anesthesia small study effects. \n\n\n\n\n\n\n Estimates (odds ratios and 95% CIs) from random effects models. Limit meta-analysis shown in light grey — unadjusted 0.94 (0.62–1.42); adjusted for small study effects: 0.98 (0.59–1.62).\n\n\n\n\n\n\n\n\n\n Figure 4. General anesthesis event rate (control arm/baseline risk) and risk ratios.  \n\n\n\n\n\n\n No suggestion for RR dependence on baseline risk. Asterisks indicate trials limited to hip fracture repair.\n\n\n\n\n\n\n\n\n\n Figure 5. Summary risk of bias from randomized clinical trials comparing regional to general anesthesia (weighted)."
  },
  {
    "objectID": "kq3.html#delayed-neurocognitive-recovery",
    "href": "kq3.html#delayed-neurocognitive-recovery",
    "title": "Regional versus General Anesthesia",
    "section": "Delayed Neurocognitive Recovery",
    "text": "Delayed Neurocognitive Recovery\n\n Table 10. Delayed neurocognitive recovery incidence and ascertainment in randomized clinical trials comparing regional to general anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n      \n        Preop\n      \n      \n        Instrument\n      \n      Dayb\n      \n        Delayed Neurocognitive Recovery\n      \n    \n    \n      MMSEa\n      MMSE\n      DST\n      MoCA\n      Other\n      N (%)\n      0 — 100%\n      RR (95% CI)\n    \n  \n  \n    Casati 2003\n\n15\nGen\n29 [24-29]\n\n✓c\n\n\n\n7\n 3 (20.0)\n\n\n—\n    \n15\nReg\n28 [25-30]\n\n\n\n\n\n\n 1 (6.7)\n\n\n0.33 (0.04-2.85)\n    Rasmussen 2003\n\n188\nGen\n\n\n✓d\n\n✓\n\n7\n37 (19.7)\n\n\n—\n    \n176\nReg\n\n\n\n\n\n\n22 (12.5)\n\n\n0.64 (0.39-1.03)\n    Silbert 2014\n\n49\nGen\n\n\n✓d\n\n✓\n\n7\n 2 (4.1)\n\n\n—\n    \n42\nReg\n\n\n\n\n\n\n 5 (11.9)\n\n\n2.92 (0.60-14.26)\n    Wang 2016\n\n103\nGen\n\n\n\n\ne\n7\n46 (44.7)\n\n\n—\n    \n103\nReg\n\n\n\n\n\n\n50 (48.5)\n\n\n1.09 (0.81-1.46)\n    Zhang 2019\n\n40\nGen\n\n✓\n\n\n\n\n1\n14 (35.0)\n\n\n—\n    \n40\nReg\n\n\n\n\n\n\n 6 (15.0)\n\n\n0.43 (0.18-1.00)\n  \n  \n  \n    \n       Mini-Mental State Exam; DST: Digit Span Test; MoCA: Montreal Cognitive Assessment; RR: risk ratio; Gen: general anesthesia; Reg: regional anesthesia.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Day of assessment.\n    \n    \n      c Difference from baseline &gt;2 points.\n    \n    \n      d Z ≥1.96.\n    \n    \n      e Not reported.\n    \n  \n\n\n\n\n\nPooled\n Figure 6. Postoperative neurocognitive disorder (regional versus general anesthesia; randomized clinical trials)."
  },
  {
    "objectID": "kq3.html#neurocognitive-disorder",
    "href": "kq3.html#neurocognitive-disorder",
    "title": "Regional versus General Anesthesia",
    "section": "Neurocognitive Disorder",
    "text": "Neurocognitive Disorder\n Table 11. Neurcognitive disorder and ascertainment. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Drug\n      \n        Preop\n      \n      \n        Instrument\n      \n      Dayb\n      \n        Neurocognitive Disorder\n      \n    \n    \n      MMSEa\n      MMSE\n      DST\n      MoCA\n      Other\n      N (%)\n      0 — 100%\n      RR (95% CI)\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Rasmussen 2003\n\n188\nGen\n\n\n✓c\n\n✓\n\n90\n25 (13.3)\n\n\n—\n    \n176\nReg\n\n\n\n\n\n\n23 (13.1)\n\n\n0.98 (0.58-1.67)\n  \n  \n  \n    \n       Mini-Mental State Exam; DST: Digit Span Test; MoCA: Montreal Cognitive Assessment; RR: risk ratio; Gen: general anesthesia; Reg: regional anesthesia.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Day of assessment.\n    \n    \n      c Z ≥1.96."
  },
  {
    "objectID": "kq3.html#complications",
    "href": "kq3.html#complications",
    "title": "Regional versus General Anesthesia",
    "section": "Complications",
    "text": "Complications\n\n Table 13. Reported complications for regional versus general anesthesia — cardiovascular, stroke, renal, pulmonary, and reintubation. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n          Age\n      Surgery\n      N (%)\n      0 – 100%\n      RD (95% CI)\n    \n  \n  \n    \n      MI\n    \n    Lewis 2008\n\n1752\nGen\n70.0 (8.8)\n\nVarious\n 4 (0.2)\n\n\n—\n    \n1771\nBlock\n69.0 (8.8)\n\n\n 9 (0.5)\n\n\n0.3% (-0.1, 0.7)\n    Parker 2015\n\n164\nGen\n83.0 [59-99]\n\nOrtho\n 1 (0.6)\n\n\n—\n    \n158\nNeur\n82.9 [25-105]\n\n\n 1 (0.6)\n\n\n0.0% (-1.7, 1.7)\n    Liang 2017\n\n66\nGen\n68.0 (11.0)\n\nOrtho\n 2 (3.0)\n\n\n—\n    \n66\nNeur\n67.0 (12.0)\n\n\n 1 (1.5)\n\n\n-1.5% (-6.6, 3.6)\n    \n66\nNeur\n66.0 (10.0)\n\n\n 2 (3.0)\n\n\n0.0% (-5.8, 5.8)\n    Brown 2021\n\n106\nGen\n72.0 {69-76}\n\nSpine\n 0 (0.0)\n\n\n—\n    \n111\nNeur\n73.0 {69-78}\n\n\n 1 (0.9)\n\n\n0.9% (-1.6, 3.4)\n    Neuman 2021\n\n793\nGen\n78.4 (10.6)\n\nOrtho\n 9 (1.1)\n\n\n—\n    \n783\nNeur\n77.7 (10.7)\n\n\n 6 (0.8)\n\n\n-0.4% (-1.3, 0.6)\n    Li 2022\n\n471\nGen\n77.0 {71-82}\n\nOrtho\n 0 (0.0)\n\n\n—\n    \n471\nNeur\n77.0 {72-82}\n\n\n 1 (0.2)\n\n\n0.2% (-0.4, 0.8)\n    \n      Cardiac Arrest\n    \n    Kasprzak 2006\n\n95\nGen\n69.0 (8.0)\n\nCardiac\n 0 (0.0)\n\n\n—\n    \n91\nBlock\n69.0 (8.0)\n\n\n 0 (0.0)\n\n\n0.0% (-2.1, 2.1)\n    Neuman 2021\n\n793\nGen\n78.4 (10.6)\n\nOrtho\n 0 (0.0)\n\n\n—\n    \n783\nNeur\n77.7 (10.7)\n\n\n 2 (0.3)\n\n\n0.3% (-0.2, 0.7)\n    \n      Other Cardiac\n    \n    Rasmussen 2003a\n217\nGen\n70.8 [61-84]\n\nVarious\n 2 (0.9)\n\n\n—\n    \n211\nNeur\n71.1 [61-84]\n\n\n 3 (1.4)\n\n\n0.5% (-1.5, 2.5)\n    Chu 2006b\n30\nGen\n69.0 {62-74}\n\nOrtho\n 2 (6.7)\n\n\n—\n    \n30\nNeur\n65.0 {62-68}\n\n\n 0 (0.0)\n\n\n-6.7% (-17.2, 3.9)\n    Carron 2007c\n20\nGen\n62.6 (10.7)\n\nOther\n 0 (0.0)\n\n\n—\n    \n20\nNeur\n65.5 (16.8)\n\n\n 1 (5.0)\n\n\n5.0% (-7.8, 17.8)\n    Nishikawa 2007bc\n40\nGen\n73.0 (6.0)\n\nUrol\n 0 (0.0)\n\n\n—\n    \n40\nNeur\n71.0 (6.0)\n\n\n 0 (0.0)\n\n\n0.0% (-4.8, 4.8)\n    Weber 2009a\n23\nGen\n67.0 (9.0)\n\nVarious\n 0 (0.0)\n\n\n—\n    \n17\nBlock\n66.0 (8.0)\n\n\n 0 (0.0)\n\n\n0.0% (-9.5, 9.5)\n    Parker 2015d\n164\nGen\n83.0 [59-99]\n\nOrtho\n 3 (1.8)\n\n\n—\n    \n158\nNeur\n82.9 [25-105]\n\n\n 0 (0.0)\n\n\n-1.8% (-4.2, 0.5)\n    Shin 2020e\n60\nGen\n79.4 (7.7)\n\nOrtho\n 3 (5.0)\n\n\n—\n    \n58\nGen\n80.5 (6.7)\n\n\n 2 (3.4)\n\n\n-1.6% (-8.8, 5.7)\n    \n58\nNeur\n81.6 (6.7)\n\n\n 2 (3.4)\n\n\n-1.6% (-8.8, 5.7)\n    Wongyingsinn 2020c\n18\nGen\n67.7 (15.1)\n\nGI/Abd\n 3 (16.7)\n\n\n—\n    \n18\nNeur\n64.9 (10.3)\n\n\n 2 (11.1)\n\n\n-5.6% (-28.1, 17.0)\n    Bielka 2021c\n29\nGen\n73.0 {72-74}\n\nOrtho\n 1 (3.4)\n\n\n—\n    \n29\nBlock\n72.0 {68-73}\n\n\n 1 (3.4)\n\n\n0.0% (-9.4, 9.4)\n    \n29\nNeur\n72.0 {70-73}\n\n\n 3 (10.3)\n\n\n6.9% (-6.0, 19.8)\n    Li 2022\n\n471\nGen\n77.0 {71-82}\n\nOrtho\n 4 (0.8)\n\n\n—\n    \n471\nNeur\n77.0 {72-82}\n\n\n 3 (0.6)\n\n\n-0.2% (-1.3, 0.9)\n    \n      Stroke\n    \n    Kasprzak 2006\n\n95\nGen\n69.0 (8.0)\n\nCardiac\n 1 (1.1)\n\n\n—\n    \n91\nBlock\n69.0 (8.0)\n\n\n 2 (2.2)\n\n\n1.1% (-2.5, 4.8)\n    Lewis 2008\n\n1752\nGen\n70.0 (8.8)\n\nVarious\n70 (4.0)\n\n\n—\n    \n1771\nBlock\n69.0 (8.8)\n\n\n66 (3.7)\n\n\n-0.3% (-1.5, 1.0)\n    Brown 2021\n\n106\nGen\n72.0 {69-76}\n\nSpine\n 0 (0.0)\n\n\n—\n    \n111\nNeur\n73.0 {69-78}\n\n\n 2 (1.8)\n\n\n1.8% (-1.2, 4.8)\n    Neuman 2021\n\n793\nGen\n78.4 (10.6)\n\nOrtho\n 7 (0.9)\n\n\n—\n    \n783\nNeur\n77.7 (10.7)\n\n\n 5 (0.6)\n\n\n-0.2% (-1.1, 0.6)\n    Hestin 2022\n\n30\nGen\n75.0 (9.0)\n\nHeadneck\n 1 (3.3)\n\n\n—\n    \n30\nBlock\n76.0 (11.0)\n\n\n 0 (0.0)\n\n\n-3.3% (-12.1, 5.4)\n    Li 2022\n\n471\nGen\n77.0 {71-82}\n\nOrtho\n 1 (0.2)\n\n\n—\n    \n471\nNeur\n77.0 {72-82}\n\n\n 0 (0.0)\n\n\n-0.2% (-0.8, 0.4)\n    \n      Renal\n    \n    Parker 2015\n\n164\nGen\n83.0 [59-99]\n\nOrtho\n 2 (1.2)\n\n\n—\n    \n158\nNeur\n82.9 [25-105]\n\n\n 0 (0.0)\n\n\n-1.2% (-3.3, 0.8)\n    Liang 2017\n\n66\nGen\n68.0 (11.0)\n\nOrtho\n 1 (1.5)\n\n\n—\n    \n66\nNeur\n67.0 (12.0)\n\n\n 0 (0.0)\n\n\n-1.5% (-5.6, 2.6)\n    \n66\nNeur\n66.0 (10.0)\n\n\n 0 (0.0)\n\n\n-1.5% (-5.6, 2.6)\n    Brown 2021\n\n106\nGen\n72.0 {69-76}\n\nSpine\n 0 (0.0)\n\n\n—\n    \n111\nNeur\n73.0 {69-78}\n\n\n 1 (0.9)\n\n\n0.9% (-1.6, 3.4)\n    Neuman 2021\n\n793\nGen\n78.4 (10.6)\n\nOrtho\n55 (6.9)\n\n\n—\n    \n783\nNeur\n77.7 (10.7)\n\n\n32 (4.1)\n\n\n-2.8% (-5.1, -0.6)\n    \n      Pulmonary\n    \n    Shin 2020\n\n60\nGen\n79.4 (7.7)\n\nOrtho\n 4 (6.7)\n\n\n—\n    \n58\nGen\n80.5 (6.7)\n\n\n 5 (8.6)\n\n\n2.0% (-7.6, 11.5)\n    \n58\nNeur\n81.6 (6.7)\n\n\n 4 (6.9)\n\n\n0.2% (-8.8, 9.3)\n    Hestin 2022\n\n30\nGen\n75.0 (9.0)\n\nHeadneck\n 1 (3.3)\n\n\n—\n    \n30\nBlock\n76.0 (11.0)\n\n\n 0 (0.0)\n\n\n-3.3% (-12.1, 5.4)\n    \n      Pneumonia\n    \n    Chu 2006\n\n30\nGen\n69.0 {62-74}\n\nOrtho\n 1 (3.3)\n\n\n—\n    \n30\nNeur\n65.0 {62-68}\n\n\n 0 (0.0)\n\n\n-3.3% (-12.1, 5.4)\n    Kasprzak 2006\n\n95\nGen\n69.0 (8.0)\n\nCardiac\n 1 (1.1)\n\n\n—\n    \n91\nBlock\n69.0 (8.0)\n\n\n 0 (0.0)\n\n\n-1.1% (-4.0, 1.8)\n    Parker 2015\n\n164\nGen\n83.0 [59-99]\n\nOrtho\n 3 (1.8)\n\n\n—\n    \n158\nNeur\n82.9 [25-105]\n\n\n 2 (1.3)\n\n\n-0.6% (-3.3, 2.1)\n    Liang 2017\n\n66\nGen\n68.0 (11.0)\n\nOrtho\n 1 (1.5)\n\n\n—\n    \n66\nNeur\n67.0 (12.0)\n\n\n 0 (0.0)\n\n\n-1.5% (-5.6, 2.6)\n    \n66\nNeur\n66.0 (10.0)\n\n\n 1 (1.5)\n\n\n0.0% (-4.2, 4.2)\n    Bielka 2021\n\n29\nGen\n73.0 {72-74}\n\nOrtho\n 4 (13.8)\n\n\n—\n    \n29\nBlock\n72.0 {68-73}\n\n\n 0 (0.0)\n\n\n-13.8% (-27.4, -0.2)\n    \n29\nNeur\n72.0 {70-73}\n\n\n 1 (3.4)\n\n\n-10.3% (-24.5, 3.9)\n    Brown 2021\n\n106\nGen\n72.0 {69-76}\n\nSpine\n 0 (0.0)\n\n\n—\n    \n111\nNeur\n73.0 {69-78}\n\n\n 2 (1.8)\n\n\n1.8% (-1.2, 4.8)\n    Neuman 2021\n\n793\nGen\n78.4 (10.6)\n\nOrtho\n16 (2.0)\n\n\n—\n    \n783\nNeur\n77.7 (10.7)\n\n\n 8 (1.0)\n\n\n-1.0% (-2.2, 0.2)\n    Li 2022\n\n471\nGen\n77.0 {71-82}\n\nOrtho\n 1 (0.2)\n\n\n—\n    \n471\nNeur\n77.0 {72-82}\n\n\n 0 (0.0)\n\n\n-0.2% (-0.8, 0.4)\n    \n      Pulmonary Congestion\n    \n    Neuman 2021\n\n793\nGen\n78.4 (10.6)\n\nOrtho\n 8 (1.0)\n\n\n—\n    \n783\nNeur\n77.7 (10.7)\n\n\n 9 (1.1)\n\n\n0.1% (-0.9, 1.2)\n    \n      PE\n    \n    Rasmussen 2003\n\n217\nGen\n70.8 [61-84]\n\nVarious\n 2 (0.9)\n\n\n—\n    \n211\nNeur\n71.1 [61-84]\n\n\n 0 (0.0)\n\n\n-0.9% (-2.5, 0.6)\n    Kasprzak 2006\n\n95\nGen\n69.0 (8.0)\n\nCardiac\n 0 (0.0)\n\n\n—\n    \n91\nBlock\n69.0 (8.0)\n\n\n 0 (0.0)\n\n\n0.0% (-2.1, 2.1)\n    Lewis 2008\n\n1752\nGen\n70.0 (8.8)\n\nVarious\n 0 (0.0)\n\n\n—\n    \n1771\nBlock\n69.0 (8.8)\n\n\n 0 (0.0)\n\n\n0.0% (-0.1, 0.1)\n    Harsten 2013\n\n60\nGen\n68.0 (7.0)\n\nOrtho\n 1 (1.7)\n\n\n—\n    \n60\nNeur\n67.0 (7.0)\n\n\n 1 (1.7)\n\n\n0.0% (-4.6, 4.6)\n    Parker 2015\n\n164\nGen\n83.0 [59-99]\n\nOrtho\n 2 (1.2)\n\n\n—\n    \n158\nNeur\n82.9 [25-105]\n\n\n 0 (0.0)\n\n\n-1.2% (-3.3, 0.8)\n    Liang 2017\n\n66\nGen\n68.0 (11.0)\n\nOrtho\n 2 (3.0)\n\n\n—\n    \n66\nNeur\n67.0 (12.0)\n\n\n 0 (0.0)\n\n\n-3.0% (-8.0, 2.0)\n    \n66\nNeur\n66.0 (10.0)\n\n\n 1 (1.5)\n\n\n-1.5% (-6.6, 3.6)\n    Brown 2021\n\n106\nGen\n72.0 {69-76}\n\nSpine\n 1 (0.9)\n\n\n—\n    \n111\nNeur\n73.0 {69-78}\n\n\n 1 (0.9)\n\n\n-0.0% (-2.6, 2.5)\n    Neuman 2021\n\n793\nGen\n78.4 (10.6)\n\nOrtho\n 5 (0.6)\n\n\n—\n    \n783\nNeur\n77.7 (10.7)\n\n\n 4 (0.5)\n\n\n-0.1% (-0.9, 0.6)\n    \n      Reintubation\n    \n    Neuman 2021\n\n793\nGen\n78.4 (10.6)\n\nOrtho\n 7 (0.9)\n\n\n—\n    \n783\nNeur\n77.7 (10.7)\n\n\n 4 (0.5)\n\n\n-0.4% (-1.2, 0.4)\n  \n  \n  \n    \n       Gen: general anesthesia; Neur: neuraxial; RD: risk difference; Ortho: orthopedic; GI: gastrointestinal; Abd: abdominal; PE: pulmonary embolism; Ophtho: ophthalmologic.\n    \n    \n      a Unspecified adverse cardiac events.\n    \n    \n      b Tachycardia\n    \n    \n      c Bradycardia.\n    \n    \n      d Arrhythmia.\n    \n    \n      e MI, heart failure, new onset arrhythmia.\n    \n  \n\n\n\n\n\nPooled\n\nMyocardial Infarction\n Figure 7. Risk ratio for myocardial infarction (regional versus general anesthesia; randomized clinical trials). \n \n Figure 8. Risk difference for myocardial infarction (regional versus general anesthesia; randomized clinical trials). \n \n\n\nCardiac Arrest\n Figure 9. Risk difference for cardiac arrest (regional versus general anesthesia; randomized clinical trials). \n\n\n\nStroke\n Figure 10. Risk ratio for stroke (regional versus general anesthesia; randomized clinical trials). \n \n Figure 11. Risk difference for stroke (regional versus general anesthesia; randomized clinical trials). \n\n\n\nRenal\n Figure 12. Risk ratio for renal complications (regional versus general anesthesia; randomized clinical trials). \n\n Figure 13. Risk difference for renal complications (regional versus general anesthesia; randomized clinical trials). \n\n\n\nPulmonary\n Figure 14. Risk ratio for pulmonary complications (regional versus general anesthesia; randomized clinical trials). \n\n Figure 15. Risk difference for pulmonary complications (regional versus general anesthesia; randomized clinical trials). \n\n\n\nPneumonia\n Figure 16. Risk ratio for pneumonia (regional versus general anesthesia; randomized clinical trials). \n\n Figure 17. Risk difference for pneumonia (regional versus general anesthesia; randomized clinical trials). \n\n\n\nPulmonary Embolism\n Figure 18. Risk ratio for pulmonary embolism (regional versus general anesthesia; randomized clinical trials). \n\n Figure 19. Risk difference for pulmonary embolism (regional versus general anesthesia; randomized clinical trials)."
  },
  {
    "objectID": "kq3.html#patient-satisfaction",
    "href": "kq3.html#patient-satisfaction",
    "title": "Regional versus General Anesthesia",
    "section": "Patient Satisfaction",
    "text": "Patient Satisfaction\n\n Table 14. Patient satisfaction comparing higher versus lower categories according to regional or general anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N\n      Anesth\n      \n        ASA\n      \n      Agea\n      N (%)  \n      0 – 100%\n      RD (95% CI)\n    \n    \n      PS\n    \n  \n  \n    \n      Orthopedic\n    \n    Harsten 2015\n\n60\nGen\n123 \n68.0 (9.0)\n\n 55 (91.7)b\n\n\n—\n    \n58\nNeur\n\n66.0 (7.8)\n\n 45 (77.6)b\n\n\n-14.1% (-26.9, -1.3)\n    Meuret 2018\n\n21\nGen\n123 \n85.0 (5.0)\n\n 15 (71.4)c\n\n\n—\n    \n19\nNeur\n\n83.0 (6.0)\n\n 17 (89.5)c\n\n\n18.0% (-5.7, 41.8)\n    Xu 2020\n\n80\nGen\nNR\n75.4 (5.6)\n\n 69 (86.2)d\n\n\n—\n    \n160\nNeur\n\n75.6 (5.5)\n\n 66 (82.5)d\n\n\n3.1% (-5.8, 12.1)\n    Neuman 2022\n\n661\nGen\nNR\n78.0 (11.0)\n\n564 (85.3)e\n\n\n—\n    \n647\nNeur\n\n78.0 (11.0)\n\n562 (86.9)e\n\n\n1.5% (-2.2, 5.3)\n    \n      Urologic\n    \n    Salonia 2004\n\n34\nGen\nNR\n66.0 (6.8)\n\n 32 (94.1)b\n\n\n—\n    \n36\nNeur\n\n65.3 (6.9)\n\n 35 (97.2)b\n\n\n3.1% (-6.5, 12.7)\n    Nishikawa 2007b\n\n40\nGen\n12  \n73.0 (6.0)\n\n 32 (80.0)f\n\n\n—\n    \n40\nNeur\n\n71.0 (6.0)\n\n 28 (70.0)f\n\n\n-10.0% (-28.9, 8.9)\n    Ornek 2010\n\n30\nGen\n 23 \n70.0 (9.6)\n\n 22 (73.3)g\n\n\n—\n    \n30\nNeur\n\n76.4 (11.8)\n\n 25 (83.3)g\n\n\n10.0% (-10.7, 30.7)\n    \n      Neurosurgical\n    \n    Apan 2016\n\n25\nGen\n123 \n62.7 (14.3)\n\n 24 (96.0)b\n\n\n—\n    \n25\nNeur\n\n67.0 (10.4)\n\n 22 (88.0)b\n\n\n-8.0% (-22.9, 6.9)\n    \n      Vascular\n    \n    Nesek-Adam 2012\n\n20\nGen\n 23 \n61.2 (10.5)\n\n 12 (60.0)b\n\n\n—\n    \n20\nNeur\n\n60.6 (9.7)\n\n 18 (90.0)b\n\n\n30.0% (4.8, 55.2)\n    \n      Other\n    \n    Carron 2007\n\n20\nGen\n123 \n62.6 (10.7)\n\n 14 (70.0)b\n\n\n—\n    \n20\nNeur\n\n65.5 (16.8)\n\n 18 (90.0)b\n\n\n20.0% (-4.0, 44.0)\n  \n  \n  \n    \n       Gen: general; Neur: neuraxial; Anesth: anesthetic; ASA PS: ASA Physical Status; RD: risk difference.\n    \n    \n      a Mean (SD).\n    \n    \n      b Satisfied.\n    \n    \n      c Excellent/good\n    \n    \n      d Not specified\n    \n    \n      e Satisfaction with all aspects of anesthesia care\n    \n    \n      f Very satisfied\n    \n    \n      g Very good\n    \n  \n\n\n\n\n\nPooled\n Figure 20. Risk ratio comparing higher versus lower categories of patient satisfaction (Regional versus general anesthesia; randomized clinical trials)."
  },
  {
    "objectID": "kq3.html#length-of-stay",
    "href": "kq3.html#length-of-stay",
    "title": "Regional versus General Anesthesia",
    "section": "Length of Stay",
    "text": "Length of Stay\n\n Table 15. Length of stay according to procedure classification and comparator. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Anesth\n      PSa\n          Ageb\n          LOSb\n      0 – 20 days\n      Country\n    \n  \n  \n    \n      Orthopedic\n    \n    Chu 2006\n\n30\nGen\n123 \n69.0 {62-74}\n\n9.0 {7-10}\n\n\n\nChina\n    \n30\nNeur\n123 \n65.0 {62-68}\n\n7.5 {6-11}\n\n\n\n\n    Harsten 2013\n\n60\nGen\n123 \n68.0 (7.0)\n\n3.0 [1-4]\n\n\n\nSweden\n    \n60\nNeur\n123 \n67.0 (7.0)\n\n3.0 [1-4]\n\n\n\n\n    Parker 2015\n\n164\nGen\n1234\n83.0 [59-99]\n\n15.9 (13.7)\n\n\n\nUK\n    \n158\nNeur\n1234\n82.9 [25-105]\n\n16.2 (14.6)\n\n\n\n\n    Tzimas 2018\n\n33\nGen\n123 \n75.1 (6.1)\n\n8.2\n\n\n\nGreece\n    \n37\nNeur\n123 \n77.1 (6.5)\n\n8.2\n\n\n\n\n    Shin 2020\n\n60\nGen\nNR\n79.4 (7.7)\n\n6.5 {5-9}\n\n\n\nSouth Korea\n    \n58\nGen\nNR\n80.5 (6.7)\n\n7.0 {5-9}\n\n\n\n\n    \n58\nNeur\nNR\n81.6 (6.7)\n\n7.0 {5-11}\n\n\n\n\n    Xu 2020\n\n80\nGen\nNR\n75.4 (5.6)\n\n4.3 (0.9)\n\n\n\nChina\n    \n80\nNeur\nNR\n75.6 (5.5)\n\n4.1 (1.1)\n\n\n\n\n    \n80\nNeur\nNR\n75.0 (5.2)\n\n4.2 (0.9)\n\n\n\n\n    Neuman 2021 (Canada)\n\n211\nGen\n\n\n6.0 {5-10}\n\n\n\nCanada\n    \n210\nNeur\n\n\n6.0 {4-9}\n\n\n\n\n    Neuman 2021 (USA)\n\n593\nGen\n\n\n3.0 {3-5}\n\n\n\nUSA\n    \n585\nNeur\n\n\n3.0 {2-5}\n\n\n\n\n    Ren 2021\n\n154\nGen\n123 \n74.1 (4.2)\n\n9.2 (2.1)\n\n\n\nChina\n    \n127\nNeur\n123 \n73.1 (6.2)\n\n9.0 (2.1)\n\n\n\n\n    Li 2022\n\n471\nGen\n1234\n77.0 {71-82}\n\n7.0 {6-10}\n\n\n\nChina\n    \n471\nNeur\n1234\n77.0 {72-82}\n\n7.0 {5-10}\n\n\n\n\n    \n      Various\n    \n    Rasmussen 2003\n\n217\nGen\n1234\n70.8 [61-84]\n\n8.0 [2-20]\n\n\n\nDenmark\n    \n211\nNeur\n1234\n71.1 [61-84]\n\n9.0 [2-21]\n\n\n\n\n    Weber 2009\n\n23\nGen\nNR\n67.0 (9.0)\n\n6.5 (2.9)\n\n\n\nGermany\n    \n17\nBlock\nNR\n66.0 (8.0)\n\n5.2 (2.2)\n\n\n\n\n    \n      Gastrointestinal/Abdominal\n    \n    Jia 2014\n\n116\nGen\nNR\n74.8 (4.0)\n\n13.2 (1.3)\n\n\n\nChina\n    \n117\nNeur\nNR\n75.7 (4.2)\n\n9.0 (1.8)\n\n\n\n\n    \n      Head & Neck\n    \n    Hestin 2022\n\n30\nGen\n1234\n75.0 (9.0)\n\n4.0 [2-76]\n\n\n\nFrance\n    \n30\nBlock\n1234\n76.0 (11.0)\n\n5.0 [2-20]\n\n\n\n\n    \n      Other\n    \n    Carron 2007\n\n20\nGen\n123 \n62.6 (10.7)\n\n9.1 (6.3)\n\n\n\nItaly\n    \n20\nNeur\n123 \n65.5 (16.8)\n\n7.2 (3.4)\n\n\n\n\n    \n      Spine\n    \n    Brown 2021\n\n106\nGen\nNR\n72.0 {69-76}\n\n3.0 {2-3}\n\n\n\nUSA\n    \n111\nNeur\nNR\n73.0 {69-78}\n\n3.0 {2-3}\n\n\n\n\n  \n  \n  \n    \n       Anesth: anesthetic; NR: not reported.\n    \n    \n      a ASA Physical Status.\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n  \n\n\n\n\n\nPooled\n Figure 21. Mean difference in lengths of stay (regional versus general anesthesia; randomized clinical trials)."
  },
  {
    "objectID": "kq3.html#discharge-location",
    "href": "kq3.html#discharge-location",
    "title": "Regional versus General Anesthesia",
    "section": "Discharge Location",
    "text": "Discharge Location\n\n Table 16. Discharge location in studies comparing regional with general anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n         Agea\n      Country\n      \n        Discharge to Institution\n      \n      RR (95% CI)\n    \n    \n      N (%)\n      0 — 100%\n    \n  \n  \n    \n      Randomized Clinical Trial — Orthopedic\n    \n    Neuman 2021\n\n777\nGen\n78.4 (10.6)\n\nUSA\n586 (75.4)\n\n\n\n    \n777\nNeur\n77.7 (10.7)\n\n\n576 (74.1)\n\n\n0.98 (0.93-1.04)\n  \n  \n  \n    \n       Gen: general; Neur: neuraxial; RR: risk ratio.\n    \n    \n      a Mean Med (SD)[Range]{IQR}."
  },
  {
    "objectID": "kq3.html#mortality",
    "href": "kq3.html#mortality",
    "title": "Regional versus General Anesthesia",
    "section": "Mortality",
    "text": "Mortality\n\n Table 17. Reported in-hospital, 30-day, and 1-year mortality from randomized clinical trials.\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N  \n      Arm\n      Surgery\n      \n        ASA\n      \n      Agea\n      \n        Mortality\n      \n      RD (95% CI)\n    \n    \n      PS\n      N (%)\n      0 - 100%\n    \n  \n  \n    \n      Hospital\n    \n    Rasmussen 2003\n\n217\nGen\nVarious\n1234\n70.8 [61-84]\n\n 3 (1.4)\n\n\n—\n    \n211\nNeur\n\n\n71.1 [61-84]\n\n 0 (0.0)\n\n\n-1.4% (-3.2, 0.4)\n    Kasprzak 2006\n\n95\nGen\nCardiac\nNR\n69.0 (8.0)\n\n 1 (1.1)\n\n\n—\n    \n91\nBlock\n\n\n69.0 (8.0)\n\n 0 (0.0)\n\n\n-1.1% (-4.0, 1.8)\n    Harsten 2013\n\n60\nGen\nOrtho\n123 \n68.0 (7.0)\n\n 0 (0.0)\n\n\n—\n    \n60\nNeur\n\n\n67.0 (7.0)\n\n 0 (0.0)\n\n\n0.0% (-3.2, 3.2)\n    Shin 2020\n\n60\nGen\nOrtho\nNR\n79.4 (7.7)\n\n 1 (1.7)\n\n\n—\n    \n58\nGen\n\n\n80.5 (6.7)\n\n 0 (0.0)\n\n\n-1.7% (-6.2, 2.9)\n    \n58\nNeur\n\n\n81.6 (6.7)\n\n 2 (3.4)\n\n\n1.8% (-3.9, 7.5)\n    Brown 2021\n\n106\nGen\nSpine\nNR\n72.0 {69-76}\n\n 1 (0.9)\n\n\n—\n    \n111\nNeur\n\n\n73.0 {69-78}\n\n 0 (0.0)\n\n\n-0.9% (-3.5, 1.6)\n    Neuman 2021\n\n790\nGen\nOrtho\n1234\n78.4 (10.6)\n\n13 (1.6)\n\n\n—\n    \n782\nNeur\n\n\n77.7 (10.7)\n\n 5 (0.6)\n\n\n-1.0% (-2.1, 0.0)\n    \n      30-day\n    \n    Lewis 2008\n\n1752\nGen\nVarious\n1234\n70.0 (8.8)\n\n26 (1.5)\n\n\n—\n    \n1771\nBlock\n\n\n69.0 (8.8)\n\n19 (1.1)\n\n\n-0.4% (-1.2, 0.3)\n    Parker 2015\n\n164\nGen\nOrtho\n1234\n83.0 [59-99]\n\n 8 (4.9)\n\n\n—\n    \n158\nNeur\n\n\n82.9 [25-105]\n\n 5 (3.2)\n\n\n-1.7% (-6.0, 2.6)\n    Harsten 2015\n\n60\nGen\nOrtho\n123 \n68.0 (9.0)\n\n 0 (0.0)\n\n\n—\n    \n58\nNeur\n\n\n66.0 (7.8)\n\n 0 (0.0)\n\n\n0.0% (-3.3, 3.3)\n    Meuret 2018\n\n21\nGen\nOrtho\n123 \n85.0 (5.0)\n\n 0 (0.0)\n\n\n—\n    \n19\nNeur\n\n\n83.0 (6.0)\n\n 0 (0.0)\n\n\n0.0% (-9.3, 9.3)\n    Shin 2020\n\n60\nGen\nOrtho\nNR\n79.4 (7.7)\n\n 2 (3.3)\n\n\n1.7% (-3.9, 7.2)\n    \n58\nGen\n\n\n80.5 (6.7)\n\n 1 (1.7)\n\n\n0.1% (-4.6, 4.7)\n    \n58\nNeur\n\n\n81.6 (6.7)\n\n 1 (1.7)\n\n\n0.1% (-4.6, 4.7)\n    Li 2022\n\n464\nGen\nOrtho\n1234\n77.0 {71-82}\n\n 4 (0.9)\n\n\n—\n    \n469\nNeur\n\n\n77.0 {72-82}\n\n 8 (1.7)\n\n\n0.8% (-0.6, 2.3)\n    \n      90-day\n    \n    Rasmussen 2003\n\n217\nGen\nVarious\n1234\n70.8 [61-84]\n\n 1 (0.5)\n\n\n-0.9% (-2.7, 0.9)\n    \n211\nNeur\n\n\n71.1 [61-84]\n\n 0 (0.0)\n\n\n-1.4% (-3.2, 0.4)\n    Parker 2015\n\n164\nGen\nOrtho\n1234\n83.0 [59-99]\n\n12 (7.3)\n\n\n2.4% (-2.7, 7.6)\n    \n158\nNeur\n\n\n82.9 [25-105]\n\n12 (7.6)\n\n\n2.7% (-2.6, 8.0)\n    Shin 2020\n\n60\nGen\nOrtho\nNR\n79.4 (7.7)\n\n 3 (5.0)\n\n\n3.3% (-3.1, 9.7)\n    \n58\nGen\n\n\n80.5 (6.7)\n\n 2 (3.4)\n\n\n1.8% (-3.9, 7.5)\n    \n58\nNeur\n\n\n81.6 (6.7)\n\n 3 (5.2)\n\n\n3.5% (-3.1, 10.1)\n    \n      1-year\n    \n    Parker 2015\n\n164\nGen\nOrtho\n1234\n83.0 [59-99]\n\n19 (11.6)\n\n\n6.7% (0.8, 12.6)\n    \n158\nNeur\n\n\n82.9 [25-105]\n\n32 (20.3)\n\n\n15.4% (8.3, 22.5)\n  \n  \n  \n    \n       ASA PS: American Society of Anesthesiologists Physical Status; RD: risk difference; GI: gastrointestinal; Abd: abdominal (includes hepatic); Various: more that one procedure category.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n  \n\n\n\n\n\nPooled\n Figure 22. Risk ratio for hospital or 30-day mortality (regional versus general; randomized clinical trials). \n\n\n Figure 23. Risk difference for hospital or 30-day mortality (regional versus general; randomized clinical trials). \n\n Figure 24. Risk ratio for 90-day mortality (regional versus general; randomized clinical trials). \n\n Figure 25. Risk difference for 90-day mortality (regional versus general; randomized clinical trials)."
  },
  {
    "objectID": "kq3.html#risk-of-bias",
    "href": "kq3.html#risk-of-bias",
    "title": "Regional versus General Anesthesia",
    "section": "Risk of Bias",
    "text": "Risk of Bias\n Figure 26. Summary risk of bias assessments for randomized clinical trials (unweighted). \n\n\n\n\n\n\n\n\n\n Figure 27. Summary risk of bias assessments for randomized clinical trials (weighted by sample size). \n\n\n\n\n\n\n\n\n\n Figure 28. Risk of bias assessments for randomized clinical trials."
  },
  {
    "objectID": "kq2.html",
    "href": "kq2.html",
    "title": "Prehabilitation",
    "section": "",
    "text": "Among patients older patients anticipating surgery and anesthesia, do interventions targeted at improving physical function, cognition, and nutritional status before surgery (“prehabilitation”) improve postoperative outcomes?"
  },
  {
    "objectID": "kq2.html#key-question",
    "href": "kq2.html#key-question",
    "title": "Prehabilitation",
    "section": "",
    "text": "Among patients older patients anticipating surgery and anesthesia, do interventions targeted at improving physical function, cognition, and nutritional status before surgery (“prehabilitation”) improve postoperative outcomes?"
  },
  {
    "objectID": "kq5.html",
    "href": "kq5.html",
    "title": "Potentially Inappropriate Medications",
    "section": "",
    "text": "Among older patients undergoing surgery and anesthesia, do commonly used potentially inappropriate medications administered during the perioperative period increase the risk of postoperative delirium or other adverse outcomes?"
  },
  {
    "objectID": "kq5.html#key-question",
    "href": "kq5.html#key-question",
    "title": "Potentially Inappropriate Medications",
    "section": "",
    "text": "Among older patients undergoing surgery and anesthesia, do commonly used potentially inappropriate medications administered during the perioperative period increase the risk of postoperative delirium or other adverse outcomes?"
  },
  {
    "objectID": "kq5.html#outcome-importance",
    "href": "kq5.html#outcome-importance",
    "title": "Potentially Inappropriate Medications",
    "section": "Outcome Importance",
    "text": "Outcome Importance\n Table 1.  Rankings for the 5 most important outcomes (11 respondents)."
  },
  {
    "objectID": "kq5.html#outcomes-reported",
    "href": "kq5.html#outcomes-reported",
    "title": "Potentially Inappropriate Medications",
    "section": "Outcomes Reported",
    "text": "Outcomes Reported\n Table 2. Dichotomous and count outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 29\n      Crossover, N = 1\n      NR Trial, N = 1\n      Quasi-exp, N = 2\n      Prosp Coh, N = 6\n      Retro Coh, N = 20\n      Case-Cont, N = 2\n    \n  \n  \n    ADL\n1 (3.4%)\n—\n—\n—\n—\n—\n—\n    Complications\n13 (45%)\n—\n—\n—\n—\n—\n1 (50%)\n    DNCR/PND\n8 (28%)\n—\n—\n—\n—\n—\n—\n    Delirium\n21 (72%)\n1 (100%)\n1 (100%)\n2 (100%)\n6 (100%)\n19 (95%)\n2 (100%)\n    Delirium duration\n1 (3.4%)\n—\n—\n—\n—\n—\n—\n    Discharge location\n1 (3.4%)\n—\n—\n—\n—\n1 (5.0%)\n—\n    Mortality\n8 (28%)\n1 (100%)\n—\n—\n—\n—\n1 (50%)\n    Opioid use\n—\n—\n—\n—\n—\n—\n—\n    Pain\n—\n—\n—\n—\n—\n—\n—\n    QoR\n1 (3.4%)\n—\n—\n—\n—\n—\n—\n    Readmission\n—\n—\n—\n—\n—\n—\n—\n    Satisfaction\n—\n—\n—\n—\n—\n—\n—\n  \n  \n  \n    \n       RCT: randomized clinical trial; Crossover: crossover trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort; Case-Cont: case-control.\n    \n  \n\n\n\n\n Table 3. Continuous outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 29\n      Crossover, N = 1\n      NR Trial, N = 1\n      Quasi-exp, N = 2\n      Prosp Coh, N = 6\n      Retro Coh, N = 20\n      Case-Cont, N = 2\n    \n  \n  \n    Delirium duration\n5 (17%)\n—\n—\n—\n1 (17%)\n—\n—\n    Length of stay\n8 (28%)\n1 (100%)\n—\n—\n—\n1 (5.0%)\n1 (50%)\n    Opioid use\n2 (6.9%)\n—\n—\n—\n—\n—\n—\n  \n  \n  \n    \n       RCT: randomized clinical trial; Crossover: crossover trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort; Case-Cont: case-control.\n    \n  \n\n\n\n\n Table 4. Likert and ordinal outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 29\n      Crossover, N = 1\n      NR Trial, N = 1\n      Quasi-exp, N = 2\n      Prosp Coh, N = 6\n      Retro Coh, N = 20\n      Case-Cont, N = 2\n    \n  \n  \n    ADL\n—\n—\n—\n—\n—\n—\n—\n    DNCR/PNCD\n9 (31%)\n—\n—\n—\n—\n—\n—\n    Delirium\n5 (17%)\n—\n—\n1 (50%)\n—\n—\n—\n    Complications\n—\n—\n—\n—\n—\n—\n—\n    Pain\n2 (6.9%)\n—\n—\n—\n—\n—\n—\n    Quality of life\n—\n—\n—\n—\n—\n—\n—\n    QoR\n—\n—\n—\n—\n—\n—\n—\n    Satisfaction\n—\n—\n—\n—\n—\n—\n—\n  \n  \n  \n    \n       RCT: randomized clinical trial; Crossover: crossover trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort; Case-Cont: case-control."
  },
  {
    "objectID": "kq5.html#causal-model",
    "href": "kq5.html#causal-model",
    "title": "Potentially Inappropriate Medications",
    "section": "Causal Model",
    "text": "Causal Model\n Figure 5. Causal model for the relationship between potentially inappropriate medications and outcomes. Likely mediators include anesthetics, other drugs, pain, hypotension, clinical instability, infection, electrolytes, and sleep deprivation. \n\n\n\n\n\n PIM: potentially inappropriate medications; dNCR: delayed neurcognitive recovery (&lt;30 days); POCD: postoperative cognitive disorder (30 days to 1 year); NCD: neurocognitive disorders (&gt; 1 year)."
  },
  {
    "objectID": "kq5.html#included-studies",
    "href": "kq5.html#included-studies",
    "title": "Potentially Inappropriate Medications",
    "section": "Included Studies",
    "text": "Included Studies\n Table 5. Number of studies by design. \n\n\n\n\n\n\n  \n    \n    \n  \n  \n    \n    \n      Design\n      Studies\n    \n  \n  \n    Randomized Clinical Trial\n27\n    Randomized Cluster Crossover Trial\n1\n    Nonrandomized Trial\n1\n    Before-After/Time Series\n2\n    Prospective Cohort\n6\n    Retrospective Cohort\n8\n    Case-Control\n2\n    Total\n47\n  \n  \n  \n    \n       Studies with multiple publications counted only once (applies to 3 trials with 2 publications [see next table])."
  },
  {
    "objectID": "kq5.html#design-centers-country-surgery",
    "href": "kq5.html#design-centers-country-surgery",
    "title": "Potentially Inappropriate Medications",
    "section": "Design, centers, country, surgery",
    "text": "Design, centers, country, surgery\n Table 6. Study design, enrollment, centers, country, and surgery (see References for citations). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      ID\n      Study\n      Centers\n      Enrolled\n      Countrya\n      Drug Class\n      Surgery\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    1505\nHongyu 2019\n\n1\n90\nChinaa\nAnticholinergics\n\nThoracic\n\n    8574\nKalisvaart 2005 (Slor 2011a)\n\n1\n430\nNetherlands\nAntipsychotics\n\nOrtho\n\n    16607\nPrakanrattana 2007\n\n1\n126\nThailand\nAntipsychotics\n\nCardiac\n\n    7098\nLarsen 2010\n\n1\n495\nUSA\nAntipsychotics\n\nOrtho\n\n    4824\nHakim 2012\n\n1\n101\nEgypta\nAntipsychotics\n\nCardiac\n\n    9196\nWang 2012\n\n2\n457\nChinaa\nAntipsychotics\n\nGI/AbdominalNeuroOrthoThoracic\n\n    8864\nFukata 2014\n\n5\n121\nJapan\nAntipsychotics\n\nGI/AbdominalOrtho\n\n    7309\nFukata 2017\n\n3\n201\nJapan\nAntipsychotics\n\nGI/AbdominalHepaticOrtho\n\n    1937\nHollinger 2021\n\n2\n143\nSwitzerland\nAntipsychotics\n\nVariousb\n    9620\nAizawa 2002\n\n1\n42\nJapan\nBenzodiazepine (la)\n\nGI/Abdominal\n\n    17055\nDianatkhah 2015\n\n1\n145\nIrana\nBenzodiazepine (la)\n\nCardiac\n\n    5164\nSultan 2010\n\n1\n152\nEgypta\nBenzodiazepine (sa)\n\nOrtho\n\n    13731\nYu 2017\n\n1\n92\nChinaa\nBenzodiazepine (sa)\n\nThoracic\n\n    13579\nAzeem 2018\n\n1\n70\nEgypta\nBenzodiazepine (sa)\n\nCardiac\n\n    13568\nHe 2018\n\n1\n90\nChinaa\nBenzodiazepine (sa)\n\nThoracic\n\n    1117\nMansouri 2019\n\n1\n150\nIrana\nBenzodiazepine (sa)\n\nOphtho\n\n    742\nLi 2019\n\n1\n164\nChinaa\nBenzodiazepine (sa)\n\nOrtho\n\n    1625\nWang 2020a\n\n1\n44\nChinaa\nBenzodiazepine (sa)\n\nOralmax\n\n    9157\nTan 2022\n\n1\n99\nChinaa\nBenzodiazepine (sa)\n\nGI/Abdominal\n\n    16533\nDieleman 2012 (Ottens 2014)\n\n8\n4,494\nNetherlands\nCorticosteroids\n\nCardiac\n\n    14006\nMardani 2013\n\n1\n110\nIrana\nCorticosteroids\n\nCardiac\n\n    10036\nSauer 2014\n\n1\n737\nNetherlands\nCorticosteroids\n\nCardiac\n\n    10075\nOttens 2014 (Dieleman 2012)\n\n3\n291\nNetherlands\nCorticosteroids\n\nCardiac\n\n    10515\nWhitlock 2015 (Royse 2017)\n\n80\n7,507\nCanada\nCorticosteroids\n\nCardiac\n\n    2778\nGlumac 2017\n\n1\n169\nCroatia\nCorticosteroids\n\nCardiac\n\n    3250\nRoyse 2017 (Whitlock 2015)\n\n3\n555\nAustralia\nCorticosteroids\n\nCardiac\n\n    7686\nXiang 2022\n\n1\n174\nChinaa\nCorticosteroids\n\nGI/Abdominal\n\n    5765\nZhu 2018\n\n1\n178\nChinaa\nNSAIDs\n\nOrtho\n\n    5809\nZhou 2019a\n\n1\n180\nChinaa\nNSAIDs\n\nOrtho\n\n    \n      Randomized Cluster Crossover Trial\n    \n    5365\nSpence 2020\n\n2\n800\nCanada\nBenzodiazepine (sa)\n\nCardiac\n\n    \n      Before-After/Time Series\n    \n    9464\nUshida 2009\n\n1\n122\nJapan\nCorticosteroids\n\nOrtho\n\n    10090\nYamasaki 2019\n\n1\n21\nJapan\nH2 blockers\n\nGI/Abdominal\n\n    \n      Nonrandomized Trial\n    \n    750\nVan Grootven 2016\n\n5\n86\nBelgium\nBenzodiazepine (ns)\n\nOrtho\n\n    \n      Prospective Cohort\n    \n    2985\nPipanmekaporn 2021\n\n1\n429\nThailand\nBenzodiazepine (ns)\n\nVariousb\n    7722\nDuprey 2022\n\n2\n566\nUSA\nBenzodiazepine (ns)AntipsychoticsNSAIDsAnticholinergics\n\nNon-cardiac\n\n    1332\nWang 2021\n\n1\n1,266\nUSA\nBenzodiazepine (sa)\n\nVariousb\n    7522\nLeigheb 2022\n\n1\n83\nItaly\nBenzodiazepine (sa)\n\nOrtho\n\n    6840\nKe 2022a (Ke 2022b)\n\n4\n98\nSingapore\nBenzodiazepine (sa)\n\nOther\n\n    16970\nAoki 2023\n\n1\n222\nJapan\nBenzodiazepine (sa)\n\nCardiac\n\n    \n      Retrospective Cohort\n    \n    17141\nSlor 2011c (Slor 2011a)\n\n1\n526\nNetherlands\nAnticholinergics\n\nOrtho\n\n    17142\nMueller 2020b (Mueller 2020a)\n\n2\n651\nGermany\nAntipsychotics\n\nGynGI/AbdominalThoracicUrol\n\n    17140\nSlor 2011b (Slor 2011a)\n\n1\n526\nNetherlands\nBenzodiazepine (ns)\n\nOrtho\n\n    4888\nWeinstein 2018a (Weinstein 2018b)\n\n1\n41,766\nUSA\nBenzodiazepine (ns)\n\nOrtho\n\n    17143\nWeinstein 2018b (Weinstein 2018a)\n\n1\n41,766\nUSA\nBenzodiazepine (ns)\n\nOrtho\n\n    8003\nFuchita 2019a (Fuchita 2019b)\n\n1\n84\nUSA\nBenzodiazepine (ns)\n\nThoracic\n\n    118\nMueller 2020a (Mueller 2020b)\n\n2\n651\nGermany\nBenzodiazepine (sa)\n\nGynGI/AbdominalThoracicUrol\n\n    17038\nLiu 2023a (Liu 2023b)\n\n1\n195\nChinaa\nBenzodiazepine (sa)\n\nUrol\n\n    16961\nKoch 2023\n\n1\n1,058\nGermany\nBenzodiazepine (sa)\n\nVariousb\n    5163\nMemtsoudis 2019 THA\n\n4,400\n564,226\nUSA\nBenzodiazepine (sa)Benzodiazepine (la)Benzodiazepine (any)CorticosteroidsNSAIDsNSAIDs\n\nOrtho\n\n    17134\nMemtsoudis 2019 TKA\n\n4,400\n1,130,569\nUSA\nBenzodiazepine (sa)Benzodiazepine (la)Benzodiazepine (any)CorticosteroidsNSAIDsNSAIDs\n\nOrtho\n\n    17148\nFuchita 2019b (Fuchita 2019a)\n\n1\n84\nUSA\nCorticosteroids\n\nThoracic\n\n    17006\nBurfeind 2022\n\n1\n1,627\nUSA\nCorticosteroidsH2 blockersBenzodiazepine (sa)\n\nVariousb\n    3727\nMangusan 2015\n\n1\n656\nUSA\nNSAIDsNonbenzodiazepine hypnoticsBenzodiazepine (ns)\n\nCardiac\n\n    \n      Case-Control\n    \n    9279\nNandi 2014\n\n1\n463\nUSA\nBenzodiazepine (ns)\n\nOrtho\n\n    9977\nChoi 2019\n\n1\n58\nSouth Korea\nCorticosteroids\n\nThoracic\n\n  \n  \n  \n    \n       Antichol: anticholinergics; Antipsych: antipsychotics; la: long-acting; sa: short-acting; ns: not stated; GI: gastrointestinal; Ortho: orthopedic; Neuro: neurological; Oralmax: oral maxillofacial; Vasc: vascular.\n    \n    \n      a Non very-high Human Development Index country.\n    \n    \n      b Described as various or more than 4 different types of surgery.\n    \n  \n\n\n\n\n\nCountry Summary\n Table 7. Summary of studies by country where conducted. \n\n\n\n\n\n\n  \n    \n    \n      \n      N = 47a\n    \n  \n  \n    Country\n\n        China\n11 (23%)\n        USA\n9 (19%)\n        Japan\n6 (13%)\n        Egypt\n3 (6.4%)\n        Iran\n3 (6.4%)\n        Netherlands\n3 (6.4%)\n        Germany\n2 (4.3%)\n        Thailand\n2 (4.3%)\n        Australia\n1 (2.1%)\n        Belgium\n1 (2.1%)\n        Canada\n1 (2.1%)\n        Croatia\n1 (2.1%)\n        Italy\n1 (2.1%)\n        Singapore\n1 (2.1%)\n        South Korea\n1 (2.1%)\n        Switzerland\n1 (2.1%)\n  \n  \n  \n    \n      a n (%)"
  },
  {
    "objectID": "kq5.html#drugs-by-study",
    "href": "kq5.html#drugs-by-study",
    "title": "Potentially Inappropriate Medications",
    "section": "Drugs by Study",
    "text": "Drugs by Study\n\nBenzodiazepines\n Table 8. Studies examining benzodiazepines, dose, and timing according to study design. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Benzodiazepines (short-acting)\n    \n    \n    \n      Study\n      N\n      Drug\n      \n        ASA\n      \n      \n        Anesthetic\n      \n        Ageb\n       MMSEb\n      Dosing\n      Timingc\n      Surgery\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n      Sed\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Sultan 2010\n\n49\nNone\n123 \n\n\n✓\n\n72.3 (6.4)\n\n\n \n\nOrtho\n    \n53\nMelatonin\n123 \n\n\n✓\n\n70.4 (7.1)\n\n\n \n\n\n    \n50\nMidazolam\n123 \n\n\n✓\n\n69.9 (8.2)\n\n\n7.5mg (qd×2d)\n▆▁▁\n\n\n    Yu 2017\n\n46\nDexmedetomidine\n12  \n\n✓\n\n\n68.7 (4.3)\n\n29.8 (0.7)\n\n \n\nThoracic\n    \n46\nMidazolam\n12  \n\n✓\n\n\n69.1 (4.9)\n\n29.8 (0.7)\n\n0.05ug/kg (bid×1d)\n▁▆▁\n\n\n    He 2018\n\n30\nPlacebo\n123 \n✓\n✓\n\n\n83.2 (5.1)\n\n\n \n\nThoracic\n    \n30\nDexmedetomidine\n123 \n✓\n✓\n\n\n82.5 (5.4)\n\n\n \n\n\n    \n30\nMidazolam\n123 \n✓\n✓\n\n\n81.9 (6.2)\n\n\n0.03mg/kg (qd×1d)\n▆▁▁\n\n\n    Azeem 2018\n\n30\nDexmedetomidine\nNR\n\n✓\n\n\n65.3 (4.8)\n\n\n \n\nCardiac\n    \n30\nMidazolam\nNR\n\n✓\n\n\n66.7 (5.6)\n\n\n0.05mg/kg \n\n\n    Li 2019\n\n55\nPropofol\n123 \n\n\n✓\n\n68.2 (6.4)\n\n\n \n\nOrtho\n    \n55\nDexmedetomidine\n123 \n\n\n✓\n\n69.3 (7.1)\n\n\n \n\n\n    \n54\nMidazolam\n123 \n\n\n✓\n\n66.9 (6.6)\n\n\n d\n▁▆▁\n\n\n    Mansouri 2019\n\n50\nPlacebo\n12  \n\n✓\n\n\n64.0 (7.2)\n\n\n \n\nOphtho\n    \n50\nDexmedetomidine\n12  \n\n✓\n\n\n66.5 (1.6)\n\n\n \n\n\n    \n50\nMidazolam\n12  \n\n✓\n\n\n63.6 (8.3)\n\n\n0.1mg/kg (qd×1d)\n▁▆▁\n\n\n    Wang 2020a\n\n20\nDexmedetomidine\nNR\n\n✓\n\n\n60.0 (10.1)\n\n\n \n\nOralmax\n    \n20\nMidazolam\nNR\n\n✓\n\n\n60.5 (8.2)\n\n\n0.03mg/kg (1d)\n\n\n    Tan 2022\n\n33\nPropofol\n12  \n\n\n\n✓\n66.2 (5.0)\n\n\n \n\nGI/Abd\n    \n33\nRemimazolam\n123 \n\n\n\n✓\n66.4 (4.8)\n\n\n0.1mg/kg (qd×1d)\n▁▆▁\n\n\n    \n33\nRemimazolam\n123 \n\n\n\n✓\n65.5 (5.2)\n\n\n0.2mg/kg (qd×1d)\n▁▆▁\n\n\n    \n      Randomized Cluster Crossover Trial\n    \n    Spence 2020\n\n389\nMidazolam (liberal)e\nNR\n\n\n\n\n67.2 (10.0)\n\n\n5.2mg f\n▆▆▆\n\nCardiac\n    \n411\nMidazolam (restricted)e\nNR\n\n\n\n\n66.7 (11.3)\n\n\n4.6mg f\n▆▆▆\n\n\n    \n      Prospective Cohort\n    \n    Wang 2021\n\n357\nNone\n1234\n\n\n\n\n74.5 (6.6)\n\n\n \n\nVarious\n    \n357\nMidazolam\n1234\n\n\n\n\n74.1 (4.2)\n\n\n1.99mg f\n▆▁▁\n\n\n    Ke 2022a\n\n91\nNone\nNR\n\n\n\n\n\n\n \n\nOther\n    \n7\nMidazolam\nNR\n\n\n\n\n\n\n \n▁▆▁\n\n\n    Leigheb 2022\n\n36\nNone\n1234\n\n\n\n\n\n\n \n\nOrtho\n    \n47\nMidazolam\n1234\n\n\n\n\n\n\nmg \n▆▁▁\n\n\n    Aoki 2023\n\n124\nNone\n 23 \n✓\n✓\n\n\n77.2 (5.9)\n\n28.0 (1.7)\n\n \n\nCardiac\n    \n76\nRemimazolam\n 23 \n\n✓\n\n\n77.7 (6.1)\n\n28.0 (1.5)\n\nNR\n▁▆▁\n\n\n    \n      Retrospective Cohort\n    \n    Memtsoudis 2019 THA\n\n107,736\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n373,219\nBenzodiazepine (any sa)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n15,329\nBenzodiazepine (any la)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n67,942\nBenzodiazepine (any sa/la)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    Memtsoudis 2019 TKA\n\n175,288\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n778,956\nBenzodiazepine (any sa)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n25,667\nBenzodiazepine (any la)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n150,658\nBenzodiazepine (any sa/la)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    Mueller 2020a\n\n82\nNone\n1234\n\n\n\n\n71.8 (4.9)\n\n28.6 (4.9)\n\n \n\nVarious\n    \n529\nMidazolam\n1234\n\n\n\n\n71.8 (4.9)\n\n28.6 (4.9)\n\n6.1mg \n▆▁▁\n\n\n    Koch 2023\n\n1,001\nNone\n1234\n\n\n\n\n69.7 (6.3)\n\n28.9 (1.4)\n\n \n\nVarious\n    \n57\nMidazolam\n1234\n\n\n\n\n69.7 (6.3)\n\n28.9 (1.4)\n\nNR\n▆▁▁\n\n\n    Liu 2023a\n\n50\nNone\n1234\n\n\n\n\n68.0 [66-72]\n\n\n \n\nUrol\n    \n145\nMidazolam\n1234\n\n\n\n\n68.0 [66-72]\n\n\nNR\n▁▆▁\n\n\n  \n  \n  \n    \n       PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; Sed: sedation; MMSE: Mini-Mental State Exam; THA: total hip arthroplasty; TKA: total knee arthroplasty.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n    \n      c Bars indicate adminstration times from left to right: preoperative, induction/intraoperative, and postoperative (includes PACU).\n    \n    \n      d Dose adjusted to maintain light sedation.\n    \n    \n      e Liberal or restricted administration relevant to intraoperative period.\n    \n    \n      f Mean intraoperative dose.\n    \n  \n\n\n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Benzodiazepines (long-acting)\n    \n    \n    \n      Study\n      N\n      Drug\n      \n        ASA\n      \n      \n        Anesthetic\n      \n        Ageb\n       MMSEb\n      Dosing\n      Timingc\n      Surgery\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n      Sed\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Aizawa 2002\n\n20\nNone\nNR\n✓\n✓\n\n\n76.2 (4.1)\n\n\n \n\nGI/Abd\n    \n20\nFlunitrazepam\nNR\n✓\n✓\n\n\n75.9 (4.5)\n\n\n0.4mg/kg (qd×3d)\n▆▁▁\n\n\n    Dianatkhah 2015\n\n66\nMelatonin\nNR\n\n\n\n\n60.0 (10.2)\n\n\n \n\nCardiac\n    \n71\nOxazepam\nNR\n\n\n\n\n61.7 (9.9)\n\n\n10mg (qd×10d)\n▆▁▆\n\n\n    \n      Retrospective Cohort\n    \n    Memtsoudis 2019 THA\n\n107,736\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n373,219\nBenzodiazepine (any sa)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n15,329\nBenzodiazepine (any la)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n67,942\nBenzodiazepine (any sa/la)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    Memtsoudis 2019 TKA\n\n175,288\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n778,956\nBenzodiazepine (any sa)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n25,667\nBenzodiazepine (any la)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n150,658\nBenzodiazepine (any sa/la)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n  \n  \n  \n    \n       PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; Sed: sedation; MMSE: Mini-Mental State Exam.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n    \n      c Bars indicate adminstration times from left to right: preoperative, induction/intraoperative, and postoperative (includes PACU).\n    \n  \n\n\n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Benzodiazepine (any or not specified)\n    \n    \n    \n      Study\n      N\n      Drug\n      \n        ASA\n      \n      \n        Anesthetic\n      \n        Ageb\n       MMSEb\n      Dosing\n      Timingc\n      Surgery\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n      Sed\n    \n  \n  \n    \n      Retrospective Cohort\n    \n    Slor 2011b\n\n96\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n430\nBenzodiazepine (ns sa/la)\nNR\n\n\n\n\n\n\nNR\nd Unspecified\n\n\n    Mangusan 2015\n\n36\nZolpidem\nNR\n\n\n\n\n66.5 (10.8)\n\n\nNR\n▁▁▆\n\nCardiac\n    \n232\nBenzodiazepine (ns sa/la)\nNR\n\n\n\n\n66.5 (10.8)\n\n\nNR\n▁▁▆\n\n\n    \n287\nKetoprofen\nNR\n\n\n\n\n66.5 (10.8)\n\n\nNR\n▁▁▆\n\n\n    Weinstein 2018a\n\n2,643\nNone\nNR\n\n\n✓\n\n\n\n \n\nOrtho\n    \n33,223\nBenzodiazepine (ns sa/la)\nNR\n\n\n✓\n\n\n\n \n▁▆▁\n\n\n    Weinstein 2018b\n\n33,500\nNone\nNR\n\n\n✓\n\n\n\n \n\nOrtho\n    \n3,451\nBenzodiazepine (ns sa/la)\nNR\n\n\n✓\n\n\n\n \n▁▁▆\n\n\n    Memtsoudis 2019 THA\n\n107,736\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n373,219\nBenzodiazepine (any sa)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n15,329\nBenzodiazepine (any la)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n67,942\nBenzodiazepine (any sa/la)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    Fuchita 2019a\n\n3\nNone\nNR\n\n\n\n\n61.7 (10.5)\n\n\n \n\nThoracic\n    \n81\nBenzo_ns\nNR\n\n\n\n\n61.7 (10.5)\n\n\n \n▁▆▁\n\n\n    Memtsoudis 2019 TKA\n\n175,288\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n778,956\nBenzodiazepine (any sa)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n25,667\nBenzodiazepine (any la)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n150,658\nBenzodiazepine (any sa/la)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n      Case-Control\n    \n    Nandi 2014\n\n376\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n87\nBenzodiazepine (ns sa/la)\nNR\n\n\n\n\n\n\n \n▁▆▆\n\n\n    \n      Nonrandomized Trial\n    \n    Van Grootven 2016\n\n62\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n24\nBenzodiazepine (ns sa/la)\nNR\n\n\n\n\n80.1 (6.8)\n\n\nNR\nd Unspecified\n\n\n    \n      Prospective Cohort\n    \n    Pipanmekaporn 2021\n\n173\nNone\nNR\n\n\n\n\n\n\n \n\nVarious\n    \n256\nBenzodiazepine (ns sa/la)\nNR\n\n\n\n\n\n\n \n▆▁▁\n\n\n    Duprey 2022\n\ne \nAntipsychotic (any)\nNR\n\n\n\n\n76.6 (5.0)\n\n\nNR\n▁▁▆\n\nVarious\n    \ne \nBenzodiazepine (ns sa/la)\nNR\n\n\n\n\n76.6 (5.0)\n\n\nNR\n▁▁▆\n\n\n  \n  \n  \n    \n       PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; Sed: sedation; MMSE: Mini-Mental State Exam; THA: total hip arthroplasty; TKA: total knee arthroplasty.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n    \n      c Bars indicate adminstration times from left to right: preoperative, induction/intraoperative, and postoperative (includes PACU).\n    \n    \n      d Not specified.\n    \n    \n      e Reported only results from proportional hazards models.\n    \n  \n\n\n\n\n\n\nAntipsychotics\n Table 9. Studies examining antipsychotics, dose, and timing according to study design. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Antipsychotics\n    \n    \n    \n      Study\n      N\n      Drug\n      \n        ASA\n      \n      \n        Anesthetic\n      \n        Ageb\n       MMSEb\n      Dosing\n      Timingc\n      Surgery\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n      Sed\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Kalisvaart 2005\n\n218\nPlacebo\nNR\n\n\n\n\n79.6 (6.3)\n\n24.5 (4.2)\n\n \n\nOrtho\n    \n212\nHaloperidol\nNR\n\n\n\n\n78.7 (6.0)\n\n25.0 (6.8)\n\n0.5mg (tid×5d)\n▆▁▁\n\n\n    Prakanrattana 2007\n\n63\nPlacebo\nNR\n✓\n✓\n\n\n60.7 (9.8)\n\n\n \n\nCardiac\n    \n63\nRisperidone\nNR\n✓\n✓\n\n\n61.3 (9.7)\n\n\n1mg (qd×1d)\n\n\n    Larsen 2010\n\n204\nPlacebo\n123 \n✓\n\n✓\n\n74.0 (6.2)\n\n\n \n\nOrtho\n    \n196\nOlanzapine\n123 \n✓\n\n✓\n\n73.4 (6.1)\n\n\n5mg (bid×1d)\n▆▁▁\n\n\n    Hakim 2012\n\n50\nPlacebo\nNR\n✓\n\n\n\n\n\n \n\nCardiac\n    \n51\nRisperidone\nNR\n✓\n\n\n\n\n\n0.5mg (bid)\n\n\n    Wang 2012\n\n228\nPlacebo\n 234\n\n\n\n\n74.4 (7.0)\n\n\n \n\nVarious\n    \n229\nHaloperidol\n 234\n\n\n\n\n74.0 (5.8)\n\n\n5mg (qd×1d)\n\n\n    Fukata 2014\n\n62\nNone\nNR\n\n\n\n\n80.2 (3.9)\n\n23.0 (5.4)\n\n \n\nVarious\n    \n59\nHaloperidol\nNR\n\n\n\n\n80.5 (3.8)\n\n23.3 (6.4)\n\n2.5mg (qd×3d)\n\n\n    Fukata 2017\n\n100\nNone\nNR\n\n\n\n\n81.3 (4.3)\n\n25.1 (5.6)\n\n \n\nVarious\n    \n101\nHaloperidol\nNR\n\n\n\n\n82.0 (4.4)\n\n24.6 (5.2)\n\n5mg (qd×6d)\n\n\n    Hollinger 2021\n\n44\nPlacebo\nNR\n\n\n\n\n74.8 (6.6)\n\n28.3 (2.3)\n\n \n\nVarious\n    \n47\nKetamine\nNR\n\n\n\n\n73.4 (6.1)\n\n27.7 (1.7)\n\n \n\n\n    \n45\nHaloperidol\nNR\n\n\n\n\n73.4 (6.3)\n\n28.0 (1.3)\n\n5ug/kg (qd×1d)\n▁▆▁\n\n\n    \n      Retrospective Cohort\n    \n    Mueller 2020b\n\n558\nNone\n1234\n\n\n\n\n71.8 (31.5)\n\n28.6 (4.9)\n\n \n\nVarious\n    \n92\nHaloperidol\n1234\n\n\n\n\n71.8 (4.9)\n\n28.6 (4.9)\n\n \n▁▁▆\n\n\n    \n      Prospective Cohort\n    \n    Duprey 2022\n\nd \nAntipsychotic (any)\nNR\n\n\n\n\n76.6 (5.0)\n\n\nNR\n▁▁▆\n\nVarious\n    \nd \nBenzodiazepine (ns sa/la)\nNR\n\n\n\n\n76.6 (5.0)\n\n\nNR\n▁▁▆\n\n\n  \n  \n  \n    \n       PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; Sed: sedation; MMSE: Mini-Mental State Exam.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n    \n      c Bars indicate adminstration times from left to right: preoperative, induction/intraoperative, and postoperative (includes PACU).\n    \n    \n      d Reported only results from proportional hazards models.\n    \n  \n\n\n\n\n\n\nAnticholinergics\n Table 10. Studies examining anticholinergics, dose, and timing according to study design. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Anticholinergic drugs\n    \n    \n    \n      Study\n      N\n      Drug\n      \n        ASA\n      \n      \n        Anesthetic\n      \n        Ageb\n       MMSEb\n      Dosing\n      Timingc\n      Surgery\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n      Sed\n    \n  \n  \n    \n      Retrospective Cohort\n    \n    Slor 2011c\n\n480\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n46\nAnticholinergic (any)\nNR\n\n\n\n\n\n\nNR\nd Unspecified\n\n\n    \n      Randomized Clinical Trial\n    \n    Hongyu 2019\n\n30\nPlacebo\n123 \n✓\n\n\n\n69.1 (8.3)\n\n27.1 (2.6)\n\n \n\nThoracic\n    \n30\nPenehyclidine\n123 \n✓\n\n\n\n72.4 (5.7)\n\n27.8 (2.1)\n\n0.01mg/kg (qd×1d)\n▆▁▁\n\n\n  \n  \n  \n    \n       PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; Sed: sedation; MMSE: Mini-Mental State Exam.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n    \n      c Bars indicate adminstration times from left to right: preoperative, induction/intraoperative, and postoperative (includes PACU).\n    \n    \n      d Not specified.\n    \n  \n\n\n\n\n\n\nCorticosteroids\n Table 11. Studies examining corticosteroids, dose, and timing according to study design. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Corticosteroids\n    \n    \n    \n      Study\n      N\n      Drug\n      \n        ASA\n      \n      \n        Anesthetic\n      \n        Ageb\n       MMSEb\n      Dosing\n      Timingc\n      Surgery\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n      Sed\n    \n  \n  \n    \n      Before-After/Time Series\n    \n    Ushida 2009\n\n81\nMethylprednisolone\nNR\n✓\n✓\n\n\n69.8 [53-84]\n\n\n2500mg \n▁▆▁\n\nOrtho\n    \n41\nMethylprednisolone\nNR\n✓\n✓\n\n\n68.1 [52-86]\n\n\n2000mg \n▁▆▆\n\n\n    \n      Randomized Clinical Trial\n    \n    Dieleman 2012\n\n2,247\nPlacebo\nNR\n✓\n✓\n\n\n66.1 (10.7)\n\n\n \n\nCardiac\n    \n2,235\nDexamethasone\nNR\n✓\n✓\n\n\n66.2 (11.0)\n\n\n1mg/kg (qd×1d)\n▁▆▁\n\n\n    Mardani 2013\n\n50\nPlacebo\nNR\n\n\n\n\n60.0 (12.8)\n\n27.8 (3.1)\n\n \n\nCardiac\n    \n43\nDexamethasone\nNR\n\n\n\n\n64.5 (11.1)\n\n28.6 (3.1)\n\n8mg (tid×3d)\n▆▁▁\n\n\n    Sauer 2014\n\n370\nPlacebo\nNR\n\n\n\n\n66.0 (12.0)\n\n\n \n\nCardiac\n    \n367\nDexamethasone\nNR\n\n\n\n\n67.0 (12.0)\n\n\n1mg/kg (qd×1d)\n▁▆▁\n\n\n    Ottens 2014\n\n138\nPlacebo\nNR\n✓\n✓\n\n\n65.4 (11.5)\n\n\n \n\nCardiac\n    \n140\nDexamethasone\nNR\n✓\n✓\n\n\n63.4 (12.3)\n\n\n1mg/kg (qd×1d)\n▁▆▁\n\n\n    Whitlock 2015\n\n3,752\nPlacebo\nNR\n\n\n\n\n67.3 (13.8)\n\n\n \n\nCardiac\n    \n3,755\nMethylprednisolone\nNR\n\n\n\n\n67.5 (13.6)\n\n\n250mg (bid×1d)\n▁▆▁\n\n\n    Glumac 2017\n\n81\nPlacebo\nNR\n✓\n\n\n\n64.2 (9.4)\n\n28.3 (1.2)\n\n \n\nCardiac\n    \n80\nDexamethasone\nNR\n✓\n\n\n\n63.7 (9.0)\n\n28.1 (1.2)\n\n0.1mg/kg (qd×1d)\n▆▁▁\n\n\n    Royse 2017\n\n246\nPlacebo\nNR\n\n\n\n\n74.3 (9.3)\n\n\n \n\nCardiac\n    \n236\nMethylprednisolone\nNR\n\n\n\n\n73.4 (10.5)\n\n\n250mg (bid×1d)\n▁▆▁\n\n\n    Xiang 2022\n\n84\nPlacebo\n 23 \n\n✓\n✓\n\n70.0 {68-73}\n\n23 {22-24}\n\n \n\nGI/Abd\n    \n84\nMethylprednisolone\n 23 \n\n✓\n✓\n\n71.0 {68-74}\n\n22 {22-24}\n\n2mg/kg (qd×1d)\n▆▁▁\n\n\n    \n      Case-Control\n    \n    Choi 2019\n\n16\nMethylprednisolone &gt; 72h\n1234\n\n\n\n\n71.0 {63-74}\n\n\n1.5mg/kg (qd×28d)\n\nThoracic\n    \n42\nMethylprednisolone ≤ 72h\n1234\n\n\n\n\n70.0 {61-72}\n\n\n1.5mg/kg (qd×28d)\n\n\n    \n      Retrospective Cohort\n    \n    Memtsoudis 2019 THA\n\n542,536\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n21,690\nCorticosteroid (any)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    Memtsoudis 2019 TKA\n\n1,082,854\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n47,715\nCorticosteroid (any)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    Fuchita 2019b\n\n77\nNone\nNR\n\n\n\n\n61.7 (10.5)\n\n\n \n\nThoracic\n    \n7\nDexamethasone\nNR\n\n\n\n\n61.7 (10.5)\n\n\n \n▁▆▁\n\n\n    Burfeind 2022\n\n74\nNone\n1234\n✓\n✓\n✓\n\n76.9 (6.7)\n\n\n \n\nVarious\n    \n417\nNone\n1234\n✓\n✓\n✓\n\n76.9 (6.7)\n\n\n \n\n\n    \n104\nFamotidine/Midzolam/Dexamethasone\n1234\n✓\n✓\n✓\n\n72.3 (5.6)\n\n\n \n▁▆▆\n\n\n    \n1,006\nFamotidine/Midzolam/Dexamethasone\n1234\n✓\n✓\n✓\n\n72.3 (5.6)\n\n\n \n▁▆▆\n\n\n  \n  \n  \n    \n       PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; Sed: sedation; MMSE: Mini-Mental State Exam.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n    \n      c Bars indicate adminstration times from left to right: preoperative, induction/intraoperative, and postoperative (includes PACU).\n    \n  \n\n\n\n\n\n\nNSAIDs\n Table 12. Studies examining NSAIDs, dose, and timing according to study design. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      NSAIDs\n    \n    \n    \n      Study\n      N\n      Drug\n      \n        ASA\n      \n      \n        Anesthetic\n      \n        Ageb\n       MMSEb\n      Dosing\n      Timingc\n      Surgery\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n      Sed\n    \n  \n  \n    \n      Retrospective Cohort\n    \n    Mangusan 2015\n\n36\nZolpidem\nNR\n\n\n\n\n66.5 (10.8)\n\n\nNR\n▁▁▆\n\nCardiac\n    \n232\nBenzodiazepine (ns sa/la)\nNR\n\n\n\n\n66.5 (10.8)\n\n\nNR\n▁▁▆\n\n\n    \n287\nKetoprofen\nNR\n\n\n\n\n66.5 (10.8)\n\n\nNR\n▁▁▆\n\n\n    Memtsoudis 2019 THA\n\n309,921\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n254,305\nNSAID (any)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    Memtsoudis 2019 THA\n\n344,467\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n219,759\nCOX-2 inhibitor\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    Memtsoudis 2019 TKA\n\n569,339\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n561,230\nNSAID (any)\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    Memtsoudis 2019 TKA\n\n710,381\nNone\nNR\n\n\n\n\n\n\n \n\nOrtho\n    \n420,188\nCOX-2 inhibitor\nNR\n\n\n\n\n\n\nNR\n▁▆▆\n\n\n    \n      Randomized Clinical Trial\n    \n    Zhu 2018\n\n82\nPlacebo\nNR\n\n✓\n\n\n70.8 (5.2)\n\n27.6 (2.7)\n\n \n\nOrtho\n    \n81\nCelocoxib\nNR\n\n✓\n\n\n71.4 (5.6)\n\n28.1 (3.2)\n\n200mg (bid×7d)\n▆▁▁\n\n\n    Zhou 2019a\n\n60\nNone\n12  \n✓\n\n\n\n75.2 (5.3)\n\n28.9 (1.2)\n\n \n\nOrtho\n    \n60\nFlurbiprofen\n12  \n✓\n\n\n\n78.3 (6.1)\n\n\n50mg (qd×1d)\n▆▁▁\n\n\n    \n60\nFlurbiprofen\n12  \n✓\n\n\n\n76.1 (5.9)\n\n28.1 (1.4)\n\n50mg (qd×1d)\n▁▆▁\n\n\n  \n  \n  \n    \n       PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; Sed: sedation; MMSE: Mini-Mental State Exam.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n    \n      c Bars indicate adminstration times from left to right: preoperative, induction/intraoperative, and postoperative (includes PACU)."
  },
  {
    "objectID": "kq5.html#outcomes",
    "href": "kq5.html#outcomes",
    "title": "Potentially Inappropriate Medications",
    "section": "Outcomes",
    "text": "Outcomes\n\nDelirium"
  },
  {
    "objectID": "kq5.html#delirium-incidence",
    "href": "kq5.html#delirium-incidence",
    "title": "Potentially Inappropriate Medications",
    "section": "Delirium Incidence",
    "text": "Delirium Incidence\n\nBenzodiazepines\n Table 14. Delirium incidence and ascertainment during hospitalization in studies examining benzodiazepines. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Benzodiazepines (short-acting) — randomized designs\n    \n    \n    \n      Study\n       N\n      Arm\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n      Surgery\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Sultan 2010\n\n49\nNone\nOther\n3\n    16 (32.7)\n\n\n—\n\nOrtho\n    \n53\nMelatonin\n\n\n     5 (9.4)\n\n\n0.29 (0.11-0.73)\n\n\n    \n50\nMidazolam\n\n\n    22 (44.0)\n\n\n1.35 (0.81-2.24)\n\n\n    Yu 2017\n\n46\nDexmedetomidine\nCAM\n3\n     3 (6.5)\n\n\n—\n\nThoracic\n    \n46\nMidazolam\n\n\n    10 (21.7)\n\n\n3.33 (0.98-11.33)\n\n\n    Azeem 2018\n\n30\nDexmedetomidine\nCAM\n7\n     1 (3.3)\n\n\n—\n\nCardiac\n    \n30\nMidazolam\n\n\n     2 (6.7)\n\n\n2.00 (0.19-20.90)\n\n\n    He 2018\n\n30\nPlacebo\nCAM\nNoteb\n    15 (50.0)\n\n\n—\n\nThoracic\n    \n30\nDexmedetomidine\n\n\n     7 (23.3)\n\n\n0.47 (0.22-0.98)\n\n\n    \n30\nMidazolam\n\n\n    17 (56.7)\n\n\n1.13 (0.70-1.82)\n\n\n    Wang 2020a\n\n20\nDexmedetomidine\nNR\nStay\n     1 (5.0)\n\n\n—\n\nOralmax\n    \n20\nMidazolam\n\n\n     9 (45.0)\n\n\n9.00 (1.25-64.59)\n\n\n    \n      Randomized Cluster Crossover Trial\n    \n    Spence 2020\n\n389\nMidazolam (liberal)\nCAM\nStay\n    55 (14.1)\n\n\n—\n\nCardiac\n    \n411\nMidazolam (restricted)\n\n\n    72 (17.5)\n\n\n1.24 (0.90-1.71)\n\n\n  \n  \n  \n    \n       RR: risk ratio; CAM: Confusion Assessment Method; NR: not reported.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n    \n      b Maximum of reported daily incidence.\n    \n  \n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Benzodiazepines (short-acting) — nonrandomized designs\n    \n    \n    \n      Study\n       N\n      Arm\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR aOR (95% CI)\n      Surgery\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Retrospective Cohort\n    \n    Memtsoudis 2019 THA\n\n107,736\nNone\nOtherb\nStay\n 2,844 (2.6)\n\n\n—\n\nOrtho\n    \n373,219\nBenzodiazepine (any sa)\n\n\n 7,068 (1.9)\n\n\n0.79 (0.72-0.87)\n\n    \n15,329\nBenzodiazepine (any la)\n\n\n 1,075 (7.0)\n\n\n2.10 (1.82-2.42)\n\n    \n67,942\nBenzodiazepine (any sa/la)\n\n\n 3,798 (5.6)\n\n\n1.74 (1.56-1.94)\n\n    Memtsoudis 2019 TKA\n\n175,288\nNone\nOtherb\nStay\n 4,783 (2.7)\n\n\n—\n\nOrtho\n    \n778,956\nBenzodiazepine (any sa)\n\n\n16,603 (2.1)\n\n\n0.82 (0.77-0.88)\n\n    \n25,667\nBenzodiazepine (any la)\n\n\n 1,928 (7.5)\n\n\n2.24 (2.01-2.49)\n\n    \n150,658\nBenzodiazepine (any sa/la)\n\n\n 9,070 (6.0)\n\n\n1.78 (1.64-1.92)\n\n    Mueller 2020a\n\n82\nNone\nCAM\n7\n    11 (13.4)\n\n\n—\n\nVarious\n    \n529\nMidazolam\n\n\n    51 (9.6)\n\n\n0.72 (0.39-1.32)\n\n\n    Koch 2023\n\n1,001\nNone\nDSM\n7\n   184 (18.4)\n\n\n—\n\nVarious\n    \n57\nMidazolam\n\n\n    14 (24.6)\n\n\n1.34 (0.83-2.15)\n\n\n    Liu 2023a\n\n50\nNone\nOtherb\nStay\n     5 (10.0)\n\n\n—\n\nUrol\n    \n145\nMidazolam\n\n\n    14 (9.7)\n\n\n0.97 (0.37-2.54)\n\n\n    \n      Prospective Cohort\n    \n    Wang 2021\n\n357\nNone\nCAM\nNotec\n    89 (24.9)\n\n\n—\n\nVarious\n    \n357\nMidazolam\n\n\n    83 (23.2)\n\n\n0.93 (0.72-1.21)\n\n\n    Ke 2022a\n\n91\nNone\nOtherb\nStay\n    10 (11.0)\n\n\n—\n\nOther\n    \n7\nMidazolam\n\n\n     1 (14.3)\n\n\n1.30 (0.19-8.75)\n\n\n    Leigheb 2022\n\n36\nNone\nDRS\nStay\n     5 (13.9)\n\n\n—\n\nOrtho\n    \n47\nMidazolam\n\n\n    12 (25.5)\n\n\n1.84 (0.71-4.75)\n\n\n    Aoki 2023\n\n124\nNone\nCAM\n5\n    33 (26.6)\n\n\n—\n\nCardiac\n    \n76\nRemimazolam\n\n\n    23 (30.3)\n\n\n1.14 (0.73-1.78)\n\n\n  \n  \n  \n    \n       RR: risk ratio; aOR: adjusted odds ratio; ns: not specified; sa: short-acting; la: long-acting; CAM: Confusion Assessment Method; THA: total hip arthroplasty; TKA: total knee arthroplasty.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n    \n      b Claims-based algorithm.\n    \n    \n      c Maximum of reported daily incidence.\n    \n  \n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Benzodiazepine (any or not specified) — nonrandomized designs\n    \n    \n    \n      Study\n       N\n      Arm\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR aOR (95% CI)\n      Surgery\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Retrospective Cohort\n    \n    Slor 2011b\n\n96\nNone\nCAM/DSM\n5\n    24 (25.0)\n\n\n—\n\nOrtho\n    \n430\nBenzodiazepine (ns sa/la)\n\n\n    36 (8.4)\n\n\n0.73 (0.35-1.51)\n\n    Mangusan 2015\n\n36\nZolpidem\nNR\nStay\n    15 (41.7)\n\n\n—\n\nCardiac\n    \n232\nBenzodiazepine (ns sa/la)\n\n\n    71 (30.6)\n\n\n0.73 (0.48-1.13)\n\n\n    \n287\nKetoprofen\n\n\n    57 (19.9)\n\n\n0.48 (0.30-0.75)\n\n\n    Weinstein 2018a\n\n2,643\nNone\nOther\nStay\n   161 (6.1)\n\n\n—\n\nOrtho\n    \n33,223\nBenzodiazepine (ns sa/la)\n\n\n   636 (1.9)\n\n\n0.31 (0.27-0.37)\n\n\n    Weinstein 2018b\n\n33,500\nNone\nOther\nStay\n   620 (1.9)\n\n\n—\n\nOrtho\n    \n3,451\nBenzodiazepine (ns sa/la)\n\n\n   164 (4.8)\n\n\n2.57 (2.17-3.04)\n\n\n    Fuchita 2019a\n\n3\nNone\nCAM\nStay\n     1 (33.3)\n\n\n—\n\nThoracic\n    \n81\nBenzo_ns\n\n\n    26 (32.1)\n\n\n0.96 (0.19-4.92)\n\n\n    Memtsoudis 2019 THA\n\n107,736\nNone\nOtherb\nStay\n 2,844 (2.6)\n\n\n—\n\nOrtho\n    \n373,219\nBenzodiazepine (any sa)\n\n\n 7,068 (1.9)\n\n\n0.79 (0.72-0.87)\n\n    \n15,329\nBenzodiazepine (any la)\n\n\n 1,075 (7.0)\n\n\n2.10 (1.82-2.42)\n\n    \n67,942\nBenzodiazepine (any sa/la)\n\n\n 3,798 (5.6)\n\n\n1.74 (1.56-1.94)\n\n    Memtsoudis 2019 TKA\n\n175,288\nNone\nOtherb\nStay\n 4,783 (2.7)\n\n\n—\n\nOrtho\n    \n778,956\nBenzodiazepine (any sa)\n\n\n16,603 (2.1)\n\n\n0.82 (0.77-0.88)\n\n    \n25,667\nBenzodiazepine (any la)\n\n\n 1,928 (7.5)\n\n\n2.24 (2.01-2.49)\n\n    \n150,658\nBenzodiazepine (any sa/la)\n\n\n 9,070 (6.0)\n\n\n1.78 (1.64-1.92)\n\n    \n      Case-Control\n    \n    Nandi 2014\n\n376\nNone\nOther\nStay\n    57 (15.2)\n\n\n—\n\nOrtho\n    \n87\nBenzodiazepine (ns sa/la)\n\n\n    41 (47.1)\n\n\n9.68 (4.30-21.8)\n\n    \n      Prospective Cohort\n    \n    Pipanmekaporn 2021\n\n173\nNone\nCAM\nStay\n    12 (6.9)\n\n\n—\n\nVarious\n    \n256\nBenzodiazepine (ns sa/la)\n\n\n    11 (4.3)\n\n\n0.62 (0.28-1.37)\n\n\n    Duprey 2022\n\n\nAntipsychotic (any)\nCAM\nStay\n\n\n1.48 (0.75-2.93)c\nVarious\n    \n\nBenzodiazepine (ns sa/la)\n\n\n\n\n3.03 (1.97-4.67c\n\n  \n  \n  \n    \n       RR: risk ratio; aOR: adjusted odds ratio; ns: not specified; sa: short-acting; la: long-acting; THA: total hip arthroplasty; TKA: total knee arthroplasty.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n    \n      b Claims-based algorithm.\n    \n    \n      c Hazard ratio compared with not given drug.\n    \n  \n\n\n\n\n\n\nAntipsychotics\n Table 15. Delirium incidence and ascertainment during hospitalization in studies examining antipsychotics. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Antipsychotics — randomized designs\n    \n    \n    \n      Study\n       N\n      Arm\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n      Surgery\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Kalisvaart 2005\n\n218\nPlacebo\nCAM/DSM\n14\n    36 (16.5)\n\n\n—\n\nOrtho\n    \n212\nHaloperidol\n\n\n    32 (15.1)\n\n\n0.91 (0.59-1.42)\n\n\n    Prakanrattana 2007\n\n63\nPlacebo\nCAM\nStay\n    20 (31.7)\n\n\n—\n\nCardiac\n    \n63\nRisperidone\n\n\n     7 (11.1)\n\n\n0.35 (0.16-0.77)\n\n\n    Larsen 2010\n\n204\nPlacebo\nCAM/DSM\nStay\n    82 (40.2)\n\n\n—\n\nOrtho\n    \n196\nOlanzapine\n\n\n    28 (14.3)\n\n\n0.36 (0.24-0.52)\n\n\n    Hakim 2012\n\n50\nPlacebo\nDSM\nStay\n    17 (34.0)\n\n\n—\n\nCardiac\n    \n51\nRisperidone\n\n\n     7 (13.7)\n\n\n0.40 (0.18-0.89)\n\n\n    Wang 2012\n\n228\nPlacebo\nCAM\n7\n    53 (23.2)\n\n\n—\n\nVarious\n    \n229\nHaloperidol\n\n\n    35 (15.3)\n\n\n0.66 (0.45-0.97)\n\n\n    Fukata 2014\n\n60\nNone\nNEECHAM\n7\n    20 (33.3)\n\n\n—\n\nVarious\n    \n59\nHaloperidol\n\n\n    25 (42.4)\n\n\n1.27 (0.80-2.02)\n\n\n    Fukata 2017\n\n100\nNone\nNEECHAM\n10\n    32 (32.0)\n\n\n—\n\nVarious\n    \n99\nHaloperidol\n\n\n    18 (18.2)\n\n\n0.57 (0.34-0.94)\n\n\n    Hollinger 2021\n\n44\nPlacebo\nICDSC/other\n3\n     4 (9.1)\n\n\n—\n\nVarious\n    \n47\nKetamine\n\n\n     3 (6.4)\n\n\n0.70 (0.17-2.96)\n\n\n    \n45\nHaloperidol\n\n\n     5 (11.1)\n\n\n1.22 (0.35-4.25)\n\n\n  \n  \n  \n    \n       RR: risk ratio; CAM: Confusion Assessment Method; DSM: Diagnostic and Statistical Manual of Mental Disorders; NEECHAM: Neelon and Champagne confusion scale; ICDSC: Intensive Care Delirium Screening Checklist.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n  \n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Antipsychotics — nonrandomized designs\n    \n    \n    \n      Study\n       N\n      Arm\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      HR (95% CI)\n      Surgery\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Retrospective Cohort\n    \n    Mueller 2020b\n\n558\nNone\nCAM\n7\n    51 (9.1)\n\n\n—\n\nVarious\n    \n92\nHaloperidol\n\n\n    14 (15.2)\n\n\n1.66 (0.96-2.88)\n\n\n    \n      Prospective Cohort\n    \n    Duprey 2022\n\n\nAntipsychotic (any)\nCAM\nStay\n\n\n1.48 (0.75-2.93)b\nVarious\n    \n\nBenzodiazepine (ns sa/la)\n\n\n\n\n3.03 (1.97-4.67b\n\n  \n  \n  \n    \n       RR: hazard ratio; CAM: Confusion Assessment Method; DSM: Diagnostic and Statistical Manual of Mental Disorders; NEECHAM: Neelon and Champagne confusion scale; ICDSC: Intensive Care Delirium Screening Checklist.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n    \n      b Hazard ratio compared with not given drug.\n    \n  \n\n\n\n\n\n\nAnticholinergics\n Table 16. Delirium incidence and ascertainment during hospitalization in studies examining anticholinergics. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Anticholinergics — randomized designs\n    \n    \n    \n      Study\n       N\n      Arm\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n      Surgery\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Hongyu 2019\n\n30\nPlacebo\nCAM\nNoteb\n     5 (16.7)\n\n\n—\n\nThoracic\n    \n30\nPenehyclidine\n\n\n    16 (53.3)\n\n\n3.20 (1.34-7.62)\n\n\n  \n  \n  \n    \n       RR: risk ratio; CAM: Confusion Assessment Method.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n    \n      b Maximum of reported daily incidence.\n    \n  \n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Anticholinergics — nonrandomized designs\n    \n    \n    \n      Study\n       N\n      Arm\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n      Surgery\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Retrospective Cohort\n    \n    Slor 2011c\n\n480\nNone\nCAM/DSM\n5\n    52 (10.8)\n\n\n—\n\nOrtho\n    \n46\nAnticholinergic (any)\n\n\n     8 (17.4)\n\n\n1.61 (0.81-3.17)\n\n\n  \n  \n  \n    \n       RR: odds ratio; CAM: Confusion Assessment Method; DSM: Diagnostic and Statistical Manual of Mental Disorders.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n  \n\n\n\n\n\n\nCorticosteroids\n Table 17. Delirium incidence and ascertainment during hospitalization in studies examining corticosteroids. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Corticosteroids — randomized designs\n    \n    \n    \n      Study\n       N\n      Arm\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n      Surgery\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Dieleman 2012\n\n2,247\nPlacebo\nNR\nStay\n   262 (11.7)\n\n\n—\n\nCardiac\n    \n2,235\nDexamethasone\n\n\n   205 (9.2)\n\n\n0.79 (0.66-0.94)\n\n\n    Mardani 2013\n\n50\nPlacebo\nDSM\nNoteb\n    13 (26.0)\n\n\n—\n\nCardiac\n    \n43\nDexamethasone\n\n\n     4 (9.3)\n\n\n0.36 (0.13-1.02)\n\n\n    Sauer 2014\n\n370\nPlacebo\nCAM\n4\n    55 (14.9)\n\n\n—\n\nCardiac\n    \n367\nDexamethasone\n\n\n    52 (14.2)\n\n\n0.95 (0.67-1.35)\n\n\n    Whitlock 2015\n\n3,752\nPlacebo\nCAM\nNoteb\n   289 (7.7)\n\n\n—\n\nCardiac\n    \n3,755\nMethylprednisolone\n\n\n   295 (7.9)\n\n\n1.02 (0.87-1.19)\n\n\n    Xiang 2022\n\n84\nPlacebo\nCAM\nNoteb\n     7 (8.3)\n\n\n—\n\nGI/Abd\n    \n84\nMethylprednisolone\n\n\n     3 (3.6)\n\n\n0.43 (0.11-1.60)\n\n\n  \n  \n  \n    \n       RR: odds ratio; CAM: Confusion Assessment Method; DSM: Diagnostic and Statistical Manual of Mental Disorders; NR: not reported.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n    \n      b Maximum of reported daily incidence.\n    \n  \n\n\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      Corticosteroids — nonrandomized designs\n    \n    \n    \n      Study\n       N\n      Arm\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR aOR (95% CI)\n      Surgery\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Before-After/Time Series\n    \n    Ushida 2009\n\n81\nMethylprednisolone\nDOS\nStay\n    23 (28.4)\n\n\n—\n\nOrtho\n    \n41\nMethylprednisolone\n\n\n     3 (7.3)\n\n\n0.26 (0.08-0.81)\n\n\n    \n      Case-Control\n    \n    Choi 2019\n\n16\nMethylprednisolone &gt; 72h\nCAM\nStay\n    10 (62.5)\n\n\n—\n\nThoracic\n    \n42\nMethylprednisolone ≤ 72h\n\n\n    10 (23.8)\n\n\n0.38 (0.20-0.74)\n\n\n    \n      Retrospective Cohort\n    \n    Fuchita 2019b\n\n77\nNone\nCAM\nStay\n    27 (35.1)\n\n\n—\n\nThoracic\n    \n7\nDexamethasone\n\n\n     0 (0.0)\n\n\nNot estimated\n\n\n    Memtsoudis 2019 THA\n\n542,536\nNone\nOther\nStay\n14,146 (2.6)\n\n\n—\n\nOrtho\n    \n21,690\nCorticosteroid (any)\n\n\n   639 (2.9)\n\n\n0.95 (0.81-1.11)\n\n    Memtsoudis 2019 TKA\n\n1,082,854\nNone\nOther\nStay\n31,013 (2.9)\n\n\n—\n\nOrtho\n    \n47,715\nCorticosteroid (any)\n\n\n 1,371 (2.9)\n\n\n0.96 (0.86-1.06)\n\n  \n  \n  \n    \n       RR: relative risk; aOR: adjusted odds ratio; CAM: Confusion Assessment Method; DOS: delirium observation screening; THA: total hip arthroplasty; TKA: total knee arthroplasty.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n  \n\n\n\n\n\n\nNSAIDS\n Table 18. Delirium incidence and ascertainment during hospitalization in studies examining NSAIDs \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n      NSAIDs\n    \n    \n    \n      Study\n       N\n      Arm\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR aOR (95% CI)\n      Surgery\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Retrospective Cohort\n    \n    Mangusan 2015\n\n36\nZolpidem\nNR\nStay\n    15 (41.7)\n\n\n—\n\nCardiac\n    \n232\nBenzodiazepine (ns sa/la)\n\n\n    71 (30.6)\n\n\n0.73 (0.48-1.13)\n\n\n    \n287\nKetoprofen\n\n\n    57 (19.9)\n\n\n0.48 (0.30-0.75)\n\n\n    Memtsoudis 2019 THA\n\n309,921\nNone\nOtherb\nStay\n 9,316 (3.0)\n\n\n—\n\nOrtho\n    \n254,305\nNSAID (any)\n\n\n 5,469 (2.2)\n\n\n0.85 (0.79-0.91)\n\n    Memtsoudis 2019 THA\n\n344,467\nNone\n\n\n10,052 (2.9)\n\n\n—\n\nOrtho\n    \n219,759\nCOX-2 inhibitor\n\n\n 4,733 (2.2)\n\n\n0.82 (0.77-0.89)\n\n    Memtsoudis 2019 TKA\n\n569,339\nNone\nOtherb\nStay\n18,812 (3.3)\n\n\n—\n\nOrtho\n    \n561,230\nNSAID (any)\n\n\n13,572 (2.4)\n\n\n0.84 (0.80-0.88)\n\n    Memtsoudis 2019 TKA\n\n710,381\nNone\n\n\n21,502 (3.0)\n\n\n—\n\nOrtho\n    \n420,188\nCOX-2 inhibitor\n\n\n10,882 (2.6)\n\n\n0.83 (0.79-0.88)\n\n  \n  \n  \n    \n       RR: relative risk; aOR: adjusted odds ratio; CAM: Confusion Assessment Method; DOS: delirium observation screening; THA: total hip arthroplasty; TKA: total knee arthroplasty.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n    \n      b Claims-based algorithm."
  },
  {
    "objectID": "kq6.html",
    "href": "kq6.html",
    "title": "Delirium Prophylaxis",
    "section": "",
    "text": "Recent upates\n\n\n\n\n\n\n\n\n\n\n\n\nDate\nModification\n\n\n\n\n2023-10-24\nUpdated to most current included studies. Removed risk of bias tallies from forest plots where not pertinent to outcome. Added physical function table.\n\n\n2023-10-26\nAdded risk differences for hypotension and bradycardia. For other complications and mortality changed effect measure to risk difference owing to infrequent events (now consistent with tables)."
  },
  {
    "objectID": "kq6.html#key-question",
    "href": "kq6.html#key-question",
    "title": "Delirium Prophylaxis",
    "section": "Key Question",
    "text": "Key Question\nAmong older patients undergoing surgery and anesthesia, does dexmedetomidine, ketamine, ramelteon, or melatonin administered during the perioperative period decrease the risk of postoperative delirium or other adverse cognitive outcomes?"
  },
  {
    "objectID": "kq6.html#outcome-importance",
    "href": "kq6.html#outcome-importance",
    "title": "Delirium Prophylaxis",
    "section": "Outcome Importance",
    "text": "Outcome Importance\n Table 1. Rankings for the 5 most important outcomes (11 respondents)."
  },
  {
    "objectID": "kq6.html#outcomes-reported",
    "href": "kq6.html#outcomes-reported",
    "title": "Delirium Prophylaxis",
    "section": "Outcomes Reported",
    "text": "Outcomes Reported\n Table 2. Dichotomous or count outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 85\n      NR Trial, N = 3\n      Quasi-exp, N = 2\n      Prosp Coh, N = 4\n      Retro Coh, N = 6\n    \n  \n  \n    ADL\n—\n—\n—\n—\n—\n    Complications\n35 (41%)\n2 (67%)\n2 (100%)\n—\n—\n    DNCR/PND\n24 (28%)\n2 (67%)\n—\n—\n—\n    Delirium\n52 (61%)\n—\n2 (100%)\n4 (100%)\n6 (100%)\n    Delirium duration\n2 (2.4%)\n—\n—\n—\n—\n    Discharge location\n—\n—\n—\n—\n—\n    Mortality\n16 (19%)\n—\n1 (50%)\n—\n—\n    Opioid use\n3 (3.5%)\n—\n—\n—\n—\n    Pain\n2 (2.4%)\n—\n—\n—\n—\n    QoR\n—\n—\n—\n—\n—\n    Readmission\n3 (3.5%)\n—\n—\n—\n—\n    Satisfaction\n—\n—\n—\n—\n—\n  \n  \n  \n    \n       ADL: activities of daily living; NCR: neurocognitive recovery; POCD: postoperative neurocognitive disorder; QoR: quality of recovery; RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort.\n    \n  \n\n\n\n\n Table 3. Continuous outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 85\n      NR Trial, N = 3\n      Quasi-exp, N = 2\n      Prosp Coh, N = 4\n      Retro Coh, N = 6\n    \n  \n  \n    Delirium duration\n15 (18%)\n—\n1 (50%)\n—\n—\n    Length of stay\n27 (32%)\n—\n2 (100%)\n1 (25%)\n—\n    Opioid use\n13 (15%)\n—\n—\n—\n—\n  \n  \n  \n    \n       RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort.\n    \n  \n\n\n\n\n Table 4. Likert or ordinal outcomes. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT, N = 85\n      NR Trial, N = 3\n      Quasi-exp, N = 2\n      Prosp Coh, N = 4\n      Retro Coh, N = 6\n    \n  \n  \n    ADL\n2 (2.4%)\n—\n—\n—\n—\n    DNCR/PND\n38 (45%)\n3 (100%)\n—\n—\n—\n    Delirium\n6 (7.1%)\n—\n—\n—\n—\n    Complications\n—\n—\n—\n—\n—\n    Pain\n15 (18%)\n—\n—\n—\n—\n    Quality of life\n—\n—\n—\n—\n—\n    QoR\n2 (2.4%)\n—\n—\n—\n—\n    Satisfaction\n—\n—\n—\n—\n—\n  \n  \n  \n    \n       ADL: activities of daily living; NCR: neurocognitive recovery; POCD: postoperative neurocognitive disorder; QoR: quality of recovery; RCT: randomized clinical trial; NR Trial: non-randomized trial; Quasi-exp: before-after or time series; Prosp Coh: prospective cohort; Retro Coh: retrospective cohort."
  },
  {
    "objectID": "kq6.html#included-studies",
    "href": "kq6.html#included-studies",
    "title": "Delirium Prophylaxis",
    "section": "Included Studies",
    "text": "Included Studies\n Table 5. Number of studies by design. \n\n\n\n\n\n\n  \n    \n    \n  \n  \n    \n    \n      Design\n      Studies\n    \n  \n  \n    Randomized Clinical Trial\n84\n    Nonrandomized Trial\n3\n    Before-After/Time Series\n2\n    Prospective Cohort\n3\n    Retrospective Cohort\n4\n    Total\n96\n  \n  \n  \n    \n       Studies with multiple publications counted only once (applied to 1 trial with 2 publications).\n    \n  \n\n\n\n\n\nDesign, centers, country, and surgery\n Table 6. Study design, enrollment, centers, country, and surgery (see References for citations). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      ID\n      Studya\n      Centers\n      Enrolled\n      Countryb\n      Surgery\n    \n  \n  \n    \n      Dexmedetomidine - Randomized Clinical Trial\n    \n    13579\nAzeem 2018\n\n1\n70\nEgyptb\nCardiac\n    7240\nChitnis 2022\n\n1\n70\nCanada\nCardiac\n    2288\nDjainai 2016\n\n1\n185\nCanada\nCardiac\n    1819\nGao 2020\n\n1\n60\nChinab\nCardiac\n    5269\nGao 2021\n\n1\n40\nChinab\nCardiac\n    13777\nGe 2016\n\n1\n50\nChinab\nCardiac\n    24\nLi 2017\n\n2\n285\nChinab\nCardiac\n    2173\nMomeni 2021\n\n1\n420\nBelgium\nCardiac\n    17019\nQu 2023\n\n1\n469\nUSA\nCardiac\n    2396\nShehabi 2009\n\n2\n306\nAustralia\nCardiac\n    2624\nSubramaniam 2019\n\n1\n140\nUSA\nCardiac\n    16008\nTuran 2020\n\n6\n798\nUSA\nCardiac\n    16023\nWu 2020\n\n1\n80\nChinab\nCardiac\n    335\nvan Norden 2021\n\n1\n63\nGermany\nCardiac|GI/Abdominal\n    5436\nChen 2013\n\n1\n126\nChinab\nGI/Abdominal\n    889\nChen 2020\n\n1\n88\nChinab\nGI/Abdominal\n    1288\nDu 2019\n\n1\n87\nChinab\nGI/Abdominal\n    5024\nLi 2015\n\n1\n100\nChinab\nGI/Abdominal\n    4914\nLi 2021b\n\n1\n120\nChinab\nGI/Abdominal\n    13941\nMohamed 2014\n\n1\n58\nEgyptb\nGI/Abdominal\n    12900\nTang 2021\n\n1\n100\nChinab\nGI/Abdominal\n    1919\nXin 2021\n\n1\n60\nChinab\nGI/Abdominal\n    8558\nLu 2021\n\n13\n808\nChinab\nGI/Abdominal|Hepatic\n    5480\nZhang 2021\n\n1\n174\nChinab\nGI/Abdominal|Neuro|Urol\n    13483\nWang 2019\n\n1\n198\nChinab\nGI/Abdominal|Ortho|Thoracic\n    261\nLee 2018a\n\n1\n354\nSouth Korea\nGI/Abdominal|Urol\n    328\nZhang 2018b\n\n1\n120\nChinab\nHeadneck\n    1117\nMansouri 2019\n\n1\n150\nIranb\nOphtho\n    5452\nGuo 2015\n\n1\n184\nChinab\nOralmax\n    16845\nLiu 2022b\n\n1\n120\nChinab\nOralmax\n    1625\nWang 2020a\n\n1\n44\nChinab\nOralmax\n    5240\nHong 2021\n\n2\n712\nChinab\nOrtho\n    2748\nLee 2018b\n\n1\n132\nSouth Korea\nOrtho\n    742\nLi 2019\n\n1\n164\nChinab\nOrtho\n    1419\nLiu 2016\n\n1\n200\nChinab\nOrtho\n    3130\nLu 2017\n\n1\n152\nChinab\nOrtho\n    1735\nMei 2018\n\n1\n336\nChinab\nOrtho\n    1267\nMei 2020\n\n1\n415\nChinab\nOrtho\n    17001\nShin 2023\n\n1\n748\nSouth Korea\nOrtho\n    13075\nXing 2021\n\n1\n110\nChinab\nOrtho\n    16303\nYan 2021\n\n1\n100\nChinab\nOrtho\n    5147\nZhang 2020\n\n1\n240\nChinab\nOrtho\n    11129\nZhu 2021\n\n1\n187\nChinab\nOrtho\n    13568\nHe 2018\n\n1\n90\nChinab\nThoracic\n    3046\nHu 2021\n\n1\n177\nChinab\nThoracic\n    69\nHuyan 2019\n\n1\n360\nChinab\nThoracic\n    16741\nLiu 2022a\n\n1\n60\nChinab\nThoracic\n    3391\nShi 2020\n\n1\n106\nChinab\nThoracic\n    13731\nYu 2017\n\n1\n92\nChinab\nThoracic\n    4798\nDing 2015\n\n1\n40\nChinab\nUrol\n    7151\nWang 2022a\n\n1\n125\nChinab\nUrol\n    5251\nChawdhary 2020\n\n1\n87\nIndiab\nVariousc\n    2022\nDeiner 2017\n\n10\n429\nUSA\nVariousc\n    16718\nLv 2022\n\n1\n327\nChinab\nVariousc\n    16734\nWang 2022b\n\n1\n100\nChinab\nVariousc\n    3716\nZhao 2020\n\n1\n432\nChinab\nVariousc\n    \n      Dexmedetomidine - Nonrandomized Trial\n    \n    13393\nBao 2020\n\n1\n178\nChinab\nGI/Abdominal\n    13361\nWang 2020c\n\n1\n110\nChinab\nGI/Abdominal\n    13301\nLi 2020\n\n1\n87\nChinab\nThoracic\n    \n      Dexmedetomidine - Prospective Cohort\n    \n    17146\nKe 2022b (Ke 2022a)\n\n4\n98\nSingapore\nOther\n    \n      Dexmedetomidine - Retrospective Cohort\n    \n    17150\nLiu 2023b (Liu 2023a)\n\n1\n195\nChinab\nUrol\n    \n      Ketamine - Randomized Clinical Trial\n    \n    181\nHudetz 2009a (Hudetz 2009b)\n\n1\n78\nUSA\nCardiac\n    1847\nHudetz 2009b (Hudetz 2009a)\n\n1\n58\nUSA\nCardiac\n    5189\nSiripoonyothai 2021\n\n1\n75\nThailand\nCardiac\n    15285\nBornemann-Cimenti 2016\n\n1\n60\nAustria\nGI/Abdominal|Hepatic\n    2217\nRascon-Martinez 2016\n\n1\n80\nMexicob\nOphtho\n    2578\nLee 2015\n\n1\n56\nSouth Korea\nOrtho\n    3788\nRemerand 2009\n\n1\n160\nFrance\nOrtho\n    13184\nTu 2021\n\n1\n80\nChinab\nOrtho\n    2866\nAvidan 2017\n\n5\n672\nUSA\nVariousc\n    1937\nHollinger 2021\n\n2\n143\nSwitzerland\nVariousc\n    \n      Ketamine - Prospective Cohort\n    \n    1140\nJuliebo 2009\n\n1\n187\nNorway\nOrtho\n    17147\nKe 2022c (Ke 2022a)\n\n4\n98\nSingapore\nOther\n    9616\nBarreto Chang 2022\n\n1\n98\nUSA\nSpine\n    \n      Ketamine - Retrospective Cohort\n    \n    17130\nMemtsoudis 2019b (Memtsoudis 2019a)\n\n4,400\n1,694,795\nUSA\nOrtho\n    17136\nMemtsoudis 2019g (Memtsoudis 2019a)\n\n4,400\n1,130,569\nUSA\nOrtho\n    17144\nWeinstein 2018c (Weinstein 2018a)\n\n1\n41,766\nUSA\nOrtho\n    17145\nWeinstein 2018d (Weinstein 2018a)\n\n1\n41,766\nUSA\nOrtho\n    17149\nFuchita 2019c (Fuchita 2019a)\n\n1\n84\nUSA\nThoracic\n    \n      Melatonin - Randomized Clinical Trial\n    \n    17055\nDianatkhah 2015\n\n1\n145\nIranb\nCardiac\n    17057\nEl-Naggar 2018\n\n1\n50\nEgyptb\nCardiac\n    16558\nFord 2020\n\n2\n210\nAustralia\nCardiac\n    9256\nJavaherforoosh 2021\n\n1\n60\nIranb\nCardiac\n    13171\nMahrose 2021\n\n1\n110\nEgyptb\nCardiac\n    9741\nShi 2021\n\n1\n297\nChinab\nCardiac\n    17152\nEsmaeii 2022\n\n1\n150\nIranb\nGeneral|Neuro|Ortho\n    602\nFan 2017a\n\n1\n148\nChinab\nOrtho\n    17153\nFazel 2022\n\n1\n80\nIranb\nOrtho\n    17154\nMohamed 2022\n\n1\n80\nEgyptb\nOrtho\n    5164\nSultan 2010\n\n1\n152\nEgyptb\nOrtho\n    16552\nde Jonghe 2014\n\n3\n452\nNetherlands\nOrtho\n    \n      Ramelteon - Randomized Clinical Trial\n    \n    17084\nTanifuji 2022\n\n1\n112\nJapan\nGI/Abdominal|Hepatic\n    3841\nOh 2021\n\n1\n80\nUSA\nOrtho\n    4150\nJaiswal 2019\n\n1\n120\nUSA\nThoracic\n    13512\nGupta 2019\n\n1\n100\nIndiab\nVariousc\n    \n      Ramelteon - Before-After/Time Series\n    \n    693\nHokuto 2020\n\n1\n309\nJapan\nHepatic\n    2997\nMiyata 2017\n\n1\n82\nJapan\nThoracic\n    \n      Ulinastatin - Randomized Clinical Trial\n    \n    13406\nZhou 2019b\n\n1\n156\nChinab\nCardiac\n    2598\nWang 2017\n\n1\n80\nChinab\nENT\n    13546\nZhang 2018c\n\n1\n60\nChinab\nNeuro\n  \n  \n  \n    \n       GI: gastrointestinal; Ortho: orthopedic; Neuro: neurological; Oralmax: oral maxillofacial; Vasc: vascular; ENT: ear nose and throat.\n    \n    \n      a Studies examining drugs not directly relevant to recommendations but potentially to the evidence space (eg, a connected network including indirect evidence) are included here.\n    \n    \n      b Non very-high Human Development Index country.\n    \n    \n      c Described as various or more than 4 different types of surgery.\n    \n  \n\n\n\n\n\n\nCountry Summary\n Table 7. Summary of randomized clinical trials according to country. \n\n\n\n\n\n\n  \n    \n    \n      \n      N = 84a\n    \n  \n  \n    Country\n\n        China\n46 (55%)\n        USA\n8 (9.5%)\n        Egypt\n6 (7.1%)\n        Iran\n5 (6.0%)\n        South Korea\n4 (4.8%)\n        Australia\n2 (2.4%)\n        Canada\n2 (2.4%)\n        India\n2 (2.4%)\n        Austria\n1 (1.2%)\n        Belgium\n1 (1.2%)\n        France\n1 (1.2%)\n        Germany\n1 (1.2%)\n        Japan\n1 (1.2%)\n        Mexico\n1 (1.2%)\n        Netherlands\n1 (1.2%)\n        Switzerland\n1 (1.2%)\n        Thailand\n1 (1.2%)\n  \n  \n  \n    \n      a n (%)"
  },
  {
    "objectID": "kq6.html#interventions-comparators",
    "href": "kq6.html#interventions-comparators",
    "title": "Delirium Prophylaxis",
    "section": "Interventions & Comparators",
    "text": "Interventions & Comparators\n\nDexmedetomidine\n Table 8. Selected characteristics, comparators, and dosing in dexmedetomidine trials. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N\n      Comparator\n      \n        ASA\n      \n      \n        Anesthetic\n      \n      Ageb\n      MMSEb\n      \n        Dexmedetomidine mcg/kg\n      \n      Timingd\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n      Sed\n      Load\n      Maint/hrc\n      Postop\n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Shehabi 2009\n\n147\nMS\nNR\n✓\n\n\n\n71.0 {65-75}\n\n\n\n\n\n\n    \n152\nDex\n\n✓\n✓\n✓\n✓\n71.5 {66-76}\n\n\n\n(0.1–0.7)\n\n▁▁▁▆\n\n    Djainai 2016\n\n92\nProp\nNR\n✓\n\n\n\n72.4 (6.2)\n\n\n\n\n\n\n    \n91\nDex\n\n✓\n✓\n✓\n✓\n72.7 (6.4)\n\n\n0.4\n(0.2–0.7)\n\n▁▁▁▆\n\n    Ge 2016\n\n24\nPlac\n123 \n\n✓\n\n\n72.0 (4.0)\n\n26.9 (0.8)\n\n\n\n\n\n    \n24\nDex\n\n✓\n✓\n✓\n✓\n70.0 (3.0)\n\n27.2 (0.9)\n\n0.3\n0.3\n\n▁▆▆▁\n\n    Li 2017\n\n143\nPlac\n 234\n✓\n✓\n\n\n67.5 (5.3)\n\n29 [28-30]\n\n\n\n\n\n    \n142\nDex\n\n✓\n✓\n✓\n✓\n66.4 (5.4)\n\n29 [28-30]\n\n0.6\n0.4\n0.1\n▁▁▆▆\n\n    Azeem 2018\n\n30\nMid\nNR\n\n✓\n\n\n66.7 (5.6)\n\n\n\n\n\n\n    \n30\nDex\n\n✓\n✓\n✓\n✓\n65.3 (4.8)\n\n\n\n(0.4–0.7)\n\n▁▁▁▆\n\n    Subramaniam 2019\n\n61\nProp\nNR\n\n\n\n\n70.0 {64-79}\n\n\n\n\n\n\n    \n59\nDex\n\n✓\n✓\n✓\n✓\n66.5 {63-74}\n\n\n0.5\n(0.1–0.4)\n\n▁▁▁▆\n\n    Zhou 2019b\n\n39\nUlin\n123 \n✓\n✓\n\n\n70.6 (4.4)\n\n\n\n\n\n\n    \n38\nPlac\n\n✓\n✓\n✓\n✓\n70.0 (4.9)\n\n\n\n\n\n\n    \n39\nDex/Ulin\n\n✓\n✓\n✓\n✓\n69.6 (5.0)\n\n\n\n0.4\n\n▁▁▆▁\n\n    \n38\nDex\n\n✓\n✓\n✓\n✓\n69.8 (5.1)\n\n\n\n0.4\n\n▁▁▆▁\n\n    Gao 2020\n\n30\nPlac\n 23 \n\n✓\n\n\n70.4 (4.2)\n\n\n\n\n\n\n    \n30\nDex\n\n✓\n✓\n✓\n✓\n69.5 (5.1)\n\n\n1.0\n(0.3–0.5)\n\n▁▆▆▁\n\n    Turan 2020\n\n396\nPlac\n1234\n✓\n✓\n\n\n62.0 (12.0)\n\n\n\n\n\n\n    \n398\nDex\n\n✓\n✓\n✓\n✓\n63.0 (11.0)\n\n\n\n0.1\n0.4\n▁▆▆▆\n\n    Wu 2020\n\n40\nPlac\n 23 \n\n\n\n✓\n67.7 (8.8)\n\n28.2\n\n\n\n\n\n    \n40\nDex\n\n✓\n✓\n✓\n✓\n68.2 (8.6)\n\n28.1\n\n0.5\n0.6\n\n▁▆▆▁\n\n    Gao 2021\n\n20\nPlac\n 23 \n\n✓\n\n\n71.4 (4.5)\n\n28.4 (1.3)\n\n\n\n\n\n    \n20\nDex\n\n✓\n✓\n✓\n✓\n71.4 (4.5)\n\n28.5 (1.4)\n\n0.6\n0.2\n\n▁▆▆▁\n\n    Momeni 2021\n\n203\nPlac\nNR\n✓\n\n\n\n70.0 {59-81}\n\n28 {26-29}\n\n\n\n\n\n    \n205\nDex\n\n✓\n✓\n✓\n✓\n71.0 {61-81}\n\n28 {26-29}\n\n\n0.4\n\n▁▁▁▆\n\n    Chitnis 2022\n\n33\nProp\nNR\n✓\n\n\n\n78.8\n\n30.2\n\n\n\n\n\n    \n34\nDex\n\n✓\n✓\n✓\n✓\n78.7\n\n30.1\n\n\n0.5 (0–1.5)\n\n▁▁▁▆\n\n    Qu 2023\n\n206\nPlac\nNR\n\n\n\n\n70.0 {65-75}\n\n\n\n\n\n\n    \n188\nDex\n\n✓\n✓\n✓\n✓\n67.5 {63-73}\n\n\n\n\n1\n▁▁▁▆\n\n    \n      Ortho - Randomized Clinical Trial\n    \n    Liu 2016 (MCI)\n\n40\nPlac\n 23 \n\n✓\n\n\n75.2 (7.8)\n\n22.4 (2.6)\n\n\n\n\n\n    \n39\nDex\n\n✓\n✓\n✓\n✓\n72.8 (8.2)\n\n23.3 (2.7)\n\n\n(0.2–0.4)\n\n▁▁▆▁\n\n    Liu 2016 (no MCI)\n\n58\nPlac\n 23 \n\n✓\n\n\n72.8 (9.2)\n\n25.4 (2.4)\n\n\n\n\n\n    \n60\nDex\n\n✓\n✓\n✓\n✓\n71.2 (8.1)\n\n26.2 (3.5)\n\n\n(0.2–0.4)\n\n▁▁▆▁\n\n    Lu 2017\n\n76\nDex\n 23 \n\n✓\n✓\n\n65.0 (5.8)\n\n28.3 (1.3)\n\n0.5\n0.5\n\n▁▆▆▁\n\n    \n75\nDex\n\n✓\n✓\n✓\n✓\n65.5 (5.3)\n\n28.5 (1.2)\n\n0.5\n0.5\n0.06\n▁▆▆▆\n\n    Lee 2018b\n\n31\nPlac\n12  \n\n\n✓\n\n67.2 (5.0)\n\n\n\n\n\n\n    \n33\nPreg\n\n✓\n✓\n✓\n✓\n68.4 (5.1)\n\n\n\n\n\n\n    \n31\nDex\n\n✓\n✓\n✓\n✓\n68.8 (5.9)\n\n\n0.5\n0.5\n\n▁▆▆▁\n\n    \n29\nDex/Preg\n\n✓\n✓\n✓\n✓\n65.4 (9.7)\n\n\n0.5\n0.5\n\n▁▆▆▁\n\n    Mei 2018\n\n148\nProp\n 23 \n\n\n✓\n\n74.0 (6.0)\n\n25.7 (1.7)\n\n\n\n\n\n    \n148\nDex\n\n✓\n✓\n✓\n✓\n76.0 (7.0)\n\n26.2 (2.1)\n\n0.9\n(0.1–0.5)\n\n▁▆▁▁\n\n    Li 2019\n\n55\nProp\n123 \n\n\n✓\n\n68.2 (6.4)\n\n\n\n\n\n\n    \n54\nMid\n\n✓\n✓\n✓\n✓\n66.9 (6.6)\n\n\n\n\n\n\n    \n55\nDex\n\n✓\n✓\n✓\n✓\n69.3 (7.1)\n\n\n\n\n\n▁▁▆▁\n\n    Mei 2020\n\n183\nProp\nNR\n\n\n✓\n\n73.0 (11.0)\n\n27.1 (1.4)\n\n\n\n\n\n    \n183\nDex\n\n✓\n✓\n✓\n✓\n72.0 (9.0)\n\n26.6 (2.9)\n\n0.9\n(0.1–0.5)\n\n▁▁▆▁\n\n    Zhang 2020\n\n120\nPlac\n123 \n\n\n✓\n\n79.0 (6.8)\n\n\n\n\n\n\n    \n120\nDex\n\n✓\n✓\n✓\n✓\n78.1 (6.4)\n\n\n0.5\n0.3\n\n▆▁▆▁\n\n    Hong 2021\n\n354\nPlac\n1234\n✓\n\n✓\n\n71.0 (5.0)\n\n26.1 (3.0)\n\n\n\n\n\n    \n356\nDex\n\n✓\n✓\n✓\n✓\n71.0 (5.0)\n\n26.1 (2.9)\n\n\n\n0.03\n▁▁▁▆\n\n    Xing 2021\n\n55\nPlac\n 23 \n✓\n\n\n\n69.2 (3.8)\n\n\n\n\n\n\n    \n55\nDex\n\n✓\n✓\n✓\n✓\n68.3 (3.9)\n\n\n0.5\n\n\n▁▆▁▁\n\n    Yan 2021\n\n50\nPlac\n12  \n\n✓\n\n\n72.7 (4.3)\n\n29.2 (0.3)\n\n\n\n\n\n    \n50\nDex\n\n✓\n✓\n✓\n✓\n73.2 (5.8)\n\n29.5 (0.2)\n\n\n0.3\n\n▁▆▁▁\n\n    Zhu 2021\n\n92\nPlac\n123 \n\n\n✓\n\n75.2 (6.1)\n\n28.6 (0.9)\n\n\n\n\n\n    \n95\nDex\n\n✓\n✓\n✓\n✓\n74.1 (4.4)\n\n28.9 (0.8)\n\n1.0\n0.5\n\n▆▁▆▁\n\n    Shin 2023\n\n366\nProp\n12  \n\n\n✓\n\n71.0 {67-75}\n\n\n\n\n\n\n    \n366\nDex\n\n✓\n✓\n✓\n✓\n72.0 {68-76}\n\n\n1.0\n(0.1–0.5)\n\n▁▁▆▁\n\n    \n      GI/Abd - Randomized Clinical Trial\n    \n    Chen 2013\n\n63\nPlac\nNR\n\n✓\n\n\n67.9 (6.6)\n\n28.5 (1.1)\n\n\n\n\n\n    \n59\nDex\n\n✓\n✓\n✓\n✓\n66.2 (7.5)\n\n28.2 (0.8)\n\n1.0\n0.4\n\n▁▆▆▁\n\n    Mohamed 2014\n\n25\nPlac\n123 \n✓\n✓\n\n\n67.8 (5.4)\n\n\n\n\n\n\n    \n25\nDex\n\n✓\n✓\n✓\n✓\n63.9 (5.0)\n\n\n0.17\n0.4\n\n▆▆▆▁\n\n    Li 2015\n\n50\nPlac\n123 \n✓\n\n\n\n70.0 (6.0)\n\n28.3 (1.4)\n\n\n\n\n\n    \n50\nDex\n\n✓\n✓\n✓\n✓\n69.0 (5.0)\n\n28.4 (1.3)\n\n1.0\n0.4\n\n▁▆▆▁\n\n    Du 2019\n\n20\nPlac\n12  \n✓\n\n\n\n68.7 (13.5)\n\n26.8 (1.5)\n\n\n\n\n\n    \n20\nDex\n\n✓\n✓\n✓\n✓\n69.3 (12.5)\n\n26.5 (1.7)\n\n\n0.6\n\n▁▁▆▁\n\n    Chen 2020\n\n45\nPlac\n12  \n\n✓\n\n\n65.4 (11.7)\n\n29.3 (0.4)\n\n\n\n\n\n    \n43\nDex\n\n✓\n✓\n✓\n✓\n64.9 (11.4)\n\n29.4 (0.5)\n\n0.3\n1\n\n▁▁▆▁\n\n    Li 2021b\n\n30\nPlac\n123 \n\n✓\n\n\n73.4 (5.1)\n\n28.7 (2.1)\n\n\n\n\n\n    \n30\nDex\n\n✓\n✓\n✓\n✓\n74.7 (2.6)\n\n27.6 (3.2)\n\n0.3\n0.2\n\n▆▁▆▁\n\n    \n30\nDex\n\n✓\n✓\n✓\n✓\n71.2 (3.5)\n\n28.0 (1.7)\n\n0.3\n0.5\n\n▆▁▆▁\n\n    \n30\nDex\n\n✓\n✓\n✓\n✓\n69.8 (4.3)\n\n28.4 (2.6)\n\n0.3\n0.8\n\n▆▁▆▁\n\n    Lu 2021\n\n331\nPlac\n123 \n\n✓\n\n\n70.4 (6.5)\n\n\n\n\n\n\n    \n344\nDex\n\n✓\n✓\n✓\n✓\n70.1 (5.8)\n\n\n0.5\n0.2\n\n▁▆▆▁\n\n    Tang 2021\n\n50\nPlac\n12  \n✓\n✓\n\n\n70.7 (6.5)\n\n\n\n\n\n\n    \n50\nDex\n\n✓\n✓\n✓\n✓\n69.7 (6.6)\n\n\n0.5\n0.4\n\n▁▆▆▁\n\n    Xin 2021\n\n30\nPlac\n 23 \n\n✓\n\n\n68.0 [66-71]\n\n\n\n\n\n\n    \n30\nDex\n\n✓\n✓\n✓\n✓\n69.0 [67-70]\n\n\n0.5\n0.4\n\n▆▁▆▁\n\n    \n      Various - Randomized Clinical Trial\n    \n    Deiner 2017\n\n201\nPlac\n1234\n✓\n✓\n\n\n74.0 {71-78}\n\n\n\n\n\n\n    \n189\nDex\n\n✓\n✓\n✓\n✓\n74.0 {71-78}\n\n\n\n0.5\n\n▁▁▆▆\n\n    Lee 2018a\n\n109\nPlac\n123 \n✓\n\n\n\n73.1 (6.1)\n\n\n\n\n\n\n    \n95\nDex\n\n✓\n✓\n✓\n✓\n72.2 (5.4)\n\n\n1.0\n(0.2–0.7)\n\n▁▆▆▁\n\n    \n114\nDex\n\n✓\n✓\n✓\n✓\n73.1 (6.4)\n\n\n1.0\n\n\n▁▁▆▁\n\n    Wang 2019\n\n100\nMid\n123 \n\n✓\n\n\n69.4 (4.5)\n\n25.0 (3.3)\n\n\n\n\n\n    \n98\nDex\n\n✓\n✓\n✓\n✓\n70.5 (5.0)\n\n24.9 (3.9)\n\n0.5\n\n\n▆▁▁▁\n\n    Chawdhary 2020\n\n40\nProp\n123 \n✓\n\n\n\n64.7 (5.9)\n\n26.4 (1.3)\n\n\n\n\n\n    \n40\nDex\n\n✓\n✓\n✓\n✓\n66.2 (6.6)\n\n26.1 (1.2)\n\n\n(0.5–0.7)\n\n▁▁▆▁\n\n    Zhao 2020\n\n101\nNone\n 23 \n\n✓\n\n\n69.2 (4.1)\n\n27 {24-30}\n\n\n\n\n\n    \n108\nDex\n\n✓\n✓\n✓\n✓\n70.0 (4.5)\n\n27 {24-30}\n\n1.0\n100e\n\n▁▆▆▁\n\n    \n105\nDex\n\n✓\n✓\n✓\n✓\n69.4 (3.9)\n\n27 {24-30}\n\n1.0\n200e\n\n▁▆▆▁\n\n    \n102\nDex\n\n✓\n✓\n✓\n✓\n69.3 (4.1)\n\n27 {24-30}\n\n1.0\n400e\n\n▁▆▆▁\n\n    Zhang 2021\n\n87\nPlac\n 23 \n✓\n\n\n\n71.4 (4.9)\n\n25.8 (0.8)\n\n\n\n\n\n    \n87\nDex\n\n✓\n✓\n✓\n✓\n70.6 (4.2)\n\n26.1 (0.7)\n\n1.0\n0.4\n\n▁▆▆▁\n\n    van Norden 2021\n\n32\nPlac\n1234\n✓\n✓\n\n\n70.5 (6.2)\n\n\n\n\n\n\n    \n28\nDex\n\n✓\n✓\n✓\n✓\n70.4 (7.1)\n\n\n0.7\n\n\n▁▁▆▁\n\n    Lv 2022\n\n157\nPlac\nNR\n\n✓\n\n\n68.4 (6.6)\n\n\n\n\n\n\n    \n152\nDex\n\n✓\n✓\n✓\n✓\n67.9 (5.9)\n\n\n\n\n\n▁▁▁▆\n\n    Wang 2022b\n\n40\nNone\n123 \n\n✓\n\n\n71.0 (7.1)\n\n27 {23-30}\n\n\n\n\n\n    \n42\nDex\n\n✓\n✓\n✓\n✓\n69.4 (6.8)\n\n27 {23-30}\n\n0.6\n\n\n▁▆▆▁\n\n    \n      Thoracic - Randomized Clinical Trial\n    \n    Yu 2017\n\n46\nMid\n12  \n\n✓\n\n\n69.1 (4.9)\n\n29.8 (0.7)\n\n\n\n\n\n    \n46\nDex\n\n✓\n✓\n✓\n✓\n68.7 (4.3)\n\n29.8 (0.7)\n\n0.2\n0.5 (0.2–0.7)\n\n▁▆▆▁\n\n    He 2018\n\n30\nPlac\n123 \n✓\n✓\n\n\n83.2 (5.1)\n\n\n\n\n\n\n    \n30\nMid\n\n✓\n✓\n✓\n✓\n81.9 (6.2)\n\n\n\n\n\n\n    \n30\nDex\n\n✓\n✓\n✓\n✓\n82.5 (5.4)\n\n\n0.5\n0.4\n\n▆▆▆▁\n\n    Huyan 2019\n\n173\nPlac\n 23 \n\n✓\n\n\n71.0 (6.0)\n\n\n\n\n\n\n    \n173\nDex\n\n✓\n✓\n✓\n✓\n70.0 (5.0)\n\n\n0.5\n0.1\n\n▆▁▆▁\n\n    Shi 2020\n\n53\nPlac\n 23 \n\n✓\n✓\n\n68.7 (3.4)\n\n28.0 (0.9)\n\n\n\n\n\n    \n53\nDex\n\n✓\n✓\n✓\n✓\n68.7 (4.6)\n\n27.9 (0.9)\n\n\n0.5\n\n▁▆▆▁\n\n    Hu 2021\n\n87\nPlac\n123 \n\n✓\n\n\n69.1 (5.1)\n\n\n\n\n\n\n    \n90\nDex\n\n✓\n✓\n✓\n✓\n69.6 (4.5)\n\n\n0.4\n0.1\n\n▁▆▆▁\n\n    Liu 2022a\n\n31\nPlac\n12  \n\n✓\n\n\n68.5 (2.3)\n\n\n\n\n\n\n    \n29\nDex\n\n✓\n✓\n✓\n✓\n68.1 (2.6)\n\n\n1.0\n\n\n▁▆▁▁\n\n    \n      Oralmax - Randomized Clinical Trial\n    \n    Guo 2015\n\n73\nPlac\n123 \n✓\n\n\n\n71.3 (5.1)\n\n28.0 (1.6)\n\n\n\n\n\n    \n76\nDex\n\n✓\n✓\n✓\n✓\n70.7 (5.2)\n\n28.2 (1.6)\n\n\n\n0.2\n▁▁▁▆\n\n    Wang 2020a\n\n20\nMid\nNR\n\n✓\n\n\n60.5 (8.2)\n\n\n\n\n\n\n    \n20\nDex\n\n✓\n✓\n✓\n✓\n60.0 (10.1)\n\n\n1.0\n(0.2–0.7)\n\n▁▁▁▆\n\n    Liu 2022b\n\n60\nPlac\n12  \n\n✓\n\n\n72.1 (5.9)\n\n\n\n\n\n\n    \n60\nDex\n\n✓\n✓\n✓\n✓\n71.3 (6.7)\n\n\n0.5\n0.4\n\n▁▆▆▁\n\n    \n      Urol - Randomized Clinical Trial\n    \n    Ding 2015\n\n20\nPlac\nNR\n✓\n\n\n\n\n\n\n\n\n\n    \n20\nDex\n\n✓\n✓\n✓\n✓\n\n\n2\n\n\n▁▆▁▁\n\n    Wang 2022a\n\n60\nPlac\n12  \n\n✓\n\n\n66.7 (4.1)\n\n25.4 (2.2)\n\n\n\n\n\n    \n60\nDex\n\n✓\n✓\n✓\n✓\n65.6 (3.4)\n\n25.5 (2.5)\n\n\n0.4\n\n▁▆▁▁\n\n    \n      Headneck - Randomized Clinical Trial\n    \n    Zhang 2018b\n\n30\nMid/Prop\nNR\n\n✓\n\n\n69.9 (2.8)\n\n28.5 (1.2)\n\n\n\n\n\n    \n30\nMid/Sevo\n\n✓\n✓\n✓\n✓\n70.1 (3.2)\n\n28.6 (1.2)\n\n\n\n\n\n    \n30\nDex\n\n✓\n✓\n✓\n✓\n68.8 (3.0)\n\n29.0 (0.9)\n\n1.0\n0.5\n\n▁▆▆▁\n\n    \n30\nDex\n\n✓\n✓\n✓\n✓\n69.3 (3.1)\n\n28.8 (1.1)\n\n1.0\n0.5\n\n▁▆▆▁\n\n    \n      Ophtho - Randomized Clinical Trial\n    \n    Mansouri 2019\n\n50\nPlac\n12  \n\n✓\n\n\n64.0 (7.2)\n\n\n\n\n\n\n    \n50\nMid\n\n✓\n✓\n✓\n✓\n63.6 (8.3)\n\n\n\n\n\n\n    \n50\nDex\n\n✓\n✓\n✓\n✓\n66.5 (1.6)\n\n\n\n1\n\n▁▁▆▁\n\n    \n      GI/Abd - Nonrandomized Trial\n    \n    Bao 2020\n\n95\nDex/Ulin\nNR\n\n✓\n\n\n65.3 (5.7)\n\n26.4 (0.2)\n\n0.5\n0.3\n\n▁▆▆▁\n\n    \n83\nDex\n\n✓\n✓\n✓\n✓\n64.9 (5.7)\n\n27.2\n\n0.5\n0.3\n\n▁▆▆▁\n\n    Wang 2020c\n\n50\nPlac\nNR\n✓\n✓\n\n\n68.3 (2.1)\n\n28.5 (4.2)\n\n\n\n\n\n    \n60\nDex\n\n✓\n✓\n✓\n✓\n68.4 (3.3)\n\n28.5 (4.3)\n\n0.5\n0.4\n\n▆▁▁▁\n\n    \n      Thoracic - Nonrandomized Trial\n    \n    Li 2020\n\n46\nNone\nNR\n\n✓\n\n\n67.3 (2.1)\n\n28.5 (4.2)\n\n\n\n\n\n    \n41\nDex\n\n✓\n✓\n✓\n✓\n67.4 (3.3)\n\n28.5 (4.3)\n\n0.5\n0.1\n\n▁▁▆▁\n\n    \n      Other - Prospective Cohort\n    \n    Ke 2022b\n\n97\nNone\nNR\n\n\n\n\n\n\n\n\n\n\n    \n1\nDex\n\n✓\n✓\n✓\n✓\n\n\n\n\n\n▁▁▆▁\n\n    \n      Urol - Retrospective Cohort\n    \n    Liu 2023b\n\n35\nNone\n1234\n\n\n\n\n68.0 [66-72]\n\n\n\n\n\n\n    \n160\nDex\n\n✓\n✓\n✓\n✓\n68.0 [66-72]\n\n\n\n\n\n▁▁▆▁\n\n  \n  \n  \n    \n       GI: gastrointestinal; Abd: abdominal (includes hepatic); Ortho: orthopedic; Various: more that one procedure category; Oralmax: oral and maxillofacial; Ophtho; ophthalmologic; Urol: urologic; Dex: dexmedetomidine; Ulin: ulinastatin; Hal: haloperidol; Mid: midazolam; Mid/Prop: midazolam/propofol; Mid/Seve: midazolam/sevoflurane; Preg: pregabalin; Prop: propofol; Plac; placebo; PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; Sed: sedation; MMSE: Mini-Mental State Exam.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n    \n      c Maintenance range if reported in parentheses.\n    \n    \n      d Bars indicate adminstration times from left to right: preoperative, induction, intraoperative, and postoperative (includes PACU).\n    \n    \n      e Given as a single dose.\n    \n  \n\n\n\n\n\n\nKetamine\n Table 9. Selected characteristics, comparators, and dosing in ketamine studies. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N\n      Comparator\n      \n        ASA\n      \n      \n        Anesthetic\n      \n      Ageb\n      MMSEb\n      \n        Dose\n      \n      \n        Maintenance\n      \n      Timingc\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n      (mg/kg)\n        (mg/kg)\n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Hudetz 2009a\n\n26\nNone\nNR\n✓\n\n\n64.0 (7.0)\n\n\n\n\n\n    \n26\nPlac\n\n\n\n\n67.0 (8.0)\n\n\n\n\n\n    \n26\nKet\n\n\n\n\n68.0 (7.0)\n\n\n0.5\n\n▁▆▁▁\n\n    Hudetz 2009b\n\n29\nPlac\n  34\n✓\n\n\n60.8 (8.0)\n\n\n\n\n\n    \n29\nKet\n\n\n\n\n68.0 (8.0)\n\n\n0.5\n\n▁▆▁▁\n\n    Siripoonyothai 2021\n\n32\nProp\nNR\n✓\n\n\n\n\n\n\n\n    \n32\nKet\n\n\n\n\n\n\n\n1\n▁▆▆▁\n\n    \n      Ortho - Randomized Clinical Trial\n    \n    Remerand 2009\n\n75\nPlac\nNR\n✓\n\n\n65.0 (14.0)\n\n\n\n\n\n    \n79\nKet\n\n\n\n\n64.0 (13.0)\n\n\n0.5\n\n▁▁▆▆\n\n    Lee 2015\n\n26\nPlac\n123 \n✓\n\n\n68.4 (6.5)\n\n26 {24-28}\n\n\n\n\n    \n25\nKet\n\n\n\n\n68.3 (5.3)\n\n25 {24-28}\n\n0.5\n\n▁▆▁▁\n\n    Tu 2021\n\n40\nSuf\n123 \n\n✓\n\n65.3 (5.2)\n\n\n\n\n\n    \n40\nKetd\n\n\n\n\n66.0 (5.3)\n\n\n0.5\n\n▁▆▁▁\n\n    \n      GI/Abd - Randomized Clinical Trial\n    \n    Bornemann-Cimenti 2016\n\n19\nPlac\n123 \n✓\n✓\n\n61.0 (12.4)\n\n\n\n\n\n    \n19\nKetd\n\n\n\n\n58.4 (8.1)\n\n\n\n0.01\n▁▁▆▆\n\n    \n18\nKetd\n\n\n\n\n62.2 (9.8)\n\n\n0.25\n0.12\n▁▁▆▆\n\n    \n      Various - Randomized Clinical Trial\n    \n    Avidan 2017\n\n222\nPlac\nNR\n\n\n\n70.0 (6.9)\n\n\n\n\n\n    \n227\nKet\n\n\n\n\n70.0 (7.2)\n\n\n0.5\n\n▁▁▆▁\n\n    \n223\nKet\n\n\n\n\n70.0 (7.3)\n\n\n1\n\n\n    Hollinger 2021\n\n44\nPlac\nNR\n\n\n\n74.8 (6.6)\n\n28.3 (2.3)\n\n\n\n\n    \n45\nHal\n\n\n\n\n73.4 (6.3)\n\n28.0 (1.3)\n\n\n\n\n    \n47\nKet\n\n\n\n\n73.4 (6.1)\n\n27.7 (1.7)\n\n1\n\n▆▁▁▁\n\n    \n      Ophtho - Randomized Clinical Trial\n    \n    Rascon-Martinez 2016\n\n32\nPlac\n123 \n\n\n✓\n70.5 (4.7)\n\n\n\n\n\n    \n33\nKet\n\n\n\n\n68.7 (7.1)\n\n\n0.3\n\n\n    \n      Ortho - Prospective Cohort\n    \n    Juliebo 2009\n\n119\nNone\nNR\n\n\n✓\n\n\n\n\n\n    \n68\nKet\n\n\n\n\n\n\n\n\n▁▁▆▁\n\n    \n      Spine - Prospective Cohort\n    \n    Barreto Chang 2022\n\n38\nNone\n123 \n\n\n\n71.0 {68-78}\n\n\n\n\n\n    \n60\nKet\n\n\n\n\n70.0 {67-75}\n\n\n\n\nUnspecified\n\n    \n      Other - Prospective Cohort\n    \n    Ke 2022c\n\n92\nNone\nNR\n\n\n\n\n\n\n\n\n    \n6\nKet\n\n\n\n\n\n\n\n\n▁▁▆▁\n\n    \n      Ortho - Retrospective Cohort\n    \n    Weinstein 2018c\n\n31796\nNone\nNR\n\n\n✓\n\n\n\n\n\n    \n4070\nKet\n\n\n\n\n\n\n\n\n\n    Weinstein 2018d\n\n36852\nNone\nNR\n\n\n✓\n\n\n\n\n\n    \n99\nKet\n\n\n\n\n\n\n\n\n▁▁▁▆\n\n    Memtsoudis 2019b\n\n538559\nNone\nNR\n\n\n\n\n\n\n\n\n    \n25667\nKet\n\n\n\n\n\n\n\n\n▁▁▆▆\n\n    Memtsoudis 2019g\n\n1081139\nNone\nNR\n\n\n\n\n\n\n\n\n    \n49430\nKet\n\n\n\n\n\n\n\n\n▁▁▆▆\n\n    \n      Thoracic - Retrospective Cohort\n    \n    Fuchita 2019c\n\n74\nNone\nNR\n\n\n\n61.7 (10.5)\n\n\n\n\n\n    \n10\nKet\n\n\n\n\n61.7 (10.5)\n\n\n\n\n▁▁▆▁\n\n  \n  \n  \n    \n       GI: gastrointestinal; Abd: abdominal (includes hepatic); Ortho: orthopedic; Various: more that one procedure category; Dex: dexmedetomidine; Hal: haloperidol; Suf: sufentanil; Prop: propofol; Plac; placebo; PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; MMSE: Mini-Mental State Exam.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n    \n      c Bars indicate adminstration times from left to right: preoperative, induction, intraoperative, and postoperative (includes PACU).\n    \n    \n      d S-Ketamine.\n    \n  \n\n\n\n\n\n\nMelatonin/Ramelteon\n Table 10. Selected characteristics, comparators, and dosing in melatonin and ramelteon studies. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N\n      Comparator\n      \n        ASA\n      \n      \n        Anesthetic\n      \n      Ageb\n      MMSEb\n      Dosing\n      Timingc\n    \n    \n        PSa\n      Vol\n      TIVA\n      Reg\n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Dianatkhah 2015\n\n71\nOxaz\nNR\n\n\n\n61.7 (9.9)\n\n\n\n\n    \n66\nMel\n\n\n\n\n60.0 (10.2)\n\n\n3mg × 10\n▆▆\n\n    El-Naggar 2018\n\n25\nPlac\n  34\n✓\n\n\n67.9 (4.1)\n\n29 [28-30]\n\n\n\n    \n25\nMel\n\n\n\n\n66.6 (4.8)\n\n29 [27-30]\n\n3mg × 5\n▆▆\n\n    Ford 2020\n\n104\nPlac\nNR\n\n\n\n67.6 (8.0)\n\n\n\n\n    \n98\nMel\n\n\n\n\n69.0 (8.3)\n\n\n3mg × 7\n▆▆\n\n    Javaherforoosh 2021\n\n30\nPlac\nNR\n✓\n\n\n62.9 (8.1)\n\n\n\n\n    \n30\nMel\n\n\n\n\n60.3 (9.5)\n\n\n3mg × 3\n▆▆\n\n    Mahrose 2021\n\n55\nDex\nNR\n✓\n✓\n\n66.1 (6.3)\n\n\n\n\n    \n55\nMel/Dex\n\n\n\n\n67.0 (6.7)\n\n\n5mg × 4\n▆▆\n\n    Shi 2021\n\n149\nPlac\nNR\n\n\n\n71.6 (6.6)\n\n\n\n\n    \n148\nMel\n\n\n\n\n71.5 (6.7)\n\n\n3mg × 7\n▁▆\n\n    \n      Ortho - Randomized Clinical Trial\n    \n    Sultan 2010\n\n49\nNone\n123 \n\n\n✓\n72.3 (6.4)\n\n\n\n\n    \n50\nMid\n\n\n\n\n69.9 (8.2)\n\n\n\n\n    \n53\nMel\n\n\n\n\n70.4 (7.1)\n\n\n5mg × 2\n▆▁\n\n    de Jonghe 2014\n\n192\nPlac\nNR\n\n\n\n83.4 (7.5)\n\n23 {10-28}\n\n\n\n    \n186\nMel\n\n\n\n\n84.1 (8.0)\n\n23 {12-29}\n\n3mg × 5\n▆▆\n\n    Fan 2017a\n\n70\nPlac\n123 \n\n\n✓\n74.6 (5.4)\n\n27.1 (0.3)\n\n\n\n    \n69\nMel\n\n\n\n\n74.5 (5.7)\n\n27.3 (0.2)\n\n1mg × 6\n▆▆\n\n    Oh 2021\n\n39\nPlac\nNR\n\n\n\n75.4 (5.0)\n\n28.2 (1.9)\n\n\n\n    \n41\nRam\n\n\n\n\n74.3 (5.5)\n\n28.6 (1.5)\n\n8mg × 3\n▆▆\n\n    Fazel 2022\n\n36\nPlac\nNR\n\n\n✓\n\n\n\n\n    \n36\nMel\n\n\n\n\n\n\n5mg × 4\n▆▆\n\n    Mohamed 2022\n\n40\nPlac\n123 \n\n\n\n\n\n\n\n    \n40\nMel\n\n\n\n\n\n\n5mg × 2\n▆▁\n\n    \n      GI/Abd - Randomized Clinical Trial\n    \n    Tanifuji 2022\n\n19\nPlac\nNR\n\n\n\n73.7 (5.8)\n\n\n\n\n    \n23\nRam\n\n\n\n\n72.7 (5.2)\n\n\n4mg × 14\n▆▁\n\n    \n      Thoracic - Randomized Clinical Trial\n    \n    Jaiswal 2019\n\n58\nPlac\nNR\n\n\n\n56.1 (15.8)\n\n\n\n\n    \n59\nRam\n\n\n\n\n58.1 (14.1)\n\n\n8mg × 6\n▆▆\n\n    \n      Various - Randomized Clinical Trial\n    \n    Gupta 2019\n\n50\nPlac\n12  \n\n\n✓\n70.6 (3.8)\n\n\n\n\n    \n50\nRam\n\n\n\n\n69.3 (4.0)\n\n\n8mg × 2\n▆▁\n\n    Esmaeii 2022\n\n49\nNone\nNR\n✓\n✓\n\n73.7 (6.0)\n\n26.2 (2.2)\n\n\n\n    \n51\nMel\n\n\n\n\n75.9 (6.1)\n\n26.4 (2.1)\n\n5mg × 2\n▆▁\n\n    \n      GI/Abd - Before-After/Time Series\n    \n    Hokuto 2020\n\n186\nNone\n123 \n\n\n\n69.0 [30-88]\n\n\n\n\n    \n120\nRam\n\n\n\n\n71.0 [34-85]\n\n\n8mg × 4\n▆▆\n\n    \n      Thoracic - Before-After/Time Series\n    \n    Miyata 2017\n\n58\nNone\nNR\n✓\n\n✓\n76.5 [70-87]\n\n\n\n\n    \n24\nRam\n\n\n\n\n79.0 [70-89]\n\n\n8mg × 7\n▁▆\n\n  \n  \n  \n    \n       GI: gastrointestinal; Abd: abdominal (includes hepatic); Ortho: orthopedic; Various: more that one procedure category; PS: physical status; Vol: volatile; TIVA: total intravenous anesthesia; Reg: regional; MMSE: Mini-Mental State Exam; Mel: melatonin; Ram: ramelteon; Oxaz: oxazepam; Dex: dexmedetomidine; Mid: midazolam; Plac; placebo.\n    \n    \n      a ASA Physical Status of patients included (proportions can be found here[link to table add]).\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n    \n      c Bars indicate adminstration times from left to right: preoperative and postoperative."
  },
  {
    "objectID": "kq6.html#delirium-incidence",
    "href": "kq6.html#delirium-incidence",
    "title": "Delirium Prophylaxis",
    "section": "Delirium Incidence",
    "text": "Delirium Incidence\n\n\n\n\n\n\n Figure 1. Delirium incidence by surgical category across all treatment arms in randomized clinical trials. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\nDex: dexmedetomidine; Ket: ketamine; Mel: melatonin; Ram: ramelteon; Oxaz: oxazepam; MS: morphine sulfate; Prop: propofol; Plac/None: placebo or no active comparator.  Note that the “Any” and “Plac/None” box plots are not mutually exclusive. \n\n\n\n\nDexmedetomidine\n Table 11. Delirium incidence and ascertainment during hospitalization in trials of dexmedetomidine. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Drug\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Shehabi 2009\n\n147\nMS\nCAM\n5\n22 (15.0)\n\n\n—\n    \n152\nDex\n\n\n13 (8.6)\n\n\n0.57 (0.30-1.09)b\n    Djainai 2016\n\n92\nProp\nCAM\n5\n29 (31.5)\n\n\n—\n    \n91\nDex\n\n\n16 (17.6)\n\n\n0.56 (0.33-0.95)b\n    Li 2017\n\n143\nPlac\nCAM\n5\n11 (7.7)\n\n\n—\n    \n142\nDex\n\n\n 7 (4.9)\n\n\n0.64 (0.26-1.61)\n    Azeem 2018\n\n30\nMid\nCAM\n7\n 2 (6.7)\n\n\n—\n    \n30\nDex\n\n\n 1 (3.3)\n\n\n0.50 (0.05-5.22)b\n    Subramaniam 2019\n\n61\nProp\nCAM\nStay\n13 (21.3)\n\n\n—\n    \n59\nDex\n\n\n10 (16.9)\n\n\n0.80 (0.38-1.67)b\n    Turan 2020\n\n396\nPlac\nCAM\n5\n46 (11.6)\n\n\n—\n    \n398\nDex\n\n\n67 (16.8)\n\n\n1.45 (1.02-2.05)\n    Gao 2021\n\n20\nPlac\nDSM\nNotec\n10 (50.0)d\n\n\n—\n    \n20\nDex\n\n\n 3 (15.0)d\n\n\n0.30 (0.10-0.93)\n    Momeni 2021\n\n203\nPlac\nCAM\nStay\n33 (16.3)\n\n\n—\n    \n205\nDex\n\n\n31 (15.1)\n\n\n0.93 (0.59-1.46)b\n    Chitnis 2022\n\n33\nProp\nICDSC\n5\n14 (42.4)\n\n\n—\n    \n34\nDex\n\n\n 8 (23.5)\n\n\n0.55 (0.27-1.14)b\n    Qu 2023e\n206\nPlac\nCAM\n3\n25 (12.1)\n\n\n—\n    \n188\nDex\n\n\n14 (7.4)\n\n\n0.61 (0.33-1.14)b\n    \n      Ortho - Randomized Clinical Trial\n    \n    Liu 2016 (MCI)\n\n40\nPlac\nCAM\n7\n25 (62.5)\n\n\n—\n    \n39\nDex\n\n\n10 (25.6)\n\n\n0.41 (0.23-0.74)\n    Liu 2016 (no MCI)\n\n58\nPlac\nCAM\n7\n18 (31.0)\n\n\n—\n    \n60\nDex\n\n\n 5 (8.3)\n\n\n0.27 (0.11-0.68)\n    Lee 2018b\n\n31\nPlac\nPsych\nStay\n11 (35.5)\n\n\n—\n    \n33\nPreg\n\n\n14 (42.4)\n\n\n1.20 (0.64-2.22)\n    \n31\nDex\n\n\n 3 (9.7)\n\n\n0.27 (0.08-0.88)\n    \n29\nDex/Preg\n\n\n 7 (24.1)\n\n\n0.68 (0.31-1.52)\n    Mei 2018\n\n148\nProp\nCAM\n3\n24 (16.2)\n\n\n—\n    \n148\nDex\n\n\n11 (7.4)\n\n\n0.46 (0.23-0.90)\n    Mei 2020\n\n183\nProp\nCAM\n7\n43 (23.5)\n\n\n—\n    \n183\nDex\n\n\n26 (14.2)\n\n\n0.60 (0.39-0.94)\n    Zhang 2020\n\n120\nPlac\nCAM/DSM\n3\n36 (30.0)\n\n\n—\n    \n120\nDex\n\n\n20 (16.7)\n\n\n0.56 (0.34-0.90)\n    Hong 2021\n\n354\nPlac\nCAM\n5\n26 (7.3)\n\n\n—\n    \n356\nDex\n\n\n17 (4.8)\n\n\n0.65 (0.36-1.18)b\n    Xing 2021\n\n55\nPlac\nNotef\n1\n 8 (14.5)\n\n\n—\n    \n55\nDex\n\n\n 2 (3.6)\n\n\n0.25 (0.06-1.12)\n    Yan 2021\n\n50\nPlac\nCAM\n7\n13 (26.0)\n\n\n—\n    \n50\nDex\n\n\n 5 (10.0)\n\n\n0.38 (0.15-1.00)\n    Shin 2023\n\n366\nProp\nCAM\n3\n24 (6.6)\n\n\n—\n    \n366\nDex\n\n\n11 (3.0)\n\n\n0.46 (0.23-0.92)\n    \n      Various - Randomized Clinical Trial\n    \n    Deiner 2017\n\n201\nPlac\nCAM\n5\n23 (11.4)\n\n\n—\n    \n189\nDex\n\n\n23 (12.2)\n\n\n1.06 (0.62-1.83)\n    Lee 2018a\n\n109\nPlac\nCAM\n5\n27 (24.8)\n\n\n—\n    \n95\nDex\n\n\n 9 (9.5)\n\n\n0.38 (0.19-0.77)\n    \n114\nDex\n\n\n21 (18.4)\n\n\n0.74 (0.45-1.23)\n    Zhao 2020\n\n101\nNone\nCAM\n7\n19 (18.8)\n\n\n—\n    \n108\nDex\n\n\n15 (13.9)\n\n\n0.74 (0.40-1.37)\n    \n105\nDex\n\n\n 5 (4.8)\n\n\n0.25 (0.10-0.65)\n    \n102\nDex\n\n\n 5 (4.9)\n\n\n0.26 (0.10-0.67)\n    van Norden 2021\n\n32\nPlac\nCAM/ICDSC\n14\n14 (43.8)\n\n\n—\n    \n28\nDex\n\n\n 5 (17.9)\n\n\n0.41 (0.17-0.99)\n    Lv 2022\n\n157\nPlac\nCAM\n7\n46 (29.3)\n\n\n—\n    \n152\nDex\n\n\n21 (13.8)\n\n\n0.47 (0.30-0.75)b\n    \n      Thoracic - Randomized Clinical Trial\n    \n    Yu 2017\n\n46\nMid\nCAM\n3\n10 (21.7)\n\n\n—\n    \n46\nDex\n\n\n 3 (6.5)\n\n\n0.30 (0.09-1.02)\n    He 2018\n\n30\nPlac\nCAM\nNotec\n15 (50.0)d\n\n\n—\n    \n30\nMid\n\n\n17 (56.7)d\n\n\n1.13 (0.70-1.82)\n    \n30\nDex\n\n\n 7 (23.3)d\n\n\n0.47 (0.22-0.98)\n    Huyan 2019\n\n173\nPlac\nICDSC\nNotec\n47 (27.2)d\n\n\n—\n    \n173\nDex\n\n\n27 (15.6)d\n\n\n0.57 (0.38-0.88)\n    Shi 2020\n\n53\nPlac\nCAM\n7\n 6 (11.3)\n\n\n—\n    \n53\nDex\n\n\n 4 (7.5)\n\n\n0.67 (0.20-2.23)\n    Hu 2021\n\n87\nPlac\nCAM\n4\n32 (36.8)\n\n\n—\n    \n90\nDex\n\n\n15 (16.7)\n\n\n0.45 (0.26-0.78)\n    \n      Oralmax - Randomized Clinical Trial\n    \n    Wang 2020a\n\n20\nMid\nNS\nStay\n 9 (45.0)\n\n\n—\n    \n20\nDex\n\n\n 1 (5.0)\n\n\n0.11 (0.02-0.80)b\n    Liu 2022b\n\n60\nPlac\nCAM\n5\n 8 (13.3)\n\n\n—\n    \n60\nDex\n\n\n 5 (8.3)\n\n\n0.62 (0.22-1.80)\n    \n      GI/Abd - Randomized Clinical Trial\n    \n    Lu 2021\n\n331\nPlac\nCAM\nNotec\n43 (13.0)d\n\n\n—\n    \n344\nDex\n\n\n41 (11.9)d\n\n\n0.92 (0.61-1.37)\n    Xin 2021\n\n30\nPlac\nCAM\n7\n10 (33.3)\n\n\n—\n    \n30\nDex\n\n\n 3 (10.0)\n\n\n0.30 (0.09-0.98)\n    \n      Other - Prospective Cohort\n    \n    Ke 2022b\n\n97\nNone\n\nStay\n11 (11.3)\n\n\n—\n    \n1\nDex\n\n\n 0 (0.0)\n\n\nNot estimated\n    \n      Urol - Retrospective Cohort\n    \n    Liu 2023b\n\n35\nNone\n\nStay\n 7 (20.0)\n\n\n—\n    \n160\nDex\n\n\n12 (7.5)\n\n\n0.37 (0.16-0.88)\n  \n  \n  \n    \n       RR: risk ratio; Dex: dexmedetomidine; Mid: midazolam; Prop: propofol; MS: morphine sulfate; Preg: pregabalin; Plac: placebo; DSM: Diagnostic and Statistical Manual of Mental Disorders; ICDSC: Intensive Care Delirium Screening Checklist; Psych: psychiatrist interview; NS: not specified.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n    \n      b Postoperative dexmedetomidine only.\n    \n    \n      c Reported only daily incidence.\n    \n    \n      d Maximum of reported daily incidence.\n    \n    \n      e Primary outcome was delirium on postoperative day 1 — OR 0.32 (95% CI, 0.10–0.83)\n    \n    \n      f Tool reported in the `Chinese Expert Consensus on the Prevention and Treatment of Postoperative Delirium in Elderly Patients.'\n    \n  \n\n\n\n\n\n\nKetamine\n Table 12. Delirium incidence and days of ascertainment during hospitalization in ketamine studies. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Drug\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Hudetz 2009b\n\n29\nPlac\nICDSC\n5\n     9 (31.0)\n\n\n—\n    \n29\nKet\n\n\n     1 (3.4)\n\n\n0.11 (0.02-0.82)\n    Siripoonyothai 2021\n\n32\nProp\nCAM\n1\n    18 (56.2)\n\n\n—\n    \n32\nKet\n\n\n    10 (31.2)\n\n\n0.56 (0.31-1.01)\n    \n      Ortho - Prospective Cohort\n    \n    Juliebo 2009\n\n119\nNone\nCAM\n5\n    38 (31.9)\n\n\n—\n    \n68\nKet\n\n\n    30 (44.1)\n\n\n1.38 (0.95-2.01)\n    \n      Various - Randomized Clinical Trial\n    \n    Avidan 2017\n\n222\nPlac\nCAM\n3\n    43 (19.4)\n\n\n—\n    \n227\nKet\n\n\n    39 (17.2)\n\n\n0.89 (0.60-1.31)\n    \n223\nKet\n\n\n    46 (20.6)\n\n\n1.06 (0.73-1.54)\n    Hollinger 2021\n\n44\nPlac\nICDSC\n3\n     4 (9.1)\n\n\n—\n    \n45\nHal\n\n\n     5 (11.1)\n\n\n1.22 (0.35-4.25)\n    \n47\nKet\n\n\n     3 (6.4)\n\n\n0.70 (0.17-2.96)\n    \n      Ortho - Retrospective Cohort\n    \n    Weinstein 2018c\n\n31796\nNone\n\nStay\n   713 (2.2)\n\n\n—\n    \n4070\nKet\n\n\n    84 (2.1)\n\n\n0.92 (0.74-1.15)\n    Weinstein 2018d\n\n36852\nNone\n\nStay\n   771 (2.1)\n\n\n—\n    \n99\nKet\n\n\n    13 (13.1)\n\n\n6.28 (3.76-10.47)\n    Memtsoudis 2019b\n\n538559\nNone\n\nStay\n14,082 (2.6)\n\n\n—\n    \n25667\nKet\n\n\n   703 (2.7)\n\n\n1.05 (0.97-1.13)\n    Memtsoudis 2019g\n\n1081139\nNone\n\nStay\n30,978 (2.9)\n\n\n—\n    \n49430\nKet\n\n\n 1,406 (2.8)\n\n\n0.99 (0.94-1.05)\n    \n      Thoracic - Retrospective Cohort\n    \n    Fuchita 2019c\n\n74\nNone\nCAM\nStay\n    24 (32.4)\n\n\n—\n    \n10\nKet\n\n\n     3 (30.0)\n\n\n0.92 (0.34-2.52)\n    \n      Spine - Prospective Cohort\n    \n    Barreto Chang 2022\n\n38\nNone\nCAM/ICDSC\nStay\n     7 (18.4)\n\n\n—\n    \n60\nKet\n\n\n    19 (31.7)\n\n\n1.72 (0.80-3.70)\n    \n      Other - Prospective Cohort\n    \n    Ke 2022c\n\n92\nNone\n\nStay\n    10 (10.9)\n\n\n—\n    \n6\nKet\n\n\n     1 (16.7)\n\n\n1.53 (0.23-10.07)\n  \n  \n  \n    \n       RR: risk ratio; Ket: ketamine; Plac: placebo; Prop: propofol; Hal: haloperidol; ICDSC: Intensive Care Delirium Screening Checklist;  CAM: Confusion Assessment Method.\n    \n    \n      a Days over which incidence assessed. Stay indicates duration of hospital stay.\n    \n  \n\n\n\n\n\n\nMelatonin/Ramelteon\n Table 13. Delirium incidence and days of ascertainment during hospitalization in melatonin and ramelteon studies. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Drug\n      Scale\n      Day(s)a\n      \n        Incidence Proportion\n      \n      RR (95% CI)\n    \n    \n      N (%)\n      0 – 100%\n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Dianatkhah 2015\n\n71\nOxaz\n\nStay\n 9 (12.7)\n\n\n—\n    \n66\nMel\n\n\n 4 (6.1)\n\n\n0.48 (0.15-1.48)\n    El-Naggar 2018\n\n25\nPlac\nICDSC\n3\n 7 (28.0)\n\n\n—\n    \n25\nMel\n\n\n 2 (8.0)\n\n\n0.29 (0.07-1.24)\n    Ford 2020\n\n104\nPlac\nCAM/DSM\n7\n21 (20.2)\n\n\n—\n    \n98\nMel\n\n\n21 (21.4)\n\n\n1.06 (0.62-1.82)\n    Javaherforoosh 2021\n\n30\nPlac\nCAM\nNoteb\n14 (46.7)c\n\n\n—\n    \n30\nMel\n\n\n 4 (13.3)c\n\n\n0.29 (0.11-0.77)\n    Mahrose 2021\n\n55\nDex\nCAM\n5\n15 (27.3)\n\n\n—\n    \n55\nMel/Dex\n\n\n 6 (10.9)\n\n\n0.40 (0.17-0.95)\n    Shi 2021\n\n149\nPlac\nCAM\n7\n59 (39.6)\n\n\n—\n    \n148\nMel\n\n\n40 (27.0)\n\n\n0.68 (0.49-0.95)\n    \n      Ortho - Randomized Clinical Trial\n    \n    Sultan 2010\n\n49\nNone\nAMT\n3\n16 (32.7)\n\n\n—\n    \n50\nMid\n\n\n22 (44.0)\n\n\n1.35 (0.81-2.24)\n    \n53\nMel\n\n\n 5 (9.4)\n\n\n0.29 (0.11-0.73)\n    de Jonghe 2014\n\n192\nPlac\nDSM\n8\n49 (25.5)\n\n\n—\n    \n186\nMel\n\n\n55 (29.6)\n\n\n1.16 (0.83-1.61)\n    Oh 2021\n\n39\nPlac\nCAM/DRS/DSM\n2\n 2 (5.1)\n\n\n—\n    \n41\nRam\n\n\n 3 (7.3)\n\n\n1.43 (0.25-8.09)\n    Fazel 2022\n\n36\nPlac\nAMT\nNoteb\n16 (44.4)c\n\n\n—\n    \n36\nMel\n\n\n 8 (22.2)c\n\n\n0.50 (0.25-1.02)\n    Mohamed 2022\n\n40\nPlac\nAMT\n3\n21 (52.5)\n\n\n—\n    \n40\nMel\n\n\n10 (25.0)\n\n\n0.48 (0.26-0.88)\n    \n      Various - Randomized Clinical Trial\n    \n    Gupta 2019\n\n50\nPlac\nCAM\n3\n 6 (12.0)\n\n\n—\n    \n50\nRam\n\n\n 2 (4.0)\n\n\n0.33 (0.07-1.57)\n    Esmaeii 2022\n\n49\nNone\nAMT\nNoteb\n10 (20.4)c\n\n\n—\n    \n51\nMel\n\n\n 4 (7.8)c\n\n\n0.38 (0.13-1.14)\n    \n      Thoracic - Randomized Clinical Trial\n    \n    Jaiswal 2019\n\n58\nPlac\nCAM\nStay\n22 (37.9)\n\n\n—\n    \n59\nRam\n\n\n19 (32.2)\n\n\n0.85 (0.52-1.39)\n    \n      GI/Abd - Before-After/Time Series\n    \n    Hokuto 2020\n\n186\nNone\nDSM\n7\n28 (15.1)\n\n\n—\n    \n120\nRam\n\n\n 7 (5.8)\n\n\n0.39 (0.17-0.86)\n    \n      Thoracic - Before-After/Time Series\n    \n    Miyata 2017\n\n58\nNone\nICDSC\n9\n 5 (8.6)\n\n\n—\n    \n24\nRam\n\n\n 0 (0.0)\n\n\nNot estimated\n    \n      GI/Abd - Randomized Clinical Trial\n    \n    Tanifuji 2022\n\n19\nPlac\nCAM\n7\n 4 (21.1)\n\n\n—\n    \n23\nRam\n\n\n 1 (4.3)\n\n\n0.21 (0.03-1.70)\n  \n  \n  \n    \n       RR: risk ratio; MMSE: Mini-Mental State Examination; Mel: melatonin; Ram: ramelteon; Dex: dexmedetomidine; Oxaz: oxazepam; Mid: midazolam; AMT: Abbreviated Mental Test; DRS: Delirium Rating Scale; DSM: Diagnostic and Statistical Manual of Mental Disorders; CAM: Confusion Assessment Method; ICDSC: Intensive Care Delirium Screening Checklist.\n    \n    \n      a Day(s) over which incidence proportion assessed. Stay indicates duration of hospitalization.\n    \n    \n      b Reported only daily incidence.\n    \n    \n      c Maximum of reported daily incidence.\n    \n  \n\n\n\n\n\n\nPooled\n\nComparator Network\n Figure 2. Randomized clinical trials and comparators reporting overall incidence of delirium. \n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Ket: ketamine; Mel/Ram: melatonin or ramelteon; Benz: benzodiazepine (midazolam or oxazepam); MS: morphine sulfate; Plac/None: placebo or no intervention; Prop: propofol.\n\n\nDexmedetomidine\n Figure 3. Dexmedetomidine compared with placebo or no intervention. \n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo; RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – .  Harbord test for small study effects P = 0.0003. Delirium a designated primary outcome in 78.3%; a secondary outcome in 8.7%. Excluding Turan 2020 reduced heterogeneity substantially — I 2 = 21%, \\(\\tau\\)2 = 0.04, and pooled RR 0.55 (95% CI, 0.48-0.65). *Trials conducted in China.\n Figure 4. Dexmedetomidine compared with placebo or no intervention — trials from China vs. other countries. \n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo; RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – .  Meta-regression (China vs. Other), I 2 = 39%.  *Trials conducted in China. \n\n\n\n\n\n\n Figure 5. Dexmedetomidine compared with placebo or no intervention small study effects. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Estimates (odds ratio and 95% CI) from random effects models — unadjusted 0.50 (0.39–0.64); adjusted for small study effects: 0.85 (0.56–1.30). *Trials conducted in China.\n\n\n\n\n\n\n\n\n\n Figure 6. Dexmedetomidine compared with placebo or no intervention — small study effects in trials conducted in China. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Estimates (odds ratio and 95% CI) from random effects models — unadjusted 0.50 (0.39–0.64); adjusted for small study effects: 0.66 (0.41–1.05). Harbord test for small study effects P = 0.0202.\n\n\n\n\n\n\n\n\n\n Figure 7. Dexmedetomidine compared with placebo or no intervention — small study effects in trials conducted outside of China. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Too few studies for tests of small study effects.\n\n\n\n\n\n\n\n\n\n Figure 8. Dexmedetomidine compared with placebo or no intervention — postoperative administration only or at other times. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo; RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – . *Trials conducted in China.\n\n\n\n\n\n\n\n\n\n Figure 9. Dexmedetomidine compared with placebo or no intervention — any postoperative administration or at other times. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo; RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – . *Trials conducted in China.\n\n\n\n\n\n\n\n\n\n Figure 10. Dexmedetomidine compared with placebo or no intervention — by surgical category. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo; RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – .  Hartung-Knapp adjustment not applied owing to &lt; 5 trials in some subgroups. *Trials conducted in China.\n\n\n\n\n\n\n\n\n\n Figure 11.  Dexmedetomidine compared with placebo or no intervention — according to reporting incidence proportion. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo; RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – . Hartung-Knapp adjustment not applied. *Trials conducted in China.\n\n\n\n\n\n\n\n\n\n Figure 12. Dexmedetomidine compared with placebo or no intervention — according to risk of bias appraisal. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo; RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – . *Trials conducted in China.\n\n\n\n\n\n\n\n\n\n Figure 13. Summary risk of bias from randomized clinical trials of dexmedetomidine compared with placebo or no intervention. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubgroup Summary\n Figure 14. Summary of subgroup results. \n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo; RR: risk ratio. \n\n\nTiming\n\n\n\n\n\n\n Exploratory network meta-analysis examining timing of dexmedetomidine administration. \n\n\n\n\n\n\n\n\n\n\n\n  \n    \n    \n  \n  \n    \n    \n      Time (dexmedetomidine) or arm\n      Studies\n    \n  \n  \n    Plac\n26\n    Preop/Induct/Intra\n23\n    Postop\n10\n    Prop\n6\n    Mid\n4\n    Preop/Induct/Intra|Postop\n3\n    MS\n1\n  \n  \n  \n    \n       MS: morphine sulfate; Mid: midazolam; Preop/Induction/Intra|Postop: given any of preoperative, intraoperative, or intraoperative periods and postoperatively; Preop/Induction/Intra: given any of preoperative, intraoperative, or intraoperative periods.\n    \n  \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n MS: morphine sulfate; Mid: midazolam; Prop: propofol; Plac: placebo; Preop: preoperative; Induct: induction; Intra: intraoperative; Postop: postop.  Excludes Lee 2018b pregabalin arms (pregabalin alone and with dexmedetomidine). \n\n\n\n\n\nKetamine\n Figure 15. Ketamine compared with placebo. \n\n\n\n\n\n\n\n\n\n D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – .  \n\n\nMelatonin/Ramelteon\n Figure 16. Melatonin and ramelteon compared with placebo or no intervention. \n\n\n\n\n\n\n\n\n\n\nMel: melatonin; Ram: ramelteon; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias.\nRisk of bias ratings: low +, some concerns ?, high – .\nHarbord test for small study effects P = 0.03.\nDelirium a designated primary outcome in 100.0%.\n\n\n\n\n\n\n\n Figure 17. Melatonin or ramelteon compared with placebo or no intervention — small study effects. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Estimates (odds ratio and 95% CI) from random effects models — unadjusted OR 0.50 (0.32–0.78); adjusted for small study effects: 0.78 (0.40–1.51).\n\n\n\n Figure 18. Ramelteon compared with placebo (before-after studies). \n\n\n\n\n\n\n\n\n\n D1: Bias due to confounding; D2: Bias in selection of participants into the study; D3: Bias in classification of interventions; D4: Bias due to deviations from intended interventions; D5: Bias due to missing data; D6: Bias in measurement of outcomes; D7: Bias in selection of reported results; All: overall risk of bias. Risk of bias ratings: low ++, moderate +, serious -, critical - - ; NI: no information; NA: not applicable.\n\n\nAll Comparators\n Figure 19. Network meta-analysis of delirium incidence including all comparators.\n\n\n\n\n\n\n\n\n\n Dex: Dexmedetomidine; Ket: Ketamine; Mel/Ram: Melatonin or Ramelteon; Mid: Midazolam; MS: Morphine; Prop: Propofol; Plac/None: Placebo or no comparator. \n\n Table 14. League table of risk ratios and 95% confidence intervals from network meta-analysis (random effects model). Comparisons from direct evidence displayed in the upper diagonal; network comparisons shown on the lower diagonal. \n\n\n\n\n\n  \n  \n    Dex\n\n\n\n2.50(0.87;  7.15)\n\n0.26(0.09;  0.72)\n\n0.57(0.24;  1.37)\n\n0.56(0.40;  0.80)\n\n0.58 (0.49;  0.70)\n\n    0.83(0.50;  1.39)\n\nKet\n\n\n\n\n\n0.56(0.24;  1.29)\n\n0.77 (0.42;  1.39)\n\n    0.91(0.66;  1.24)\n\n1.09(0.62;  1.92)\n\nMel/Ram\n\n\n0.30(0.13;  0.68)\n\n\n\n0.64 (0.49;  0.83)\n\n    2.50(0.87;  7.15)\n\n3.01(0.94;  9.69)\n\n2.76(0.92;  8.28)\n\nMel/Dex\n\n\n\n\n.\n\n    0.33(0.19;  0.58)\n\n0.40(0.19;  0.83)\n\n0.37(0.21;  0.65)\n\n0.13(0.04;  0.44)\n\nBenzo\n\n\n\n1.35 (0.62;  2.94)\n\n    0.57(0.24;  1.37)\n\n0.69(0.25;  1.90)\n\n0.63(0.25;  1.60)\n\n0.23(0.06;  0.90)\n\n1.72(0.61;  4.85)\n\nMS\n\n\n.\n\n    0.55(0.39;  0.76)\n\n0.66(0.38;  1.14)\n\n0.60(0.38;  0.95)\n\n0.22(0.07;  0.66)\n\n1.65(0.87;  3.14)\n\n0.96(0.38;  2.44)\n\nProp\n\n.\n\n    0.58(0.49;  0.70)\n\n0.70(0.43;  1.16)\n\n0.65(0.49;  0.84)\n\n0.23(0.08;  0.68)\n\n1.76(1.02;  3.02)\n\n1.02(0.42;  2.50)\n\n1.07(0.74;  1.54)\n\nPlac/None\n\n  \n  \n  \n    \n       Dex: Dexmedetomidine; Ket: Ketamine; Mel/Ram: Melatonin or Ramelteon; Mid: Midazolam; MS: Morphine; Prop: Propofol; Plac/None: Placebo or no comparator.\n    \n  \n\n\n\n\n\n\n\n\n\n Figure 20. Comparison adjusted funnel plot. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Figure 21. Comparison of direct and indirect evidence in network meta-analysis (node splitting forest plot). \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Dex: Dexmedetomidine; Ket: Ketamine; Mel/Ram: Melatonin/Ramelteon; Mid: Midazolam; MS: Morphine; Prop: Propofol; Plac/None: Placebo or no comparator."
  },
  {
    "objectID": "kq6.html#delayed-neurocognitive-recovery",
    "href": "kq6.html#delayed-neurocognitive-recovery",
    "title": "Delirium Prophylaxis",
    "section": "Delayed Neurocognitive Recovery",
    "text": "Delayed Neurocognitive Recovery\n\nDexmedetomidine\n Table 15. Delayed neurocognitive recovery incidence and ascertainment in trials of dexmedetomidine. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Drug\n      \n        Preop\n      \n      \n        Instrument\n      \n      Dayb\n      \n        Delayed Neurocognitive Recovery\n      \n    \n    \n      MMSEa\n      MMSE\n      DST\n      MoCA\n      Other\n      N (%)\n      0 — 100%\n      RR (95% CI)\n    \n  \n  \n    \n      GI/Abd\n    \n    Chen 2013\n\n63\nPlac\n28.5 (1.1)\n\n✓c\n\n\n\n1\n17 (27.0)\n\n\n—\n    \n59\nDex\n28.2 (0.8)\n\n\n\n\n\n\n 9 (15.3)\n\n\n0.57 (0.27-1.17)\n    Mohamed 2014\n\n25\nPlac\n\n\n\n\n✓\n\n7\n 5 (20.0)\n\n\n—\n    \n25\nDex\n\n\n\n\n\n\n 6 (24.0)\n\n\n1.20 (0.42-3.43)\n    Li 2015\n\n50\nPlac\n28.3 (1.4)\n\n✓d\n\n\n\n1\n21 (42.0)\n\n\n—\n    \n50\nDex\n28.4 (1.3)\n\n\n\n\n\n\n10 (20.0)\n\n\n0.48 (0.25-0.91)\n    Chen 2020\n\n45\nPlac\n29.3 (0.4)\n\n✓e\n\n\n\n3\n29 (64.4)\n\n\n—\n    \n43\nDex\n29.4 (0.5)\n\n\n\n\n\n\n 7 (16.3)\n\n\n0.25 (0.12-0.51)\n    Li 2021b\n\n30\nPlac\n28.7 (2.1)\n\n✓d\n\n\n\n7\n12 (40.0)\n\n\n—\n    \n30\nDex\n27.6 (3.2)\n\n\n\n\n\n\n11 (36.7)\n\n\n0.92 (0.48-1.74)\n    \n30\nDex\n28.0 (1.7)\n\n\n\n\n\n\n 4 (13.3)\n\n\n0.33 (0.12-0.92)\n    \n30\nDex\n28.4 (2.6)\n\n\n\n\n\n\n 2 (6.7)\n\n\n0.17 (0.04-0.68)\n    \n      Various\n    \n    Wang 2019\n\n100\nMid\n25.0 (3.3)\n\n✓f\n\n\n\n7\n28 (28.0)\n\n\n—\n    \n98\nDex\n24.9 (3.9)\n\n\n\n\n\n\n24 (24.5)\n\n\n0.87 (0.55-1.40)\n    Chawdhary 2020\n\n40\nProp\n26.4 (1.3)\n\n✓g\n✓\n\n\n✓h\n7\n11 (27.5)\n\n\n—\n    \n40\nDex\n26.1 (1.2)\n\n\n\n\n\n\n 8 (20.0)\n\n\n0.73 (0.33-1.62)\n    Zhao 2020\n\n101\nNone\n27 {24-30}\n\n✓i\n\n\n\n7\n10 (9.9)\n\n\n—\n    \n108\nDex\n27 {24-30}\n\n\n\n\n\n\n14 (13.0)\n\n\n1.31 (0.61-2.81)\n    \n105\nDex\n27 {24-30}\n\n\n\n\n\n\n 5 (4.8)\n\n\n0.48 (0.17-1.36)\n    \n102\nDex\n27 {24-30}\n\n\n\n\n\n\n 2 (2.0)\n\n\n0.20 (0.04-0.88)\n    Zhang 2021\n\n87\nPlac\n25.8 (0.8)\n\n✓f\n\n\n\n1\n 8 (9.2)\n\n\n—\n    \n87\nDex\n26.1 (0.7)\n\n\n\n\n\n\n13 (14.9)\n\n\n1.63 (0.71-3.72)\n    \n      Ortho\n    \n    Lu 2017\n\n76\nDex\n28.3 (1.3)\n\n✓i\n\n\n\n7\n13 (17.1)\n\n\n—\n    \n75\nDex\n28.5 (1.2)\n\n\n\n\n\n\n 5 (6.7)\n\n\n0.39 (0.15-1.04)\n    Li 2019\n\n55\nProp\n\n\n✓j\n\n✓k\n7\n10 (18.2)\n\n\n—\n    \n54\nMid\n\n\n\n\n\n\n28 (51.9)\n\n\n2.85 (1.54-5.28)\n    \n55\nDex\n\n\n\n\n\n\n22 (40.0)\n\n\n2.20 (1.15-4.20)\n    \n      Cardiac\n    \n    Zhou 2019b\n\n38\nPlac\n\n\n\n✓j\n\n7\n12 (31.6)\n\n\n—\n    \n39\nUlin\n\n\n\n\n\n\n 7 (17.9)\n\n\n0.57 (0.25-1.29)\n    \n39\nDex/Ulin\n\n\n\n\n\n\n 4 (10.3)\n\n\n0.32 (0.11-0.92)\n    \n38\nDex\n\n\n\n\n\n\n 6 (15.8)\n\n\n0.50 (0.21-1.19)\n    Gao 2020\n\n30\nPlac\n\n✓\n\n\n\n✓l\n7\n 5 (16.7)\n\n\n—\n    \n30\nDex\n\n\n\n\n\n\n 0 (0.0)\n\n\nNot estimated\n    Gao 2021\n\n20\nPlac\n28.4 (1.3)\n\n✓\n\n\n\n\n30\n 4 (20.0)\n\n\n—\n    \n20\nDex\n28.5 (1.4)\n\n\n\n\n\n\n 0 (0.0)\n\n\nNot estimated\n    \n      Ophtho\n    \n    Mansouri 2019\n\n50\nPlac\n\n✓m\n\n\n\n7\n10 (20.0)\n\n\n—\n    \n50\nMid\n\n\n\n\n\n\n 6 (12.0)\n\n\n0.60 (0.24-1.53)\n    \n50\nDex\n\n\n\n\n\n\n 6 (12.0)\n\n\n0.60 (0.24-1.53)\n    \n      Thoracic\n    \n    Shi 2020\n\n53\nPlac\n28.0 (0.9)\n\n✓n\n\n✓\n\n\n7\n19 (35.8)\n\n\n—\n    \n53\nDex\n27.9 (0.9)\n\n\n\n\n\n\n 7 (13.2)\n\n\n0.37 (0.17-0.80)\n    \n      Urol\n    \n    Ding 2015\n\n20\nPlac\n\n✓d\n✓\n\n\n✓o\n5\n 4 (20.0)\n\n\n—\n    \n20\nDex\n\n\n\n\n\n\n 1 (5.0)\n\n\n0.25 (0.03-2.05)\n    \n      Nonrandomized Trial—GI/Abd\n    \n    Bao 2020\n\n95\nDex/Ulin\n26.4 (0.2)\n\n✓p\n\n\n\n3\n 1 (1.1)\n\n\n—\n    \n83\nDex\n27.2\n\n\n\n\n\n\n 5 (6.0)\n\n\n5.72 (0.68-48.00)\n    Wang 2020c\n\n50\nPlac\n28.5 (4.2)\n\n✓\n\n\n\n\n2\n20 (40.0)\n\n\n—\n    \n60\nDex\n28.5 (4.3)\n\n\n\n\n\n\n12 (20.0)\n\n\n0.50 (0.27-0.92)\n  \n  \n  \n    \n       Mini-Mental State Exam; DST: Digit Span Test; MoCA: Montreal Cognitive Assessment; RR: risk ratio; Dex: Dexmedetomidine; Mid: Midazolam; Prop: Propofol; Ulin: ulinastatin; Plac/None: placebo or no intervention.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Day of assessment.\n    \n    \n      c MMSE &lt;27.\n    \n    \n      d Difference from baseline ≥1 SD.\n    \n    \n      e MMSE &lt;24.\n    \n    \n      f Threshold not specified.\n    \n    \n      g Difference from baseline ≥2 SD.\n    \n    \n      h Visual Verbal Learning Tests; Trail Making Test; Stroop Color Word Test.\n    \n    \n      i Difference from baseline &gt;2 pts.\n    \n    \n      j Z ≥1.96.\n    \n    \n      k Stroop Color-Word Test; Associative Learning And Memory Test.\n    \n    \n      l American Psychiatric Association postoperative cognitive dysfunction diagnostic criteria.\n    \n    \n      m MMSE &lt;26.\n    \n    \n      n Z &gt;2.\n    \n    \n      o Trail Making Test; Words Recall Test; Verbal Fluency Test.\n    \n    \n      p Low score not specified.\n    \n  \n\n\n\n\n\n\nKetamine\n Table 16. Delayed neurocognitive recovery incidence and ascertainment in randomized clinical trials of ketamine. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Drug\n      \n        Preop\n      \n      \n        Instrument\n      \n      Dayb,b\n      \n        Delayed Neurocognitive Recovery\n      \n    \n    \n      MMSEa,a\n      MMSE\n      DST\n      MoCA\n      Other\n      N (%)\n      0 — 100%\n      RR (95% CI)\n    \n  \n  \n    \n      Various\n    \n    Hollinger 2021\n\n44\nPlac\n28.3 (2.3)\n\n✓c\n\n\n\n3\n 6 (13.6)\n\n\n—\n    \n45\nHal\n28.0 (1.3)\n\n\n\n\n\n\n 7 (15.6)\n\n\n1.14 (0.42-3.13)\n    \n47\nKet\n27.7 (1.7)\n\n\n\n\n\n\n10 (21.3)\n\n\n1.56 (0.62-3.93)\n    \n      Ortho\n    \n    Lee 2015\n\n26\nPlac\n26 {24-28}\n\n✓d\n\n\n\n6\n 0 (0.0)\n\n\n—\n    \n25\nKet\n25 {24-28}\n\n\n\n\n\n\n 1 (4.0)\n\n\nNot estimated\n    \n      Cardiac\n    \n    Hudetz 2009a\n\n26\nPlac\n\n\n✓\n\n\n✓e\n7\n21 (80.8)\n\n\n—\n    \n26\nKet\n\n\n\n\n\n\n 7 (26.9)\n\n\n0.33 (0.17-0.65)\n    \n      Ophtho\n    \n    Rascon-Martinez 2016\n\n32\nPlac\n\n\n\n\n✓f\n0\n 8 (25.0)\n\n\n—\n    \n33\nKet\n\n\n\n\n\n\n 5 (15.2)\n\n\n0.61 (0.22-1.66)\n  \n  \n  \n    \n       Mini-Mental State Exam; DST: Digit Span Test; MoCA: Montreal Cognitive Assessment; RR: risk ratio; Ket: ketamine; Hal: haloperidol; Plac: placebo.\n    \n    \n       Mini-Mental State Exam; DST: Digit Span Test; MoCA: Montreal Cognitive Assessment; RR: risk ratio; Dex: Dexmedetomidine; Mid: Midazolam; Prop: Propofol; Ulin: ulinastatin; Plac/None: placebo or no intervention.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Day of assessment.\n    \n    \n      c MMSE &lt;24.\n    \n    \n      d Z ≥1.96.\n    \n    \n      e Short Portable Mental Status Questionnaire.\n    \n    \n      f Repeatable Battery for the Assessment Of Neuropsychological Status Subtests; Brief Visual Memory Test Revised; Backward Digit Span; Semantic Fluency; Phonemic Fluency.\n    \n  \n\n\n\n\n\n\nMelatonin/Ramelteon\nNo studies\n\n\n\nPooled\n\nComparator Network\n Figure 22. Randomized clinical trials and comparators reporting delayed neurocognitive recovery. \n\n\n\n\n\n\n\n\n\n Dex: Dexmedetomidine; Ket: ketamine; Hal: haloperidol; Mid: midazolam; Prop: propofol; Ulin: ulinastatin; Plac/None: Placebo or no intervention; Prop: Propofol.  Zhao 2020 no intervention (usual care) arm included as placebo.\n\n\nDexmedetomidine\n Figure 23. Dexmedetomidine compared with placebo or no intervention (randomized clinical trials, delayed neurocognitive recovery assessed postop day 3 or later). \n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo; RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – .   Neurocognitive recovery a designated primary outcome in 88.9%; a secondary outcome in 0.0%. Six trials conducted in China and 1 each in Egypt and Iran. Using odds ratios, pooled OR 0.36 (95% CI, 0.19–0.70; I 2 44%), prediction interval (0.09–1.45). \n\n\n\n\n\n\n Figure 24. Dexmedetomidine compared with placebo or no intervention according to risk of bias appraisals (randomized clinical trials; delayed neurocognitive recovery). \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo; RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – .0.5 added to cells of studies without events in one arm. \n\n\n\n\n\n\n\n\n\n Figure 25. Dexmedetomidine compared with placebo or no intervention small study effects — funnel plot (delayed neurocognitive recovery). \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Figure 26. Summary risk of bias from randomized clinical trials of dexmedetomidine compared with placebo or no intervention (delayed neurocognitive recovery). \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nKetamine\n Figure 27. Ketamine compared with placebo or no intervention (randomized clinical trials, delayed neurocognitive recovery). \n\n\n\n\n\n\n\n\n\n Plac: placebo; RR: risk ratio; D1: bias arising from the randomization process; D2: bias due to deviations from intended interventions; D3: bias due to missing outcome data; D4: bias in measurement of the outcome; D5: bias in selection of the reported result: All: overall risk of bias. Risk of bias ratings: low +, some concerns ?, high – .  Too few studies to examine small study effects. \n\n\nAll Comparators\n Figure 28. Network meta-analysis of delayed neurocognitive recovery including all comparators.\n\n\n\n\n\n\n\n\n\n Dex: Dexmedetomidine; Ket: ketamine; Hal: haloperidol; Mid: midazolam; Prop: propofol; Ulin: ulinastatin; Plac/None: Placebo or no intervention; Prop: Propofol. \n\n Table 17. League table of risk ratios and 95% confidence intervals from network meta-analysis (random effects model). Comparisons from direct evidence displayed in the upper diagonal; network comparisons shown on the lower diagonal. \n\n\n\n\n\n  \n  \n    Dex\n\n\n\n\n\n0.85(0.51; 1.39)\n\n1.35(0.69; 2.65)\n\n0.46(0.31; 0.68)\n\n    1.16(0.43; 3.14)\n\nDex/Ulin\n\n\n0.72(0.24; 2.15)\n\n\n\n\n0.41(0.16; 1.09)\n\n    0.68(0.31; 1.50)\n\n0.58(0.19; 1.84)\n\nKet\n\n\n1.37(0.47; 4.02)\n\n\n\n0.67(0.33; 1.33)\n\n    0.92(0.46; 1.85)\n\n0.79(0.30; 2.06)\n\n1.36(0.55; 3.35)\n\nUlin\n\n\n\n\n0.49(0.27; 0.88)\n\n    0.66(0.21; 2.05)\n\n0.57(0.14; 2.31)\n\n0.97(0.35; 2.70)\n\n0.72(0.21; 2.41)\n\nHal\n\n\n\n1.14(0.35; 3.75)\n\n    0.76(0.47; 1.22)\n\n0.65(0.22; 1.93)\n\n1.12(0.45; 2.77)\n\n0.83(0.36; 1.88)\n\n1.15(0.34; 3.88)\n\nMid\n\n2.85(1.18; 6.89)\n\n0.60(0.19; 1.85)\n\n    1.43(0.74; 2.74)\n\n1.23(0.38; 4.01)\n\n2.10(0.76; 5.83)\n\n1.55(0.60; 4.00)\n\n2.16(0.59; 7.96)\n\n1.88(0.92; 3.81)\n\nProp\n\n\n    0.45(0.31; 0.66)\n\n0.39(0.16; 0.97)\n\n0.67(0.33; 1.33)\n\n0.49(0.27; 0.88)\n\n0.68(0.24; 1.98)\n\n0.59(0.33; 1.06)\n\n0.32(0.15; 0.67)\n\nPlac\n\n  \n  \n  \n    \n       Dex: Dexmedetomidine; Ket: ketamine; Hal: haloperidol; Mid: midazolam; Prop: propofol; Ulin: ulinastatin; Prop: Propofol; Plac/None: Placebo or no intervention.\n    \n  \n\n\n\n\n\n\n\n\n\n Figure 29. Comparison adjusted funnel plot (delayed neurocognitive recovery). \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Figure 30. Comparison of direct and indirect evidence in network meta-analysis (node splitting forest plot, delayed neurocognitive recovery). \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Dex: Dexmedetomidine; Ket: Ketamine; Mel/Ram: Melatonin/Ramelteon; Mid: Midazolam; MS: Morphine; Prop: Propofol; Plac/None: Placebo or no comparator."
  },
  {
    "objectID": "kq6.html#neurocognitive-disorder",
    "href": "kq6.html#neurocognitive-disorder",
    "title": "Delirium Prophylaxis",
    "section": "Neurocognitive Disorder",
    "text": "Neurocognitive Disorder\n\nDexmedetomidine or Melatonin\n Table 18. Neurocognitive disorder and ascertainment reported in dexmedetomidine and melatonin trials. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Drug\n      \n        Preop\n      \n      \n        Instrument\n      \n      Dayb\n      \n        Neurocognitive Disorder\n      \n    \n    \n      MMSEa\n      MMSE\n      DST\n      MoCA\n      Other\n      N (%)\n      0 — 100%\n      RR (95% CI)\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    de Jonghe 2014\n\n151\nPlac\n23 {10-28}\n\n✓\n\n\n\n✓\n\n90\n105 (69.5)\n\n\n—\n    \n147\nMel\n23 {12-29}\n\n\n\n\n\n\n 87 (59.2)\n\n\n0.85 (0.72-1.01)\n    Li 2019\n\n55\nProp\n\n\n✓c\n\n✓d\n365\n  5 (9.1)\n\n\n—\n    \n54\nMid\n\n\n\n\n\n\n  7 (13.0)\n\n\n1.43 (0.48-4.22)\n    \n55\nDex\n\n\n\n\n\n\n  6 (10.9)\n\n\n1.20 (0.39-3.70)\n    Wang 2019\n\n100\nMid\n25.0 (3.3)\n\n✓e\n\n\n\n90\n  7 (7.0)\n\n\n—\n    \n98\nDex\n24.9 (3.9)\n\n\n\n\n\n\n  9 (9.2)\n\n\n1.31 (0.51-3.38)\n    Gao 2021\n\n20\nPlac\n28.4 (1.3)\n\n✓\n\n\n\n\n90\n  2 (10.0)\n\n\n—\n    \n20\nDex\n28.5 (1.4)\n\n\n\n\n\n\n  0 (0.0)\n\n\nNot estimated\n  \n  \n  \n    \n       Mini-Mental State Exam; DST: Digit Span Test; MoCA: Montreal Cognitive Assessment; RR: risk ratio; Dex: dexmedetomidine: Mel: melatonin; Plac: placebo.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Day of assessment.\n    \n    \n      c Z ≥1.96.\n    \n    \n      d Stroop Color-Word Test; Associative Learning And Memory Test.\n    \n    \n      e Threshold not specified.\n    \n  \n\n\n\n\n\n\nKetamine\nNo studies"
  },
  {
    "objectID": "kq6.html#complications",
    "href": "kq6.html#complications",
    "title": "Delirium Prophylaxis",
    "section": "Complications",
    "text": "Complications\n\nDexmedetomidine\n Table 20. Bradycardia in dexmedetomidine studies (randomized clinical trials unless noted). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n          Age\n      Surgery\n      N (%)\n      0 – 100%\n      RD (95% CI)\n      Criteria\n    \n  \n  \n    \n      Bradycardia\n    \n    Shehabi 2009\n\n147\nMS\n71.0 {65-75}\n\nCardiac\n  9 (6.1)\n\n\n—\n\n    \n152\nDex\n71.5 {66-76}\n\n\n 25 (16.4)\n\n\n10.3% (3.3, 17.4)\n\n    Li 2017\n\n143\nPlac\n67.5 (5.3)\n\nCardiac\n 14 (9.8)\n\n\n—\n&lt;45 bpm or ↓30%\n    \n142\nDex\n66.4 (5.4)\n\n\n 21 (14.8)\n\n\n5.0% (-2.6, 12.6)\n\n    Wu 2020\n\n40\nPlac\n67.7 (8.8)\n\nCardiac\n  2 (5.0)\n\n\n—\nNR\n    \n40\nDex\n68.2 (8.6)\n\n\n  1 (2.5)\n\n\n-2.5% (-10.8, 5.8)\n\n    Chen 2020\n\n45\nPlac\n65.4 (11.7)\n\nGI/Abd\n  4 (8.9)\n\n\n—\n&lt;40 bpm\n    \n43\nDex\n64.9 (11.4)\n\n\n  1 (2.3)\n\n\n-6.6% (-16.0, 2.9)\n\n    Wang 2020ca\n50\nPlac\n68.3 (2.1)\n\nGI/Abd\n  3 (6.0)\n\n\n—\n&lt;55 bpm\n    \n60\nDex\n68.4 (3.3)\n\n\n  4 (6.7)\n\n\n0.7% (-8.5, 9.8)\n\n    Li 2021b\n\n30\nPlac\n73.4 (5.1)\n\nGI/Abd\n  7 (23.3)\n\n\n—\nNR\n    \n30\nDex\n74.7 (2.6)\n\n\n  8 (26.7)\n\n\n3.3% (-18.6, 25.2)\n\n    \n30\nDex\n71.2 (3.5)\n\n\n 12 (40.0)\n\n\n16.7% (-6.5, 39.8)\n\n    \n30\nDex\n69.8 (4.3)\n\n\n 20 (66.7)\n\n\n43.3% (20.7, 66.0)\n\n    Lu 2021\n\n331\nPlac\n70.4 (6.5)\n\nGI/Abd\n 12 (3.6)\n\n\n—\n&lt;50 bpm\n    \n344\nDex\n70.1 (5.8)\n\n\n 22 (6.4)\n\n\n2.8% (-0.5, 6.0)\n\n    Guo 2015\n\n73\nPlac\n71.3 (5.1)\n\nOralmax\n  2 (2.7)\n\n\n—\n&lt;50 bpm\n    \n76\nDex\n70.7 (5.2)\n\n\n  5 (6.6)\n\n\n3.8% (-2.9, 10.6)\n\n    Wang 2020a\n\n20\nMid\n60.5 (8.2)\n\nOralmax\n  2 (10.0)\n\n\n—\n&lt;50 bpm\n    \n20\nDex\n60.0 (10.1)\n\n\n  8 (40.0)\n\n\n30.0% (4.8, 55.2)\n\n    Lu 2017\n\n76\nDex\n65.0 (5.8)\n\nOrtho\n  0 (0.0)\n\n\n—\n\n    \n75\nDex\n65.5 (5.3)\n\n\n  0 (0.0)\n\n\n0.0% (-2.6, 2.6)\n\n    Lee 2018b\n\n31\nPlac\n67.2 (5.0)\n\nOrtho\n  7 (22.6)\n\n\n—\n&lt;45 bpm or ↓30%\n    \n33\nPreg\n68.4 (5.1)\n\n\n  8 (24.2)\n\n\n1.7% (-19.1, 22.4)\n\n    \n31\nDex\n68.8 (5.9)\n\n\n 19 (61.3)\n\n\n38.7% (16.1, 61.3)\n\n    \n29\nDex/Preg\n65.4 (9.7)\n\n\n 19 (65.5)\n\n\n42.9% (20.2, 65.6)\n\n    Zhang 2020\n\n120\nPlac\n79.0 (6.8)\n\nOrtho\n 18 (15.0)\n\n\n—\n&lt;60 bpm\n    \n120\nDex\n78.1 (6.4)\n\n\n 20 (16.7)\n\n\n1.7% (-7.6, 10.9)\n\n    Hong 2021\n\n354\nPlac\n71.0 (5.0)\n\nOrtho\n  1 (0.3)\n\n\n—\n&lt;50 bpm\n    \n356\nDex\n71.0 (5.0)\n\n\n  1 (0.3)\n\n\n-0.0% (-0.8, 0.8)\n\n    Li 2020a\n46\nNone\n67.3 (2.1)\n\nThoracic\n  2 (4.3)\n\n\n—\nNR\n    \n41\nDex\n67.4 (3.3)\n\n\n  1 (2.4)\n\n\n-1.9% (-9.5, 5.6)\n\n    Shi 2020\n\n53\nPlac\n68.7 (3.4)\n\nThoracic\n 13 (24.5)\n\n\n—\n&lt;55 bpm\n    \n53\nDex\n68.7 (4.6)\n\n\n 26 (49.1)\n\n\n24.5% (6.8, 42.3)\n\n    Hu 2021\n\n87\nPlac\n69.1 (5.1)\n\nThoracic\n  0 (0.0)\n\n\n—\n&lt;40 bpm\n    \n90\nDex\n69.6 (4.5)\n\n\n  0 (0.0)\n\n\n0.0% (-2.2, 2.2)\n\n    Zhao 2020\n\n101\nNone\n69.2 (4.1)\n\nVarious\n  3 (3.0)\n\n\n—\nNR\n    \n108\nDex\n70.0 (4.5)\n\n\n  8 (7.4)\n\n\n4.4% (-1.5, 10.4)\n\n    \n105\nDex\n69.4 (3.9)\n\n\n  8 (7.6)\n\n\n4.6% (-1.4, 10.7)\n\n    \n102\nDex\n69.3 (4.1)\n\n\n  8 (7.8)\n\n\n4.9% (-1.3, 11.1)\n\n    van Norden 2021\n\n32\nPlac\n70.5 (6.2)\n\nVarious\n 19 (59.4)\n\n\n—\nNR\n    \n28\nDex\n70.4 (7.1)\n\n\n 17 (60.7)\n\n\n1.3% (-23.5, 26.2)\n\n    Lv 2022\n\n157\nPlac\n68.4 (6.6)\n\nVarious\n  9 (5.7)\n\n\n—\nNR\n    \n152\nDex\n67.9 (5.9)\n\n\n 16 (10.5)\n\n\n4.8% (-1.3, 10.9)\n\n  \n  \n  \n    \n       RD: risk difference; Dex: Dexmedetomidine; Dex/Preg: Dexmedetomidine/Pregabalin; Mid: Midazolam; Prop: Propofol; Ram: ramelteon; Plac: placebo; None: no active or placebo comparator; GI/Abd: gastrointestinal/abdominal; Ortho: orthopedic; Oralmax: oral or maxilofacial.\n    \n    \n      a Nonrandomized Trial\n    \n  \n\n\n\n\n Table 21. Hypotension in dexmedetomidine studies (randomized clinical trials unless noted). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n          Age\n      Surgery\n      N (%)\n      0 – 100%\n      RD (95% CI)\n      Criteria\n    \n  \n  \n    \n      Hypotension\n    \n    Chen 2013\n\n63\nPlac\n67.9 (6.6)\n\nGI/Abd\n  0 (0.0)\n\n\n—\nMAP &lt;60\n    \n59\nDex\n66.2 (7.5)\n\n\n  0 (0.0)\n\n\n0.0% (-3.2, 3.2)\n\n    Chawdhary 2020\n\n40\nProp\n64.7 (5.9)\n\nVarious\n  4 (10.0)\n\n\n—\nMAP ≤70\n    \n40\nDex\n66.2 (6.6)\n\n\n  7 (17.5)\n\n\n7.5% (-7.5, 22.5)\n\n    Deiner 2017\n\n201\nPlac\n74.0 {71-78}\n\nVarious\n 95 (47.3)\n\n\n—\nNS\n    \n189\nDex\n74.0 {71-78}\n\n\n102 (54.0)\n\n\n6.7% (-3.2, 16.6)\n\n    Li 2020a\n46\nNone\n67.3 (2.1)\n\nThoracic\n  1 (2.2)\n\n\n—\nNS\n    \n41\nDex\n67.4 (3.3)\n\n\n  1 (2.4)\n\n\n0.3% (-6.1, 6.6)\n\n    Turan 2020\n\n393\nPlac\n62.0 (12.0)\n\nCardiac\n140 (35.6)\n\n\n—\nNS\n    \n395\nDex\n63.0 (11.0)\n\n\n224 (56.7)\n\n\n21.4% (14.6, 28.1)\n\n    Zhao 2020\n\n101\nNone\n69.2 (4.1)\n\nVarious\n  6 (5.9)\n\n\n—\nNS\n    \n108\nDex\n70.0 (4.5)\n\n\n 15 (13.9)\n\n\n7.9% (-0.0, 15.9)\n\n    \n105\nDex\n69.4 (3.9)\n\n\n  6 (5.7)\n\n\n-0.2% (-6.6, 6.2)\n\n    \n102\nDex\n69.3 (4.1)\n\n\n  7 (6.9)\n\n\n0.9% (-5.8, 7.7)\n\n    Hu 2021\n\n75\nPlac\n69.1 (5.1)\n\nThoracic\n 32 (42.7)\n\n\n-4.0% (-19.2, 11.2)\nNS\n    \n77\nDex\n69.6 (4.5)\n\n\n 42 (54.5)\n\n\n—\n\n    Li 2021b\n\n30\nPlac\n73.4 (5.1)\n\nGI/Abd\n  8 (26.7)\n\n\n—\nNS\n    \n30\nDex\n74.7 (2.6)\n\n\n 11 (36.7)\n\n\n10.0% (-13.4, 33.4)\n\n    \n30\nDex\n71.2 (3.5)\n\n\n 10 (33.3)\n\n\n6.7% (-16.5, 29.8)\n\n    \n30\nDex\n69.8 (4.3)\n\n\n 21 (70.0)\n\n\n43.3% (20.5, 66.1)\n\n    Oh 2021\n\n39\nPlac\n75.4 (5.0)\n\nOrtho\n  1 (2.6)\n\n\n—\nNS\n    \n41\nRam\n74.3 (5.5)\n\n\n  2 (4.9)\n\n\n2.3% (-5.9, 10.6)\n\n    Xing 2021\n\n55\nPlac\n69.2 (3.8)\n\nOrtho\n  1 (1.8)\n\n\n—\nNS\n    \n55\nDex\n68.3 (3.9)\n\n\n  1 (1.8)\n\n\n0.0% (-5.0, 5.0)\n\n    Lv 2022\n\n157\nPlac\n68.4 (6.6)\n\nVarious\n 13 (8.3)\n\n\n—\nNS\n    \n152\nDex\n67.9 (5.9)\n\n\n 52 (34.2)\n\n\n25.9% (17.2, 34.6)\n\n    Lee 2018b\n\n31\nPlac\n67.2 (5.0)\n\nOrtho\n 11 (35.5)\n\n\n—\nSBP &lt;90\n    \n33\nPreg\n68.4 (5.1)\n\n\n 14 (42.4)\n\n\n6.9% (-16.9, 30.8)\n\n    \n31\nDex\n68.8 (5.9)\n\n\n 19 (61.3)\n\n\n25.8% (1.8, 49.8)\n\n    \n29\nDex/Preg\n65.4 (9.7)\n\n\n 21 (72.4)\n\n\n36.9% (13.5, 60.3)\n\n    Wang 2020ca\n50\nPlac\n68.3 (2.1)\n\nGI/Abd\n  6 (12.0)\n\n\n—\nSBP &lt;90\n    \n60\nDex\n68.4 (3.3)\n\n\n  5 (8.3)\n\n\n-3.7% (-15.1, 7.7)\n\n    Liu 2022b\n\n60\nPlac\n72.1 (5.9)\n\nOralmax\n  1 (1.7)\n\n\n—\nSBP &lt;90\n    \n60\nDex\n71.3 (6.7)\n\n\n  3 (5.0)\n\n\n3.3% (-3.1, 9.7)\n\n    Wang 2022a\n\n60\nPlac\n66.7 (4.1)\n\nUrol\n  0 (0.0)\n\n\n—\nSBP &lt;90\n    \n60\nDex\n65.6 (3.4)\n\n\n  0 (0.0)\n\n\n0.0% (-3.2, 3.2)\n\n    Qu 2023\n\n206\nPlac\n70.0 {65-75}\n\nCardiac\n 13 (6.3)\n\n\n—\nSBP &lt;90\n    \n188\nDex\n67.5 {63-73}\n\n\n 20 (10.6)\n\n\n4.3% (-1.2, 9.8)\n\n    Subramaniam 2019\n\n61\nProp\n70.0 {64-79}\n\nCardiac\n 21 (34.4)\n\n\n—\nSBP &lt;90. ≥5 min\n    \n59\nDex\n66.5 {63-74}\n\n\n 21 (35.6)\n\n\n1.2% (-15.9, 18.2)\n\n    Xin 2021\n\n30\nPlac\n68.0 [66-71]\n\nGI/Abd\n  6 (20.0)\n\n\n—\nSBP &lt;95\n    \n30\nDex\n69.0 [67-70]\n\n\n  4 (13.3)\n\n\n-6.7% (-25.5, 12.1)\n\n    Wang 2020a\n\n20\nMid\n60.5 (8.2)\n\nOralmax\n  3 (15.0)\n\n\n-5.0% (-28.5, 18.5)\n↓MAP &gt;20%\n    \n20\nDex\n60.0 (10.1)\n\n\n  4 (20.0)\n\n\n—\n\n    Azeem 2018\n\n30\nMid\n66.7 (5.6)\n\nCardiac\n  0 (0.0)\n\n\n—\n↓SBP &gt;20%\n    \n30\nDex\n65.3 (4.8)\n\n\n  0 (0.0)\n\n\n0.0% (-6.3, 6.3)\n\n    Lu 2021\n\n331\nPlac\n70.4 (6.5)\n\nGI/Abd\n 45 (13.6)\n\n\n—\n↓SBP &gt;20% or &lt;80\n    \n344\nDex\n70.1 (5.8)\n\n\n 30 (8.7)\n\n\n-4.9% (-9.6, -0.1)\n\n    Zhang 2020\n\n120\nPlac\n79.0 (6.8)\n\nOrtho\n  8 (6.7)\n\n\n—\n↓SBP &gt;20% or &lt;90\n    \n120\nDex\n78.1 (6.4)\n\n\n 10 (8.3)\n\n\n1.7% (-5.0, 8.3)\n\n    Shi 2020\n\n53\nPlac\n68.7 (3.4)\n\nThoracic\n  4 (7.5)\n\n\n—\n↓SBP &gt;20% or &lt;95\n    \n53\nDex\n68.7 (4.6)\n\n\n  6 (11.3)\n\n\n3.8% (-7.3, 14.9)\n\n    Guo 2015\n\n73\nPlac\n71.3 (5.1)\n\nOralmax\n  2 (2.7)\n\n\n-2.5% (-8.8, 3.7)\n↓SBP &gt;30%\n    \n76\nDex\n70.7 (5.2)\n\n\n  4 (5.3)\n\n\n—\n\n    Hong 2021\n\n354\nPlac\n71.0 (5.0)\n\nOrtho\n  3 (0.8)\n\n\n0.3% (-0.9, 1.5)\n↓SBP &gt;30% or &lt;90\n    \n356\nDex\n71.0 (5.0)\n\n\n  2 (0.6)\n\n\n—\n\n    Shehabi 2009\n\n147\nMS\n71.0 {65-75}\n\nCardiac\n 56 (38.1)\n\n\n—\n↓SBP ≥20% or &lt;90\n    \n152\nDex\n71.5 {66-76}\n\n\n 35 (23.0)\n\n\n-15.1% (-25.4, -4.8)\n\n    Li 2017\n\n143\nPlac\n67.5 (5.3)\n\nCardiac\n 10 (7.0)\n\n\n—\n↓SPB &gt;30% ≥15 min\n    \n142\nDex\n66.4 (5.4)\n\n\n 10 (7.0)\n\n\n0.0% (-5.9, 6.0)\n\n  \n  \n  \n    \n       RD: risk difference; MAP: mean arterial blood pressure; Dex: Dexmedetomidine; Dex/Preg: Dexmedetomidine/Pregabalin; Mid: Midazolam; Prop: Propofol; Ram: ramelteon; Plac: placebo; None: no active or placebo comparator; GI/Abd: gastrointestinal/abdominal; Ortho: orthopedic;  Urol: urologic; Oralmax: oral or maxilofacial; NS: not specified.\n    \n    \n      a Nonrandomized Trial\n    \n  \n\n\n\n\n Table 22. Other reported complications in dexmedetomidine studies — cardiac, MI, stroke, pulmonary, pneumonia, and renal (randomized clinical trials unless noted). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n          Age\n      Surgery\n      N (%)\n      0 – 100%\n      RD (95% CI)\n    \n  \n  \n    \n      Other Arrhythmia\n    \n    Turan 2020\n\n390\nPlac\n62.0 (12.0)\n\nCardiac\n134 (34.4)\n\n\n—\n    \n394\nDex\n63.0 (11.0)\n\n\n121 (30.7)\n\n\n-3.6% (-10.2, 2.9)\n    Gao 2021\n\n20\nPlac\n71.4 (4.5)\n\nCardiac\n  0 (0.0)\n\n\n—\n    \n20\nDex\n71.4 (4.5)\n\n\n  0 (0.0)\n\n\n0.0% (-9.2, 9.2)\n    Xing 2021\n\n55\nPlac\n69.2 (3.8)\n\nOrtho\n  1 (1.8)\n\n\n—\n    \n55\nDex\n68.3 (3.9)\n\n\n  1 (1.8)\n\n\n0.0% (-5.0, 5.0)\n    \n      MI\n    \n    Turan 2020\n\n390\nPlac\n62.0 (12.0)\n\nCardiac\n  3 (0.8)\n\n\n—\n    \n394\nDex\n63.0 (11.0)\n\n\n  3 (0.8)\n\n\n-0.0% (-1.2, 1.2)\n    Lu 2021\n\n331\nPlac\n70.4 (6.5)\n\nGI/Abd\n  0 (0.0)\n\n\n—\n    \n344\nDex\n70.1 (5.8)\n\n\n  0 (0.0)\n\n\n0.0% (-0.6, 0.6)\n    Deiner 2017\n\n157\nPlac\n74.0 {71-78}\n\nVarious\n  0 (0.0)\n\n\n—\n    \n147\nDex\n74.0 {71-78}\n\n\n  1 (0.7)\n\n\n0.7% (-1.2, 2.5)\n    \n      Cardiac Arrest\n    \n    Shehabi 2009\n\n147\nMS\n71.0 {65-75}\n\nCardiac\n  1 (0.7)\n\n\n—\n    \n152\nDex\n71.5 {66-76}\n\n\n  2 (1.3)\n\n\n0.6% (-1.6, 2.9)\n    \n      Stroke\n    \n    Djainai 2016\n\n92\nProp\n72.4 (6.2)\n\nCardiac\n  3 (3.3)\n\n\n—\n    \n91\nDex\n72.7 (6.4)\n\n\n  4 (4.4)\n\n\n1.1% (-4.4, 6.7)\n    Li 2017\n\n143\nPlac\n67.5 (5.3)\n\nCardiac\n  3 (2.1)\n\n\n—\n    \n142\nDex\n66.4 (5.4)\n\n\n  3 (2.1)\n\n\n0.0% (-3.3, 3.3)\n    Turan 2020\n\n390\nPlac\n62.0 (12.0)\n\nCardiac\n  4 (1.0)\n\n\n—\n    \n394\nDex\n63.0 (11.0)\n\n\n  4 (1.0)\n\n\n-0.0% (-1.4, 1.4)\n    Qu 2023\n\n205\nPlac\n70.0 {65-75}\n\nCardiac\n  1 (0.5)\n\n\n—\n    \n183\nDex\n67.5 {63-73}\n\n\n  0 (0.0)\n\n\n-0.5% (-1.9, 0.9)\n    Lu 2021\n\n331\nPlac\n70.4 (6.5)\n\nGI/Abd\n  0 (0.0)\n\n\n—\n    \n344\nDex\n70.1 (5.8)\n\n\n  0 (0.0)\n\n\n0.0% (-0.6, 0.6)\n    Deiner 2017\n\n157\nPlac\n74.0 {71-78}\n\nVarious\n  1 (0.6)\n\n\n—\n    \n147\nDex\n74.0 {71-78}\n\n\n  0 (0.0)\n\n\n-0.6% (-2.4, 1.1)\n    \n      Renal\n    \n    Shehabi 2009\n\n147\nMS\n71.0 {65-75}\n\nCardiac\n  6 (4.1)\n\n\n—\n    \n152\nDex\n71.5 {66-76}\n\n\n  4 (2.6)\n\n\n-1.5% (-5.5, 2.6)\n    Li 2017\n\n143\nPlac\n67.5 (5.3)\n\nCardiac\n 44 (30.8)\n\n\n—\n    \n142\nDex\n66.4 (5.4)\n\n\n 37 (26.1)\n\n\n-4.7% (-15.2, 5.7)\n    Turan 2020\n\n390\nPlac\n62.0 (12.0)\n\nCardiac\n 30 (7.7)\n\n\n—\n    \n394\nDex\n63.0 (11.0)\n\n\n 41 (10.4)\n\n\n2.7% (-1.3, 6.7)\n    Gao 2021\n\n20\nPlac\n71.4 (4.5)\n\nCardiac\n  1 (5.0)\n\n\n—\n    \n20\nDex\n71.4 (4.5)\n\n\n  1 (5.0)\n\n\n0.0% (-13.5, 13.5)\n    Momeni 2021\n\n203\nPlac\n70.0 {59-81}\n\nCardiac\n  2 (1.0)\n\n\n—\n    \n205\nDex\n71.0 {61-81}\n\n\n  2 (1.0)\n\n\n-0.0% (-1.9, 1.9)\n    Remerand 2009\n\n75\nPlac\n65.0 (14.0)\n\nOrtho\n 10 (13.3)\n\n\n—\n    \n79\nKet\n64.0 (13.0)\n\n\n  9 (11.4)\n\n\n-1.9% (-12.3, 8.5)\n    \n      Pulmonary\n    \n    Li 2017\n\n143\nPlac\n67.5 (5.3)\n\nCardiac\n 27 (18.9)\n\n\n—\n    \n142\nDex\n66.4 (5.4)\n\n\n 15 (10.6)\n\n\n-8.3% (-16.5, -0.2)\n    Wu 2020\n\n40\nPlac\n67.7 (8.8)\n\nCardiac\n  5 (12.5)\n\n\n—\n    \n40\nDex\n68.2 (8.6)\n\n\n  3 (7.5)\n\n\n-5.0% (-18.1, 8.1)\n    Gao 2021\n\n20\nPlac\n71.4 (4.5)\n\nCardiac\n  5 (25.0)\n\n\n—\n    \n20\nDex\n71.4 (4.5)\n\n\n  4 (20.0)\n\n\n-5.0% (-30.8, 20.8)\n    Chen 2020\n\n45\nPlac\n65.4 (11.7)\n\nGI/Abd\n  3 (6.7)\n\n\n—\n    \n43\nDex\n64.9 (11.4)\n\n\n  0 (0.0)\n\n\n-6.7% (-14.9, 1.6)\n    Guo 2015\n\n73\nPlac\n71.3 (5.1)\n\nOralmax\n  0 (0.0)\n\n\n—\n    \n76\nDex\n70.7 (5.2)\n\n\n  0 (0.0)\n\n\n0.0% (-2.6, 2.6)\n    Wang 2020a\n\n20\nMid\n60.5 (8.2)\n\nOralmax\n  7 (35.0)\n\n\n—\n    \n20\nDex\n60.0 (10.1)\n\n\n  1 (5.0)\n\n\n-30.0% (-53.0, -7.0)\n    Zhao 2020\n\n101\nNone\n69.2 (4.1)\n\nVarious\n  0 (0.0)\n\n\n—\n    \n108\nDex\n70.0 (4.5)\n\n\n  0 (0.0)\n\n\n0.0% (-1.9, 1.9)\n    \n105\nDex\n69.4 (3.9)\n\n\n  0 (0.0)\n\n\n0.0% (-1.9, 1.9)\n    \n102\nDex\n69.3 (4.1)\n\n\n  0 (0.0)\n\n\n0.0% (-1.9, 1.9)\n    \n      Pneumonia\n    \n    Deiner 2017\n\n157\nPlac\n74.0 {71-78}\n\nVarious\n  1 (0.6)\n\n\n—\n    \n147\nDex\n74.0 {71-78}\n\n\n  3 (2.0)\n\n\n1.4% (-1.2, 4.0)\n    \n      Pulmonary Congestiona\n    \n    Deiner 2017\n\n157\nPlac\n74.0 {71-78}\n\nVarious\n  0 (0.0)\n\n\n—\n    \n147\nDex\n74.0 {71-78}\n\n\n  1 (0.7)\n\n\n0.7% (-1.2, 2.5)\n    \n      PE\n    \n    Deiner 2017\n\n157\nPlac\n74.0 {71-78}\n\nVarious\n  1 (0.6)\n\n\n—\n    \n147\nDex\n74.0 {71-78}\n\n\n  1 (0.7)\n\n\n0.0% (-1.8, 1.9)\n    \n      Respiratory Failure\n    \n    Deiner 2017\n\n157\nPlac\n74.0 {71-78}\n\nVarious\n  1 (0.6)\n\n\n—\n    \n147\nDex\n74.0 {71-78}\n\n\n  2 (1.4)\n\n\n0.7% (-1.5, 3.0)\n    \n      Reintubation\n    \n    Shehabi 2009\n\n147\nMS\n71.0 {65-75}\n\nCardiac\n  4 (2.7)\n\n\n—\n    \n152\nDex\n71.5 {66-76}\n\n\n  5 (3.3)\n\n\n0.6% (-3.3, 4.4)\n    \n      NA\n    \n    Shehabi 2009\n\n147\nMS\n71.0 {65-75}\n\nCardiac\n  9 (6.1)\n\n\n—\n    \n152\nDex\n71.5 {66-76}\n\n\n 25 (16.4)\n\n\n10.3% (3.3, 17.4)\n    Li 2017\n\n143\nPlac\n67.5 (5.3)\n\nCardiac\n 14 (9.8)\n\n\n—\n    \n142\nDex\n66.4 (5.4)\n\n\n 21 (14.8)\n\n\n5.0% (-2.6, 12.6)\n    Wu 2020\n\n40\nPlac\n67.7 (8.8)\n\nCardiac\n  2 (5.0)\n\n\n—\n    \n40\nDex\n68.2 (8.6)\n\n\n  1 (2.5)\n\n\n-2.5% (-10.8, 5.8)\n    Chen 2020\n\n45\nPlac\n65.4 (11.7)\n\nGI/Abd\n  4 (8.9)\n\n\n—\n    \n43\nDex\n64.9 (11.4)\n\n\n  1 (2.3)\n\n\n-6.6% (-16.0, 2.9)\n    Wang 2020cb\n50\nPlac\n68.3 (2.1)\n\nGI/Abd\n  3 (6.0)\n\n\n—\n    \n60\nDex\n68.4 (3.3)\n\n\n  4 (6.7)\n\n\n0.7% (-8.5, 9.8)\n    Li 2021b\n\n30\nPlac\n73.4 (5.1)\n\nGI/Abd\n  7 (23.3)\n\n\n—\n    \n30\nDex\n74.7 (2.6)\n\n\n  8 (26.7)\n\n\n3.3% (-18.6, 25.2)\n    \n30\nDex\n71.2 (3.5)\n\n\n 12 (40.0)\n\n\n16.7% (-6.5, 39.8)\n    \n30\nDex\n69.8 (4.3)\n\n\n 20 (66.7)\n\n\n43.3% (20.7, 66.0)\n    Lu 2021\n\n331\nPlac\n70.4 (6.5)\n\nGI/Abd\n 12 (3.6)\n\n\n—\n    \n344\nDex\n70.1 (5.8)\n\n\n 22 (6.4)\n\n\n2.8% (-0.5, 6.0)\n    Guo 2015\n\n73\nPlac\n71.3 (5.1)\n\nOralmax\n  2 (2.7)\n\n\n—\n    \n76\nDex\n70.7 (5.2)\n\n\n  5 (6.6)\n\n\n3.8% (-2.9, 10.6)\n    Wang 2020a\n\n20\nMid\n60.5 (8.2)\n\nOralmax\n  2 (10.0)\n\n\n—\n    \n20\nDex\n60.0 (10.1)\n\n\n  8 (40.0)\n\n\n30.0% (4.8, 55.2)\n    Lu 2017\n\n76\nDex\n65.0 (5.8)\n\nOrtho\n  0 (0.0)\n\n\n—\n    \n75\nDex\n65.5 (5.3)\n\n\n  0 (0.0)\n\n\n0.0% (-2.6, 2.6)\n    Lee 2018b\n\n31\nPlac\n67.2 (5.0)\n\nOrtho\n  7 (22.6)\n\n\n—\n    \n33\nPreg\n68.4 (5.1)\n\n\n  8 (24.2)\n\n\n1.7% (-19.1, 22.4)\n    \n31\nDex\n68.8 (5.9)\n\n\n 19 (61.3)\n\n\n38.7% (16.1, 61.3)\n    \n29\nDex/Preg\n65.4 (9.7)\n\n\n 19 (65.5)\n\n\n42.9% (20.2, 65.6)\n    Zhang 2020\n\n120\nPlac\n79.0 (6.8)\n\nOrtho\n 18 (15.0)\n\n\n—\n    \n120\nDex\n78.1 (6.4)\n\n\n 20 (16.7)\n\n\n1.7% (-7.6, 10.9)\n    Hong 2021\n\n354\nPlac\n71.0 (5.0)\n\nOrtho\n  1 (0.3)\n\n\n—\n    \n356\nDex\n71.0 (5.0)\n\n\n  1 (0.3)\n\n\n-0.0% (-0.8, 0.8)\n    Li 2020b\n46\nNone\n67.3 (2.1)\n\nThoracic\n  2 (4.3)\n\n\n—\n    \n41\nDex\n67.4 (3.3)\n\n\n  1 (2.4)\n\n\n-1.9% (-9.5, 5.6)\n    Shi 2020\n\n53\nPlac\n68.7 (3.4)\n\nThoracic\n 13 (24.5)\n\n\n—\n    \n53\nDex\n68.7 (4.6)\n\n\n 26 (49.1)\n\n\n24.5% (6.8, 42.3)\n    Hu 2021\n\n87\nPlac\n69.1 (5.1)\n\nThoracic\n  0 (0.0)\n\n\n—\n    \n90\nDex\n69.6 (4.5)\n\n\n  0 (0.0)\n\n\n0.0% (-2.2, 2.2)\n    Zhao 2020\n\n101\nNone\n69.2 (4.1)\n\nVarious\n  3 (3.0)\n\n\n—\n    \n108\nDex\n70.0 (4.5)\n\n\n  8 (7.4)\n\n\n4.4% (-1.5, 10.4)\n    \n105\nDex\n69.4 (3.9)\n\n\n  8 (7.6)\n\n\n4.6% (-1.4, 10.7)\n    \n102\nDex\n69.3 (4.1)\n\n\n  8 (7.8)\n\n\n4.9% (-1.3, 11.1)\n    van Norden 2021\n\n32\nPlac\n70.5 (6.2)\n\nVarious\n 19 (59.4)\n\n\n—\n    \n28\nDex\n70.4 (7.1)\n\n\n 17 (60.7)\n\n\n1.3% (-23.5, 26.2)\n    Lv 2022\n\n157\nPlac\n68.4 (6.6)\n\nVarious\n  9 (5.7)\n\n\n—\n    \n152\nDex\n67.9 (5.9)\n\n\n 16 (10.5)\n\n\n4.8% (-1.3, 10.9)\n  \n  \n  \n    \n       RD: risk difference; MI: myocardial infarction.\n    \n    \n      a Pulmonary congestion includes heart failure diagnosis.\n    \n    \n      b Nonrandomized Trial\n    \n  \n\n\n\n\n\n\nKetamine\nNo studies\n\n\nRamelteon\n Table 23. Report complications in ramelteon studies — cardiac, MI, stroke, pulmonary, pneumonia, and renal (all before-after designs). \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n          Age\n      Surgery\n      N (%)\n      0 – 100%\n      RD (95% CI)\n    \n  \n  \n    \n      Arrhythmia\n    \n    Miyata 2017a\n58\nNone\n76.5 [70-87]\n\nThoracic\n  5 (8.6)\n\n\n—\n    \n24\nRam\n79.0 [70-89]\n\nThoracic\n  0 (0.0)\n\n\n-8.6% (-17.8, 0.6)\n    \n      Pulmonary\n    \n    Hokuto 2020a\n186\nNone\n69.0 [30-88]\n\nGI/Abd\n  4 (2.2)\n\n\n—\n    \n120\nRam\n71.0 [34-85]\n\nGI/Abd\n  4 (3.3)\n\n\n1.2% (-2.6, 5.0)\n    \n      Pneumonia\n    \n    Hokuto 2020a\n186\nNone\n69.0 [30-88]\n\nGI/Abd\n  3 (1.6)\n\n\n—\n    \n120\nRam\n71.0 [34-85]\n\nGI/Abd\n  2 (1.7)\n\n\n0.1% (-2.9, 3.0)\n    Miyata 2017a\n58\nNone\n76.5 [70-87]\n\nThoracic\n  4 (6.9)\n\n\n—\n    \n24\nRam\n79.0 [70-89]\n\nThoracic\n  1 (4.2)\n\n\n-2.7% (-13.0, 7.6)\n  \n  \n  \n    \n      a Before-After/Time Series\n    \n  \n\n\n\n\n\n\nPooled\n Figure 31. Risk ratio for bradycardia (dexmedetomidine versus placebo or no interventions; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n Harbord test for small study effects P = 0.23. Similar arms combined in Li 2021b and Zhao 2020. \n\n\n\n\n\n\n Figure 32. Dexmedetomidine compared with placebo or no intervention small study effects and bradycardia — funnel plot and limit meta-analysis. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Estimates (odds ratio and 95% CI) from random effects model — unadjusted 1.80 (1.32–2.45); adjusted for small study effects: 2.47 (1.31–4.66).\n\n\n\n Figure 33. Risk difference for bradycardia (dexmedetomidine versus placebo or no interventions; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n Figure 34. Risk ratio for hypotension (dexmedetomidine versus placebo or no interventions; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n Harbord test for small study effects P = 0.36.  Similar arms combined in Li 2021b and Zhao 2020. \n\n\n\n\n\n\n Figure 35. Dexmedetomidine compared with placebo or no intervention small study effects and hypotension — funnel plot. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Estimates (odds ratio and 95% CI) from random effects models — unadjusted 1.55 (1.14–2.12); adjusted for small study effects: 1.71 (1.14–2.55).\n\n\n\n Figure 36. Risk difference for hypotension (dexmedetomidine versus placebo or no interventions; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n Figure 37. Risk differences for other complications — myocardial infarction, other arrhythmia (excludes bradycardia), stroke, pulmonary, and renal (dexmedetomidine versus placebo or no interventions; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n RD: risk ratio.  Similar arms combined for Zhao 2020. \n\n\n\n\n\n\n Figure 39. Risk difference in pneumonia (ramelteon versus no interventions; before-after studies)."
  },
  {
    "objectID": "kq6.html#length-of-stay",
    "href": "kq6.html#length-of-stay",
    "title": "Delirium Prophylaxis",
    "section": "Length of Stay",
    "text": "Length of Stay\n Table 24. Length of stay according to procedure classification and comparator. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Comparator\n      PSa\n          Ageb\n          LOSb\n      0 – 25 days\n      Country\n    \n  \n  \n    \n      Cardiac - Randomized Clinical Trial\n    \n    Hudetz 2009a\n\n26\nPlac\n  34\n67.0 (8.0)\n\n7.0 (3.0)\n\n\n\nUSA\n    \n26\nKet\n  34\n68.0 (7.0)\n\n8.0 (4.0)\n\n\n\n\n    Shehabi 2009\n\n147\nMS\nNR\n71.0 {65-75}\n\n8.0 {7-11}\n\n\n\nAustralia\n    \n152\nDex\nNR\n71.5 {66-76}\n\n8.0 {7-11}\n\n\n\n\n    Djainai 2016\n\n92\nProp\nNR\n72.4 (6.2)\n\n7.0 [4-74]\n\n\n\nCanada\n    \n91\nDex\nNR\n72.7 (6.4)\n\n7.0 [4-35]\n\n\n\n\n    Ge 2016\n\n24\nPlac\n123 \n72.0 (4.0)\n\n4.6 (1.1)\n\n\n\nChina\n    \n24\nDex\n123 \n70.0 (3.0)\n\n4.6 (1.3)\n\n\n\n\n    Li 2017\n\n143\nPlac\n 234\n67.5 (5.3)\n\n9.0 {8-10}\n\n\n\nChina\n    \n142\nDex\n 234\n66.4 (5.4)\n\n9.0 {8-10}\n\n\n\n\n    Subramaniam 2019\n\n61\nProp\nNR\n70.0 {64-79}\n\n8.0 {6-11}\n\n\n\nUSA\n    \n59\nDex\nNR\n66.5 {63-74}\n\n8.0 {6-10}\n\n\n\n\n    Ford 2020\n\n104\nPlac\nNR\n67.6 (8.0)\n\n7.0 {6-8}\n\n\n\nAustralia\n    \n98\nMel\nNR\n69.0 (8.3)\n\n8.0 {6-10}\n\n\n\n\n    Turan 2020\n\n396\nPlac\n1234\n62.0 (12.0)\n\n6.0 {5-7}\n\n\n\nUSA\n    \n398\nDex\n1234\n63.0 (11.0)\n\n6.0 {5-8}\n\n\n\n\n    Gao 2021\n\n20\nPlac\n 23 \n71.4 (4.5)\n\n13.0 (2.0)\n\n\n\nChina\n    \n20\nDex\n 23 \n71.4 (4.5)\n\n10.0 (1.0)\n\n\n\n\n    Mahrose 2021\n\n55\nDex\nNR\n66.1 (6.3)\n\n13.8 (6.2)\n\n\n\nEgypt\n    \n55\nMel/Dex\nNR\n67.0 (6.7)\n\n11.9 (5.3)\n\n\n\n\n    Momeni 2021\n\n203\nPlac\nNR\n70.0 {59-81}\n\n7.0 {7-10}\n\n\n\nBelgium\n    \n205\nDex\nNR\n71.0 {61-81}\n\n8.0 {7-10}\n\n\n\n\n    Shi 2021\n\n149\nPlac\nNR\n71.6 (6.6)\n\n13.4 (6.6)\n\n\n\nChina\n    \n148\nMel\nNR\n71.5 (6.7)\n\n15.9 (9.7)\n\n\n\n\n    Chitnis 2022\n\n33\nProp\nNR\n78.8\n\n12.2\n\n\n\nCanada\n    \n34\nDex\nNR\n78.7\n\n10.2\n\n\n\n\n    Qu 2023\n\n206\nPlac\nNR\n70.0 {65-75}\n\n6.0 {5-7}\n\n\n\nUSA\n    \n188\nDex\nNR\n67.5 {63-73}\n\n6.0 {5-8}\n\n\n\n\n    \n      Ortho - Randomized Clinical Trial\n    \n    Remerand 2009\n\n75\nPlac\nNR\n65.0 (14.0)\n\n8.3 (1.6)\n\n\n\nFrance\n    \n79\nKet\nNR\n64.0 (13.0)\n\n8.8 (3.2)\n\n\n\n\n    de Jonghe 2014\n\n192\nPlac\nNR\n83.4 (7.5)\n\n11.0 {8-17}\n\n\n\nNetherlands\n    \n186\nMel\nNR\n84.1 (8.0)\n\n11.0 {6-14}\n\n\n\n\n    Fan 2017a\n\n70\nPlac\n123 \n74.6 (5.4)\n\n7.0 [5-21]\n\n\n\nChina\n    \n69\nMel\n123 \n74.5 (5.7)\n\n7.0 [5-19]\n\n\n\n\n    Mei 2018\n\n148\nProp\n 23 \n74.0 (6.0)\n\n6.8 (2.0)\n\n\n\nChina\n    \n148\nDex\n 23 \n76.0 (7.0)\n\n6.3 (1.6)\n\n\n\n\n    Hong 2021\n\n354\nPlac\n1234\n71.0 (5.0)\n\n5.0 {5-6}\n\n\n\nChina\n    \n356\nDex\n1234\n71.0 (5.0)\n\n5.0 {5-6}\n\n\n\n\n    Yan 2021\n\n50\nPlac\n12  \n72.7 (4.3)\n\n16.1 (0.7)\n\n\n\nChina\n    \n50\nDex\n12  \n73.2 (5.8)\n\n13.2 (0.9)\n\n\n\n\n    \n      GI/Abd - Randomized Clinical Trial\n    \n    Lu 2021\n\n331\nPlac\n123 \n70.4 (6.5)\n\n15.0 {11-18}\n\n\n\nChina\n    \n344\nDex\n123 \n70.1 (5.8)\n\n13.0 {10-17}\n\n\n\n\n    \n      Thoracic - Randomized Clinical Trial\n    \n    Huyan 2019\n\n173\nPlac\n 23 \n71.0 (6.0)\n\n9.0 {7-11}\n\n\n\nChina\n    \n173\nDex\n 23 \n70.0 (5.0)\n\n8.0 {6-10}\n\n\n\n\n    Jaiswal 2019\n\n58\nPlac\nNR\n56.1 (15.8)\n\n12.0 {10-14}\n\n\n\nUSA\n    \n59\nRam\nNR\n58.1 (14.1)\n\n12.0 {10-16}\n\n\n\n\n    \n      Various - Randomized Clinical Trial\n    \n    Deiner 2017\n\n201\nPlac\n1234\n74.0 {71-78}\n\n4.0 {3-6}\n\n\n\nUSA\n    \n189\nDex\n1234\n74.0 {71-78}\n\n4.0 {3-6}\n\n\n\n\n    van Norden 2021\n\n32\nPlac\n1234\n70.5 (6.2)\n\n21.0 (15.6)\n\n\n\nGermany\n    \n28\nDex\n1234\n70.4 (7.1)\n\n23.5 (20.3)\n\n\n\n\n    Lv 2022\n\n157\nPlac\nNR\n68.4 (6.6)\n\n17.2 (6.3)\n\n\n\nChina\n    \n152\nDex\nNR\n67.9 (5.9)\n\n15.6 (4.2)\n\n\n\n\n    \n      Oralmax - Randomized Clinical Trial\n    \n    Liu 2022b\n\n60\nPlac\n12  \n72.1 (5.9)\n\n9.0 (2.8)\n\n\n\nChina\n    \n60\nDex\n12  \n71.3 (6.7)\n\n9.0 (2.5)\n\n\n\n\n    \n      GI/Abd - Before-After/Time Series\n    \n    Hokuto 2020\n\n186\nNone\n123 \n69.0 [30-88]\n\n9.0 [5-162]\n\n\n\nJapan\n    \n120\nRam\n123 \n71.0 [34-85]\n\n9.0 [4-80]\n\n\n\n\n    \n      Thoracic - Before-After/Time Series\n    \n    Miyata 2017\n\n58\nNone\nNR\n76.5 [70-87]\n\n13.6 (7.8)\n\n\n\nJapan\n    \n24\nRam\nNR\n79.0 [70-89]\n\n13.5 (9.6)\n\n\n\n\n    \n      Spine - Prospective Cohort\n    \n    Barreto Chang 2022\n\n38\nNone\n123 \n71.0 {68-78}\n\n4.0 {3-6}\n\n\n\nUSA\n    \n60\nKet\n123 \n70.0 {67-75}\n\n4.0 {2-6}\n\n\n\n\n  \n  \n  \n    \n       NR: not reported\n    \n    \n      a ASA Physical Status.\n    \n    \n      b Mean Med (SD)[Range]{IQR}.\n    \n  \n\n\n\n\n\nPooled\n\nDexmedetomidine\n Figure 40. Mean difference in lengths of stay (dexmedetomidine versus placebo; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n MD: mean difference; Dex: Dexmedetomidine. When the mean or standard deviation were not reported, they were imputed from from the median, interquartile range, and/or range. \n\n\nMelatonin/Ramelteon\n Figure 41. Mean difference in lengths of stay (melatonin or ramelteon versus placebo; randomized clinical trials). \n\n\n\n\n\n\n\n\n\n MD: mean difference; Mel: melatonin; Ram: ramelteon. When the mean or standard deviation were not reported, they were imputed from from the median, interquartile range, and/or range."
  },
  {
    "objectID": "kq6.html#mortality",
    "href": "kq6.html#mortality",
    "title": "Delirium Prophylaxis",
    "section": "Mortality",
    "text": "Mortality\n\nDexmedetomidine\n Table 25. Reported in-hospital, 30-day, 90-day, and 1-year mortality in dexmedetomidine randomized clinical trials by comparator and surgical category.\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N\n      Drug\n      Surgery\n      \n        ASA\n      \n      Agea\n      \n        Mortality\n      \n      RD (95% CI)\n    \n    \n      PS\n      N (%)\n      0 - 100%\n    \n  \n  \n    \n      Hospital\n    \n    Shehabi 2009\n\n147\nMS\nCardiac\nNR\n71.0 {65-75}\n\n 4 (2.7)\n\n\n—\n    \n152\nDex\n\n\n71.5 {66-76}\n\n 2 (1.3)\n\n\n-1.4% (-4.6, 1.8)\n    Djainai 2016\n\n92\nProp\nCardiac\nNR\n72.4 (6.2)\n\n 0 (0.0)\n\n\n—\n    \n91\nDex\n\n\n72.7 (6.4)\n\n 1 (1.1)\n\n\n1.1% (-1.9, 4.1)\n    Deiner 2017\n\n201\nPlac\nVarious\n1234\n74.0 {71-78}\n\n 3 (1.5)\n\n\n—\n    \n189\nDex\n\n\n74.0 {71-78}\n\n 1 (0.5)\n\n\n-1.0% (-2.9, 1.0)\n    Zhou 2019b\n\n39\nPlac\nCardiac\n123 \n70.0 (4.9)\n\n 1 (2.6)\n\n\n—\n    \n39\nUlin\n\n\n70.6 (4.4)\n\n 0 (0.0)\n\n\n-2.6% (-9.4, 4.3)\n    \n39\nDex/Ulin\n\n\n69.6 (5.0)\n\n 0 (0.0)\n\n\n-2.6% (-9.4, 4.3)\n    \n39\nDex\n\n\n69.8 (5.1)\n\n 1 (2.6)\n\n\n0.0% (-7.0, 7.0)\n    Turan 2020\n\n387\nPlac\nCardiac\n1234\n62.0 (12.0)\n\n 1 (0.3)\n\n\n—\n    \n391\nDex\n\n\n63.0 (11.0)\n\n 1 (0.3)\n\n\n-0.0% (-0.7, 0.7)\n    Momeni 2021\n\n203\nPlac\nCardiac\nNR\n70.0 {59-81}\n\n10 (4.9)\n\n\n—\n    \n205\nDex\n\n\n71.0 {61-81}\n\n 1 (0.5)\n\n\n-4.4% (-7.6, -1.3)\n    Chitnis 2022\n\n33\nProp\nCardiac\nNR\n78.8\n\n 0 (0.0)\n\n\n—\n    \n33\nDex\n\n\n78.7\n\n 0 (0.0)\n\n\n0.0% (-5.7, 5.7)\n    Qu 2023\n\n206\nPlac\nCardiac\nNR\n70.0 {65-75}\n\n 1 (0.5)\n\n\n—\n    \n188\nDex\n\n\n67.5 {63-73}\n\n 3 (1.6)\n\n\n1.1% (-0.9, 3.1)\n    \n      30-day\n    \n    Li 2017\n\n135\nPlac\nCardiac\n 234\n67.5 (5.3)\n\n 4 (3.0)\n\n\n—\n    \n139\nDex\n\n\n66.4 (5.4)\n\n 2 (1.4)\n\n\n-1.5% (-5.0, 2.0)\n    Hong 2021\n\n354\nPlac\nOrtho\n1234\n71.0 (5.0)\n\n 0 (0.0)\n\n\n—\n    \n356\nDex\n\n\n71.0 (5.0)\n\n 0 (0.0)\n\n\n0.0% (-0.6, 0.6)\n    Lu 2021\n\n331\nPlac\nGI/Abd\n123 \n70.4 (6.5)\n\n 0 (0.0)\n\n\n—\n    \n344\nDex\n\n\n70.1 (5.8)\n\n 1 (0.3)\n\n\n0.3% (-0.5, 1.1)\n    Lv 2022\n\n157\nPlac\nVarious\nNR\n68.4 (6.6)\n\n 7 (4.5)\n\n\n—\n    \n152\nDex\n\n\n67.9 (5.9)\n\n 5 (3.3)\n\n\n-1.2% (-5.5, 3.1)\n    Qu 2023\n\n206\nPlac\nCardiac\nNR\n70.0 {65-75}\n\n 1 (0.5)\n\n\n0.0% (-1.3, 1.3)\n    \n188\nDex\n\n\n67.5 {63-73}\n\n 3 (1.6)\n\n\n1.1% (-0.9, 3.1)\n    \n      90-day\n    \n    van Norden 2021\n\n32\nPlac\nVarious\n1234\n70.5 (6.2)\n\n 5 (15.6)\n\n\n—\n    \n28\nDex\n\n\n70.4 (7.1)\n\n 0 (0.0)\n\n\n-15.6% (-29.2, -2.1)\n    Qu 2023\n\n206\nPlac\nCardiac\nNR\n70.0 {65-75}\n\n 1 (0.5)\n\n\n0.0% (-1.3, 1.3)\n    \n188\nDex\n\n\n67.5 {63-73}\n\n 4 (2.1)\n\n\n1.6% (-0.6, 3.9)\n  \n  \n  \n    \n       ASA PS: American Society of Anesthesiologists Physical Status; RD: risk difference; GI: gastrointestinal; Abd: abdominal (includes hepatic); Ortho: orthopedic; Various: more that one procedure category; Dex: Dexmedetomidine; Ulin: Ulinastatin; MS: morphine sulfate; Plac; placebo.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n  \n\n\n\n\n\n\nKetamine\nNo studies\n\n\n\nMelatonin/Ramelteon\n Table 26. Reported in-hospital, 30-day, 90-day, and 1-year mortality in melatonin and ramelteon studies by comparator and surgical category.\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N\n      Drug\n      Surgery\n      \n        ASA\n      \n      Agea\n      \n        Mortality\n      \n      RD (95% CI)\n    \n    \n      PS\n      N (%)\n      0 - 100%\n    \n  \n  \n    \n      Hospital\n    \n    de Jonghe 2014b\n192\nPlac\nOrtho\nNR\n83.4 (7.5)\n\n 4 (2.1)\n\n\n—\n    \n186\nMel\n\n\n84.1 (8.0)\n\n 4 (2.2)\n\n\n0.1% (-2.8, 3.0)\n    Jaiswal 2019b\n58\nPlac\nThoracic\nNR\n56.1 (15.8)\n\n 4 (6.9)\n\n\n—\n    \n59\nRam\n\n\n58.1 (14.1)\n\n 3 (5.1)\n\n\n-1.8% (-10.4, 6.8)\n    \n      30-day\n    \n    Shi 2021b\n149\nPlac\nCardiac\nNR\n71.6 (6.6)\n\n21 (14.1)\n\n\n—\n    \n148\nMel\n\n\n71.5 (6.7)\n\n18 (12.2)\n\n\n-1.9% (-9.6, 5.7)\n    Hokuto 2020c\n186\nNone\nGI/Abd\n123 \n69.0 [30-88]\n\n 0 (0.0)\n\n\n—\n    \n120\nRam\n\n\n71.0 [34-85]\n\n 0 (0.0)\n\n\n0.0% (-1.4, 1.4)\n    \n      90-day\n    \n    de Jonghe 2014b\n192\nPlac\nOrtho\n\n83.4 (7.5)\n\n41 (21.4)\n\n\n19.3% (13.1, 25.4)\n    \n186\nMel\n\n\n84.1 (8.0)\n\n39 (21.0)\n\n\n18.9% (12.7, 25.1)\n  \n  \n  \n    \n       ASA PS: American Society of Anesthesiologists Physical Status; RD: risk difference; GI: gastrointestinal; Abd: abdominal (includes hepatic); Ortho: orthopedic; Various: more that one procedure category; Ram: ramelteon; Mel: melatonin; Plac; placebo.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Randomized clinical trial.\n    \n    \n      c Before-after design.\n    \n  \n\n\n\n\n\n\nPooled\n\nDexmedetomidine\n Figure 42. Risk difference for hospital and 30-day mortality – dexmedetomidine compared with placebo or no intervention. \n\n\n\n\n\n\n\n\n\n Dex: dexmedetomidine; Plac: placebo. \n\n\n\n\n\n\n Figure 43. Mortality for dexmedetomidine compared with placebo or no intervention small study effects — funnel plot. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nMelatonin/Ramelteon\n Figure 44. Risk difference for hospital and 30-day mortality – melatonin or ramelteon compared with placebo or no intervention. \n\n\n\n\n\n\n\n\n\n Mel: melatonin; Ram: ramelteon; Plac: placebo."
  },
  {
    "objectID": "kq6.html#risk-of-bias",
    "href": "kq6.html#risk-of-bias",
    "title": "Delirium Prophylaxis",
    "section": "Risk of Bias",
    "text": "Risk of Bias\n\nRandomized\n Figure 45. Summary risk of bias assessment for randomized clinical trials. \n\n\n\n\n\n Figure 46. Risk of bias assessments for randomized clinical trials. \n\n\n\n\n\n\n\nNonrandomized\n Figure 47. Summary risk of bias assessment for nonrandomized studies. \n\n\n\n\n\n Figure 48. Risk of bias assessments for nonrandomized studies."
  },
  {
    "objectID": "balance_tables.html",
    "href": "balance_tables.html",
    "title": "DRAFT Balance Tables",
    "section": "",
    "text": "Recent updates (last 2024-01-03)\n\n\n\n\n\n\n\n\n\n\n\n\nDate               \nModification\n\n\n\n\n2024-01-03\nUpdated melatonin/ramelteon delirium as new studies added (note GRADE has not been updated)  Edits to correct inconsistencies in usage and removed links from footnotes."
  },
  {
    "objectID": "balance_tables.html#expanded-preoperative-evaluation",
    "href": "balance_tables.html#expanded-preoperative-evaluation",
    "title": "DRAFT Balance Tables",
    "section": "Expanded Preoperative Evaluation",
    "text": "Expanded Preoperative Evaluation\n Table 1. Benefits, harms, and strength of evidence (GRADE) for expanded versus standard preoperative evaluation. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      \n      \n        Preoperative Evaluation\n      \n      \n    \n    \n      Outcome\n      RCT\n      NRSI\n      \n        Expanded\n      \n      \n        Standard\n      \n      GRADE*\n      Effect\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Delirium incidence\n6\n\n189 (662)\n253 (703)\n⨁⨁⨁◯\n\nRR\n0.77 (0.60–0.99)\n    Hip fracture\n4\n\n168 (450)\n212 (479)\n\n\n0.84 (0.71–0.99)\n    Other\n2\n\n21 (212)\n41 (224)\n\n\n0.54 (0.33–0.89)\n    Any procedure\n\n6\n119 (958)\n148 (816)\n⨁⨁◯◯\n\nRR\n0.65 (0.49–0.87)\n    Delayed neurocognitive recovery\n\n1\n13 (96)\n16 (84)\n⨁◯◯◯\n\nRR\n0.71 (0.36-1.39)\n    Postoperative neurocognitive disorder\nnone\n\n\n\n\n\n\n    Physical function\n4\n\n(495)\n(507)\n⨁⨁◯◯\n\nSMD\n-0.00 (-0.17 to 0.16)\n    \n\n2\n(130)\n(92)\n⨁◯◯◯\n\nSMD\n-0.05 (-0.41 to 0.30)\n    Complications†\n4\n7\n\n\n⨁⨁◯◯⨁◯◯◯\n\n\nsee Appendix\n    Patient satisfaction\n\n1\n32 (32)\n29 (30)\n⨁◯◯◯\n\n\nDifference undetected\n    Length of stay (days)\n6\n\n(900)\n(932)\n⨁◯◯◯\n\nMD\n0.1 (-1.9 to 2.0)\n    \n\n11\n(1692)\n(1590)\n⨁◯◯◯\n\nMD\n-0.9 (-2.1 to 0.3)\n    Discharge to institution\n4\n\n252 (419)\n271 (424)\n⨁⨁◯◯\n\nRR\n0.98 (0.76-1.27)\n    \n\n4\n258 (647)\n250 (477)\n⨁⨁◯◯\n\nRR\n0.65 (0.43–0.96)\n    Mortality (in-hospital or 30-day)\n4\n\n19 (498)\n19 (526)\n⨁◯◯◯\n\nRR\n1.02 (0.12–8.46)\n    \n\n12\n106 (5566)\n195 (6903)\n⨁⨁◯◯\n\nRR\n0.67 (0.49–0.91)\n  \n  \n  \n    \n       RCT: randomized clinical trial; NRSI: nonrandomized studies of interventions (includes before-after designs);  GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; MD: mean difference.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      † Cardiovascular, pulmonary, and renal.\n    \n  \n\n\n\n\n\n Table 2. Included complications and strength of evidence (GRADE) for expanded versus standard preoperative evaluation. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      \n      \n        Preoperative Evaluation\n      \n      \n    \n    \n      Outcome\n      RCT\n      NRSI\n      \n        Expanded\n      \n      \n        Standard\n      \n      GRADE*\n      Effect\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Cardiac arrest\n1\n\n1 (85)\n5 (91)\n⨁◯◯◯\n\nRD\n-4.3% (-9.5 to 0.9)\n    \n\n1\n1 (183)\n2 (143)\n⨁◯◯◯\n\nRD\n-0.9% (-3.1 to 1.3)\n    Myocardial infarction\n1\n\n0 (155)\n1 (164)\n⨁◯◯◯\n\nRD\n-0.6% (-2.3 to 1.1)\n    \n\n4\n9 (656)\n11 (550)\n⨁◯◯◯\n\nRR\n0.60 (0.24-1.47)\n    Pulmonary complications†\n3\n\n60 (375)\n53 (390)\n⨁⨁◯◯\n\nRR\n1.18 (0.84-1.67)\n    Pneumonia\n2\n\n14 (240)\n18 (255)\n⨁◯◯◯\n\nRR\n0.82 (0.42-1.61)\n    \n\n6\n62 (967)\n65 (889)\n⨁◯◯◯\n\nRR\n0.95 (0.56-1.62)\n    Respiratory failure\n\n1\n16 (183)\n21 (143)\n⨁◯◯◯\n\nRD\n-5.9% (-13.0 to 1.2)\n    Pulmonary embolism\n\n3\n6 (414)\n3 (300)\n⨁◯◯◯\n\nRR\n1.21 (0.32–4.67)\n    Renal complications\n2\n\n11 (290)\n4 (299)\n⨁◯◯◯\n\nRR\n2.83 (0.91-8.80)\n    \n\n3\n41 (404)\n56 (392)\n⨁◯◯◯\n\nRR\n0.81 (0.57-1.15)\n  \n  \n  \n    \n       RCT: randomized clinical trial; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; MD: mean difference.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      † Unspecified in 2 studies and COPD exacerabation or pneumonia in the other."
  },
  {
    "objectID": "balance_tables.html#regional-versus-general-anesthesia",
    "href": "balance_tables.html#regional-versus-general-anesthesia",
    "title": "DRAFT Balance Tables",
    "section": "Regional versus General Anesthesia",
    "text": "Regional versus General Anesthesia\n Table 3. Benefits, harms, and strength of evidence (GRADE) for regional versus general anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT\n      \n        Regional\n      \n      \n        General\n      \n      GRADE*\n      Effect\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Delirium\n12\n231 (1947)\n229 (1928)\n⨁⨁⨁◯\n\nRR\n 0.97 (0.69–1.36)†\n    Delayed neurocognitive recovery\n4\n78 (336)\n88 (355)\n⨁⨁◯◯\n\nRR\n 0.91 (0.56–1.48)\n    Postoperative neurocognitive disorder\n1\n23 (176)\n25 (188)\n⨁◯◯◯\n\nRR\n 0.98 (0.58–1.67)\n    Physical function\n1\n\n\n⨁◯◯◯\n\nSMD\n 0.26 (-0.25 to 0.78)\n    Complications‡\n17\n\n\n⨁⨁◯◯⨁◯◯◯\n\n\nSee Table 4\n    Patient satisfaction\n10\n913 (1055)\n839 (991)\n⨁◯◯◯\n\nRR\n 1.02 (0.98 to 1.05)§\n    Length of stay (days)\n15\n(2402)\n(2426)\n⨁◯◯◯\n\nMD\n-0.5 (-1.3 to 0.3)\n    Discharged to institution\n1\n576 (777)\n586 (777)\n⨁◯◯◯\n\nRR\n 0.98 (0.93-1.04)\n    Mortality (in-hospital and 30-day)\n\n\n\n\n\n\n    All procedures\n8\n38 (3711)\n58 (3708)\n⨁⨁◯◯\n\nRR\n 0.68 (0.43–1.07)\n    \n10\n38 (3788)\n58 (3789)\n\nRD/1000\n-5.2 (-10.4 to -0.1)\n    Hip fracture\n4\n19 (1467)\n27 (1478)\n\nRR\n 0.73 (0.22–2.39)\n    \n5\n19 (1486)\n27 (1499)\n\nRD/1000\n-3.9 (-17.7 to 9.9)\n    Other\n4\n19 (2184)\n31 (2170)\n\nRR\n 0.65 (0.35–1.22)\n    \n6\n19 (2302)\n31 (2290)\n\nRD/1000\n-5.6 (-9.9 to -1.3)\n    Mortality (90-day)\n3\n15 (427)\n16 (441)\n⨁⨁◯◯\n\nRR\n 0.68 (0.43–1.07)\n    \n\n\n\n\nRD/1000\n-4.1 (-16.4 to 8.2)\n  \n  \n  \n    \n       RCT: randomized clinical trial; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; RD/1000: risk difference per 1000.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      † Hip fracture trials RR 1.03 (0.77–1.32); others RR 0.90 (0.62–1.29).\n    \n    \n      ‡ Complications reported variously across the 17 trials. \n    \n    \n      § Comparing higher/highest category or categories with lower ones.\n    \n  \n\n\n\n\n\n Table 4. Included complications and strength of evidence (GRADE) for regional versus general anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT\n      \n        Regional\n      \n      \n        General\n      \n      GRADE*\n      Effect†\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Myocardial infarction\n6\n21 (3426)\n16 (3352)\n⨁⨁◯◯\n\nRR\n 1.17 (0.59–2.32)\n\n    \n\n\n\n\nRD/1000\n 1.9 (-0.6 to 4.5)\n\n    Cardiac arrest\n2\n2 (874)\n0 (888)\n⨁◯◯◯\n\nRD/1000\n 2.3 (-2.2 to 6.7)\n\n    Stroke\n6\n75 (3257)\n80 (3247)\n⨁⨁◯◯\n\nRR\n 0.93 (0.68–1.26)\n\n    \n\n\n\n\nRD/1000\n-1.7 (-6.2 to 2.7)\n\n    Renal\n4\n33 (1118)\n58 (1129)\n⨁⨁◯◯\n\nRR\n 0.59 (0.39–0.89)\n\n    \n\n\n\n\nRD/1000\n-11.8 (-28.5 to 4.5)\n\n    Pulmonary complications‡\n2\n4 (88)\n10 (148)\n⨁◯◯◯\n\nRR\n 0.81 (0.28–2.35)\n\n    \n\n\n\n\nRD/1000\n-14.7 (-77.7 to 48.3)\n\n    Pneumonia\n8\n14 (1834)\n27 (1754)\n⨁⨁◯◯\n\nRR\n 0.50 (0.26–0.96)\n\n    \n\n\n\n\nRD/1000\n-3.8 (-10.2 to 2.6)\n\n    Pulmonary congestion\n1\n9 (783)\n8 (793)\n⨁◯◯◯\n\nRR\n 1.14 (0.44–2.94)\n\n    \n\n\n\n\nRD/1000\n 1.4 (-8.8 to 11.6)\n\n    Pulmonary embolism\n6\n7 (2055)\n13 (1406)\n⨁◯◯◯\n\nRR\n 0.56 (0.27–1.16)\n\n    \n8\n7 (3317)\n13 (3253)\n\nRD/1000\n-0.1 (-1.1 to 0.8)\n\n    Reintubation\n1\n4 (783)\n7 (793)\n⨁◯◯◯\n\nRR\n 0.37 (0.17–1.97)\n\n    \n\n\n\n\nRD/1000\n-3.7 (-11.9 to 4.5)\n\n  \n  \n  \n    \n       RCT: randomized clinical trial; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; RD/1000: risk difference per 1000.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      † Fixed/common effects models when 2 studies.\n    \n    \n      ‡ Complications reported included pneumonia, respiratory failure, or unspecified."
  },
  {
    "objectID": "balance_tables.html#tiva-versus-inhaled-anesthesia",
    "href": "balance_tables.html#tiva-versus-inhaled-anesthesia",
    "title": "DRAFT Balance Tables",
    "section": "TIVA versus Inhaled Anesthesia",
    "text": "TIVA versus Inhaled Anesthesia\n Table 5. Benefits, harms, and strength of evidence (GRADE) for TIVA versus inhaled anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT\n      NRSI\n      \n        Regional\n      \n      \n        General\n      \n      GRADE*\n      Effect\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Delirium\n6\n\n95 (795)\n120 (793)\n⨁◯◯◯†\nRR\n0.81 (0.59–1.12)\n    \n\n3\n10,287 (142,689)\n32,931 (427,763)\n⨁◯◯◯\n\nOR\n0.61 (0.27–1.36)\n    Delayed neurocognitive recovery\n7\n\n131 (850)\n206 (900)\n⨁⨁◯◯\n\nRR\n0.70 (0.52–0.93)\n    \n\n1\n24 (160)\n24 (119)\n⨁◯◯◯\n\nRR\n0.74 (0.44–1.24)\n    Postoperative neurocognitive disorder\n\n2\n29 (203)\n19 (153)\n⨁◯◯◯\n\nRR\n1.15 (0.68–1.95)\n    Complications\n8\n5\n\n\n⨁⨁◯◯⨁◯◯◯\n\n\nSee Table 6\n    Patient satisfaction\n3\n\n90 (109)\n82 (141)\n⨁⨁◯◯\n\nRR\n1.39 (1.19–1.63)‡\n    Length of stay (days)\n4\n\n(698)\n(696)\n⨁◯◯◯\n\nMD\n 0.2 (-1.6 to 1.9)\n    \n\n3\n(147,789)\n(432,867)\n⨁◯◯◯\n\nMD\n-0.2 (-2.0 to 1.5)\n    Discharged to institution\nnone\n\n\n\n\n\n\n    Mortality (in-hospital and 30-day)\n5\n\n11 (566)\n8 (565)\n⨁⨁◯◯\n\nRR\n1.16 (0.46–2.92)\n    \n\n5\n1,876 (149,333)\n5,175 (434,640)\n⨁◯◯◯\n\nRR\n0.87 (0.32–2.41)\n  \n  \n  \n    \n       RCT: randomized clinical trial; NRSI: nonrandomized studies of interventions; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; OR: odds ratio; MD: mean difference.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      † Pending formal inclusion of Cao 2023.\n    \n    \n      ‡ Comparing higher/highest category or categories with lower ones.\n    \n  \n\n\n\n\n\n Table 6. Included complications and strength of evidence (GRADE) for TIVA versus inhaled anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT\n      NRSI\n      \n        Regional\n      \n      \n        General\n      \n      GRADE*\n      Effect\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Cardiac complications†\n5\n\n17 (363)\n18 (394)\n⨁◯◯◯\n\nOR\n1.18 (0.44–3.15)\n    Myocardial infarction\n2\n3\n3,939 (149,289)\n8,813 (434,363)\n⨁◯◯◯\n\nOR\n0.90 (0.87–0.94)\n    Cardiac arrest\n\n1\n2 (1,374)\n0 (1,202)\n⨁◯◯◯\n\nRD\n0.1% (-0.1 to 0.4)\n    Acute kidney injury\n\n3\n782 (144,060)\n2,241 (429,558)\n⨁◯◯◯\n\nOR\n0.99 (0.91–1.08)\n    Pneumonia\n3\n\n16 (522)\n22 (522)\n⨁⨁◯◯\n\nOR\n0.72 (0.37–1.40)\n    Pulmonary congestion/edema\n\n2\n0 (143,939)\n3 (428,897)\n⨁◯◯◯\n\n\nno events one study; in second difference undetected\n    Pulmonary embolism\n1\n2\n189 (144,093)\n432 (429,050)\n⨁◯◯◯\n\nOR\n1.33 (0.93–1.90)\n    Respiratory failure\n1\n1\n420 (142,565)\n1,487 (427,695)\n⨁◯◯◯\n\n\nfew events one study; in second difference detected\n  \n  \n  \n    \n       RCT: randomized clinical trial; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; MD: mean difference.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      † Complications bradycardia (3 studies); atrial fibrillation (1 study); cardiac dysfunction (1 study)."
  },
  {
    "objectID": "balance_tables.html#delirium-prophylaxis",
    "href": "balance_tables.html#delirium-prophylaxis",
    "title": "DRAFT Balance Tables",
    "section": "Delirium Prophylaxis",
    "text": "Delirium Prophylaxis\n\nDexmedetomidine\n Table 7. Benefits, harms, and strength of evidence (GRADE) for dexmedetomidine versus placebo. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT\n      NRSI\n      \n        Dexmedetomidine\n      \n      \n        Placebo\n      \n      GRADE*\n      Effect\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Delirium\n24\n\n420 (3,598)\n580 (3,296)\n⨁⨁◯◯\n\nRR\n0.60 (0.50–0.72)\n    Delayed neurocognitive recovery\n8\n\n66 (616)\n94 (344)\n\nRR\n0.47 (0.31–0.71)\n    Postoperative neurocognitive disorder\n2\n\n15 (153)\n19 (209)\n⨁⨁◯◯\n\n\nDifferences undetected\n    Bradycardia\n14\n\n213 (1,667)\n111 (1,486)\n⨁⨁◯◯\n\nRR\n1.55 (1.21-1.99)\n    Hypotension\n20\n\n603 (3,073)\n400 (2,812)\n⨁⨁⨁◯\n\nRR\n1.40 (1.11–1.77)\n    Complications\n24\n2\n\n\n\n\nsee Table 8\n    Length of stay (days)\n14\n\n(2,590)\n(2,606)\n⨁◯◯◯\n\nMD\n-0.4 (-0.9 to 0.2)\n    Mortality, in-hospital and 30-day\n10\n\n16 (2,284)\n27 (2,289)\n⨁◯◯◯\n\nRR\n0.70 (0.36–1.36)\n  \n  \n  \n    \n       RCT: randomized clinical trial; NRSI: nonrandomized studies of interventions; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; OR: odds ratio; MD: mean difference.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n  \n\n\n\n\n\n Table 8. Included complications and strength of evidence (GRADE) for dexmedetomidine versus placebo. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT\n      NRSI\n      \n        Dexmedetomidine\n      \n      \n        Placebo\n      \n      GRADE*\n      Effect\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Cardiac complications†\n17\n2\n340 (2,711)\n251 (2,414)\n⨁⨁◯◯\n\nRR\n1.39 (1.09–1.78)\n    Myocardial infarction\n4\n\n4 (1,166)\n3 (1,154)\n⨁⨁◯◯\n\nRR\n1.25 (0.30–5.21)\n    Cardiac arrest\n1\n\n2 (152)\n1 (147)\n⨁◯◯◯\n\nRD\n0.6% (-1.6 to 2.9)\n    Stroke\n6\n\n7 (1,491)\n9 (1,502)\n⨁⨁◯◯\n\nRR\n0.84 (0.33–2.15)\n    Acute kidney injury\n3\n\n80 (741)\n76 (736)\n⨁⨁◯◯\n\nRR\n1.05 (0.69–1.59)\n    Pulmonary complications\n5\n\n18 (616)\n35 (402)\n⨁⨁◯◯\n\nRR\n0.54 (0.32–0.92)\n    Pneumonia\n2\n\n4 (428)\n8 (433)\n⨁◯◯◯\n\nRR\n0.65 (0.03–13.96)\n    Pulmonary congestion\n1\n\n1 (147)\n0 (157)\n⨁◯◯◯\n\nRR\n3.20 (0.13–78.02)\n    Pulmonary embolism\n2\n\n2 (428)\n1 (433)\n⨁◯◯◯\n\nRR\n1.65 (0.20–13.33)\n    Respiratory Failure\n2\n\n2 (428)\n1 (433)\n⨁◯◯◯\n\nRR\n2.14 (0.20–23.31)\n    Reintubation\n1\n\n5 (152)\n4 (147)\n⨁◯◯◯\n\nRD\n0.6% (-3.3 to 4.4)\n  \n  \n  \n    \n       RCT: randomized clinical trial; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; MD: mean difference.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      † Complications reported as heart failure (1 study), arrhythmia (1 study), or bradycardia (17 studies).\n    \n  \n\n\n\n\n\n\nKetamine\n Table 9. Benefits, harms, and strength of evidence (GRADE) for ketamine versus placebo. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT\n      NRSI\n      \n        Ketamine\n      \n      \n        Placebo\n      \n      GRADE*\n      Effect\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Delirium\n3\n\n89 (526)\n56 (295)\n⨁◯◯◯\n\nRR\n0.57 (0.18–1.82)\n    \n\n1\n19 (60)\n7 (38)\n⨁◯◯◯\n\nRR\n1.72 (0.80-3.70)\n    Delayed neurocognitive recovery\n3\n\n18 (98)\n27 (96)\n⨁◯◯◯\n\nRR\n0.84 (0.23–3.15)\n    Postoperative neurocognitive disorder\nnone\n\n\n\n\n\n\n    Complications\nnone\n\n\n\n\n\n\n    Length of stay (days)\n1\n\n(26)\n(26)\n⨁◯◯◯\n\n\nDifference undetected\n    \n\n1\n(60)\n(38)\n⨁◯◯◯\n\n\nDifference undetected\n    Mortality, in-hospital and 30-day\nnone\n\n\n\n\n\n\n  \n  \n  \n    \n       RCT: randomized clinical trial; NRSI: nonrandomized studies of interventions; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; OR: odds ratio; MD: mean difference.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n  \n\n\n\n\n\n\nMelatonin or Ramelteon\n Table 10. Benefits, harms, and strength of evidence (GRADE) for melatonin or ramelteon versus placebo. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT\n      NRSI\n      \n        Melatoninor Ramelteon\n      \n      \n        Placebo\n      \n      GRADE*\n      Effect\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Delirium\n13\n\n174 (832)\n247 (839)\n⨁⨁◯◯\n\nRR\n0.61 (0.44–0.86)\n    Delayed neurocognitive recovery\nnone\n\n\n\n\n\n\n    Postoperative neurocognitive disorder\n1\n\n87 (147)\n105 (151)\n⨁◯◯◯\n\nRR\n0.85 (0.72–1.01)\n    Complications\n\n2\n\n\n\n\nsee Table 11\n    Length of stay (days)\n5\n\n(560)\n(573)\n⨁◯◯◯\n\nMD\n0.4 (-0.8–1.6)\n    Mortality, in-hospital and 30-day\n3\n\n25 (393)\n29 (399)\n⨁⨁◯◯\n\nRR\n0.87 (0.52–1.44)\n  \n  \n  \n    \n       RCT: randomized clinical trial; NRSI: nonrandomized studies of interventions; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; OR: odds ratio; MD: mean difference.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n  \n\n\n\n\n\n Table 11. Included complications and strength of evidence (GRADE) for melatonin or ramelteon versus placebo. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT\n      NRSI\n      \n        Melatoninor Ramelteon\n      \n      \n        Placebo\n      \n      GRADE*\n      Effect\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Cardiac complications\n\n1\n0 (24)\n5 (58)\n⨁◯◯◯\n\nRD\n-8.6 (-17.8 to 0.6)\n    Myocardial infarction\nnone\n\n\n\n\n\n\n    Cardiac arrest\nnone\n\n\n\n\n\n\n    Stroke\nnone\n\n\n\n\n\n\n    Acute kidney injury\nnone\n\n\n\n\n\n\n    Pulmonary complications\n\n1\n4 (120)\n4 (186)\n⨁◯◯◯\n\nRD\n1.2 (-2.6 to 5.0)\n    Pneumonia\n\n2\n3 (144)\n7 (244)\n⨁◯◯◯\n\nRR\n0.82 (0.21–3.18)\n    Pulmonary congestion\nnone\n\n\n\n\n\n\n    Pulmonary embolism\nnone\n\n\n\n\n\n\n    Respiratory Failure\nnone\n\n\n\n\n\n\n    Reintubation\nnone\n\n\n\n\n\n\n  \n  \n  \n    \n       RCT: randomized clinical trial; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; MD: mean difference.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁."
  },
  {
    "objectID": "kq1.html#patient-satisfaction",
    "href": "kq1.html#patient-satisfaction",
    "title": "Expanded Preoperative Evaluation",
    "section": "Patient Satisfaction",
    "text": "Patient Satisfaction\n Table 14. Patient satisfaction according to expanded or standard preoperative evaluation. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N\n      Anesth\n      \n        ASA\n      \n      Agea\n      N (%)  \n      0 – 100%\n      RD (95% CI)\n    \n    \n      PS\n    \n  \n  \n    \n      Various (pelvic floor)\n    \n    Richter 2005\n\n30\nStd\n123 \n72.6 (8.3)\n\n29 (96.7)b\n\n\n—\n    \n32\nExp\n\n70.9 (6.3)\n\n32 (100.0)b\n\n\n3.3% (-5.3, 12.0)\n  \n  \n  \n    \n       Std: standard evaluation; Exp: expanded evaluation; ASA PS: ASA Physical Status; RD: risk difference.\n    \n    \n      a Mean (SD).\n    \n    \n      b High satisfaction."
  },
  {
    "objectID": "kq3.html#postoperative-neurocognitive-disorder",
    "href": "kq3.html#postoperative-neurocognitive-disorder",
    "title": "Regional versus General Anesthesia",
    "section": "Postoperative Neurocognitive Disorder",
    "text": "Postoperative Neurocognitive Disorder\n\n Table 11. Postoperative neurocognitive disorder incidence and ascertainment in a randomized clinical trial comparing regional to general anesthesia.\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Arm\n      \n        Preop\n      \n      \n        Instrument\n      \n      Dayb\n      \n        Postoperative Neurocognitive Disorder\n      \n    \n    \n      MMSEa\n      MMSE\n      DST\n      MoCA\n      Other\n      N (%)\n      0 — 100%\n      RR (95% CI)\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Rasmussen 2003\n\n188\nGen\n\n\n✓c\n\n✓\n\n90\n25 (13.3)\n\n\n—\n    \n176\nReg\n\n\n\n\n\n\n23 (13.1)\n\n\n0.98 (0.58-1.67)\n  \n  \n  \n    \n       Mini-Mental State Exam; DST: Digit Span Test; MoCA: Montreal Cognitive Assessment; RR: risk ratio; Gen: general anesthesia; Reg: regional anesthesia.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Day of assessment.\n    \n    \n      c Z ≥1.96."
  },
  {
    "objectID": "kq3.html#physical-function",
    "href": "kq3.html#physical-function",
    "title": "Regional versus General Anesthesia",
    "section": "Physical Function",
    "text": "Physical Function\n\n Table 12. Physical functional status in a randomized clinical trial comparing regional to general anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N\n      Arm\n          Agea\n      Scale\n      Range\n      Days\n      Ratinga\n      SMD (95% CI)\n    \n  \n  \n    \n      30-90 days\n    \n    Purwar 2015\n\n28\nGen\n65.1 (12.5)\n\nSF-36 physical\n0→100\n84\n44.2 (8.3)\n\n\n    \n31\nNeur\n60.6 (11.5)\n\n\n\n\n47.1 (12.7)\n\n0.26 (-0.25 to 0.78)\n  \n  \n  \n    \n       SMD: standardized mean difference; Gen: general; Neur: neuraxial.\n    \n    \n      a Mean Med (SD)[Range]{IQR}."
  },
  {
    "objectID": "kq4.html#physical-function",
    "href": "kq4.html#physical-function",
    "title": "TIVA versus Inhaled Anesthesia",
    "section": "Physical Function",
    "text": "Physical Function\nNo studies"
  },
  {
    "objectID": "kq6.html#physical-function",
    "href": "kq6.html#physical-function",
    "title": "Delirium Prophylaxis",
    "section": "Physical Function",
    "text": "Physical Function\n Table 19. Physical functional status for expanded versus standard preoperative evaluation. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N\n      Arm\n          Agea\n      Scale\n      Range\n      Days\n      Ratinga\n      SMD (95% CI)\n    \n  \n  \n    \n      30-90 days\n    \n    de Jonghe 2014\n\n192\nPlac\n83.4 (7.5)\n\nKatz ADL score\n15→0\n90\n9 [5-13]\n\n\n    \n186\nMel\n84.1 (8.0)\n\n\n\n\n9 [5-13]\n\n0.00 (-0.20 to 0.20)\n    \n      &gt;90 days\n    \n    Chitnis 2022\n\n31\nProp\n78.8\n\nSF-36 physical\n0→100\n182.5\n73.7\n\n\n    \n30\nDex\n78.7\n\n\n\n\n76.1\n\n0.39 (-1.57, 2.34)\n  \n  \n  \n    \n       SMD: standardized mean difference\n    \n    \n      a Mean Med (SD)[Range]{IQR}."
  },
  {
    "objectID": "protocol.html#modifications",
    "href": "protocol.html#modifications",
    "title": "Protocol",
    "section": "",
    "text": "History\n\n\n\n\n\n+———————–+——————–+———————————————————————————————————————————————————-+ | Date | Section | Modification | +:===============+:===================+:=========================================================================================================================================================+ | July 2021 | None | First draft | +—————-+——————–+———————————————————————————————————————————————————-+ | June 2022 | Key questions | Key questions removed: EEG monitoring and cognitive function; sedation titration with EEG monitoring; and maintaining intraoperative high blood pressure | +—————-+——————–+———————————————————————————————————————————————————-+ | February 2023 | Key questions | KQ8 combined with KQ1; KQ2 (prehabilitation) and KQ7 (pain) removed | +—————-+——————–+———————————————————————————————————————————————————-+ | September 2023 | Key questions | Reworded to “older patients” | +—————-+——————–+———————————————————————————————————————————————————-+ | | PICOTS | Updated to be consistent with deleted and combined key questions | +—————-+——————–+———————————————————————————————————————————————————-+ | | Analytic framework | Updated to be consistent with deleted and combined key questions | +—————-+——————–+———————————————————————————————————————————————————-+"
  },
  {
    "objectID": "kq5.html#risk-of-bias",
    "href": "kq5.html#risk-of-bias",
    "title": "Potentially Inappropriate Medications",
    "section": "Risk of Bias",
    "text": "Risk of Bias\n\nRandomized\n Figure 1. Summary risk of bias assessment for randomized clinical trials. \n\n\n\n\n\n Figure 2. Risk of bias assessments for randomized clinical trials. \n\n\n\n\n\n\n\nNonrandomized\n Figure 3. Summary risk of bias assessment for nonrandomized studies. \n\n\n\n\n\n Figure 4. Risk of bias assessments for nonrandomized studies."
  },
  {
    "objectID": "kq5.html#study-primary-aim",
    "href": "kq5.html#study-primary-aim",
    "title": "Potentially Inappropriate Medications",
    "section": "Study Primary Aim",
    "text": "Study Primary Aim\n\nDelirium Prevention\n Table 19. Studies examining delirium prevention. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N\n      Drug Class\n      Study Aim\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Aizawa 2002\n\n42\nBenzodiazepine (la)\n\n“We attempted to control disturbances of the sleepwake cycle by medication after surgery as a mean of preventing POD, but bearing in mind there was a risk that artificial regulation of the sleep rhythm would have significant side effects that outweighed its benefits.”\n\n    Kalisvaart 2005\n\n430\nAntipsychotics\n\n“This was a randomized, placebo-controlled, doubleblind, clinical trial of low-dose haloperidol prophylaxis for postoperative delirium in elderly hip-surgery patients who were at intermediate or high risk for this complication. The aim was to assess the effectiveness of 1.5 mg of haloperidol daily versus placebo on the primary (incident delirium) and secondary (deterioration of delirium) prevention of postoperative delirium in hip-surgery patients.”\n\n    Prakanrattana 2007\n\n126\nAntipsychotics\n\n“This study was primarily aimed to evaluate the potential of a single dose of risperidone to prevent postoperative delirium in adult patients undergoing cardiac surgery with cardiopulmonary bypass.”\n\n    Larsen 2010\n\n495\nAntipsychotics\n\n“Our study sought to evaluate the impact of the perioperative administration of olanzapine on the prevention of postoperative delirium in elderly patients undergoing elective joint-replacement surgery. Secondary objectives included the length of stay, medical complications, the severity and duration of delirium, and disposition after hospital discharge.”\n\n    Hakim 2012\n\n101\nAntipsychotics\n\n“The aim of this trial was to test the hypothesis that administration of risperidone to elderly patients who developed subsyndromal delirium after cardiac surgery would result in reduction of the incidence of clinical delirium.”\n\n    Wang 2012\n\n457\nAntipsychotics\n\n“The purpose of this study was to determine the efficacy and safety of short-term administration of low-dose intravenous haloperidol in preventing delirium in critically ill elderly patients after noncardiac surgery.”\n\n    Dieleman 2012\n\n4,494\nCorticosteroids\n\n“We conducted a large randomized clinical trial to quantify the effect of a single intraoperative dose of dexamethasone on the incidence of major adverse events in patients undergoing cardiac surgery.” Delirium was specified as a secondary outcome (adverse event).\n\n    Mardani 2013\n\n110\nCorticosteroids\n\n“Therefore, this study was conducted with aim of evaluation of DEX effects on post‑operative delirium and complications after cardiac surgery.” Posited potential beneficial effects.\n\n    Fukata 2014\n\n121\nAntipsychotics\n\n“[T]o investigate the efficacy and safety of the daily postoperative administration of low-dose haloperidol on postoperative delirium in 75-year-old or older patients who underwent abdominal or orthopedic surgery.”\n\n    Sauer 2014\n\n737\nCorticosteroids\n\n“The objective of the present study was to investigate in detail whether the intraoperative administration of high-dose dexamethasone to patients undergoing cardiac surgery affects the incidence of postoperative delirium during the first 4 postoperative days. We hypothesized that dexamethasone administration would reduce the incidence of delirium at any time point during the first 4 postoperative days.”\n\n    Ottens 2014\n\n291\nCorticosteroids\n\n“In this study, we assessed the effect of an intraoperative high dose of dexamethasone on cognitive outcome of patients who underwent cardiac surgery with the use of CPB. We hypothesized that the incidence of POCD at 1 month after surgery would be lower in patients who received dexamethasone compared with those who received placebo.” Preplanned substudy of Dieleman 2012.\n\n    Glumac 2017\n\n169\nCorticosteroids\n\n“The aim of the current study was to assess the effects of preoperative dexamethasone on cognitive outcomes on the 6th day after surgery and also on the inflammatory response in patients who had undergone cardiac surgery. We hypothesised that the incidence of early POCD and the magnitude of the inflammatory response would be reduced in patients who received dexamethasone compared with those who received placebo.”\n\n    Royse 2017\n\n555\nCorticosteroids\n\n“Our goal was to determine whether high-dose methylprednisolone improves the quality of postoperative recovery and reduces the incidence of delirium after cardiac surgery involving cardiopulmonary bypass. Specifically, we tested the primary hypothesis that high-dose methylprednisolone improves the quality of recovery compared to placebo. Secondarily, we tested the hypothesis that high-dose methylprednisolone reduces the incidence of delirium during the initial three postoperative days.”\n\n    Fukata 2017\n\n201\nAntipsychotics\n\n“The aim of this study was to evaluate the safety and efficacy of the early administration haloperidol in preventing the aggravation of postoperative delirium in elderly patients.”\n\n    Zhu 2018\n\n178\nNSAIDs\n\n“This study was conducted to investigate the effect of celecoxib in POCD incidence in geriatric patients undergoing total knee arthroplasty (TKA).”\n\n    Mansouri 2019\n\n150\nBenzodiazepine (sa)\n\n“[T]he present study aims to compare the effects of preoperative intravenous administration of midazolam and dexmedetomidine on the prevention of POCD among the elderly candidates for cataract surgery.”\n\n    Zhou 2019a\n\n180\nNSAIDs\n\n“The aims of this study were to evaluate the postoperative pain, cognitive function and serum levels of pro-inflammatory cytokines in patients undergoing hip arthroplasty surgery with pre- or intraoperative flurbiprofen.” Posited that flurbiprofen preventive for dNCR.\n\n    Hollinger 2021\n\n143\nAntipsychotics\n\n“This randomised, double-blinded, placebo-controlled study aimed to compare haloperidol and ketamine separately and in combination to prevent the incidence of postoperative delirium.”\n\n    Xiang 2022\n\n174\nCorticosteroids\n\n“This randomized, double-blind, placebo-controlled trial was designed to evaluate whether a single preoperative dose of methylprednisolone reduced the rate of POD in older patients undergoing gastrointestinal surgery and its association with the shedding of endothelial glycocalyx markers.”\n\n  \n  \n  \n\n\n\n\n\n\nOther Studies\n Table 20. Studies with aim including examining adverse effects of a potentially inappropriate medication outside a delirium prevention trial. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n      N\n      Drug Class\n      Study Aim\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Sultan 2010\n\n152\nBenzodiazepine (sa)\n\n“The incidence of postoperative delirium will be tested if affected by three different sedative drugs including melatonin.” But included midazolam as comparator without hypothesized impact on delirium.\n\n    Whitlock 2015\n\n7,507\nCorticosteroids\n\n“We aimed to assess whether prophylactic steroids benefit patients at high risk of morbidity and mortality undergoing cardiac surgery with cardiopulmonary bypass.” Delirium was included as a safety outcome.\n\n    Dianatkhah 2015\n\n145\nBenzodiazepine (la)\n\n“Based on the above-affirmed data, the present study sought to evaluate the effect of melatonin on postoperative sleep in patients undergoing CABG.”\n\n    Yu 2017\n\n92\nBenzodiazepine (sa)\n\n“Therefore, the comparison of the post-anesthesia delirium of elderly patients treated with thoracic surgery between Dexmedetomidine and Midazolam Maleate was discussed in this paper, expecting to provide clinical references.” Midazolam noted only as comparator without posited effect on delirium.\n\n    He 2018\n\n90\nBenzodiazepine (sa)\n\n“To study the preventive effect of dexmedetomidine (DEX) on the postoperative delirium (POD) in elderly patients aged over 75 years old after vertebral fracture operation, and its regulating effect on the depth of anesthesia during operation.”\n\n    Azeem 2018\n\n70\nBenzodiazepine (sa)\n\n“This study was designed to compare dexmedetomidine with morphine and midazolam‑based regimen after cardiac surgery at equivalent levels of sedation and analgesia to decrease the incidence of postoperative delirium.”\n\n    Li 2019\n\n164\nBenzodiazepine (sa)\n\n“The primary aim of this study was to evaluate the short-term (1 week postoperatively) and long-term (1 year postoperatively) incidence of POCD after elective joint replacement surgery in patients aged ≥65 years.” Delirium prevention trial included benzodiazepines as a comparator, with authors noting its potential to cause delirium.\n\n    Hongyu 2019\n\n90\nAnticholinergics\n\n“Pentanethaquine hydrochloride (PHC) is a novel, selective anticholinergic drug. Due to its strong anti-cholinergic effect on the central and peripheral nerves and no side effect of accelerated heart rate, it has been increasingly used in general anesthesia recently. However, studies have shown that PHC may increase the incidence of POCD and PD and may decrease the concentration of inflammatory cytokines, but there is no clear evidence to confirm either the pros and cons of this drug.\nTherefore, the elderly patients with lung cancer undergoing thoracoscopic surgery under general anesthesia were selected to determine whether PHC is suitable for use in elderly patients.”\n\n    Wang 2020a\n\n44\nBenzodiazepine (sa)\n\n“… [R]etrospectively compare[d] the effects of hydromorphone plus midazolam and hydromorphone plus dexmedetomidine as sedatives following oral and maxillofacial surgery.”\n\n    Tan 2022\n\n99\nBenzodiazepine (sa)\n\n“[W]e aimed to evaluate the effect of RT [remimazolam tosilate] on the early cognitive function of elderly patients undergoing upper GI endoscopy.”\n\n    \n      Randomized Cluster Crossover Trial\n    \n    Spence 2020\n\n800\nBenzodiazepine (sa)\n\n“[W]e designed a pragmatic randomised cluster crossover trial to test whether an institutional policy of restricted use of benzodiazepines during surgery (compared with liberal use) reduces postoperative delirium.”\n\n    \n      Nonrandomized Trial\n    \n    Van Grootven 2016\n\n86\nBenzodiazepine (ns)\n\n“The aim of the present secondary data analysis was therefore to investigate if preoperative state anxiety is a risk factor for postoperative delirium in older hip fracture patients.”\n\n    \n      Before-After/Time Series\n    \n    Ushida 2009\n\n122\nCorticosteroids\n\n“The aim of the present study was to investigate factors contributing to the development of postoperative delirium in cervical surgery.”\n\n    Yamasaki 2019\n\n21\nH2 blockers\n\n“The present study evaluated and compared the incidence rates and severities of postoperative delirium between the famotidine and omeprazole groups in patients receiving hepatectomy who were over 65 years of age.”\n\n    \n      Prospective Cohort\n    \n    Wang 2021\n\n1,266\nBenzodiazepine (sa)\n\n“[T]he aim of this study is to assess the effect of intravenous midazolam as a premedication on the incidence of postoperative delirium in older adults.”\n\n    Pipanmekaporn 2021\n\n429\nBenzodiazepine (ns)\n\nrisk factors of delirium\n\n    Ke 2022a\n\n98\nBenzodiazepine (sa)\n\nRisk factor study aimed to do a pragmatic observational study using Nu-DESC to understand the incidence of PACU delirium in patients aged 65 years and older after major non-cardiac surgery\n\n    Leigheb 2022\n\n83\nBenzodiazepine (sa)\n\nrisk factors for delirium\n\n    Duprey 2022\n\n566\nBenzodiazepine (ns)AntipsychoticsNSAIDsAnticholinergics\n\n“To better understand the important potential role of presurgical and postsurgical medication use on postoperative delirium and PND [postoperative neurocognitive disorder] in older adults undergoing major surgery, we sought to investigate 3 associations: (1) presurgical medication use and postoperative delirium; (2) inpatient, postsurgical medication use and postoperative delirium; and (3) the delirium-independent relationship between inpatient, postsurgical medication use and cognition 1 month after surgery.”\n\n    Aoki 2023\n\n222\nBenzodiazepine (sa)\n\n“[W]e conducted a prospective observational study to investigate whether general anesthesia with remimazolam is associated with the development of postoperative delirium when compared with other anesthetic agents.”\n\n    \n      Retrospective Cohort\n    \n    Slor 2011b\n\n526\nBenzodiazepine (ns)\n\nThis study examined the effect of general anesthesia on postoperative delirium in a large homogeneous participant group. Study outcomes were also stratified for delirium risk factors, examining risk of delirium associated with general anesthesia in individuals undergoing hip surgery with and without cognitive impairment. Effects of classes of medications on postoperative delirium were explored. Understanding the role of anesthetic technique and perioperative medications as risk factors for postoperative delirium may further increase knowledge of potential methods to prevent postoperative delirium.\n\n    Mangusan 2015\n\n656\nNSAIDsNonbenzodiazepine hypnoticsBenzodiazepine (ns)\n\n“The purpose of this study was to examine the effect of postoperative delirium on 5 outcome measures in patients who had cardiovascular surgery with use of cardiopulmonary bypass: length of postoperative hospital stay, prevalence of falls, discharge to a nursing facility (skilled nursing facility, long-term acute care facility, rehabilitation center), discharge to home with home health services, and use of inpatient physical therapy.”\n\n    Weinstein 2018a\n\n41,766\nBenzodiazepine (ns)\n\nrisk factors of delirium\n\n    Weinstein 2018b\n\n41,766\nBenzodiazepine (ns)\n\nrisk factors of delirium\n\n    Memtsoudis 2019 THA\n\n564,226\nBenzodiazepine (sa)Benzodiazepine (la)Benzodiazepine (any)CorticosteroidsNSAIDsNSAIDs\n\n“We hypothesized that the incidence of postoperative delirium and its risk factors among joint arthroplasty patients would be reduced over time and that modifiable risk factors could be identified.”\n\n    Fuchita 2019a\n\n84\nBenzodiazepine (ns)\n\nRisk factor study.\n\n    Fuchita 2019b\n\n84\nCorticosteroids\n\nRisk factor study.\n\n    Mueller 2020a\n\n651\nBenzodiazepine (sa)\n\nrisk factors for delirium\n\n    Mueller 2020b\n\n651\nAntipsychotics\n\nrisk factors for delirium\n\n    Burfeind 2022\n\n1,627\nCorticosteroidsH2 blockersBenzodiazepine (sa)\n\n“[O]ur objective was to assess whether perioperative PIM administration was associated with poor outcomes in geriatric patients with preexisting frailty or cognitive impairment.”\n\n    Koch 2023\n\n1,058\nBenzodiazepine (sa)\n\ndepth of anesthesia and cognitive outcomes\n\n    Liu 2023a\n\n195\nBenzodiazepine (sa)\n\nrisk factors for delirium\n\n    \n      Case-Control\n    \n    Nandi 2014\n\n463\nBenzodiazepine (ns)\n\n“The aim of this study was to explore if administration of specific anesthetic agents, opiate pain medications, or benzodiazepines increases the risk of post-operative delirium following total hip and knee arthroplasty.”\n\n    Choi 2019\n\n58\nCorticosteroids\n\n“The objective of this study was to investigate the beneficial effects of early (within 72 h) treatment with corticosteroids in patients with postoperative ALI [acute lung injury] compared with late treatment. Our hypothesis was that fibroproliferation, which is an early response to lung injury, would be inhibited by early corticosteroid treatment without serious adverse events.”"
  },
  {
    "objectID": "soe_formatting_error.html",
    "href": "soe_formatting_error.html",
    "title": "Strength of Evidence",
    "section": "",
    "text": "Table 1. Strength of evidence summaries — expanded versus standard preoperative evaluation. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      Studies (Pts)\n      Study Design\n      GRADE1\n      ACCF AHA2\n      Importance3\n      Summary\n      Result Detail\n    \n  \n  \n    Delirium incidence\n\n4 (  929)\n\nRCT\n⨁⨁⨁◯\n\nB-R\n+++\nPooled estimate from 4 RCTs suggested a lower risk of postoperative delirium with expanded versus standard preoperative evaluation.  RR 0.84  (95% CI, 0.71-0.99; I 2 = 7%)\n\nTable: 10  \nFigure: 1  \n\n    \n2 (  436)\n\nRCT\n⨁⨁◯◯\n\nC-LD\n+++\nPooled estimate from 2 RCTs suggested a lower risk of postoperative delirium with expanded versus standard preoperative evaluation.  RR 0.54  (95% CI, 0.33-0.89; I 2 = 0%)\n\n](kq1.html#delirium-incidence) \n\nFigure: [1  ](kq1.html#pooled)\"&gt;Table: 10  \nFigure: 1  \n\n    \n6 (1,365)\n\nRCT\n⨁⨁⨁◯\n\nB-R\n+++\nPooled estimate from 6 RCTs was consistent with a lower risk of postoperative delirium for expanded versus standard preoperative evaluation.  RR 0.77  (95% CI, 0.60-0.99; I 2 = 26%) \nIn hip fracture studies  (n = 4)RR 0.84  (95% CI, 0.71-0.99; I 2 = 7%) \nIn studies of various surgeries (n = 2)RR 0.54  (95% CI, 0.33-0.89; I 2 = 0%)\n\n](kq1.html#delirium-incidence) \n\nFigure: [1  ](kq1.html#pooled)\"&gt;Table: 10  \nFigure: 1  \n\n    \n6 (1,774)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 6 non-randomized studies was consistent with a lower risk of postoperative delirium with expanded versus standard preoperative evaluation.  RR 0.65  (95% CI, 0.49-0.87; I 2 = 33%)\n\n](kq1.html#delirium-incidence) \n\nFigure: [2  ](kq1.html#pooled)\"&gt;Table: 10  \nFigure: 2  \n\n  \n  \n  \n    \n       Pts: patients; RCT: randomized clinical trial; NRSI: non-randomized studies of interventions (inlcudes non-randomized trials, before-after/time series, and observational); GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; ACCF/AHA: American College of Cardiology Foundation/American Heart Association; RR: risk ratio; OR: odds ratio; MD: mean difference; RD: risk difference.\n    \n    \n      1 Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      2 A: high-quality evidence from more than 1 RCT; B-R: moderate-quality evidence from more than 1 RCT; B-NR: moderate-quality evidence from more than one observational study; C-LD: randomized or non-randomized observational or registry studies with limited data; C-EO: consensus of expert opinion.\n    \n    \n      3 Limited +; Important ++; Critical +++.\n    \n  \n\n\n\n\n\n\n[conflicted] Removing existing preference.\n[conflicted] Will prefer dplyr::lag over any other package.\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      Studies (Pts)\n      Study Design\n      GRADE1\n      ACCF AHA2\n      Importance3\n      Summary\n      Result Detail\n    \n  \n  \n    Delirium incidence\n\n6 (1,365)\n\nRCT\n⨁⨁⨁◯\n\nB-R\n+++\nPooled estimate from 6 RCTs was consistent with a lower risk of postoperative delirium for expanded versus standard preoperative evaluation.  RR 0.77  (95% CI, 0.60-0.99; I 2 = 26%)  In hip fracture studies (n = 4)RR 0.84  (95% CI, 0.71-0.99; I 2 = 7%)  In studies of various surgeries (n = 2)RR 0.54  (95% CI, 0.33-0.89; I 2 = 0%)\n\nTable: 10  \n\n  \n  \n  \n    \n       Pts: patients; RCT: randomized clinical trial; NRSI: non-randomized studies of interventions (inlcudes non-randomized trials, before-after/time series, and observational); GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; ACCF/AHA: American College of Cardiology Foundation/American Heart Association; RR: risk ratio; OR: odds ratio; MD: mean difference; RD: risk difference.\n    \n    \n      1 Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      2 A: high-quality evidence from more than 1 RCT; B-R: moderate-quality evidence from more than 1 RCT; B-NR: moderate-quality evidence from more than one observational study; C-LD: randomized or non-randomized observational or registry studies with limited data; C-EO: consensus of expert opinion.\n    \n    \n      3 Limited +; Important ++; Critical +++."
  },
  {
    "objectID": "soe_formatting_error.html#expanded-preoperative-evaluation",
    "href": "soe_formatting_error.html#expanded-preoperative-evaluation",
    "title": "Strength of Evidence",
    "section": "",
    "text": "Table 1. Strength of evidence summaries — expanded versus standard preoperative evaluation. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      Studies (Pts)\n      Study Design\n      GRADE1\n      ACCF AHA2\n      Importance3\n      Summary\n      Result Detail\n    \n  \n  \n    Delirium incidence\n\n4 (  929)\n\nRCT\n⨁⨁⨁◯\n\nB-R\n+++\nPooled estimate from 4 RCTs suggested a lower risk of postoperative delirium with expanded versus standard preoperative evaluation.  RR 0.84  (95% CI, 0.71-0.99; I 2 = 7%)\n\nTable: 10  \nFigure: 1  \n\n    \n2 (  436)\n\nRCT\n⨁⨁◯◯\n\nC-LD\n+++\nPooled estimate from 2 RCTs suggested a lower risk of postoperative delirium with expanded versus standard preoperative evaluation.  RR 0.54  (95% CI, 0.33-0.89; I 2 = 0%)\n\n](kq1.html#delirium-incidence) \n\nFigure: [1  ](kq1.html#pooled)\"&gt;Table: 10  \nFigure: 1  \n\n    \n6 (1,365)\n\nRCT\n⨁⨁⨁◯\n\nB-R\n+++\nPooled estimate from 6 RCTs was consistent with a lower risk of postoperative delirium for expanded versus standard preoperative evaluation.  RR 0.77  (95% CI, 0.60-0.99; I 2 = 26%) \nIn hip fracture studies  (n = 4)RR 0.84  (95% CI, 0.71-0.99; I 2 = 7%) \nIn studies of various surgeries (n = 2)RR 0.54  (95% CI, 0.33-0.89; I 2 = 0%)\n\n](kq1.html#delirium-incidence) \n\nFigure: [1  ](kq1.html#pooled)\"&gt;Table: 10  \nFigure: 1  \n\n    \n6 (1,774)\n\nNRSI\n⨁◯◯◯\n\nC-LD\n+++\nPooled estimate from 6 non-randomized studies was consistent with a lower risk of postoperative delirium with expanded versus standard preoperative evaluation.  RR 0.65  (95% CI, 0.49-0.87; I 2 = 33%)\n\n](kq1.html#delirium-incidence) \n\nFigure: [2  ](kq1.html#pooled)\"&gt;Table: 10  \nFigure: 2  \n\n  \n  \n  \n    \n       Pts: patients; RCT: randomized clinical trial; NRSI: non-randomized studies of interventions (inlcudes non-randomized trials, before-after/time series, and observational); GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; ACCF/AHA: American College of Cardiology Foundation/American Heart Association; RR: risk ratio; OR: odds ratio; MD: mean difference; RD: risk difference.\n    \n    \n      1 Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      2 A: high-quality evidence from more than 1 RCT; B-R: moderate-quality evidence from more than 1 RCT; B-NR: moderate-quality evidence from more than one observational study; C-LD: randomized or non-randomized observational or registry studies with limited data; C-EO: consensus of expert opinion.\n    \n    \n      3 Limited +; Important ++; Critical +++.\n    \n  \n\n\n\n\n\n\n[conflicted] Removing existing preference.\n[conflicted] Will prefer dplyr::lag over any other package.\n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      Studies (Pts)\n      Study Design\n      GRADE1\n      ACCF AHA2\n      Importance3\n      Summary\n      Result Detail\n    \n  \n  \n    Delirium incidence\n\n6 (1,365)\n\nRCT\n⨁⨁⨁◯\n\nB-R\n+++\nPooled estimate from 6 RCTs was consistent with a lower risk of postoperative delirium for expanded versus standard preoperative evaluation.  RR 0.77  (95% CI, 0.60-0.99; I 2 = 26%)  In hip fracture studies (n = 4)RR 0.84  (95% CI, 0.71-0.99; I 2 = 7%)  In studies of various surgeries (n = 2)RR 0.54  (95% CI, 0.33-0.89; I 2 = 0%)\n\nTable: 10  \n\n  \n  \n  \n    \n       Pts: patients; RCT: randomized clinical trial; NRSI: non-randomized studies of interventions (inlcudes non-randomized trials, before-after/time series, and observational); GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; ACCF/AHA: American College of Cardiology Foundation/American Heart Association; RR: risk ratio; OR: odds ratio; MD: mean difference; RD: risk difference.\n    \n    \n      1 Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      2 A: high-quality evidence from more than 1 RCT; B-R: moderate-quality evidence from more than 1 RCT; B-NR: moderate-quality evidence from more than one observational study; C-LD: randomized or non-randomized observational or registry studies with limited data; C-EO: consensus of expert opinion.\n    \n    \n      3 Limited +; Important ++; Critical +++."
  },
  {
    "objectID": "evidence_tables.html",
    "href": "evidence_tables.html",
    "title": "Evidence Tables",
    "section": "",
    "text": "Note: Clicking on the author name will take you to the DOI of the reference (if it was available)."
  },
  {
    "objectID": "kq3.html#balance-tables",
    "href": "kq3.html#balance-tables",
    "title": "Regional versus General Anesthesia",
    "section": "Balance Tables",
    "text": "Balance Tables\n Benefits, harms, and strength of evidence (GRADE) for regional versus general anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT\n      \n        Regional\n      \n      \n        General\n      \n      GRADE*\n      Effect\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Delirium\n12\n231 (1947)\n229 (1928)\n⨁⨁⨁◯\n\nRR\n 0.97 (0.69–1.36)†\n    Delayed neurocognitive recovery\n4\n78 (336)\n88 (355)\n⨁⨁◯◯\n\nRR\n 0.91 (0.56–1.48)\n    Postoperative neurocognitive disorder\n1\n23 (176)\n25 (188)\n⨁◯◯◯\n\nRR\n 0.98 (0.58–1.67)\n    Physical function\n1\n\n\n⨁◯◯◯\n\nSMD\n 0.26 (-0.25 to 0.78)\n    Complications‡\n17\n\n\n⨁⨁◯◯⨁◯◯◯\n\n\nSee below\n    Patient satisfaction\n10\n913 (1055)\n839 (991)\n⨁◯◯◯\n\nRR\n 1.02 (0.98 to 1.05)§\n    Length of stay (days)\n15\n(2402)\n(2426)\n⨁◯◯◯\n\nMD\n-0.5 (-1.3 to 0.3)\n    Discharged to institution\n1\n576 (777)\n586 (777)\n⨁◯◯◯\n\nRR\n 0.98 (0.93-1.04)\n    Mortality (in-hospital and 30-day)\n\n\n\n\n\n\n    All procedures\n8\n38 (3711)\n58 (3708)\n⨁⨁◯◯\n\nRR\n 0.68 (0.43–1.07)\n    \n10\n38 (3788)\n58 (3789)\n\nRD/1000\n-5.2 (-10.4 to -0.1)\n    Hip fracture\n4\n19 (1467)\n27 (1478)\n\nRR\n 0.73 (0.22–2.39)\n    \n5\n19 (1486)\n27 (1499)\n\nRD/1000\n-3.9 (-17.7 to 9.9)\n    Other\n4\n19 (2184)\n31 (2170)\n\nRR\n 0.65 (0.35–1.22)\n    \n6\n19 (2302)\n31 (2290)\n\nRD/1000\n-5.6 (-9.9 to -1.3)\n    Mortality (90-day)\n3\n15 (427)\n16 (441)\n⨁⨁◯◯\n\nRR\n 0.68 (0.43–1.07)\n    \n\n\n\n\nRD/1000\n-4.1 (-16.4 to 8.2)\n  \n  \n  \n    \n       RCT: randomized clinical trial; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; RD/1000: risk difference per 1000.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      † Hip fracture trials RR 1.03 (0.77–1.32); others RR 0.90 (0.62–1.29).\n    \n    \n      ‡ Complications reported variously across the 17 trials. \n    \n    \n      § Comparing higher/highest category or categories compared with lower ones.\n    \n  \n\n\n\n\n Included complications and strength of evidence (GRADE) for regional versus general anesthesia. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Outcome\n      RCT\n      \n        Regional\n      \n      \n        General\n      \n      GRADE*\n      Effect†\n      Estimate (95% CI)\n    \n    \n      N (Total)\n      N (Total)\n    \n  \n  \n    Myocardial infarction\n6\n21 (3426)\n16 (3352)\n⨁⨁◯◯\n\nRR\n 1.17 (0.59–2.32)\n\n    \n\n\n\n\nRD/1000\n 1.9 (-0.6 to 4.5)\n\n    Cardiac arrest\n2\n2 (874)\n0 (888)\n⨁◯◯◯\n\nRD/1000\n 2.3 (-2.2 to 6.7)\n\n    Stroke\n6\n75 (3257)\n80 (3247)\n⨁⨁◯◯\n\nRR\n 0.93 (0.68–1.26)\n\n    \n\n\n\n\nRD/1000\n-1.7 (-6.2 to 2.7)\n\n    Renal\n4\n33 (1118)\n58 (1129)\n⨁⨁◯◯\n\nRR\n 0.59 (0.39–0.89)\n\n    \n\n\n\n\nRD/1000\n-11.8 (-28.5 to 4.5)\n\n    Pulmonary complications‡\n2\n4 (88)\n10 (148)\n⨁◯◯◯\n\nRR\n 0.81 (0.28–2.35)\n\n    \n\n\n\n\nRD/1000\n-14.7 (-77.7 to 48.3)\n\n    Pneumonia\n8\n14 (1834)\n27 (1754)\n⨁⨁◯◯\n\nRR\n 0.50 (0.26–0.96)\n\n    \n\n\n\n\nRD/1000\n-3.8 (-10.2 to 2.6)\n\n    Pulmonary congestion\n1\n9 (783)\n8 (793)\n⨁◯◯◯\n\nRR\n 1.14 (0.44–2.94)\n\n    \n\n\n\n\nRD/1000\n 1.4 (-8.8 to 11.6)\n\n    Pulmonary embolism\n6\n7 (2055)\n13 (1406)\n⨁◯◯◯\n\nRR\n 0.56 (0.27–1.16)\n\n    \n8\n7 (3317)\n13 (3253)\n\nRD/1000\n-0.1 (-1.1 to 0.8)\n\n    Reintubation\n1\n4 (783)\n7 (793)\n⨁◯◯◯\n\nRR\n 0.37 (0.17–1.97)\n\n    \n\n\n\n\nRD/1000\n-3.7 (-11.9 to 4.5)\n\n  \n  \n  \n    \n       RCT: randomized clinical trial; GRADE: Grades of Recommendation, Assessment, Development, and Evaluation; RR: risk ratio; RD/1000: risk difference per 1000.\n    \n    \n      * Very low: ⨁◯◯◯; Low: ⨁⨁◯◯; Moderate: ⨁⨁⨁◯; High: ⨁⨁⨁⨁.\n    \n    \n      † Fixed/common effects models when 2 studies.\n    \n    \n      ‡ Complications reported included pneumonia, respiratory failure, or unspecified."
  },
  {
    "objectID": "summary_kq3.html#primary-outcomes",
    "href": "summary_kq3.html#primary-outcomes",
    "title": "Study/Patient Characteristics Regional versus General Anesthesia",
    "section": "Primary Outcomes",
    "text": "Primary Outcomes\n Table 3. Primary outcomes. \n\n\n\n\n\n\n  \n    \n    \n      Outcome\n      RCT, N = 45a\n    \n  \n  \n    Postoperative delirium\n6 (13%)\n    Delayed neurocognitive recovery\n11 (24%)\n    Quality of recovery\n1 (2.2%)\n    Depression\n1 (2.2%)\n    Patient/caregiver satisfaction\n6 (13%)\n    Functional status (ADL, IADL, mobility)\n5 (11%)\n    Pain\n17 (38%)\n    Opioid use\n5 (11%)\n    Complications\n6 (13%)\n    Length of stay\n6 (13%)\n    Mortality (30-, 180-, 365-day)\n2 (4.4%)\n    Other\n9 (20%)b\n  \n  \n  \n    \n      a n (%)\n    \n    \n      b “[A]cceptibility, efficacy, and reliability” of general versus spinal anesthesia. Surgery time; blood loss; hemodynamics. Stroke (including retinal infarction), myocardial infarction. Laboratory results. Composite of death or an inability to walk 10ft or across a room independently or with a walker/cane but without the assistance of another person at 60 days postop. Hemodynamic changes; PONV. Hypotension; heart rate; bradycardia; PACU discharge. Perioperative blood loss; time to first meal; time to first ambulation. Analgesic Requirements; length of PACU stay."
  },
  {
    "objectID": "kq6.html#postoperative-neurocognitive-disorder",
    "href": "kq6.html#postoperative-neurocognitive-disorder",
    "title": "Delirium Prophylaxis",
    "section": "Postoperative Neurocognitive Disorder",
    "text": "Postoperative Neurocognitive Disorder\n\nDexmedetomidine or Melatonin\n Table 18. Neurocognitive disorder and ascertainment reported in dexmedetomidine and melatonin trials. \n\n\n\n\n\n\n  \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n    \n  \n  \n    \n    \n      Study\n       N\n      Drug\n      \n        Preop\n      \n      \n        Instrument\n      \n      Dayb\n      \n        Neurocognitive Disorder\n      \n    \n    \n      MMSEa\n      MMSE\n      DST\n      MoCA\n      Other\n      N (%)\n      0 — 100%\n      RR (95% CI)\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    de Jonghe 2014\n\n151\nPlac\n23 {10-28}\n\n✓\n\n\n\n✓\n\n90\n105 (69.5)\n\n\n—\n    \n147\nMel\n23 {12-29}\n\n\n\n\n\n\n 87 (59.2)\n\n\n0.85 (0.72-1.01)\n    Li 2019\n\n55\nProp\n\n\n✓c\n\n✓d\n365\n  5 (9.1)\n\n\n—\n    \n54\nMid\n\n\n\n\n\n\n  7 (13.0)\n\n\n1.43 (0.48-4.22)\n    \n55\nDex\n\n\n\n\n\n\n  6 (10.9)\n\n\n1.20 (0.39-3.70)\n    Wang 2019\n\n100\nMid\n25.0 (3.3)\n\n✓e\n\n\n\n90\n  7 (7.0)\n\n\n—\n    \n98\nDex\n24.9 (3.9)\n\n\n\n\n\n\n  9 (9.2)\n\n\n1.31 (0.51-3.38)\n    Gao 2021\n\n20\nPlac\n28.4 (1.3)\n\n✓\n\n\n\n\n90\n  2 (10.0)\n\n\n—\n    \n20\nDex\n28.5 (1.4)\n\n\n\n\n\n\n  0 (0.0)\n\n\nNot estimated\n  \n  \n  \n    \n       Mini-Mental State Exam; DST: Digit Span Test; MoCA: Montreal Cognitive Assessment; RR: risk ratio; Dex: dexmedetomidine: Mel: melatonin; Plac: placebo.\n    \n    \n      a Mean Med (SD)[Range]{IQR}.\n    \n    \n      b Day of assessment.\n    \n    \n      c Z ≥1.96.\n    \n    \n      d Stroop Color-Word Test; Associative Learning And Memory Test.\n    \n    \n      e Threshold not specified.\n    \n  \n\n\n\n\n\n\nKetamine\nNo studies"
  }
]